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ABSTRACT 
Subclinical thyroid dysfunction (SCTD), characterised by abnormal serum 
thyrotrophin concentrations (TSH) with normal free thyroxine (FT4), is regularly 
encountered in primary care. The clinical manifestations of SCTD are not well 
established, particularly in older individuals in whom SCTD, co-morbid conditions 
and symptoms frequently occur.  
 
This thesis clarifies the clinical expression and pathophysiological consequences of 
SCTD in the elderly with reference to existing evidence and a cross-sectional study 
evaluating thyroid function (TF), health status and specific symptoms in community 
dwelling individuals aged 65 years and above.  
 
TF for 2870 participants was categorised, 2703 (94%) euthyroid, 138 (4.8%) 
subclinical hypothyroidism and 29 (1%) subclinical hyperthyroidism. No significant 
differences in the prevalence of individual symptoms, pairs of symptoms or multiple 
symptoms were observed between TF groups. In the presence of individual or 
multiple symptoms, health status scores were significantly lower. 
 
In conclusion, symptoms and impaired health status were not associated with SCTD 
in this study. Results suggest that assessment of symptoms and health status does 
not aid clinical decision making with respect to management of SCTD in the elderly. 
Coupled with weak evidence demonstrating pathophysiological consequences in 
SCTD, overall findings suggest this population is unlikely to benefit from treatment 
for SCTD. 
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INTRODUCTION 
Thyroid dysfunction is common in older age and often encountered in primary care. 
Elderly individuals frequently consult general practitioners (GPs) regarding 
symptoms such as dry skin, frequent palpitation, poor memory, weak muscles and 
lethargy which are traditionally associated with overt thyroid dysfunction. When 
elderly individuals present with these symptoms, GPs generally request thyroid 
function tests (TFT) which measure serum concentrations of thyrotrophin (also 
known as thyroid stimulating hormone [TSH]) and free thyroxine (FT4). Normal or 
euthyroid function is defined by serum concentrations of thyrotrophin and free 
thyroxine within their respective local laboratory reference criteria. In contrast overt 
thyroid dysfunction is diagnosed when the serum concentrations of both thyrotrophin 
and FT4 are outside of their respective reference range. In older individuals TFT 
results more frequently reveal subclinical thyroid dysfunction, defined by serum 
thyrotrophin concentration outside of the local laboratory reference range 
accompanied by FT4 concentration within the reference range.  
On receipt of TFT results indicating subclinical thyroid dysfunction in an elderly 
individual with symptoms, a GP has to decide to either closely monitor thyroid 
function via repeated TFT or to commence treatment aimed at restoring normal 
thyroid function. 
Whilst the signs and symptoms of overt thyroid dysfunction are well established and 
adverse clinical consequences are widely documented, data related to the 
pathophysiological consequences of subclinical thyroid dysfunction are inconsistent. 
Consequentially there is no consensus with respect to recommendations for 
screening, management and treatment for subclinical thyroid dysfunction. Essentially 
subclinical thyroid dysfunction, as the name suggests is a biochemical diagnosis. 
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Nonetheless given the biochemical profile it is reasonable to assume that subclinical 
thyroid dysfunction is a mild form of overt thyroid function and as such is associated 
with a similar albeit less severe adverse clinical consequences. Furthermore a 
greater prevalence of symptoms and moderate benefits of treatment in terms of 
decreasing symptom severity have been described in younger adults with subclinical 
thyroid dysfunction compared with euthyroid individuals. In older individuals however 
the relationship between symptoms and subclinical thyroid dysfunction remains 
ambiguous. This is predominantly because the symptoms traditionally associated 
with overt thyroid dysfunction also accompany normal healthy ageing. Similarly the 
benefits of treating elderly individuals are uncertain with polypharmacy being an 
additional burden in this population.  
To further inform the debate with regard to screening, monitoring and treatment it is 
therefore necessary to establish the pathophysiological consequences of subclinical 
thyroid dysfunction in individuals‟ age 65 years or more. Furthermore it is necessary 
to confirm whether symptoms in this population are pathophysiological or 
physiological in origin. Clarification of the pathophysiological consequences and 
characterisation of symptoms associated with subclinical thyroid dysfunction in this 
population will further support GP decision making when ordering TFTs and 
commencing treatment. Furthermore these data will enable development of 
recommendations for GP management of subclinical thyroid dysfunction in older 
individuals and thereby reduce unnecessary investigation and treatment in this 
population based upon presentation of symptoms.  
The questions which remain unanswered are;  
i) Are symptoms usually associated with overt thyroid dysfunction prevalent 
in elderly individuals with subclinical thyroid dysfunction? 
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ii) Is subclinical thyroid dysfunction in elderly individuals associated with 
similar adverse pathophysiological consequences as overt thyroid 
dysfunction?  
 
This thesis therefore explores the pathophysiological manifestations of subclinical 
thyroid dysfunction in the elderly with reference to i) the large body of existing 
evidence pertaining to the clinical expression and pathophysiological consequences 
of subclinical thyroid dysfunction and ii) the results of a cross-sectional study 
evaluating thyroid function and the presence, severity and change in expression of 
symptoms suggestive of overt thyroid dysfunction and perceived health status in a 
large UK based community dwelling population aged 65 years and above.  
Following the introduction and presentation of the aims and objectives of this thesis, 
chapter 1 provides a broad overview of the function of the thyroid gland and 
describes the relationships between biochemical parameters of thyroid function. 
Subsequently the clinical presentation and pathophysiological consequences of overt 
thyroid dysfunction are described before subclinical thyroid dysfunction is introduced 
and defined in chapter 2. Chapter 2 further describes the prevalence and aetiology of 
subclinical thyroid dysfunction and reports current expert opinion and 
recommendations for management of subclinical thyroid dysfunction. Chapters 3-6 
summarise the large body of literature surrounding the clinical presentation and 
pathophysiological consequences of subclinical thyroid dysfunction. The 
pathophysiological consequences and physical signs of subclinical hypothyroidism 
and subclinical hyperthyroidism are described respectively in chapters 3 and 4. In 
chapters 5 and 6 the evidence related to expression of symptoms in individuals with 
and with out subclinical hypothyroidism and subclinical hyperthyroidism is presented 
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and examined. Evidence reported in these four chapters is then summarised before 
the rationale for the cross sectional study exploring symptoms and perceived health 
status in elderly individuals with and without subclinical thyroid dysfunction is further 
clarified. The methodology and results of a cross sectional study are then reported in 
Chapters 8-15. The findings of the literature review and cross sectional study are 
further examined with reference to existing literature and strengths and limitations of 
the thesis are discussed. Chapter 17 concludes that the evidence demonstrating 
pathophysiological consequences of subclinical thyroid dysfunction in the over 65s is 
insufficient to justify treatment and recommends a degree of caution with respect to 
repeat testing and initiation of treatment based upon impaired health status and 
presentation of symptoms in this population.  
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AIM 
The aim of this thesis is to determine the association between symptoms suggestive 
of overt thyroid dysfunction and subclinical thyroid dysfunction and further clarify the 
pathophysiological consequences of subclinical hypothyroidism and subclinical 
hyperthyroidism in the elderly community dwelling population.  
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OBJECTIVES 
To fulfil the aim of this thesis, there were four objectives; 
 
1. To clarify the importance of subclinical hypothyroidism and subclinical 
hyperthyroidism with reference to existing evidence pertaining to the 
clinical presentation and pathophysiological consequences of 
subclinical thyroid dysfunction. 
 
This objective was addressed by means of a systematic literature review which 
collates, interprets and summarises current evidence related to the 
pathophysiological consequences of subclinical thyroid dysfunction. 
 
2. To characterise individual symptoms and combinations of symptoms 
associated with subclinical hypothyroidism and subclinical 
hyperthyroidism in an elderly UK based community dwelling population. 
 
This objective was addressed using a cross-sectional study design to evaluate 
thyroid function and self-reported symptoms suggestive of overt thyroid dysfunction 
in a large cohort (n= 5881) of community dwelling elderly individuals. Concurrent 
thyroid function testing enabled biochemical classification of thyroid function as 
euthyroid, subclinical hypothyroidism or subclinical hyperthyroidism. The prevalence 
of individual symptoms, combinations of symptoms and total number of symptoms 
reported were compared between the euthyroidism group and the groups with 
subclinical hypothyroidism and subclinical hyperthyroidism.   
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3. To evaluate the relationship between health status and subclinical 
thyroid dysfunction and explore the impact of individual symptoms on 
perceived health status in an elderly community dwelling cohort.  
 
To fulfil this objective data related to perceived health status was collected alongside 
data relating to symptoms. Exploratory analysis is undertaken to investigate the 
impact of both subclinical thyroid dysfunction and the presence of individual 
symptoms on health status and the impact of individual and total number of 
symptoms on health status. Findings provide an improved understanding of the 
relationship between subclinical thyroid dysfunction and health status and enable 
determination of whether health status is independently associated with symptoms or 
with subclinical thyroid dysfunction.  
 
4. To establish the relationship between serum concentrations of the 
thyroid parameters thyrotrophin and free thyroxine and expression of 
individual symptoms and combinations of symptoms in an elderly 
community dwelling cohort.  
 
In fulfilment of this aim, the distribution of serum concentrations of thyrotrophin and 
free thyroxine are compared between groups reporting presence and absence of 
individual symptoms and combinations of symptoms.  
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CHAPTER 1 THYROID FUNCTION 
Overview of chapter 1 
This chapter sets the background for this body of work by presenting a brief overview 
of the anatomy and normal function of the thyroid gland. In addition, the relationship 
between the hormone that regulates thyroid function and the hormones synthesised 
and secreted by the thyroid gland will be presented. Knowledge of normal thyroid 
function and the relationship between these thyroid parameters is essential for 
understanding of the physiological effects and clinical manifestations of thyroid 
dysfunction. This is followed by a description of the abnormal biochemical profile 
observed in overt hypothyroidism and overt hypothyroidism and the adverse clinical 
consequences associated with overt thyroid dysfunction. 
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1.1 Thyroid anatomy and location  
The thyroid is a bi-lobed gland situated at the upper end of the trachea. The lateral 
lobes are approximately 4 cm in length and 2 cm in thickness, and are connected by 
a thin band of tissue called the isthmus. Each lobe receives a rich and rapid (4-
6ml/min/g of tissue) supply of blood from two sources; the superior thyroid artery (a 
branch of the external carotid artery) and the interior thyroid artery (a branch of the 
subclavian artery). Thyroid tissue comprises numerous follicles, each of which has a 
central colloid filled cavity lined with follicular cells.  
 
1.2 Function of the thyroid gland  
The function of the thyroid gland is the synthesis, storage and secretion of the 
thyroid hormones, tertraiodothyronine, (otherwise known as thyroxine [T4]) and 
triiodothyronine (T3). These thyroid hormones are responsible for control and 
regulation of basal metabolic rate (BMR, the minimum amount of energy expended 
to maintain vital processes) and have an essential role in the metabolism of 
carbohydrates, fats and proteins and in the development and maintenance of both 
mental and physical function. These hormones are involved in almost every organ 
system of the body, therefore dysfunctions of the thyroid gland exhibit a broad 
spectrum of clinical effects.   
 
1.3 Regulation of thyroid hormones 
Since the hypothalamus and anterior pituitary gland coordinate the endocrine 
system, synthesis and secretion of the thyroid hormones is ultimately under their 
control. With the anterior pituitary gland acting as a sensor of circulating thyroid 
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hormone concentration, this coordination is directed through the hormone 
thyrotrophin (otherwise known as thyroid stimulating hormone [TSH]) via a negative 
feed-back regulatory mechanism. Thyrotrophin is synthesised and secreted by the 
anterior pituitary gland in response to a decline in circulating thyroid hormone 
concentration, accompanied by secretion of thyrotrophin releasing hormone by the 
hypothalamus. Thyrotrophin continues to stimulate thyroid gland activity until 
sufficient concentrations of circulating thyroid hormone are detected by the anterior 
pituitary gland. Restoration of normal concentrations of thyroid hormones leads to 
down regulation of thyrotrophin production and subsequent reduction in thyroid gland 
activity. The inverse log-linear relationship between serum thyrotrophin and free 
thyroxine means that a small decrease in free thyroxine concentration is associated 
with exponential increases in serum thyrotrophin concentration. 
 
Thyrotrophin acts upon the thyroid gland to encourage an increased uptake of iodide 
ions thereby intensifying protein synthesis and cellular metabolism. 1 These activities 
are accompanied by an increase in the overall size, vasculature, intracellular volume 
and colloid storage capacity of the gland, allowing additional synthesis and storage 
of thyroid hormones. Meanwhile, thyroid hormones are secreted into the general 
circulation. In the blood, thyroid hormones are transported almost entirely bound to 
the plasma proteins; thyroxine binding globulin (TBG), pre-albumin and albumin. 
Howver, a small proportion remains unbound and it is this free fraction of thyroid 
hormone (free thyroxine [FT4] and free triiodothyronine [FT3]) that is biologically 
active and available to act on the tissues to promote energy production, growth and 
development. Since FT4 is converted to the more active FT3 in the tissues, both of 
the thyroid hormones have the same metabolic and physiological effects. 2  
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1.4 Nomenclature  
Thyroid gland dysfunction is commonly described as under- or over-active based 
upon the concentrations of thyroid hormone being produced. The term overt thyroid 
dysfunction is the generic term used to describe conditions that arise as a result of 
consistently altered thyroid function with excess or insufficient concentrations of 
thyroid hormone. More specifically, the condition resulting from thyroid hormone 
excess accompanied by suppressed serum thyrotrophin concentration is known as 
overt hyperthyroidism and insufficient thyroid hormone in combination with surplus 
serum thyrotrophin concentration is described as overt hypothyroidism.  
 
1.5 Physiological effects of overt hyperthyroidism  
Excessive concentrations of the thyroid hormones lead to an increase in basal 
metabolic rate with an associated increase in oxygen consumption and heat 
production (thermogenesis). 3  This general increase in cellular metabolic activity also 
results in an increased rate of carbohydrate metabolism, leading to greater 
absorption of glucose and enhanced glycolysis (conversion of glucose to lactic acid), 
glycogenolysis (catabolism of glycogen stores to produce glucose) and 
gluconeogeneisis (catabolism of non–carbohydrate sources) if carbohydrate is in 
short supply. Metabolism of fat is similarly stimulated by increased concentrations of 
thyroid hormones resulting in an increase in synthesis, mobilisation and degradation 
of lipids. When the gland is functioning normally, these effects are necessary to 
maintain basal metabolic rate and as such are relatively short lived. In altered thyroid 
function, however, these effects persist and can lead to significant morbidity and 
mortality. 1  
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1.6 Morbidity associated with overt hyperthyroidism 
A persistent excess of thyroid hormone confers high basal metabolic rate and 
increased metabolism leading to heat intolerance and weight loss. With respect to 
enhancement of the protein metabolism, protein degradation dominates which, if 
persistent, leads to a decrease in muscle mass and muscle weakness. Other 
common musculoskeletal complaints are muscle cramping, stiffness, paraesthesia 
(sensation of pins and needles), joint swelling, and carpal tunnel syndrome. 
Likewise, excess thyroid hormones enhance bone metabolism with bone resorption 
being affected to a greater extent than synthesis. This results in net loss of bone and 
reduced bone mineral density, accompanied by increased urinary excretion of 
calcium and phosphate. These effects can lead to hypercalcaemia and an increased 
risk of osteoporosis and fracture. 4-6 The cardiovascular system is also a major target 
of thyroid hormone action. 7 The indirect effects of raised metabolic rate due to 
increased demand for oxygen and heat dissipation to peripheral vessels are 
increased cardiac output and blood flow. Thyroid hormones also directly act on the 
heart to increase cardiac contractility and heart rate. Sinus tachycardia is the most 
common cardiac disturbance of overt hyperthyroidism. Atrial fibrillation (AF), a risk 
factor for embolism, is however a more clinically significant cardiac condition 
associated with overt hyperthyroidism. 8,9 AF occurs in up to 15% of patients with 
overt hyperthyroidism compared with just 4% of the general population and 
incidence increases with age. 10 Thyroid hormones also influence vascular smooth 
muscle cells to promote relaxation and reduce systemic vascular resistance. This in 
turn improves diastolic relaxation leading to more efficient use of energy and 
nutrients by the cardiomyocytes. 7,11 The increase in peripheral metabolism leads to 
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an increased demand on cardiac output. The mechanism by which increased cardiac 
output is achieved is thought to be activated by a decrease in vascular resistance 
and an increase in blood volume. Cardiac preload augments stroke volume in 
response to increased venous return and overall cardiac output is amplified in 
response to a raised stroke volume and increased heart rate. 12  
An association between overt hyperthyroidism and anxiety, depression and changes 
in mood and cognitive functions has been widely reported, however, the exact 
mechanisms for these relationships remain largely unknown. Additionally, perceived 
quality of life and health status has been shown to be significantly impaired in 
individuals with overt hyperthyroidism. 13,14,15  
The symptoms of excess thyroid hormone reflect hypersensitivity and include 
intolerance to heat, breathlessness, palpitation, diarrhoea due to intestinal 
hypermotility, excessive perspiration, tremor, weak muscles, weight loss, irritability, 
short attention span and fatigue. 16,17 Physical signs include rapid pulse, fine tremor 
and atrial fibrillation. 3 In the longer term, thyroid hormone excess is associated with 
significant morbidity in the form of osteoporosis, heart failure and AF. 18 Overt 
hyperthyroidism is also associated with an increased mortality risk particularly from 
cardiovascular and cerebrovascular causes. 19  
 
1.7 Thyroid hormone deficiency: overt hypothyroidism  
The pathophysiological effects of thyroid hormone deficiency are diametrically 
opposed to those described for overt hyperthyroidism. Diminished metabolic rate and 
thermogenesis are associated with reduced heat production, decreased oxygen 
demand and blood flow to the tissues. Since overall energy production and 
expenditure is reduced, degradation of carbohydrate and fat is diminished, leading to 
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storage of glycogen with weight gain and a rise in the concentration of plasma lipids 
which confer an increased risk for atherosclerosis. Cholesterol levels are further 
affected due to a reduction in action of thyroid hormones on production of low 
density lipoprotein cholesterol receptors by the liver and a reduction in the removal of 
low density lipoprotein cholesterol from the circulation.  
 
The accompanying effects of overt hypothyroidism manifest as intolerance to cold, 
constipation, weight gain, hoarse voice, puffy eyes, dry skin, muscle cramps, poor 
memory and delayed reflex relaxation time. Hypertension may manifest due to the 
direct effect of thyroid hormone increasing vascular resistance to prevent heat loss, 
increased arterial stiffness and/or alterations to endothelial function. 20,21,22 
Furthermore, atherosclerotic narrowing of the arteries potentiated by serum lipid 
anomalies may contribute to hypertension associated with overt hypothyroidism.  
Skeletal muscle is also a known target organ for thyroid hormones with a wide range 
of alterations in neuromuscular and neuropsychiatry function being well established 
in overt hypothyroidism. 21 Alterations in muscle structure and function can manifest 
as painful paraesthesia (partial numbness, tingling, buzzing and vibration, pins and 
needles sensations) and cramping of the hands and feet. The deficiency in thyroid 
hormones affects metabolism of the myocytes, causing a reduction in speed of 
muscle contraction and relaxation. Cell wall integrity is also adversely affected 
leading to muscle necrosis. Proximal weakness and slow reflexes are therefore well 
established findings in individuals with overt hypothyroidism. 23 Like overt 
hyperthyroidism, hypothyroidism has also been shown to impact on aspects of 
cognitive function and mood, and patients frequently have neuropsychiatric 
complaints. Most studies suggest an association between hypothyroidism and 
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depression. Overt hypothyroidism has also been associated with impaired quality of 
life. 24 However this relationship is complicated, and it is unclear whether reduced 
quality of life associated with overt hypothyroidism is a cause or a consequence of 
depression. Additionally, dementia has been widely linked to overt hypothyroidism. 25 
Despite increased bone quantity, overt hypothyroidism has also been associated 
with increased fracture risk, both before and after diagnosis. 26 In the longer term, 
overt hypothyroidism is associated with adverse cardiac consequences and events 
such as atherosclerosis, coronary heart disease, myocardial infarction; angina and 
increased cardiovascular mortality risk. 27  
 
1.8 Prevalence  
Overt thyroid dysfunction is one of the most common chronic endocrine disorders in 
the general population. In 2006, 3% of the UK population were prescribed thyroxine 
replacement therapy for treatment of overt hypothyroidism. 28 Data derived from a 
cross-sectional study of a representative sample of the UK population suggested a 
higher prevalence of overt hypothyroidism in women than in men (1.4% versus 0.1%, 
respectively) and with advancing age. 29 This study reported an overall prevalence of 
overt hyperthyroidism of 2.0% in women and around 0.2% in men. Outside of the 
UK, prevalence rates have been shown to vary considerably in accordance with 
ethnicity, age and frequency of anti-thyroid antibody status of the population studied. 
30,31,32,33 An additional explanation for the discrepancies in prevalence data from 
around the world is the difference in iodine sufficiency between geographical 
locations. However prevalence data derived in areas of iodine deficiency and 
sufficiency consistently demonstrate a higher prevalence of both hyper- and 
hypothyroidism in older age groups compared with those younger than 60 years of 
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age. Less generalisable and rigorous estimates of prevalence have been reported 
due to research methods being highly selective with respect to the populations being 
studied. Additionally, in some studies prevalence may be overestimated due to 
misclassification of thyroid function in individuals receiving drugs that interfere with 
thyroid function tests or with concomitant or acute illnesses that impact upon serum 
thyrotrophin independently of thyroid disease. Despite the discrepancies between 
smaller studies, epidemiological data from large cross-sectional and longitudinal 
screening studies demonstrates that overt thyroid dysfunction is a common and 
clinically significant disorder. 
 
1.9 Aetiology  
The predominant cause of spontaneous overt hypothyroidism is autoimmune 
infiltration and destruction of the thyroid gland due to Hashimotos thyroiditis or 
primary atrophic hypothyroidism. Alternatively, destructive treatment for overt 
hyperthyroidism in the form of total or partial thyroidectomy and/or radioiodine 
therapy can often prompt under activity of the thyroid gland and lead to reduced 
thyroid hormone synthesis. 
 
Similarly, overt hyperthyroidism can be of autoimmune or iatrogenic origin. Graves‟ 
disease is an autoimmune disease of unknown cause. In Graves‟ disease, auto 
antibodies of the immunoglobulin G subclass mimic thyrotrophin by binding to 
thyrotrophin receptors on the thyroid cell membranes and stimulate thyroid function. 
Development of autonomously functioning follicular adenomas within the gland also 
leads to overt hyperthyroidism. These benign thyroid nodules known as “hot 
nodules” cause the thyroid gland to become unresponsive to the normal secretary 
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control mechanisms and continually secrete thyroid hormone into the circulation. 
This condition is known as either solitary toxic nodule or toxic multinodular goitre 
depending upon the number of nodules. Intentional or unintentional excessive 
thyroid hormone replacement therapy can also be responsible for overt 
hyperthyroidism. 
 
Since iodine is essential for thyroid hormone production, another major cause of 
overt hypothyroidism worldwide is iodine deficiency. Insufficient dietary intake is the 
main cause of iodine deficiency with dietary sources containing varying degrees 
dependant upon the amount available in the soil and/or in animal feed. The 
recommended daily intake of iodine is 150μg with population based iodine intake 
programmes achieving adequate intake through iodisation of salt. 
Excess dietary iodine intake or iodine-containing medication or drugs that mimic 
iodine action can be responsible for overt hypothyroidism (via iodine induced 
inhibition of thyroid hormone production) or overt hyperthyroidism (through surplus 
production of thyroid hormone). The drug amiodarone, which is frequently prescribed 
for cardiac arrhythmias, is iodine rich and may be responsible for either 
hyperthyroidism or hypothyroidism in up to 18% of patients with apparently normal 
thyroid function or pre-existing disease. 34 Likewise, lithium therapy for psychotic 
disorders has been shown to induce hypothyroidism or hyperthyroidism in 10% of 
patients, particularly in the presence of thyroid auto antibodies.  
 
Altered concentrations of serum thyrotrophin and thyroid hormones are not exclusive 
to overt thyroid dysfunction, however, and may also be identified in hospitalised 
individuals, patients with transient thyroid dysfunction due to viral infection, or during 
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recovery from other non thyroidal illnesses. Transient increases in serum 
thyrotrophin concentration due to non thyroidal illnesses continue for approximately 
seven-ten days. In contrast, persistent alterations in serum thyrotrophin 
concentration will stabilise to a new baseline in six to eight weeks and are indicative 
of more permanent alterations in thyroid function.  
 
1.10 Clinical expression of overt thyroid dysfunction  
Almost all cases of overt thyroid dysfunction encountered in general practice are 
caused by primary disease of the thyroid. Biochemical measurement of thyroid 
function is required to exclude or confirm diagnosis of overt thyroid dysfunction. The 
majority of studies suggest that consideration of physical symptoms in isolation is 
associated with very poor diagnostic accuracy for overt thyroid dysfunction. 35,36 
Whilst endocrinology text books describe classical signs and symptoms of overt 
hypothyroidism and hyperthyroidism, in routine primary care practice many of these 
manifestations are rarely apparent. The clinical presentation of individuals with overt 
hypothyroidism and overt hyperthyroidism varies widely. 35,36 Additionally, many of 
the classical signs and symptoms are non-specific and as such frequently present in 
euthyroid individuals. 37,38 A number of validated instruments are available for 
evaluation of the signs and symptoms of overt hypothyroidism and overt 
hyperthyroidism. 39,40,41,42 Some of these tools are intended to aid diagnosis and 
assessment of severity of thyroid dysfunction, whereas others are designed for 
monitoring the response to treatment. In terms of diagnosis, arguably the availability 
of relatively low cost assays leads to thyroid function testing without the use of such 
instruments in the majority of cases. 43 
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Nevertheless, several investigators support the use of multiple symptoms as a 
diagnostic tool for identification of individuals in whom subsequent testing would be 
appropriate. 38,44,45 Simple scoring systems have been shown to increase the pre-
test probability of overt thyroid dysfunction by 15-19%. 38 In general, however, high 
frequencies of false positive results have been associated with these clinical scoring 
systems. A recent study to assess the significance of the clinical versus biochemical 
diagnosis of overt hypothyroidism reported correct classification of only 21% 
according to the Billewicz score. 39 Almost half of the 388 individuals with primary 
hypothyroidism were classified as euthyroid and the remaining 29% fell into the 
inconclusive category. In another recent study in which the Billewicz questionnaire 
was administered to individuals with overt hypothyroidism and age matched controls, 
the classical symptoms were described much less frequently than in the earlier 
literature. 37 There is, however, evidence to suggest that the clinical picture of overt 
thyroid dysfunction has changed over time. Classical signs and symptoms of thyroid 
dysfunction are now observed much less frequently than in earlier studies. 37 The 
most plausible explanation for this is earlier diagnosis of overt thyroid dysfunction 
due to the wide availability of more sensitive and cost-effective assays for 
measurement of serum thyrotrophin and FT4 concentrations. 46,47 Previously, the 
diagnosis may have been made based upon the clinical manifestations of more 
severe or longstanding thyroid dysfunction. Older scoring systems developed before 
the 1970s when assays for measurement of serum thyrotrophin and FT4 were not 
available may now be less sensitive and of limited use for identification of signs and 
symptoms of relatively early thyroid dysfunction. 39,40,41 The diagnosis of overt thyroid 
dysfunction can be particularly challenging in older individuals, not least because the 
signs and symptoms of this dysfunction also accompany normal healthy ageing. 
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Signs and symptoms in older people may also be masked by coexisting disease and 
concomitant medication. Several authors have documented a decrease in the 
number and severity of symptoms of overt thyroid dysfunction with increasing age. 
11,49 There are also data supporting age related alterations in the clinical 
manifestation of overt thyroid dysfunction with a different constellation of signs and 
symptoms being expressed in older individuals compared with younger people. One 
study evaluating 24 clinical signs reported a significantly lower mean number of 
signs in 67 individuals aged 70 years or more with overt hypothyroidism (mean age 
79.3 years, range 70-98 years) compared with 54 younger individuals (mean age 
40.8 years, range 23-55 years) with overt hypothyroidism (6.6 ± 4 versus 9.3 ±4.7 
respectively, p <0.01). 50 Furthermore, four signs were observed significantly less 
frequently in elderly individuals compared with younger subjects; sensitivity to cold 
temperatures (34.9% versus 64.8 %, p<0.002), paraesthesia (17.9% versus 61.1%, 
p<0.001), weight gain (23.7% versus 58.5%, p<0.001) and muscle cramps (20.3% 
versus 54.7%, p<0.001). Similarly, in a study comparing presence of 19 classic signs 
of hyperthyroidism in older (≥70 years, mean age 80.2 years) and younger (≤50 
years; mean age 37.4 years) patients with overt hyperthyroidism, the mean number 
of signs observed was significantly lower in older than younger individuals (6.0 ± 3.5 
versus 10.8 ± 3.1 respectively, p<0.001). 51 Seven of the 19 signs (hyperactive 
reflexes, excessive sweating, heat intolerance, tremor, nervousness, polydipsia, and 
increased appetite) were observed significantly less frequently in older subjects than 
in younger individuals. However anorexia was significantly more prevalent in older 
individuals than in younger individuals with overt hyperthyroidism (32% versus 4%, p 
<0.001). This study also recruited a third group which comprised 68 older (≥70 years, 
men age 81.3 years) euthyroid controls matched to older individuals with overt 
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hyperthyroidism by gender, age and co-morbidity. Comparison between the older 
groups with and without overt hyperthyroidism identified three signs, namely apathy 
(Odds Ratio, OR 14.8, 95% CI 3.8-57.5, p<0.001), weight loss (OR 8.7, 95% CI 3.1-
24.4, p<0.001) and tachycardia (OR 11.2, 95% CI 4.3-29.4, p<0.001) significantly 
associated with overt hyperthyroidism. 51 Another study described a gradual 
decrease in the total number and frequency of signs and symptoms beyond the age 
of 50 years, 49 with little change in clinical presentation observed, until the age of 50 
years. It seems therefore, that diagnosis becomes more difficult as age progresses. 
More recently, a cross-sectional study of 3049 patients with overt hyperthyroidism 
demonstrated that the majority of individuals aged 61 years or older reported a 
maximum of two symptoms (54%) compared with 36% in those aged 16-32 years, 
32% in those aged 33-44 years and 30% in 45-60 year groups. 52 Equally, the group 
aged 61 years or more was less likely to report five or more symptoms than the 
younger age groups. These results support and further extend the findings of earlier 
smaller studies by demonstrating an association between advancing age and 
number of symptoms that is independent of severity and aetiology of overt 
hyperthyroidism.  
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Summary of chapter 1 
This chapter described the clinical manifestations and pathophysiological 
consequences of overt hypothyroidism and overt hyperthyroidism. Overt thyroid 
dysfunction in the form of overt hyperthyroidism and overt hypothyroidism are 
common endocrine disorders resulting from an insufficient or excess amount of 
circulating thyroid hormones accompanied by altered serum thyrotrophin 
concentrations. Overt hyperthyroidism is associated with significant short term 
morbidity and longer term morbidity and mortality. Similarly, overt hypothyroidism is 
associated with considerable morbidity. Diagnosis of overt thyroid dysfunction 
depends first on adequate suspicion supported by clinical features, then upon 
demonstration of abnormal serum concentrations of thyrotrophin and free thyroxine. 
Clinical parameters alone fare poorly in establishing an unequivocal diagnosis of 
overt thyroid dysfunction. Age modifies the prevalence of overt thyroid dysfunction as 
well as the classic profile of signs and symptoms meaning that this disorder is more 
prevalent in older individuals but also more difficult to identify based upon clinical 
presentation.  
 
In the next chapter, subclinical hypothyroidism and subclinical hyperthyroidism are 
introduced and the distinction between subclinical and overt thyroid dysfunction is 
defined.  
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CHAPTER 2 BIOCHEMICAL DIAGNOSIS OF THYROID DYSFUNCTION 
 
Overview of chapter 2  
In this chapter the biochemical tests routinely used to confirm or refute thyroid 
dysfunction and the reference criteria upon which the diagnosis of subclinical and 
overt hyper and hypothyroidism is based are described. Subsequently, an overview 
of the aetiology and prevalence of subclinical hyperthyroidism and subclinical 
hypothyroidism is presented. Finally, statements of expert opinion and 
recommendations with regard to testing, management and treatment of subclinical 
thyroid dysfunction are presented.  
 
2.1 Definition of subclinical thyroid dysfunction 
Subclinical hypothyroidism and subclinical hyperthyroidism were identified as clinical 
entities during development of the 2nd and 3rd generation serum thyrotrophin assays, 
and as such, the diagnoses are essentially biochemical. The term „subclinical thyroid 
dysfunction‟ is used when abnormal concentrations of serum thyrotrophin and 
normal concentrations of circulating thyroxine (FT4) are observed. 53 The distinction 
between overt and subclinical thyroid dysfunction disease therefore is based purely 
upon biochemical criteria with subclinical hyperthyroidism being defined by a 
reduction in concentration of serum thyrotrophin accompanied by concentrations of 
the thyroid hormone FT4 within the standard reference range. 54 In contrast, 
subclinical hypothyroidism is characterised by a raised serum thyrotrophin 
concentration in conjunction with a serum FT4 concentration which is within the 
standard reference range. 54 Subclinical hypothyroidism is often subdivided 
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according to the degree of elevation in serum thyrotrophin concentration. A 
thyrotrophin concentration of between 4.5-10mIU/L (detected in around 75% of 
cases) is generally regarded as being indicative of less severe thyroid failure than a 
thyrotrophin concentration greater than 10mIU/L. 55,56,57  Similarly, subclinical 
hyperthyroidism is often subdivided based the upon degree of thyrotrophin 
suppression, with concentrations of less than 0.01mIU/L representative of more 
severe thyroid dysfunction than concentrations of between 0.1-0.4mIU/L. 58 This 
stratification of serum thyrotrophin concentration is frequently used to define 
subgroups for analysis in research and is utilised in guideline documents of expert 
opinion in relation to testing, management and treatment of subclinical thyroid 
dysfunction. Subclinical thyroid dysfunction is considered by some to be essentially a 
biomedical diagnosis characterised by abnormal serum thyrotrophin (TSH) in 
association with normal serum thyroid hormone. 54 Others, however, have 
designated subclinical thyroid dysfunction, a mild form of overt thyroid dysfunction 
and have demonstrated presence of symptoms suggestive of overt thyroid 
dysfunction. 59 
25 
 
2.2 Prevalence of subclinical thyroid dysfunction  
Worldwide prevalence figures for subclinical hypothyroidism and subclinical 
hyperthyroidism are variable. The use of different assays for measurement of serum 
thyrotrophin concentration, differing reference criteria for definition of subclinical 
thyroid dysfunction and inclusion of some individuals receiving treatment for thyroid 
dysfunction are the most likely reasons for the diverse prevalence estimates 
reported. Older studies of UK-based populations report a prevalence of subclinical 
hypothyroidism of around 5-6% 60,61 and subclinical hyperthyroidism of approximately 
1-2%. 62 These studies also suggest that the prevalence of subclinical 
hypothyroidism and subclinical hyperthyroidism is higher in older individuals and in 
women. Our own recent local study in which approximately 5800 community dwelling 
individuals aged 65 years or more were screened reported an overall prevalence of 
subclinical hypothyroidism of 2.9% and subclinical hyperthyroidism of 2.1%. 63 Like 
the overt forms of this dysfunction, prevalence figures vary considerably with 
ethnicity, dietary iodine intake and frequency of anti-thyroid antibodies of the 
populations studied. 64 As is the case with overt thyroid dysfunction, the prevalence 
of subclinical hypothyroidism is greater in areas of iodine sufficiency and subclinical 
hyperthyroidism is more common in areas that are iodine deficient. 65 Data derived 
from populations located in iodine sufficient and iodine deficient areas consistently 
demonstrate an increased prevalence of subclinical thyroid dysfunction in females 
and older individuals.  
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2.3 Aetiology of subclinical thyroid dysfunction  
Subclinical hyperthyroidism and subclinical hypothyroidism have similar causes to 
the overt forms of these disorders. Subclinical hypothyroidism has two main causes 
in the UK, namely autoimmunity and overzealous treatment for overt 
hyperthyroidism. The aetiology of subclinical hyperthyroidism can be divided into two 
categories: exogenous and endogenous. These terms are used to define the origins 
of the disease with endogenous being indicative of spontaneous disease (endo 
denotes from within) and exogenous disease defining disease of external origin (exo 
denoting external). Exogenous subclinical hyperthyroidism can be intentionally 
induced, for example as in patients with differentiated thyroid carcinoma (DTC) 
receiving thyrotrophin-suppressive thyroxine therapy, or unintentionally due to over 
aggressive anti thyroid therapy. The most common cause of exogenous subclinical 
hyperthyroidism is therefore the use of unintentional or intentional excessive 
suppressive doses of thyroid hormone. The endogenous form is usually related to 
autonomous thyroid dysfunction. It remains to be seen whether endogenous and 
exogenous subclinical hyperthyroidism are comparable conditions that exert 
equivalent effects.  
 
2.4 Statistical nature of defining a reference range  
Reference intervals are widely used medical decision making tools and aid the 
clinician in differentiating between healthy and „unhealthy‟ patients. In general, these 
are population, assay and statistical methodology dependent. The National 
Committee for Clinical Laboratory Standards (NCCLS) suggest that calculation of 
reference criteria is based upon measurement of at least 120 „normal‟ healthy 
27 
 
samples. The reference range is calculated from the sample mean and two standard 
deviations of the data set. The value corresponding to the 2.5th percentile defines 
the lower limit of the reference range and the value corresponding with the 97.5th 
percentile indicates the upper limit of the reference range. The most sensitive 
indicator of thyroid dysfunction is serum thyrotrophin concentration, however there 
are no universal reference criteria or reference material for definition of normal 
serum thyrotrophin concentration, therefore reference ranges vary from one 
endocrine laboratory to the next. Reference criteria for serum thyrotrophin 
concentration are derived from screened samples of healthy volunteers with no 
known or apparent thyroid dysfunction or medication known to affect thyroid function. 
However there has been much debate about this derivation method particularly in 
relation to defining the upper limit of normal. 66,67,68 Over the last 20 years the upper 
limit has been reduced from 10mIU/L to around 4mIU/L and some authors suggest 
further reductions are necessary. 69 These suggestions are based upon data derived 
from exclusion of individuals with thyroid auto antibodies, goitre or a strong family 
history of thyroid disease from the reference population. In such thyroid disease and 
risk factor free populations the upper limit decreases to between 2.5mIU/L to 3.0 
mIU/L. 66 Some argue that the refined reference range is better than the 
standardised population–based reference range particularly because elevated 
thyrotrophin values may predict future hypothyroidism. 66, 70  Additionally, current 
assays for detection of anti thyroid antibody are not sufficiently sensitive to identify all 
individuals with low grade thyroid autoimmunity. 71 Furthermore, an increased risk of 
overt hypothyroidism has been demonstrated in antibody negative individuals. This 
decreased upper limit of normal would however increase the sensitivity of the 
diagnosis and decrease specificity resulting in a greater number of individuals being 
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given a false positive diagnosis. Furthermore, lowering the upper limit of the 
reference range would have a large impact upon the prevalence figures for the older 
age groups and would lead to reclassification of one in five euthyroid individuals to 
subclinically hypothyroid. One recent study demonstrated a modified serum 
thyrotrophin distribution in older individuals and suggested that serum thyrotrophin 
progressively moves towards higher concentrations with advancing age. 72 Re-
analysis of data from the NHANES study demonstrated that the upper limit of normal 
at the 97.5th percentile was 3.56mIU/L for the 20-29 age group, 4.5mIU/L in 
individuals aged 50-59 years and 7.5mIU/L in individuals older than 80 years. 
Seventy percent of older patients with a serum thyrotrophin concentration greater 
than 4.5mI/L were therefore within their age-specific reference range. It is possible 
that current statistically defined laboratory reference criteria for serum thyrotrophin 
concentration are neither adequately sensitive nor specific for identification of 
abnormal concentrations of serum thyrotrophin in older age groups and as such 
current prevalence rates for subclinical hypothyroidism in the older individuals may 
be substantially over estimated. However, in a further study, the geometric mean 
serum thyrotrophin concentration and the 95% confidence intervals for older 
individuals (1.45mIU/L; 95% CI 0.54-3.9) did not differ significantly from that in 
middle aged individuals (1.24mIU/L; 95% CI 0.29-5.4). The investigators therefore 
concluded that one reference range is appropriate for all age groups. 73 The 
development of age-specific reference ranges would cause additional problems, with 
screening of more individuals being required in order to obtain a suitable reference 
sample. Equally, extrapolation of data from such a selected population may also be 
inappropriate. 74,75  
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2.5 Diagnosis of subclinical thyroid dysfunction in primary care 
The definitive diagnosis of subclinical thyroid dysfunction is based upon the 
relationship between serum thyrotrophin and serum free thyroxine. Expert opinion 
and guidance recommends routine front line measurement of both serum 
thyrotrophin and free thyroxine concentration for patients without a previous thyroid 
function test on record and on all specimens where the request for thyroid function 
testing is not accompanied by any additional clinical details. 43 Estimation of FT3 is 
generally recommended when serum thyrotrophin concentration is below the lower 
threshold of the laboratory reference criteria and FT4 is greater than the higher 
threshold; however protocols for measurement of FT3 are laboratory specific and 
vary accordingly.  
The annual cost of thyroid function testing in the UK is approximately £30 million. 76 
Estimates suggest that one in four people in the UK have a thyroid function test 
annually with the majority of requests for thyroid function testing coming from primary 
care. Measurement of serum thyrotrophin concentration is reported to be one of the 
most frequently requested test by primary care physicians and repeat tests are 
frequent despite normal initial findings. 77,78 In view of the high prevalence of thyroid 
dysfunction in the general population and the wide availability of cost-effective and 
sensitive assays for measurement of thyroid dysfunction this level of testing may 
seem justified. There have however been suggestions that the associated diagnostic 
yield is low. Meyerovitch et al examined data from a large health care database in 
order to determine the use of routine tests of serum thyrotrophin concentration by 
primary care physicians over a period of five years. Findings demonstrated an 
increased rate of testing with advancing age and an average frequency of three 
repeat requests for measurement of serum thyrotrophin per person during the five 
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year period. 79 Furthermore, 95% of the initial tests were within the reference range 
and remained so throughout the five year study period. More recently, a small 
retrospective observational study and survey of general practitioners in the UK 
reported variability across 19 primary care practices with respect to testing and 
treatment of subclinical thyroid dysfunction. This study suggested that thyroid 
function testing is being requested frequently and repeatedly for elderly individuals 
based upon presentation with a variety of non specific symptoms. 80 Equally, 
administration of thyroxine therapy was described in elderly individuals presenting 
with and without symptoms after one thyroid function test result. 80 Similarly, a survey 
assessing the procedural options most frequently followed and the difficulties 
encountered by GPs suggested that development of standardised protocols is 
necessary to aid GP testing and management of subclinical thyroid dysfunction. 81 
 
2.6 Current management strategies 
In terms of frequency of thyroid function testing, expert opinion from the UK 
Association for Biochemistry (ACB), the British Thyroid Association (BTA) and the 
British Thyroid Foundation (BTF) suggest repeat testing to confirm subclinical 
hyperthyroidism if initial serum thyrotrophin is below 0.1mIU/L and after exclusion of 
interference from concomitant non thyroidal illness or medication. Monitoring on a 6-
12 monthly basis is also advocated. 71 Repeated thyroid function testing should, 
however be requested based upon the clinical presentation with earlier repeat testing 
being conducted in elderly individuals and subjects with vascular disease.  
Successful treatment of overt thyroid dysfunction requires normalisation of thyroid 
hormone concentration in peripheral tissues. In overt hypothyroidism this is achieved 
through administration of thyroxine replacement therapy. Similarly, overt 
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hyperthyroidism is readily treated with anti thyroid therapy often in combination with 
thyroidectomy or radioiodine therapy. 82,83 Whilst treatment of abnormal thyroid 
hormone levels in overt thyroid dysfunction is generally accepted, the threshold and 
indications for treatment of subclinical dysfunction is an unresolved issue due to a 
lack of evidence pertaining to the clinical impact of these disorders and the benefits 
associated with treatment. 68,76,84 This is particularly so in the elderly in whom the 
burden of other existing chronic disease and polypharmacy is common. 85,86 In terms 
of treatment of subclinical hypothyroidism, expert opinion recommends treatment of 
individuals with a serum thyrotrophin concentration >10mIU/L. 87 Treatment for 
milder subclinical hypothyroidism (4.5-10mIU/L) remains controversial with frequent 
monitoring being preferential. Similarly, the benefits of treating subclinical 
hyperthyroidism particularly in older individuals are uncertain.88 Recent 
recommendations from a panel of experts suggest treatment of endogenous 
subclinical hyperthyroidism in the presence of serum thyrotrophin concentration of 
<0.1 mIU/L, 71 particularly, in individuals aged 60 years of age or more with clinical 
symptoms or at increased risk for heart disease and  osteoporosis. The panel did not 
however recommend routine treatment in individuals with serum thyrotrophin 
concentration of between 0.1–0.45mIU/L regardless of expression of symptoms.  
Another controversial aspect of subclinical thyroid dysfunction is with regard to 
routine screening. In view of the high prevalence of subclinical thyroid dysfunction in 
the general population some advocate routine screening. 55,89 Others argue however 
that screening programmes cannot be justified because the associated clinical 
burden of subclinical thyroid dysfunction is unknown and there is no robust evidence 
to demonstrate that early diagnosis and treatment in the subclinical phase improves 
clinical outcomes. 67,90 The American Thyroid Association (ATA) has recommended 
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initial screening of men and women at 35 years of age and every five years there 
after. In contrast, the America Association of Clinical Endocrinology (AACE) 
supported only screening of elderly women. 87 A more recent joint statement from a 
conference between the various US based professional organisations agreed that 
current data are insufficient to advocate population based screening due to the 
uncertainty with regard to the benefits of early treatment, although aggressive case 
finding in those aged 60 years or more is promoted. 87 
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Summary of chapter 2 
The current chapter introduced and clarified the biochemical distinction between 
overt and subclinical thyroid dysfunction and provided an overview of the aetiology 
and prevalence of subclinical hyperthyroidism and subclinical hypothyroidism. 
Subclinical thyroid dysfunction is a common disorder frequently encountered in 
primary care. It seems that despite numerous guidelines and position papers, 
testing, treatment and management of subclinical thyroid dysfunction remains largely 
intuitive and non evidence based. This is mainly due to a lack of consensus with 
regard to the clinical burden and importance of these conditions in individuals with 
subclinical thyroid dysfunction. For some authors, subclinical thyroid dysfunction 
represents a well characterised condition which requires treatment. For others, it is 
essentially a laboratory diagnosis. It seems reasonable to propose that as the 
degree of thyroid dysfunction increases, the clinical expression and 
pathophysiological consequences become more prominent. It is therefore equally 
reasonable to assume that milder symptoms and less severe adverse health 
consequences are evident in individuals with subclinical thyroid dysfunction 
compared with individuals with overt thyroid dysfunction. Primary care clinicians 
would benefit from further clarification and guidance in relation to these issues. The 
aim of the next four chapters is to clarify further the pathophysiological 
consequences and clinical presentation of subclinical hypothyroidism and subclinical 
hyperthyroidism with reference to current evidence. 
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Overview of chapters 3-6  
The aim of the next four chapters is to clarify the clinical importance and relevance of 
subclinical thyroid dysfunction with reference to the current evidence base drawing 
on the range of published literature within the field. The results of the literature 
searches will be divided into four subject areas and summarised in the following four 
chapters.  
In chapter 3 and 4, data related to the clinical signs and pathophysiological 
consequences of subclinical hypothyroidism and subclinical hyperthyroidism 
respectively are presented and summarised. Chapters 5 and 6 present and 
summarise data pertaining to expression of symptoms in subclinical hypothyroidism 
(chapter 5) and subclinical hyperthyroidism (chapter 6) respectively. For the 
purposes of this thesis, clinical signs are defined as clinical anomalies that are 
evident on physical examination or assessment by a clinician and include indicators 
of anxiety, depression and cognitive dysfunction. In contrast, symptoms are defined 
as clinical changes that are perceptible and apparent to the individual. Similarly, the 
concept of perceived health status deals with patients‟ experiences and the impact of 
disease on everyday life. As such, this is best assessed by patients themselves. 
Data related to general well being and quality of life will be considered alongside 
symptoms data.   
Initially in Chapter 3 the methodology and results of the literature searches 
conducted to identify evidence related to the adverse consequences of subclinical 
hypothyroidism and subclinical hyperthyroidism will be reported. A critical appraisal 
of a key, recent systematic review collating and examining the data pertaining to the 
clinical consequences and prognostic implications of subclinical thyroid dysfunction 
will follow.  
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CHAPTER 3 PATHOPHYSIOLOGY OF SUBCLINICAL HYPOTHYROIDISM 
 
Overview of chapter 3 
It is clear from chapter 1 that overt thyroid dysfunction is associated with significant 
morbidity and that whilst the symptoms associated with overt thyroid dysfunctions 
are well established, their clinical presentation is variable. Given the definition of 
subclinical hypothyroidism it seems reasonable to assume that it is a mild form of 
overt hypothyroidism and as such is associated with similar, albeit less severe 
adverse health outcomes.  
 
3.1 Aim of literature review  
The aim of the literature search was to identify all research related to investigation of 
the clinical signs, symptoms and adverse consequences of subclinical 
hypothyroidism and hyperthyroidism.  
 
3.1.1 Search strategy  
A systematic search of the bibliographic database PubMed (which provides access 
to bibliographic information that includes MEDLINE) was conducted using the 
medical subject heading terms (MeSH terms) and limited to adult humans. No 
restrictions were applied to publication date. The initial searches were performed 
during February 2009. These searches were repeated periodically in order to capture 
any newly indexed publications, with the final literature search being conducted on 
25th January 2011.  
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Two search strategies were used. Initially each of the search terms were explored 
independently (Appendix 1 Electronic search strategies). In the subsequent 
searches, each term was systematically combined with the MeSH term „subclinical 
hypothyroidism‟ and re-run. Publications retrieved through the combined searches 
were saved to file and exported to a reference manager database. Similarly, the 
second search strategy systematically combined each search terms with the MeSH 
term „subclinical hyperthyroidism‟. (Appendix 1 Electronic search strategies). 
 
3.1.2 Inclusion and exclusion criteria 
Publications were included where the primary aim of the study, systematic review or 
meta analyses was related to the investigation and evaluation of the detrimental 
health consequences of subclinical thyroid dysfunction. Review papers were 
excluded if they were non-systematic. Case studies, letters, discussion and position 
papers were also excluded. Literature related to subclinical thyroid dysfunction in 
pregnant or post natal women, individuals with drug-induced subclinical thyroid 
dysfunction or in cohorts defined by a specific chronic condition or medical history 
(for example a cohort with type 2 diabetes or dementia) were excluded. Furthermore, 
randomised controlled trials and trials investigating clinical interventions were 
excluded.  
 
Two reference manager databases were constructed. One comprised the search 
results for subclinical hyperthyroidism, the other comprising publications contributing 
data relevant to detrimental health consequences of subclinical hypothyroidism. 
Where papers reported both, they were filed to both databases. Within each of the 
databases a search was conducted to identify and remove duplicate publications.  
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Identification of a recent, systematic review by Biondi et al published in 2008 
indicated that significant work had already been undertaken in identifying and 
summarising the consequences of subclinical thyroid dysfunction. It was therefore 
determined that this paper would be formally appraised and if deemed to be of high 
quality would form the core of the current review, supplemented by subsequent 
evidence retrieved. 91 
Critical appraisal of this publication was undertaken in accordance with the standard 
checklist from the Critical Appraisal Skills Programme (CASP). 92 Critical appraisal 
indicated that the Biondi et al review was particularly pertinent to the focus of the 
current chapter, had been rigorously conducted and was of high quality. In this 
review, Biondi et al identified, collated and examined all high quality studies 
published between 1970 and April 2007 pertaining to the clinical consequences and 
risks associated with subclinical hyperthyroidism and subclinical hypothyroidism. The 
stated aim of the review was to answer seven questions; each question was clearly 
focused and the authors reported that the quality of the studies included had been 
critically assessed by two reviewers and all studies were of high quality. Whilst the 
search strategy was comprehensive, the inclusion and exclusion criteria for the 
articles retrieved were not explicit. It is not possible to rule out selection and 
publication bias as only English language studies were included. Furthermore, whilst 
the electronic searches were comprehensive, it was not explicit as to whether 
supplementary hand searches of additional materials were conducted. Hence, the 
Biondi review was considered to be a key publication and only data reported in meta 
analyses or systematic reviews or research papers published subsequent to this 
review were regarded as pertinent to the rationale of the current chapter.  
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The identification of this key systematic review meant that it was necessary to 
identify and review all relevant articles published prior to April 2007 that were not 
cited by Biondi et al, and all relevant articles published subsequent to this review. In 
order to ascertain whether the literature reviewed by Biondi et al was appropriate 
and comprehensive, the list of articles retrieved from the PubMed searchers was 
cross referenced with the articles cited in the review. Additional exploration of studies 
that had previously been reviewed by Biondi et al was considered unnecessary and 
therefore these articles are not examined further within the current chapter.  
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3.1.3 Application of the inclusion/exclusion criteria  
The search strategy used to identify publications related to subclinical 
hypothyroidism retrieved 513 articles (Figure 3.0). Further details of the subclinical 
hyperthyroidism search results are reported and discussed in chapter 4.0. The 
abstracts of all retrieved articles were screened to assess the inclusion/exclusion 
status of each publication. Application of the inclusion/exclusion criteria led to the 
exclusion of 396 of the articles retrieved from the subclinical hypothyroidism search 
strategy. The reasons for exclusion are listed in table 3.0. A considerable number of 
retrieved articles (n=115) were excluded from discussion in the current chapter 
because the studies were unrelated to investigation of the detrimental effects of 
subclinical hypothyroidism. A large proportion of reviews were also excluded as they 
were not systematic in their approach (n=77) or the subject of the review was 
treatment for subclinical thyroid dysfunction or the study employed an intervention 
(n=88). A further 62 duplicate articles were excluded because they had been 
included in the systematic review by Biondi et al and as such would not contribute 
additional data for examination within the scope of the current chapter.  
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Table 3.0 Exclusion of articles; subclinical hypothyroidism   
Reason for exclusion of retrieved publications Number of articles  
Not related to adverse consequences 115 
Non systematic reviews 77 
Studies of intervention/ RCT/ reviews of treatment 88 
Diseased populations 52 
Research in children 17 
Case studies 15 
Pregnant and post natal women only 11 
Letters 8 
Superseded systematic review and meta analyses 6 
Discussion paper/ editorial 5 
Included in analyses on mortality 1 
Non human subject 1 
Total number of articles excluded 396 
 
 
A large body of the literature retrieved focused upon subclinical hypothyroidism in 
specific population subgroups with significant disease. Fifty two such articles were 
retrieved to include studies showing an association between subclinical 
hypothyroidism and an increased risk of nephropathy and cardiovascular disease in 
type 2 diabetic patients, 93 insulin resistance in individuals with rheumatoid arthritis 94 
and elevated total cholesterol and low-density lipoprotein cholesterol concentrations 
in cardiology patients. 95 Further examination of this literature has not been 
undertaken however because the principal focus of this chapter is exploration of the 
adverse health consequences of subclinical hypothyroidism in a wide ranging, 
„normal‟ population. Despite the application of limits restricting the searches to 
studies of adult humans it was also necessary to exclude 17 studies of subclinical 
thyroid dysfunction in children and adolescents and one animal study. Furthermore, 
15 case studies, 11 studies of subclinical thyroid dysfunction in pregnancy, eight 
letters, six superseded systematic reviews and meta analyses and five discussion 
papers are not examined further within this chapter.      
 
41 
 
The 46 remaining supplementary articles comprised, the recent systematic review by 
Biondi et al, 18 articles pre-dating but not cited in the Biondi review and 28 articles 
post dating the Biondi review (Figure 3.0). The findings of these supplementary and 
subsequent studies are presented and summarised alongside the conclusions drawn 
by the Biondi review. Throughout the current chapter, the terminology 
„supplementary‟ and „subsequent‟ will be applied to publications that either pre or 
post date the systematic review by Biondi et al respectively and the terminology 
„Biondi et al‟ will be used to denote the systematic review.  
 
 42 
Figure 3.0 Flow diagram: literature related to subclinical hypothyroidism  
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3.2 Pathophysiological consequences of subclinical hypothyroidism    
 
3.2.1 Cardiovascular risk and subclinical hypothyroidism  
Cardiovascular risk is an important consideration for decision making with respect to 
thyroid function testing, management and treatment of subclinical hypothyroidism. 
Similar effects on the cardiovascular system have been observed in overt and 
subclinical hypothyroidism. Based upon evidence available between 1970 and April 
2007, Biondi et al reported major discrepancies in data related to cardiovascular risk.  
Supplementary and subsequent data investigating the relationship between subclinical 
hypothyroidism and cardiovascular risk do not generally support an association with 
hypertension. One supplementary cross-sectional exploration of the prevalence of 
hypertension in a random sample of 257 women aged 50 years or more failed to 
demonstrate an association between subclinical hypothyroidism and increased risk of 
hypertension. 96 Similarly, the subsequent Suita study, a large cross-sectional 
investigation of cardiovascular parameters in a community dwelling Japanese population 
found no association between subclinical hypothyroidism and hypertension. 97 However, 
two subsequent cross-sectional studies based in China report contradictory findings. 
One study of 5669 community dwelling adults demonstrated similar systolic blood 
pressure, diastolic blood pressure, and pulse pressure in individuals with subclinical 
hypothyroidism compared with euthyroid individuals after adjustment for age, gender, 
body mass index (BMI), and smoking status. Sensitivity analysis excluding patients 
receiving anti hypertensive medication showed similar results. 98 In contrast, the more 
recent cross-sectional study of 1319 adults aged between 18-85 years demonstrated a 
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modest yet statistically significant increased likelihood of hypertension in individuals with 
subclinical hypothyroidism compared with euthyroid subjects (OR 1.7, 95% CI 1.06-2.88, 
p<0.027). 99 Although the statistical analysis adjusted for age, gender, smoking status 
and BMI, the results may have been affected by the inclusion of participants receiving 
antihypertensive medication (Table 3.1). 
In general, data supplementary to Biondi et al derived from population based studies do 
not support an association between subclinical hypothyroidism and hypertension. This 
evidence is however limited by the cross-sectional study designs and additional 
prospective, longitudinal studies are required to further clarify the relationship between 
subclinical hypothyroidism and hypertension. 
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Table 3.1 Subclinical hypothyroidism and hypertension  
Author and 
date  
Design 
/setting 
Participants, 
age and thyroid 
status  
Exclusions TSH and FT4 
reference criteria 
and frequency of 
TFT 
Measures Outcome  
Akbar DH 
96
 
2004 
Saudi Arabia 
Case 
control 
Outpatients 
Random sample 
of 257 women 
aged >50 years  
90 Schypo   
 
Known thyroid 
dysfunction, history of 
neck irradiation, 
chronic disease, 
medication known to 
interfere with TFT 
TSH 0.27-4.2  
FT4 12-22  
Hypertension, 
systolic blood 
pressure, diastolic 
blood pressure 
No association with 
BMI, and 
hypertension  
Takashima N 
97
 
2007 
Japan 
Cross 
sectional, 
Community  
 
Adults  
n=3607  
377 Schypo 
3130 Euth 
Patients treated for 
thyroid dysfunction 
TSH 0.43- 3.78  
FT4 12.87-21.9  
Single TFT 
IMT surrogate marker 
of atherosclerosis 
Glucose metabolism 
– Fasting blood 
glucose (FBG) and 
lipid metabolism  
No association with 
hypertension, or 
IMT Associated 
with increase in 
FBG 
Duan Y
 98
 
2009 
China 
Cross 
sectional, 
Community  
 
Adults 
806 Schypo 
5669 Euth 
 
Systemic disease, 
pregnancy, 
medicines known to 
interfere with TF  
TSH 0.4-4.5 
FT4 10.3-24.5  
Single TFT 
Hypertension, 
systolic blood 
pressure, diastolic 
blood pressure 
No association with 
blood pressure 
Lui D 
99
 
2010 
China 
 
Cross 
sectional 
survey 
Community 
 
Adults, 18-85 yrs 
93 Schypo 
1226 Euth 
History of thyroid 
disease, overt thyroid 
dysfunction, 
medication affecting 
thyroid function, 
pregnancy, diabetes, 
TSH 0.3-4.8 
FT4 10.3-24.5  
Single TFT 
Hypertension Moderately 
icreased risk of 
hypertension in 
Schypo (OR 1.5, 
95% CI 1.06-2.88, 
p<0.027)  
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Mechanisms for an association between subclinical hypothyroidism and hypertension, 
have been proposed based upon evidence of increased arterial stiffness, increased 
peripheral vascular resistance and endothelial dysfunction in individuals with subclinical 
hypothyroidism. One small supplementary case control study reported impaired 
endothelial function. 100 Cikim et al reported significantly lower values of flow mediated 
dilation in 25 individuals with subclinical hypothyroidism compared with 23 euthyroid 
controls after reactive hyperaemia. 100 Disparate findings were reported in two 
subsequent studies in which peripheral endothelial function was assessed in response 
to reactive hyperaemia. 101,102  In a subsequent study of flow mediated vasodilatation of 
the brachial artery in 21 Brazilian females with subclinical hypothyroidism compared with 
21 euthyroid controls, endothelial dysfunction was not apparent. 102 Likewise, no 
differences in endothelial function were detected in 18 females with subclinical 
hypothyroidism compared with 22 female controls in a supplementary study conducted 
by Dagre et al. 101 More recently, anomalies in endothelial function that could be 
indicative of early vascular disease were described following investigation of 20 young 
and middle aged women with subclinical hypothyroidism and 15 euthyroid controls. In 
this study, significantly reduced coronary blood flow velocity in the distal left anterior 
descending artery was observed after sympathetic stimulus using the cold pressor test.  
103 Conversely, impaired microvascular function as assessed by coronary flow reserve 
was described in one supplementary case control study of 50 adults with subclinical 
hypothyroidism compared with 30 euthyroid controls. 104 Other indicators of 
atherosclerosis have also been widely studied in individuals with subclinical 
hypothyroidism. Carotid artery intima media thickness is another useful marker of 
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atherosclerotic vascular changes that has frequently been used as a cardiovascular 
endpoint. Biondi et al describe two studies demonstrating significantly increased carotid 
artery intima thickness in individuals with subclinical hypothyroidism compared with 
controls. 105,106 In contrast, three supplementary case control studies conducted in the 
outpatient setting did not corroborate these findings and failed to demonstrate significant 
differences in carotid artery intima media thickness in cases of subclinical 
hypothyroidism compared with euthyroid controls. 100,102,107 No association between 
subclinical hypothyroidism and carotid artery intima-media thickness was observed in an 
investigation of cardiovascular parameters in 377 community dwelling individuals with 
subclinical hypothyroidism and 3130 euthyroid individuals. 97 Comparable findings were 
reported following ultrasound evaluation of the walls of the common carotid, the internal 
and external carotid and the carotid bifurcations in 2184 subject aged over 45 years. In 
this population based sample, subclinical hypothyroidism was not associated with 
carotid artery plaques at any location (Table 3.2). 108 
In terms of arterial stiffness, an established independent predictor of hypertension and 
coronary artery disease, the evidence generally supports an association between 
subclinical hypothyroidism and arterial stiffness. Further to the review by Biondi et al, 
two studies evaluating pulse wave velocity, (a parameter known to represent arterial 
stiffness) were identified. 105,109  Hamano et al evaluated brachial-ankle pulse wave 
velocity (baPWV) in 28 individuals with subclinical hypothyroidism, seven individuals 
with overt hypothyroidism and healthy age matched controls. 109  Increased arterial wall 
stiffness was evident in both the overt and subclinical individuals compared with the 
controls. Another subsequent case control study further supports and extends these 
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findings. 105 This study by Nagasaki et al aimed to establish the affect of subclinical 
hypothyroidism on arterial stiffness in different arterial segments. Central pulse wave 
velocity (in heart-femoral segments) and peripheral pulse wave velocity (in femoral-ankle 
segments) were evaluated in 40 individuals with subclinical hypothyroidism and 50 
euthyroid controls. Significant increases in both parameters were described in 
individuals with subclinical hypothyroidism compared with euthyroid controls suggesting 
that arterial stiffening of the aorta in addition to the peripheral arteries is present in 
subclinical hypothyroidism. 105 Both of these studies were conducted in a small sample 
of Japanese subjects and it remains to be seen whether these data can be extrapolated 
to other populations (Table 3.2). 
In summary, studies to date consistently demonstrate a significant increase in arterial 
stiffness in individuals with subclinical hypothyroidism compared with euthyroid controls. 
It is therefore possible that increased arterial stiffness is an additional cardiovascular risk 
factor in individuals with subclinical hypothyroidism. Additional larger studies are 
required to determine the external validity of these findings and the potential for 
extrapolation to other populations. Whether abnormalities in endothelial function occur in 
subclinical hypothyroidism and augment cardiovascular risk remains to be elucidated. 
Subsequent study findings both contradict and extend the conclusions drawn by Biondi 
et al with respect to the association between subclinical hypothyroidism and increased 
intima media thickness. The Suita study provides good evidence that subclinical 
hypothyroidism is not associated with increased carotid intima media thickness. On this 
basis it is reasonable to conclude that subclinical hypothyroidism does not contribute to 
an increased risk of atherosclerosis. Studies to date are however limited by their cross-
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sectional design and by the fact that duration of subclinical hypothyroidism is unknown. 
It is therefore possible that these cardiovascular parameters are modified over time and 
become cardiovascular risk factors in individuals with more established subclinical 
hypothyroidism. 
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Table 3.2 Subclinical hypothyroidism and other cardiovascular risk factors 
Author and 
date  
Design 
/setting 
Participants, 
age and thyroid 
status  
Exclusions TSH and FT4 
reference criteria 
and frequency of 
TFT 
Measures Outcome  
Cikim AS 
100
 
2004 
Turkey 
Case 
control  
Outpatients  
25 Schypo  
23 Euth controls 
matched for 
smoking, 
hypertension, 
CV disease  
Atherosclerosis, other 
cardiovascular 
disease that could 
affect endothelial 
dysfunction, 
postmenopausal 
women 
TSH 0.27-4.2 
FT4 11-22 
Endothelial function 
via flow mediated 
dilation (FMD) 
Significantly lower 
FMD in Schypo 
(10.68 vs 15.92, p 
<0.05) 
Hamano K 
109
  
2005 
Japan 
Outpatients 28 Schypo  
28 Age matched 
euthyroid 
controls 
Not explicit TSH not explicit 
FT4 
Pulse wave velocity 
(PWV) as an 
indicator of arterial 
stiffness and total 
cholesterol 
Schypo associated 
with arterial wall 
stiffness  
Tanaci N 
110
 
2006 
Turkey  
Case 
control 
Outpatients 
 
Female 
15 Schypo,  
11 BMI, age 
matched Euth 
control 
Chronic disease, 
alcohol, drugs abuse 
lipid lowering 
medication or known 
to interfere with TFT 
TSH >5.0 
FT4 
 
C reactive protein, or 
homocysteine, 
glucose or lipids   
No difference in 
any parameters 
studied  
Almeida CA
107 
 
2007 
Brazil  
Case 
control 
Cross 
sectional   
Outpatients  
Women, middle 
aged,  
30 Schypo  
27 controls 
History of TD, 
treatment for TD, CV 
disease, 
hypertension, 
diabetes and 
smoking 
TSH 0.4-4.0 
FT4 10.3-23.2 
Ultrasonography of 
carotid arteries 
No significant 
differences 
Baycan S 
104 
 
2007 
Turkey  
Case 
control  
Outpatients  
50 Schypo  
30 Euthyroid 
controls 
CV disease, alcohol, 
smoking, chronic 
disease, medication 
known to interfere 
with TD  
TSH >4.0 
FT4 not explicit 
Coronary flow 
reserve (CFR) 
CFR significantly 
decreased in 
Schypo 2.23 vs 
2.98, p<0.001  
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Table 3.2 continued  
Author and 
date  
Design 
/setting 
Participants
, age and 
thyroid 
status  
Exclusions TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measures Outcome  
Dagre AG 
101 
 
2007 
Greece 
Case 
control 
Outpatients 
Female 
Adults 
18 Schypo  
22 controls 
Evidence of CV 
disease 
TSH 0.3-3.7 
FT4 4.1-15.8 
Endothelial function  No difference in any 
phase of reactive 
hyperaemia  
Nagasaki T
105 
 
2007 
Japan 
 
Cross 
sectional, 
Population 
based  
Outpatients 
40 Schypo  
50 control 
Atherosclerosis, 
chronic disease, 
medication known 
to interfere with TF, 
positive anti thyroid 
antibody 
Not explicit 
Repeat TFT 1 
monthly interval 
Central, peripheral 
pulse wave velocity 
(PWV) and brachial 
ankle (ba) PWV 
and lipid profiles 
Significant differences in 
triglyceride, 
High density lipoprotein 
cholesterol (HDL-c), 
central, peripheral PWV 
and baPWV significantly 
increased 
Dorr M 
108
 
2008 
Germany 
Random 
sample of 
292  
>45 years 
63 Schypo 
1839 Euth  
Known or possible 
thyroid disease 
TSH 0.25-2.12 
FT4 not explicit 
 
Carotid plaque at 4 
locations 
No association with 
carotid plaque using 
ultrasound or prevalence 
of stroke self reported 
physicians diagnosis  
Toruner F 
112
 
2008  
Turkey 
Case 
control 
Outpatients 
38 Schypo  
44 control 
Chronic disease or 
thyroid medication 
TSH not explicit  
FT4 not explicit 
Lipid parameters  Significantly increased 
total cholesterol, low 
density lipoprotein 
cholesterol (LDL-c) and 
triglyceride 
concentrations (TG), 
p<0.05 
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Table 3.2 continued  
Author and 
date  
Design 
/setting 
Participants, 
age and 
thyroid 
status  
Exclusions TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measures Outcome  
Biondi B
103 
 
2009 
Italy 
Case 
control 
Outpatients 
 
Middle aged, 
women 
20 Schypo 
15 controls 
Smokers, 
concomitant 
vasoconstructive 
drugs, obesity and 
dyslipidemia 
TSH 0.27-4.2 
FT4 12-22 
Single TSH  
Doppler echo and 
coronary flow 
reserve (CFR) after 
cold pressor test. 
Multiple measures 
E velocity significantly 
increased (185 vs 169). 
IVRT (ms) p<0.05 87 vs 
74. CRF 1.4 Schypo vs 2 
Euth p<0.001 
Cabral MD
102 
 
2009 
Brazil 
Case 
control 
Outpatients   
Adult women   
21 Schypo  
21 controls 
matched for 
BMI, age and 
CV risk  
Alcohol use, 
concomitant illness 
or medication that 
could interfere with 
TF, lipoprotein or 
endothelial 
function. 
TSH 0.4-4.0 
FT4 10.3-24.5  
Flow mediated 
vasodilatation of 
brachial artery, 
carotid intima 
media thickness, 
lipid parameters 
No significant differences 
between Schypo and 
euthyroid in any 
parameters measured.  
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3.2.2 Traditional cardiovascular risk factors  
Whilst plasma lipid profiles have been widely studied, Biondi et al report conflicting data 
regarding the relationship between lipid profiles and subclinical hypothyroidism. 
Similarly, supplementary and subsequent data are contradictory. Some studies support 
an association between subclinical hypothyroidism and abnormal lipid and lipoprotein 
profiles, 113,114,115 whilst others report similarities in these parameters in individuals with 
subclinical hypothyroidism compared with euthyroid controls. 102,107,110,116 A large cross-
sectional study of 66260 adults in Korea reported significant differences in total 
cholesterol (TC) and low density lipoprotein cholesterol (LDL-c) between subclinical 
hypothyroidism and euthyroid groups. 113 Whilst the authors concluded that the 
observed elevations in these atherogenic parameters lend support to calls for screening 
and treatment of subclinical hypothyroidism, the degree of elevation demonstrated was 
small and unlikely to be clinically significant (TC 201.9 ± 39.9 mg/dl versus 197.1±36.3 
mg/dl respectively, p<0.05; LDL-c 123.7±31.5 mg/dl versus 121.5 ±31.2 respectively, 
p<0.0001) (Table 3.3). Conversely, another large cross-sectional investigation of lipid 
parameters in a community dwelling adult Japanese population found no association 
between subclinical hypothyroidism and total cholesterol, high-density lipoprotein 
cholesterol or triglyceride levels. 97 The discrepancies between these studies may be 
explained by a lack of adjustment for common confounders and possible inclusion of 
patients receiving medication for thyroid dysfunction in the Korean study. In a smaller 
study increased postprandial serum triglyceride concentrations were observed in 15 
females with subclinical hypothyroidism compared with 12 age and gender matched 
euthyroid controls. However these differences were not statistically significant. 110 
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Similarly, higher serum concentrations of triglyceride and low density lipoprotein 
cholesterol and lower concentrations of high density lipoprotein cholesterol observed in 
40 cases compared with 30 euthyroid controls failed to reach statistical significance. 102 
Likewise, Almeida et al reported no differences in these lipid parameters between 30 
female cases and 30 gender matched controls. 107 In contrast, four small studies 
demonstrated statistically significant differences in some of these parameters in 
individuals with subclinical hypothyroidism compared with euthyroid subjects. 112,114,115  
One study described a significant association between subclinical hypothyroidism and 
total cholesterol, low density lipoprotein cholesterol and triglyceride concentration when 
comparing these parameters in 23 cases with 26 female euthyroid controls.  Likewise, 
Erdem et al observed a significant increase in each of these parameters and a 
significant decrease in high density lipoprotein cholesterol in 40 cases compared with 31 
matched controls. 114 In another small case control study, total cholesterol, triglyceride 
and total cholesterol/high density lipoprotein cholesterol ratio were significantly higher in 
30 cases compared with 20 euthyroid controls. 115  Four of the smaller studies also 
evaluated serum concentrations of lipoprotein A, another marker for assessing risk of 
atherosclerosis. 100,107,110,112  All four studies demonstrated similar serum concentrations 
of lipoprotein A in individuals with subclinical hypothyroidism compared with euthyroid 
subjects.  
In terms of the relationship between lipoprotein A and subclinical hypothyroidism, 
supplementary data fully support the findings of Biondi et al and demonstrate that 
subclinical hypothyroidism is not associated with abnormalities in lipoprotein A 
concentration. With respect to other lipid parameters, the data is contradictory. Whilst 
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the current literature review includes two large population based studies evaluating lipid 
parameters and Bondi et al provide data from six such studies, no two studies 
demonstrate the same collection of significant changes in association with subclinical 
hypothyroidism. In general, where statistcally significant differences in lipid parameters 
have been observed, the magnitude of change is small and unlikely to be clinically 
significant at the individual patient level. The clinical impact of subclinical hypothyroidism 
on lipid metabolism and risk of atherosclerosis requires further clarification in 
prospective population based studies.  
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Table 3.3 Subclinical hypothyroidism and traditional cardiovascular risk factors  
Author and 
date  
Design 
/setting 
Participants, 
age and 
thyroid 
status  
Exclusions TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measures Outcome  
Jung CH 
113
  
2003 
Korea 
Cross- 
sectional  
Population 
based  
 
375 Schypo  
65017 Euth 
None  TSH 0.25-5.0 
FT4 9.0-25.7  
 
Lipid 
parameters  
Schypo associated with increased 
triglyceride (201.9 vs 197.1, p<0.015), 
LDL-c (123.7 vs 121.5, p<0.0001) 
Al-Tonsi AA
116
 
2004 
Egypt 
Case 
control 
Outpatients 
 
16 Schypo,  
16 gender, 
age matched 
Euth control 
Metabolic disease 
or medication or 
hormonal treatment 
TSH 0.4-4.6 
FT4 4.5-11.7 
Lipid 
parameters  
No significant differences in lipid or 
phosphate concentrations in Schypo 
compared with 16 controls 
Pesic M 
115
  
2007 
Serbia 
Case 
control  
Outpatients  
30 Schypo  
20 controls 
History of thyroid 
dysfunction  
TSH >4.5 
FT4 normal  
Lipid 
parameters  
Schypo associated with higher 
triglyceride and total cholesterol 
Erdem TY 
114
 
2008  
Turkey 
Case 
control 
Outpatients 
Women 
40 Schypo 
31 matched 
control 
 
Medication known 
to interfere with 
thyroid dysfunction 
Not explicit  Plasma 
viscosity 
Plasma viscosity significantly 
decreased  
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3.2.3 Subclinical hypothyroidism and novel cardiovascular risk factors 
More recently, an association between subclinical hypothyroidism and novel 
cardiovascular risk factors such as homocysteine, C-reactive protein and various 
coagulation and metabolic parameters have been proposed. With respect to 
concentrations of homocysteine, Biondi et al describe consistent evidence 
demonstrating no association between subclinical hypothyroidism and 
hyperhomocysteinemia. Accordingly, two supplementary studies were also unable to 
corroborate suggestions that atherogenicity in subclinical hypothyroidism is mediated by 
abnormal concentrations of homocysteine. 113,117 Turhan et al describe similar 
concentrations of total plasma homocysteine in 53 individuals with subclinical 
hypothyroidism compared with 50 euthyroid controls. 117 These findings were 
corroborated by Jung et al in a cross-sectional study of 66260 adults in Korea. 113 
Additionally Jung et al evaluated concentrations of high sensitivity C-reactive protein in 
individuals with subclinical hypothyroidism and euthyroid subjects and failed to 
demonstrate significant differences between the groups.  
Based upon data from one large population based study and six smaller studies, Biondi 
et al report significant differences in various coagulation parameters in individuals with 
subclinical hypothyroidism compared with euthyroid subjects. Accordingly, two 
supplementary case control studies demonstrated significantly increased mean platelet 
volume in association with subclinical hypothyroidism.  118, 119 Additionally, Erikci et al 
reported a significantly higher platelet distribution width in cases of subclinical 
hypothyroidism compared with controls. 119 In contrast, a third supplementary study 
described significantly decreased serum concentrations of soluble CD40 ligand, (a 
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protein expressed mainly by activated platelets) in 22 individuals with subclinical 
hypothyroidism in comparison to 22 age matched controls (8.24 versus 9.86 ng/ml 
respectively, p<0.001). 120 Elevated levels of sCD40 ligand have been shown to be 
associated with increased risk of cardiovascular disease. 121  
Another biochemical marker for cardiovascular risk that has recently been associated 
with subclinical hypothyroidism is retinol binding protein-4 (RBP4). Elevated levels of 
retinol binding protein-4 have been shown to be positively correlated with insulin 
resistance, obesity, diabetes mellitus, and cardiovascular disease. 122 In this evaluation 
of cardiovascular risk factors in 217 randomly selected elderly individuals by Choi et al, 
40 patients with subclinical hypothyroidism had significantly greater plasma RBP4 
concentrations in comparison with 177 euthyroid individuals. The authors concluded that 
RBP4 concentration could be used as an index of cardiovascular risk in individuals with 
subclinical hypothyroidism. However, the clinical significance of elevated RBP4 requires 
further clarification since it is not known whether increased plasma RBP4 concentrations 
are a cause or a consequence of subclinical hypothyroidism. 122 In terms of metabolic 
syndromes, a small case control study demonstrated a significant association between 
insulin resistance and subclinical hypothyroidism. 123 In contrast, a large cross-sectional 
investigation (n=3607) of cardiovascular and metabolic parameters in community 
dwelling Japanese adults found no association between subclinical hypothyroidism and 
glycosylated haemoglobin. Significantly lower fasting glucose levels were however 
reported in individuals with subclinical hypothyroidism compared with euthyroid 
individuals. Once again, the differences observed were small and unlikely to be clinically 
important. 97 No other differences in cardiovascular or metabolic parameters existed 
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between the groups. Based upon alterations in glucose metabolism alone, the outcomes 
suggest that treatment of subclinical hypothyroidism is not warranted (Table 3.4). 
In summary, various novel risk factors for cardiovascular disease have been 
investigated in relation to subclinical hypothyroidism. Supplementary and subsequent 
literature fully support the findings of Biondi et al and suggest that altered coagulation 
parameters occur in subclinical hypothyroidism which may be important in the 
pathophysiology of atherothrombosis and coronary heart disease. The clinical 
significance of these small, yet statistically significant changes remains to be fully 
elucidated. Furthermore, these findings require replication reached by Biondi et al and 
demonstrate that subclinical hypothyroidism is not associated with homocysteine or C-
reactive protein. These parameters have not been widely evaluated and available data 
are generally derived from small cohorts of health seeking individuals recruited from the 
outpatient setting. Supplementary data therefore cannot be extrapolated to other 
populations. These data are not robust enough to further reconcile the current 
disagreement as to whether concentrations of high sensitivity C-reactive protein and 
homocysteine are adversely affected in subclinical hypothyroidism. In conclusion, 
studies examining the relationship between subclinical hypothyroidism and novel 
cardiovascular risk factors do not provide compelling evidence to justify clinical 
intervention.  
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Table 3.4 Novel cardiovascular risk factors and subclinical hypothyroidism  
Author and 
date  
Design 
/setting 
Participants, 
age and 
thyroid status  
Exclusions TSH and FT4 
reference 
criteria  
Measures Outcome  
Aldasouqi S 
124
 
2004 
Saudi Arabia 
Case control 
Outpatients 
47 Schypo  
50 Euth 
controls 
Thyroid surgery or 
radioiodine treatment 
TSH 0.27- 4.2 
FT412-22 
Homocysteine No significant difference in 
homocysteine Schypo 7.44 vs 
Euth 7.22 
Akinci B 
125
 
2007 
Turkey 
Case control 
Outpatients 
25-62 years 
22 Schypo 
22 age, match 
controls  
Alcohol, smoking, 
contraceptives, 
hormones, chronic 
disease, 
multivitamins 
TSH>5 
FT4 10.29-24.4  
Platelet activity, 
CD40 ligand a 
protein 
expressed by 
activated 
CD40 ligand significantly 
decreased Schypo vs control 
8.24-9.86 ng/dl, p<0.001 
Coban E 
118
 
2007 
Turkey 
Case control 
Outpatients 
 
36 Schypo  
20 age, gender, 
BMI controls 
Hypertension, 
diabetes mellitus, 
smoking, alcohol 
consumption, 
systemic disease and 
medication affecting 
platelet and TD 
TSH 0.27-1.2 
FT4 0.93-1.7 
Platelet activity  Mean platelet volume 
significantly increased iin 
Schypo compared with 
euthyroid 9.9 fl vs 9.2 fl,p 
<0.001 
Choi SH 
122 
 
2008 
South Korea 
Random 
sample 217 
elderly 
population 
based cohort  
Elderly  
40 Schypo 177 
Euth  
Diabetes mellitus and 
dyslipidemia  
TSH 0.4-4.1 
FT4 9.0-23.2l 
 
Retinal binding 
protein and 
lipid 
parameters 
Schypo associated with 
elevated RBP4  
Turhan S 
117
  
2008 
Turkey 
Case control  
Outpatients  
53 Schypo 
50 Age, 
gender, BMI 
matched 
euthyroid 
controls 
History of thyroid 
dysfunction, 
medication known to 
interfere with TFT, 
chronic disease, 
smoking, familial 
hypercholesterolemia  
TSH 0.35-4.94 
FT4 9.0-19.0 
Repeat TFT 
Lipid 
parameters  
No significant difference in 
homocysteine or lipid 
parameters  
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Table 3.4 continued 
Author and 
date  
Design /setting Participants, 
age and thyroid 
status  
Exclusions TSH and FT4 
reference criteria  
Measures Outcome  
Ericki AA 
119
 
2009 
Turkey 
Case control  
Outpatients 
47 Schypo 
30 Euth  
Known thyroid 
dysfunction and 
medication known 
to interfere with 
TFT 
TSH>5 
FT4 10.29-24.4 
Platelet activity Schypo significantly higher 
mean platelet volume  
Maratou E 
123
 
2009 
Greece 
Case control  
Outpatients 
13 Schypo 
21 Euth 
Concomitant 
medication, family 
history of diabetes 
Not explicit  Insulin 
resistance  
Association with insulin 
resistance and therefore 
associated disorders such as 
CVD 
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3.2.4 Subclinical hypothyroidism and cardiac structure and function 
Based upon available data, Biondi et al propose a continuum of cardiac changes as 
grade of thyroid dysfunction increases from subclinical to overt hypothyroidism with left 
ventricular diastolic dysfunction being the most consistent cardiac aberration described 
in subclinical hypothyroidism. 91 They describe data concerning systolic function as less 
consistent however. Further to Biondi et al, two supplementary case control studies 
using tissue Doppler echocardiography to investigate cardiac function reported impaired 
right ventricular diastolic function. 125,126 Additionally, one small supplementary case 
control study described significant impairment in both systolic and diastolic function at 
rest in individuals with subclinical hypothyroidism. 127 In another subsequent case control 
study, significantly lower systolic and diastolic indices during exercise were reported in 
25 newly diagnosed cases of subclinical hypothyroidism compared with 25 controls 
(Table 3.5). 128 In contrast, Iqbal et al published findings analysing data from the Tromso 
studies. 129 These studies employed two research methodologies; a large 
epidemiological study of thyroid function and left ventricular mass index and a nested 
case-control study with refined inclusion and exclusion criteria to minimise 
misclassification of thyroid function status and improve clinical relevance. 
The epidemiological study of 2035 adults did not find any statistical or clinical 
association between thyroid category and left ventricular mass index using conventional 
and pulse wave tissue Doppler echocardiography. Similarly, the nested case control 
study of 204 subjects (subclinical hypothyroidism n=66) with two successive thyroid 
function tests indicating stable thyroid function over a 12 month period also failed to 
identify any differences between individuals with subclinical hypothyroidism and 
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euthyroid controls. 129 Abnormalities in cardiac conduction have also been described in 
subclinical hypothyroidism. Monzani et al described anomalies in myocardial contraction 
as indicated by prolonged pre ejection fraction (isometric systole) in 14 individuals with 
subclinical hypothyroidism. 130 In addition, impaired cardiac autonomic activity was 
reported by Sahin et al following assessment of heart rate variability in 31 individuals 
with subclinical hypothyroidism compared with 28 controls (Table 3.5). 131 
Cardiopulmonary dysfunction has been described in a subsequent small case control 
study using the treadmill cardiopulmonary test. A significantly slower recovery time after 
exercise in cases compared to controls was observed as indicated by a reduction in 
diastolic blood pressure between the first and third recovery minutes. 132  However, no 
abnormalities in blood volume or renal function however were reported in eight cases 
compared to eight controls in a similar supplementary study. 133 The influence of thyroid 
hormone on serum brain natriuretic peptide (BNP) concentration has also recently been 
investigated. Natriuretic peptides are produced predominantly in the heart and secreted 
in response to volume expansion and pressure overload with serum levels being 
predominantly elevated in systolic heart failure. However, a recent cross-sectional study 
of 150 outpatients in Turkey reported similar BNP levels in subclinical hypothyroidism 
and in euthyroid controls (Table 3.5). 134  
To summarise, some supplementary and subsequent data complement the findings of 
Biondi et al and describe adverse alterations in cardiac structure and impaired cardiac 
function in individuals with subclinical hypothyroidism. In general, these data come from 
small, underpowered studies employing numerous exclusion criteria and multiple 
outcome measures. Since these data have not been corroborated by more recent 
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epidemiological studies, it is difficult to conclude that subclinical hypothyroidism is 
associated with impaired cardiac structure and function. 
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Table 3.5 Subclinical hypothyroidism and cardiac function  
Author and 
date  
Design 
/setting 
Participants, 
age and 
thyroid 
status  
Exclusions TSH and FT4 
reference criteria  
Measures Outcome  
Villabona C 
133
  
1999 
Spain 
Case control 
Outpatients 
24- 54 years 
8 Schypo 
15 Euth  
No oedema, weight 
gain, thyroid disease, 
medication containing 
iodine 
TSH 1.4-4.5 
FT4 5.46-
12.48mg/100ml 
 
Renal function, 
ERPF, GRF, 
circulated plasma 
volume, packed 
blood cell mass  
No association of Schypo 
and blood volume or renal 
function 
Kosar F 
126
  
2005 
Turkey  
Case control  
Outpatients  
36 Schypo 
28 Euth 
controls 
Cardiovascular 
disease, systematic 
disease 
TSH >4.4 
 
PWTD for 
ventricular function  
Impaired systolic and 
diastolic function 
Sahin I
 131
 
2005 
Turkey 
Case control  
Outpatients 
31 Schypo  
28 control 
Cardiovascular 
disease, other chronic 
disease, no 
medications in the last 
2 weeks 
TSH 0.4-4.3 
FT4 within local 
reference range 
Heart Rate 
Variability (HRV) 
used to asses 
autonomic function 
Significantly reduced  time 
and frequency domains in 
severe Schypo TSH>10 
mIU/L 
Zoncu S 
127 
 
2005 
Italy 
Case control 
Outpatients 
Schypo  
22 Schypo 
13 healthy 
euthyroid 
subjects 
Not willing to consent  TSH 0.3-3.0 
FT4 6.6-16pg/ml 
 
Doppler echo, 
PWTDI 
impaired systolic and 
diastolic function 
 
Arinc H 
126
 
2006 
Turkey 
Case control  
Outpatients 
Adults 
63 Schypo 
20 age 
matched 
Euthyroid  
Chronic disease, 
obesity, alcohol users, 
smokers, familial 
hyperlipidaemia, drugs 
known to affect TF  
TSH <5 
FT4 10.3-24.5 
Tissue doppler to 
investigate 
ventricular function  
No changes in Schypo 
observed 
 
Iqbal A 
129 
 
2007 
Norway 
Population 
based 
health 
survey  
 
 
 
Adults >24  
n= 2035 
118 TSH 0.4-
5.25,  
66 TSH>5.25 
 
Known cardiovascular 
disease, valvular heart 
disease and receiving 
medication for 
hypertension 
Reference range 
defined statistically  
based upon TSH 
distribution of the 
sample e.g TSH at 
2.5- 97.5 percentiles 
0.4- 5.25,No FT4  
Left ventricular 
mass index, 
hypertension, 
diastolic blood 
pressure 
Schypo not associated with 
any parameters   
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Table 3.5 continued 
Author and 
date  
Design 
/setting 
Participants, 
age and thyroid 
status  
Exclusions TSH and FT4 
reference 
criteria  
Measures Outcome  
Iqbal A 
129
  
2007 
Norway 
Nested case 
control study 
Population 
based 
 
Adults 
n=7954 
162 Euthyroid 
66 Schypo 
Patients with 
historical or active 
coronary 
infarction, angina 
pectoris, stroke, 
TF4 outside 
reference criteria, 
and patients 
receiving 
treatment of 
hypertension or 
TD, over 80 years 
 
TSH 0.5-3.49  
FT4  
9-22  
Repeat TFT  
Echocardiography (ECG) 
and 
pulse wave tissue doppler 
 
 
Mainenti MR 
132
 
2007 
Brazil 
Cross- 
sectional, 
Case control 
Outpatients  
Adult women 30-
60 years   
15 Schypo  
16 euthyroid 
controls 
matched for 
smoking and 
menopause 
Drugs that 
interfere with TFT, 
presence of 
disease, MI in the 
last 3 months, 
pain or physical 
problems, 
hypertension, 
regular exercise 
TSH >4.0 
FT4 10.2-24.5 
Repeat TFT  
ECG, cardiopulmonary 
exercise test, blood 
pressure, heart rate, 
functional capacity 
Exercise duration shorter 
and achieved lower peak 
workload in Schypo 
compared to controls (11.5% 
vs 19%, p<0.0004) 
Ertugrul DT 
134
 
2008 
Turkey 
Cross 
sectional,  
case control,  
Outpatients 
 
39 Schypo  
33 euthyroid 
Pregnancy or 
lactation, Chronic 
disease, alcohol, 
drug abuse, 
malignancy 
TSH 0.45-4.5  
FT4 not explicit 
Single TFT 
BNP produced in 
ventricular myocardium = 
possible marker of 
cardiac 
dysfunction/damage 
Schypo Brain natriuretic 
peptide (BNP) similar to 
controls 
Akcakoyun M
128
 
2009 
Turkey 
Case control 
Outpatients 
25 Schypo 
25 controls 
Pregnancy, 
chronic disease, 
AF, medication 
known to alter 
heart rate and 
TFT 
TSH 0.4- 4.0 
FT4 0.8-
1.9ng/ml 
Mitral annular systolic 
and early diastolic 
velocities during exercise 
on tissue doppler echo 
Systolic and diastolic indices 
significantly lower in Schypo 
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3.2.5 Heart failure and subclinical hypothyroidism 
Based upon available data from one population based cohort aged 70-79 years, Biondi 
et al reported a possible link between individuals with subclinical hypothyroidism with 
serum thyrotrophin concentration greater than 7.0mIU/L and congestive heart failure. 135 
Subsequent long term data on heart failure data further substantiate and extend these 
findings. A recent prospective, community based longitudinal study with approximately 
12 years follow-up demonstrated a significantly greater incidence of heart failure in 
patients with serum thyrotrophin concentration greater than 10mIU/L compared with 
euthyroid controls. The incidence of heart failure in patients with a serum thyrotrophin 
concentration between 4.5-9.9mIU/L however was similar to the euthyroid group. 
Furthermore, two adverse electrocardiographic alterations associated with heart failure 
were found exclusively in the subclinical hypothyroidism group with serum thyrotrophin 
concentrations greater than 10mIU/L (Table 3.6). 136  
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Table 3.6 Heart failure and subclinical hypothyroidism  
Author and 
date  
Design 
/setting 
Participants, 
age and thyroid 
status  
Exclusions TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measures Outcome  
Rodondi N 
136
  
2008 
Switzerland 
 
Longitudinal 
population 
based cohort 
 
>65 years  
n=3044 
478 Schypo 
(n= 428 mild 
Schypo [4.5-9.9 
mIU/L ] and n=46 
severe Schypo  
[ >10 mIU/L]) 
2526 Euth  
Receiving 
treatment for 
thyroid dysfunction, 
corticosteroids, 
amiodarone. 
Known heart failure 
at baseline  
TSH 0.4-4.5  
FT4 9-22  
Single TFT 
ECG after 5 
years and heart 
failure events 
during 15 year 
follow-up  
Schypo with TSH 
>10mIU/L adjusted 
HR for heart failure 
1.88, 95% CI 1.05-
3.34. 
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3.2.6 Coronary heart disease and cardiovascular mortality 
Much attention has focused upon the link between subclinical hypothyroidism and 
coronary heart disease. Biondi et al report an increased risk of coronary heart disease in 
individuals with subclinical hypothyroidism aged 70 years of age or less, no association 
in the 70-80 year age group and a possible protective effect in individuals over 80 years 
of age.  137, 138 More recently, in an attempt to further clarify the cardiovascular risk of 
subclinical hypothyroidism, the thyroid studies collaboration group analysed individual 
level patient data from 11 large cohort studies. Results demonstrated no significant 
impact of subclinical hypothyroidism on coronary heart disease events (harzard ratio 
(HR) 1.18, 95% CI 0.99-1.42) or on cardiovascular mortality (HR 1.14, 95% CI 0.99-
1.32). After exclusion of individuals receiving treatment for thyroid dysfunction a 
modestly increased risk of coronary heart disease events (HR 2.17, 95% CI 1.19-3.93) 
was observed in individuals with more severe subclinical hypothyroidism characterised 
by serum thyrotrophin concentrations greater than 10mIU/L compared with euthyroid 
subjects. 139 Similarly, risk of cardiovascular mortality was slightly increased in 
individuals with severe subclinical hypothyroidism compared with euthyroid subjects (HR 
1.85, 95% CI 1.13-3.05). As indicated by the relatively wide confidence interval, these 
data are limited due to the small number of coronary heart disease events (n= 29) and 
deaths related to cardiovascular disease (n=15) in subjects with serum thyrotrophin 10-
19.9mIU/L. These associations did not differ significantly by age. Previously, data 
related to coronary heart disease and cardiovascular mortality were limited by differential 
measurement and adjustment of potential confounders across studies, an inability to 
disqualify selective reporting of outcomes, publication bias and bias associated with use 
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of aggregate data. Subsequent findings are based upon data at the individual patient 
level which are not subject to these limitations. These data provide good evidence that 
subclinical hypothyroidism is not associated with increased risk of coronary heart 
disease and cardiovascular mortality. 
 
3.3 Bone turnover  
While anomalies in bone turnover are generally linked to overt hyperthyroidism, two 
supplementary studies evaluating bone turnover in relation to subclinical hypothyroidism 
were retrieved. 140,141 One small all female case control study reported no association 
between subclinical hypothyroidism and any of the parameters that influence bone 
turnover. 142 Similarly, increased bone turnover was not significantly different in 
postmenopausal women with subclinical hypothyroidism compared with postmenopausal 
women with normal thyroid function. However, significant differences in parameters 
related to bone structure were described. 141 Biondi et al do not discuss bone turnover in 
relation to subclinical hypothyroidism (Table 3.7).  
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Table 3.7 Subclinical hypothyroidism and bone turnover 
Author and date  Design 
/setting 
Participants, age 
and thyroid status  
Exclusions TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measures Outcome  
Sekeroglu MR 
142
 
2006  
Turkey  
 
Case 
control  
Outpatients  
 
Women  
Adults  
16 Schypo 
15 age matched 
controls 
Inflammatory or 
autoimmune thyroid 
dysfunction  
TSH and FT4 not 
explicit. 
Single TFT 
Markers of 
bone 
metabolism to 
include 
cytokines 
interleukin 6 
(IL-6) and 
tumour 
necrosis factor 
alpha (TNF-α). 
Schypo not associated with IL-
6 and TNF-α 
Nagata M 
141
 
2007 
Japan 
Case 
control 
Outpatients  
 
50-87 years 
Post menopausal 
women  
22 Schypo  
24 control 
Historical or current 
thyroid dysfunction, 
chronic renal 
failure, parathyroid 
or calcium related 
diseases, history of 
therapy with 
glucocorticoids, 
calcium or vitamin 
D.  
TSH 0.05-4.0 
FT4 not explicit 
Structural 
strength of 
bone using 
quantitative 
ultrasound   
No association with bone 
metabolism. Structural strength 
of bone significantly reduced in 
Schypo ( 2.15 vs.2.35 
p<0.001)  
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3.4 Neuromuscular function and subclinial hypothryoidsm  
In terms of neuromuscular function, Biondi et al describe five studies exploring a wide 
range of neuromuscular alterations in individuals with subclinical hypothyroidism 
compared with euthyroid subjects. On the whole, Biondi et al reported considerable 
disagreement between studies exploring biological parameters that reflect 
neuromuscular status and muscle metabolism either during or in response to exercise. 
Two supplementary studies evaluating neuromuscular alterations described a 
significantly higher prevalence of neuromuscular complaints in individuals with 
subclinical hypothyroidism compared with euthyroid controls (Table 3.8). 143,144 
Furthermore, a greater frequency of reduced muscle strength assessed by an 
experienced physician using the manual muscle test was observed in those with 
subclinical hypothyroidism compared with euthyroid individuals. Since these two studies 
were conducted in an outpatient setting by the same research team and were relatively 
small (< 57 cases of subclinical hypothyroidism) the findings are unlikely to be applicable 
to other community dwelling or general populations (Table 3.8). Supplementary findings 
require replication in larger population based studies before the disagreements 
regarding the role of subclinical hypothyroidism in neuromuscular function can be 
reconciled.  
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Table 3.8 Neuromuscular effects of subclinical hypothyroidism  
Author and date  Design 
/setting 
Participants, 
age and 
thyroid status  
Exclusions TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measures Outcome  
Reuters VS 143  
2006 
Brazil 
Cross-
sectional,  
outpatients  
 
18-65 years  
57 Schypo 
37 euthyroid 
controls 
matched by 
age, gender, 
socioeconomic 
status and 
culture 
>20mIU/L, thyroxine 
replacement therapy, 
concomitant disease or 
medication known to 
interfere with thyroid 
function, other chronic 
disease  
 
 
 
 
TSH 0.4-4.0 
FT410.3-23.2 
Repeat TFT at 4 
week interval  
Muscle enzymes, 
signs and 
symptoms of 
skeletal muscle 
dysfunction 
Significantly greater prevalence 
of neuromuscular symptoms 
and significantly reduced 
muscle strength. Similar levels 
of muscle enzymes. 
Reuters VS 
144
 
2009 
Brazil 
 
Cross-
sectional, 
case 
control 
outpatients 
 
 
 
 
Adults  
44 Schypo  
24 Euth,  
Patients with TSH 
greater then 20mIU/L, 
treated for thyroid 
dysfunction, chronic 
disease, neuromuscular 
disorder, use of drugs 
affecting muscle 
metabolism and drugs 
that interfere with 
thyroid function 
TSH 0.4-4.0 
FT4 11.58-23.2 
Single TFT 
Muscle strength 
and functional 
capacity 
Greater prevalence of muscular 
complaints and reduced muscle 
strength. Functional capacity 
not affected  
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3.5 Neuropsychological function and subclincal hypothyroidism   
With respect to neuropsychological function the reviewers again report discordant 
findings between studies. Despite smaller studies presenting contradictory findings, 
Biondi et al described good evidence to demonstrate that subclinical hypothyroidism is 
not associated with depression, anxiety and cognitive impairment in elderly individuals. 
145 In one supplementary study, cognitive function and depressive symptoms in an 
elderly community dwelling cohort were examined by a psychologist. The results 
demonstrated an increase in depressive symptoms in individuals with subclinical 
hypothyroidism compared with euthyroid individuals. The differences observed did not 
reach statistical significance. Similarly, no significant differences in cognition were 
reported between these groups. This study was however limited by a response rate of 
only 10.5% therefore findings cannot be considered representative of the wider 
population from which the study sample was drawn. 146 A significant increase in the 
frequency of psychiatric diagnosis based upon structured clinical interview was reported 
in a cross-sectional study of 94 middle aged outpatients with subclinical hypothyroidism 
compared with 43 age and education level matched euthyroid subjects. 147 This study 
also described a significant increase in the prevalence of anxiety symptoms as 
measured by the Hamilton anxiety and depression scales and a two-fold increased risk 
of depressive symptoms in individuals with subclinical hypothyroidism compared with 
euthyroid subjects. The higher prevalence of psychiatric diagnosis in individuals with 
subclinical hypothyroidism may, however, be subject to investigator bias since all 
interviews were conducted by one examiner who had knowledge of the subjects‟ thyroid 
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function categorisation. On the whole these studies do not demonstrate that subclinical 
hypothyroidism impacts upon anxiety, depression and cognitive function in elderly 
individuals. Data are less clear with respect to younger adults (Table 3.9). 
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Table 3.9 Neuropsychological function and subclinical hypothyroidism   
Author and 
date  
Design 
/setting 
Participants, 
age and 
thyroid 
status  
Exclusions TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measures Outcome  
Manciet G 
146
 
1995 
France 
Community 
based 
 
> 65 yrs 
18 Schypo, 
18 Schyper, 
378 Euth 
Under 65 years, 
unwilling to give 
consent 
TSH 0.5-4.5 
FT4 16-29 
Symptoms of 
depression and 
cognitive 
impairment 
Lower scores in Schypo 
not significantly different  
MMSE <23  
n=5 Schypo <23 
 
 
Almeida C 
147 
2007 
Brazil 
Cross- 
sectional 
outpatients 
94 Schypo 
43 controls 
Severe chronic 
illness, drugs that 
might interfere with 
TFT, TSH >20mIU/L 
TSH >4  
FT4 10.3-23.2 
Repeat TFT 
Psychiatric 
disease DSM-IV   
Schypo associated with 
symptoms of depression 
and anxiety on HADS and 
Beck Inventory 
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3.6 Natural history and progression to overt hypothyroidism  
Individuals with subclinical hypothyroidism are at risk for progressing to overt 
hypothyroidism, however the natural history is poorly defined. The reviewers describe 
variable findings with studies providing a range of estimates for spontaneous resolving 
and evolving serum thyrotrophin concentrations and several prognostic indicators for 
increased risk of progression. 91 Based on the available data, Biondi et al propose that 
progression to overt hypothyroidism is related to the cause of thyroid dysfunction, and is 
correlated positively with increased basal serum thyrotrophin concentration and with 
older age. Biondi et al recommend monitoring to confirm persistent subclinical 
hypothyroidism.  
Only one supplementary study exploring the natural history of subclinical hypothyroidism 
was identified. 79 Meyerovitch et al examined data from a large health care database in 
order to determine progression to overt hypothyroidism over a period of five years in 
individuals with an initial elevated serum thyrotrophin level and not receiving 
replacement therapy. The reported rate of progression from subclinical hypothyroidism 
to overt hypothyroidism over a five year period was only 2.9%. 79 Although subclinical 
hypothyroidism can lead to overt hypothyroidism, progress is generally slow. (Table 
3.10).  
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Table 3.10 Natural history of subclinical hypothyroidism 
Author and date  Design 
/setting 
Participants, 
age and 
thyroid 
status  
Exclusions TSH and FT4 
reference criteria 
and frequency of 
TFT 
Measures Outcome  
Meyerovitch J 
79
  
2007 
 
Retrospective  
survey health 
care 
database 
 
Adults 
n=422242 
 
Known thyroid 
dysfunction, treated 
with drugs known to 
interfere with thyroid 
dysfunction, pregnant 
TSH 0.35-5.5 
FT4 10.3-20  
 
Progression 2.9% progressed to 
overt 
hypothyroidism 
during 5 year follow 
up period 
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Summary of chapter 3 
In this chapter, evidence from a systematic review which compiled data related to 
subclinical hypothyroidism from studies published between 1970 and April 2007 and 
available supplementary data related to the clinical signs and pathophysiological 
consequence of subclinical hypothyroidism have been reviewed and summarised. In 
general, the current literature review contributed little additional, robust and 
generalisable data to further substantiate or significantly alter the conclusions reached 
by Biondi et al.  
Cardiovascular risk seems to be a likely adverse consequence of subclinical 
hypothyroidism; however the mechanisms for this remain unclear. To date, the evidence 
for cardiac impairment and development of cardiovascular disease in subclinical 
hypothyroidism is inconsistent. In general, supplementary evidence generated by 
multiple small studies has not been corroborated by larger population based studies. 
Whilst studies of cardiac function have consistently shown alterations in measurable 
parameters, few studies demonstrate the same constellation of abnormalities. 
Accelerated atherosclerosis in subclinical hypothyroidism is thought to occur by multiple 
mechanisms, however the majority of the evidence indicates that lipid parameters in 
individuals with subclinical hypothyroidism are similar to age and gender matched 
euthyroid controls. Furthermore, the evidence of a role for novel risk factors for 
cardiovascular disease in the development of atherosclerosis is weak due to data being 
derived from small, highly selected samples. These data require replication in larger, 
more representative groups. In relation to heart failure, coronary heart disease and 
cardiovascular mortality, supplementary and subsequent studies provide good evidence 
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which further corroborate and extend Biondi et al‟s findings that subclinical 
hypothyroidism is not associated with increased risk of coronary heart disease, heart 
failure or cardiovascular mortality.  
Multiple reasons for the lack of consistent findings reported have been proposed. 
Differences in the assay methods and diagnostic criteria for subclinical thyroid 
dysfunction are frequently observed. Other possible explanations for the conflicting data 
are differences in inclusion and exclusion criteria employed with regard to individuals 
with known thyroid disease. Furthermore, heterogeneity of the underlying cause and 
duration of subclinical hypothyroidism may lead to disparate findings. Similarly, 
differential definition of outcome measures and identification of and adjustment for 
confounders may contribute to the conflicting results reported.  
So far, this work has established that subclinical hypothyroidism, like the overt form of 
the condition, is a common disorder particularly in the elderly. The pathophysiological 
consequences of subclinical hypothyroidism are, however, less well established with 
studies reporting inconsistent findings. 
 
In the current chapter literature relating to the pathophysiological consequences of 
subclinical hypothyroidism was reviewed and summarised. In the next chapter literature 
related to the pathophysiological consequences of subclinical hyperthyroidism will be 
presented.  
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CHAPTER 4 PATHOPHYSIOLOGY OF SUBCLINICAL HYPERTHYROIDISM 
 
Overview of chapter 4 
Research related to subclinical hyperthyroidism covers both endogenous and 
exogenous subclinical hyperthyroid dysfunction. The terms endogenous and exogenous 
are used to define the origins of the disease, with endogenous being indicative of 
spontaneous disease, (endo denotes from within) and exogenous disease defining 
disease of external origin (exo denoting external). The principal difference between 
these subgroups of subclinical hyperthyroidism is that the exogenous form has been 
induced either intentionally or unintentionally, through administration of thyroxine (or 
other thyroid hormone) replacement therapy. Other important differences also exist 
between endogenous and exogenous subclinical hyperthyroidism. While the aetiology of 
exogenous subclinical hyperthyroidism is straightforward and well understood, the 
endogenous form has a variety of causes which require consideration. Euthyroid status 
is more easily achieved in exogenous subclinical hyperthyroidism through manipulation 
of thyroxine replacement therapy and the exogenous form does not carry the risk of 
progression to overt hyperthyroidism. The duration and degree of exogenous subclinical 
hyperthyroidism can be more easily calculated and defined. For these reasons, 
exogenous subclinical hyperthyroidism has been more widely studied. Due to the 
differences described, extrapolation of findings from one subgroup to the other should 
be considered with caution. This chapter will therefore focus solely upon endogenous 
subclinical hyperthyroidism since it is the clinical consequences and characteristics of 
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the spontaneous form of this diagnosis that are less established and are more frequently 
problematic for primary care practitioners. 
In this chapter, the results of the literature search related to the pathophysiological 
consequences of endogenous subclinical hyperthyroidism are presented and 
summarised in conjunction with the recent systematic review by Biondi et al.  
 
4.1 Result of the literature search 
The search strategy and inclusion/exclusion criteria have been previously described in 
chapter 3. The electronic searched retrieved 350 results. Abstracts of these articles were 
screened to assess the inclusion/exclusion status of each publication. In total 270 
papers were excluded (Table 4.0). A considerable number of retrieved articles (n=70) 
were excluded from discussion in the current chapter because the studies were 
unrelated to investigation of the detrimental effects of subclinical hyperthyroidism. A 
large proportion of reviews were also excluded as they were not systematic in their 
approach (n=67), they focused on treatment for subclinical thyroid dysfunction, or the 
study employed an intervention (n=51). A further 24 duplicate articles were excluded 
because they had been included in the systematic review by Biondi et al and as such 
would not contribute additional data for examination within the scope of the current 
chapter.  
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Table 4.0 Exclusion of literature; subclinical hyperthyroidism  
Reason for exclusion of retrieved publications Articles excluded 
Not related to adverse consequences of SCTD 70 
Non systematic reviews 67 
Studies of intervention or reviews of treatment 51 
Diseased populations  35 
Case studies 23 
Letters 9 
Pregnant and post natal women only 6 
Research in children 4 
Discussion paper/ editorial 3 
Superseded systematic review and meta analyses 1 
Non human subject  1 
Total number of articles excluded  270 
 
 
A large body of the literature retrieved (n=35) focused upon subclinical hyperthyroidism 
in specific population subgroups with significant disease. Further examination of this 
literature has not been undertaken because the principal focus of this chapter is 
exploration of the adverse health consequences of subclinical hyperthyroidism in a  
„normal‟ population. Despite the application of limits restricting the searches to studies of 
adult humans it was also necessary to exclude four studies of subclinical 
hyperthyroidism in children and adolescents and one animal study. Furthermore, 23 
case studies, six studies of subclinical thyroid dysfunction in pregnancy, nine letters, 
three discussion papers and one superseded meta analysis on mortality in subclinical 
hyperthyroidism are not examined further within this chapter.      
 
Forty two articles remained following application of the inclusion criteria, the systematic 
review by Biondi et al; 11 supplementary studies published before; but not cited in the 
review by Biondi et al; 20 subsequently published articles, and 10 publications related to 
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symptom expression in subclinical hyperthyroidism (Figure 4.0). The findings of all 31 
studies are presented and summarised alongside the relevant conclusions drawn by 
Biondi et al. Throughout this chapter the systematic review will be designated „Biondi et 
al„and the terminology „supplementary‟ and „subsequent‟ respectively will be applied to 
publications that either pre or post date the systematic review by Biondi et al. Articles 
related to expression of symptoms in subclinical hyperthyroidism are presented and 
discussed in Chapter 6. 
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Figure 4.0 Flow diagram: literature related to subclinical hyperthyroidism  
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4.2 Cardiovascular consequences of subclinical hyperthyroidism 
The effects of overt hyperthyroidism on the cardiovascular system are well established, 
however, findings from the large body of research evaluating the cardiovascular 
consequences of subclinical hyperthyroidism are less consistent. 
 
4.2.1 Subclinical hyperthyroidism and atrial fibrillation 
In terms of cardiac function, Biondi et al reported substantial evidence indicating a 
higher risk of atrial fibrillation (AF) in elderly individuals with subclinical hyperthyroidism. 
91 The estimates of relative risk reported for atrial fibrillation in individuals with subclinical 
hyperthyroidism compared with age matched controls ranged from 1.6 to 5.0, with some 
studies also suggesting a greater likelihood of AF in individuals with more severe 
subclinical hyperthyroidism (defined by serum thyrotrophin concentrations less than 
0.1mIU/L) than individuals with milder subclinical hyperthyroidism (characterised by 
serum thyrotrophin concentration of between 0.1- 0.4mIU/L). 148, 149,150  
One subsequent cross sectional community based study also revealed an increased 
likelihood of AF in elderly individuals with subclinical hyperthyroidism compared with 
euthyroid individuals (OR 1.87, 95% CI 1.01-3.57). 151 In this cohort the prevalence of 
AF in patients with more severe subclinical hyperthyroidism defined as undetectable 
serum thyrotrophin concentration and individuals with milder subclinical hyperthyroidism 
characterized by serum thyrotrophin of 0.1-0.3mIU/L was not significantly different (3.7% 
versus 11.1% respectively, p <0.46). Data related to the prevalence of AF in these 
subgroups of subclinical hyperthyroidism should be interpreted with caution however, 
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because this study was inadequately powered to detect a 7% difference in AF 
prevalence between these small subgroups of subclinical hyperthyroidism (e.g AF and 
mild subclinical hyperthyroidism n= 1, AF and severe subclinical hyperthyroidism n= 11). 
Data from smaller studies evaluating cardiac function by means of ECG lend further 
support to these findings and further provide biological plausibility to the statistically 
significant association. Two supplementary case control studies examining cardiac 
function by means of standard 12-lead electrocardiogram (ECG) also observed 
differences in markers for AF between individuals with subclinical hyperthyroidism and 
euthyroid controls. 152,153 In one investigation, significantly longer corrected QT intervals 
were observed in 32 individuals with subclinical hyperthyroidism compared with 39 
euthyroid controls. 152 Likewise, Cetinsarslan et al observed significantly higher P wave 
dispersion in 36 cases compared with 22 age and gender matched controls. 153 On the 
whole there is consistent evidence demonstrating an association between subclinical 
hyperthyroidism and AF in older individuals with severe subclinical hyperthyroidism 
characterised by serum thyrotrophin of less than 0.1mIU/L (Table 4.1).  
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Table 4.1 Literature related to subclinical hyperthyroidism and AF  
Author, 
publication date  
Design 
/setting 
Participants 
age and 
thyroid status 
Exclusion criteria TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measures 
 
Outcome 
Cetinarslan B 
153
 
2003 
Turkey 
Case control  
outpatient  
 
Adults ≥18 yrs 
36 Schyper  
22 age/ gender 
matched 
euthyroid 
controls 
 
Historical or concomitant 
chronic disease, 
pregnancy, depression, 
alcoholism or receiving 
medication known to 
affect ECG parameters  
TSH and FT4 
not explicit 
Single FTF  
 
ECG parameters 
predictive of AF 
Predictive 
accuracy Pmax = 
84%  
Pdis = 89% 
Maximal P wave duration 
(Pmax) similar. Significantly 
higher (6 units, p<0.03) P 
wave dispersion 
(Pdis=Pmax-Pmin) in 
Schpyer  
Gammage MD
151
  
2007 
UK 
Cross 
sectional, 
Community 
 
5881  
>65 years 
126 Schyper 
5519 euthyroid 
  
History of 
hyperthyroidism, currently 
receiving treatment for 
thyroid dysfunction 
TSH 0.4-5.5  
FT4 9-20 
Single TFT  
AF on ECG 
Higher prevalence of AF in 
Schyper compared with 
controls (9.5% vs 4.7%, 
p<0.01) 
 
Owecki M 
152
 
2006 
Poland 
Case control 
Outpatients 
Adults ≥18 
years 
32 Schyper  
39 controls  
Unable to source full 
article however results 
generated in this small 
select population is 
unlikely to significantly 
alter conclusions of 
Biondi et al 
TSH 0.2-4.0 
FT4 7.60-
19.67 
QTc interval 
measured by 12 
lead 
electrocardiogra
m (ECG)r 
 
QT intervals significantly 
longer in Schyper than in 
controls 0.434s vs 0.414s 
respectively p<0.001 
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4.2.2 Cardiovascular risk factors and subclinical hyperthyroidism 
Recent investigation of blood pressure variables in a prospective population based 
German cohort reported no association between subclinical hyperthyroidism and 
changes in blood pressure, pulse pressure or incident hypertension. These findings may 
have limited generalisability since the subgroups excluded and lost to follow-up were 
significantly older than the final population included in the analysis. 154 Likewise, no 
association between subclinical hyperthyroidism and hypertension was observed in two 
cross-sectional, population based studies of Japanese individuals not treated for thyroid 
disease.  97,98 The Suita study also demonstrated no association between subclinical 
hyperthyroidism and abnormal carotid artery intima media thickness (a marker of 
atherosclerosis). In contrast, Dorr et al demonstrated a higher prevalence of carotid 
plaques in 225 individuals aged 45 years and above with subclinical hyperthyroidism 
compared with 1839 euthyroid subjects (Table 4.2). 108 Furthermore, results 
demonstrated a significantly increased likelihood of presence of carotid artery plaques 
(adjusted OR 1.67, 95% CI 1.11-2.51) and for prevalent stroke (OR 1.98, 95% CI 1.05-
3.73) in individuals with subclinical hyperthyroidism compared with euthyroid subjects. 
The contradictory findings reported by these studies may be explained by differences in 
study design and genetic background and lifestyles of the populations studied. Since 
Japan is an iodine replete region and Germany is a formerly iodine deficient area, 
disparity in dietary iodine intake between the two populations could account for the 
differences observed. In accordance with one study described by Biondi et al, Coban et 
al demonstrated a significant increase in the concentration of D-dimer and fibrinogen in 
36 individuals with subclinical hyperthyroidism compared with 36 age and gender 
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matched controls. 155 Elevated concentrations of fibrinogen and D-dimer are potentially 
clinically important because these coagulation parameters are associated with increased 
risk of future myocardial infarction, stroke, and peripheral vascular disease. In contrast 
to one study described by Biondi et al, one supplementary case control study 
demonstrated significantly elevated concentrations of endothelial markers in individuals 
with subclinical hyperthyroidism compared with euthyroid controls. 156, 157 Pooling of data 
on coronary heart disease events originating from five population based, prospective 
cohort studies failed to demonstrate a significant impact of subclinical hyperthyroidism 
on coronary heart disease (HR 1.21 95% CI 0.88-1.68). 158  
In summary, Biondi et al and supplementary data demonstrate contradictory findings 
with respect to the association between subclinical hyperthyroidism and various risk 
factors for atherosclerosis and cardiovascular disease. Although population based 
studies have been conducted, findings are inconsistent due to the heterogeneity of the 
populations studied and outcomes measured. Furthermore, casual relationships are 
difficult to establish based upon data derived from studies of cross-sectional design. 
Additional longitudinal investigations of population based cohorts are required to 
reconcile current disagreement with respect to the relationship between subclinical 
hyperthyroidism and these potentially important cardiovascular risk factors.  
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Table 4.2 Cardiovascular risk factors and subclinical hyperthyroidism  
Author, 
publication 
date  
Design 
/setting 
Participants Exclusion 
criteria 
TSH and FT4 
reference criteria 
and frequency of 
TFT 
Measures 
 
Outcome 
Coban E 
156
 
2006  
Turkey 
Case 
control  
Outpatient  
 
Adults  
20 Schyper  
20 age, 
gender, BMI 
matched 
controls 
All antibody 
positive 
Hypertension, 
diabetes mellitus, 
smoking, alcohol, 
systemic disease, 
medication known 
to affect TFT and 
platelet function 
TSH 0.27-4.2  
FT4 11.97-21.9 
Single TFT 
von Willebrand 
factor (vWf) a 
marker of 
endothelial 
damage 
Significantly higher levels 
vWf in Schyper  
Takashima N 
97
 
2007 
Japan 
Cross 
sectional, 
Community 
based  
 
n=3607  
377 Schypo 
77 Schypo 
3130 Euth 
Patients treated 
for thyroid 
dysfunction 
TSH 0.43- 3.78  
FT4 12.9-21.9  
Single TFT 
IMT surrogate 
marker of 
atherosclerosis 
Glucose 
metabolism and 
lipid metabolism  
No association with 
hypertension. Schyper 
associated with increased 
HbA1c and Fasting Blood 
Glucose (FBG) on adjusted 
analysis 
Coban E 
155
 
2008 
Turkey 
Case 
control  
Outpatients 
 
36 Schyper  
36 age,  
gender and 
BMI matched 
euthyroid 
controls  
 
Concomitant 
medication 
chronic and 
systemic disease, 
smoking, alcohol, 
MI, stroke, 
hypertension, 
unstable angina 
and peripheral 
neuropathy 
TSH 0.27-4.2 
FT4 11.97-21.9 
Single TFT  
Biomarkers for 
endothelial 
dysfunction  
 
Fibrinogen ( 296.9 vs 255.0, 
p=<0.001) and D dimer 
261.9 vs 216.4, p<0.001) 
concentration significantly 
higher in Schyper than 
controls 
 
Dorr M 
108
 
2008 
Germany 
Population 
based 
cohort 
 
 
 
 
>45 years 
225 Schyper 
1839 Euth  
Known or possible 
thyroid disease 
TSH 0.25-2.12 
FT4 10-25 
 
Carotid artery 
plaques using 
ultrasound / 
prevalence of 
stroke reported 
physicians 
diagnosis 
Significantly elevated odds 
for presence of carotid 
artery plaques at any 
location compared with Euth 
(adjusted OR 1.67, 95% CI 
1.11-2.51) increased odds 
for prevalent stroke (OR 
1.98, 1.05-3.73) 
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Table 4.2 continued 
Author, 
publication 
date  
Design 
/setting 
Participants Exclusion criteria TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measures 
 
Outcome 
Duan Y 
98
 
2009 
China  
Cross 
sectional, 
community  
 
5669 Euth 
108 Schyper  
Systemic disease, 
pregnancy, 
medicines known to 
interfere with TF 
TSH 0.4-4.5 
FT4 10.3-24.5  
Single FTF 
Blood pressure No association with blood 
pressure 
Volzke H 
154
 
2009 
Germany 
Prospective 
population 
based cohort  
 
20-79 years  
n=2910 
203 Schyper 
2707 Euth 
Overt thyroid 
dysfunction and 
FT4 > 18.9 
TSH 0.25 – 2.12 
FT4 <18 
Baseline and 
follow-up TFT for 
50% of baseline 
cohort 
BP 5yr Follow-up No association with blood 
pressure/pulse pressure or 
incident hypertension 
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4.2.3 Subclinical hyperthyroidism and cardiac function 
Biondi et al also describe studies evaluating endogenous subclinical hyperthyroidism 
using ECG and Doppler echocardiography and suggest an increase in heart rate and a 
higher prevalence of atrial premature beats in individuals with endogenous subclinical 
hyperthyroidism. In a subsequent study using Doppler echocardiography, Rosario et al 
demonstrated significant increases in systolic dysfunction in 48 women with endogenous 
subclinical hyperthyroidism compared with 48 age and BMI matched euthyroid controls. 
159   Significant increases in diastolic function in women with subclinical hyperthyroidism 
compared with controls were also observed. Since all participants were women aged 
under 65 years, these findings may not be applicable to older women. Left ventricular 
mass index was also investigated in the Tromso studies. 129 These studies employed 
two research methodologies; a population based study and a nested case-control study 
with refined inclusion/exclusion criteria to minimise misclassification of thyroid function 
status and improve clinical relevance. The epidemiological study which included 2035 
adults without known cardiovascular disease did not demonstrate an association 
between serum thyrotrophin concentration and cardiac function as indicated by left 
ventricular mass index measured by conventional echocardiography. Similarly, in the 
nested case control study, no differences in cardiac function between the thyroid 
function groups were observed via conventional echocardiography. However, data 
derived from pulse wave tissue Doppler echocardiography of the mitral annulus adjusted 
for age, gender, body mass index (BMI) and blood pressure demonstrated statistically 
significant differences in wave velocities between 20 individuals with subclinical 
 94 
hyperthyroidism compared with 118 euthyroid individuals.  129   The clinical significance 
of these small increases in wave velocity are as yet undetermined. These alterations 
may constitute the pathophysiological link between subclinical hyperthyroidism and 
adverse clinical cardiac events.  
Similarly, no differences in left ventricular function were observed in 24 newly 
diagnosed, untreated individuals with subclinical hyperthyroidism compared with 24 age 
and gender matched controls. 160 This study, which employed intra-myocardial ultrasonic 
and colour Doppler imaging techniques to assess cardiac function, did demonstrate 
impaired systolic function and cardiac contractility in individuals with subclinical 
hyperthyroidism. However, issues in the study design such as recruitment from an 
outpatient setting and exclusion of older individuals, smokers and patients with 
hypertension and abnormal lipid parameters mean that these findings are unlikely to be 
generalisable to the general population.   
More recently a cross-sectional study of 150 outpatients in Turkey reported serum 
concentrations of brain natriuretic peptide (BNP) in individuals with endogenous 
subclinical hyperthyroidism almost five times higher than in euthyroid controls. 134 Brain 
natriuretic peptides which are produced by ventricular myocardium are increased in left 
ventricular dysfunction and are predominantly used in the diagnosis of systolic heart 
failure. Although study participants did not have any history or physical signs and 
symptoms of cardiac dysfunction, left ventricular function was not assessed using 
echocardiography. It is possible that some of the participants had mild diastolic 
dysfunction that was not clinically apparent and was present before development of 
subclinical hyperthyroidism. An independent and statistically significant effect of 
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subclinical hyperthyroidism on serum BNP concentration was reported, but the clinical 
significance of these findings has yet to be fully elucidated. 134  
Two small supplementary studies evaluating heart rate variability observed alterations in 
cardiovascular autonomic balance in individuals with subclinical hyperthyroidism 
compared with euthyroid individuals. Heart rate variability is a term used to describe 
variations in the beat to beat interval between heart beats and reflects the balance 
between the sympathetic and parasympathetic nervous systems. In one of these 
studies, heart rate variability in 12 individuals with endogenous subclinical 
hyperthyroidism, 19 with overt hyperthyroidism and 32 euthyroid controls was assessed 
in order to characterise autonomic control in the lying and standing positions. 161 
Although not significantly different to euthyroid or overt hyperthyroid individuals, many 
parameters in the group with subclinical hyperthyroidism were intermediate between 
individuals with overt hyperthyroidism and euthyroidism. These observations support the 
suggestion that there is a continuum of effects as degree of thyroid dysfunction 
increases. In the second study, heart rate variability in the high frequency and low 
frequency domains was assessed at rest and after vagal and sympathetic stimulation 
using the tilt test. Sixteen otherwise healthy women with endogenous subclinical 
hyperthyroidism and 16 euthyroid controls participated. A significantly lower difference in 
low frequency and high frequency ratio after tilting and low frequency and high 
frequency ratio at rest was observed in individuals with subclinical hyperthyroidism 
compared with controls (Table 4.4). 162 On the whole, supplementary data consistently 
demonstrate reduced heart rate variability indicative of modified autonomic function in 
individuals with subclinical hyperthyroidism. However, these data should be interpreted 
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with caution as they have been derived in small cohorts that are unlikely to be 
representative of the general population. The long term effects of various 
echocardiographic abnormalities and the relationship between endogenous subclinical 
hyperthyroidism and heart failure events were investigated in a large community 
dwelling elderly cohort. 136 At baseline a significantly impaired diastolic function and 
significantly increased heart rate was described between individuals with endogenous 
subclinical hyperthyroidism and euthyroid subjects. After 12 years of follow–up, 
however, no significant differences in incident heart failure events were observed 
between the groups, suggesting that these cardiac abnormalities do not result in heart 
failure in individuals with subclinical hyperthyroidism (Table 4.3). 136 More recently, 
electrocardiographic investigation of left ventricular function was undertaken at baseline 
and after five years of follow-up in 107 adults older than 45 years with subclinical 
hyperthyroidism and 1005 similarly aged euthyroid subjects. Results demonstrated that 
subclinical hyperthyroidism had no impact upon left ventricular function during this 
period. 163 Additional longitudinal studies in cohorts covering a wider age range are 
necessary to further establish the validity of these findings and enable extrapolation of 
data to younger populations. In summary, a variety of cardiac parameters and 
cardiovascular outcomes have been examined in relation to subclinical hyperthyroidism. 
Whether these statistically significant differences translate to clinically significant 
impaired cardiovascular performance is uncertain. On the whole, representativeness of 
the populations studied is reduced by stringent inclusion/exclusion criteria and 
recruitment of small samples from outpatient clinics. Additionally, data derived from 
larger population based studies often do not corroborate the findings of smaller studies. 
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Supplementary data fully support the conclusions made by Biondi et al with respect to 
the relationship between subclinical hyperthyroidism and AF. Whilst there is consistent 
evidence demonstrating an increased risk of AF in elderly individuals with subclinical 
hyperthyroidism, risk estimates vary considerably and have yet to be fully established.  
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Table 4.3 Cardiac function and subclinical hyperthyroidism  
Author, 
publication 
date  
Design 
/setting 
Participants; 
age and 
thyroid status  
Exclusions  TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measure 
 
Outcome 
Goichot B 
161
 
2004 
France   
Case control 
Outpatient  
 
Adults ≥18 
years 
12 Schyper 
32 controls 
  
Concomitant beta 
blocker, 
amiodarone or 
other anti-
arrhythmic 
medication,  
TSH 0.15-4.5  
FT4 9.5-18  
Single TFT 
Heart rate variability  
Evidence of changes in 
autonomic response not 
significantly different to 
controls 
Di Bello 
160
 
2007  
Italy 
Case control 
Outpatient  
 
Young adults 
24 new schyper 
untreated  
24 age/sex 
matched 
controls   
Patients with 
hypertension, 
abnormal lipid 
parameters and 
smokers  
 
TSH 0.3-3.8 
FT4 7.0-17.0 
Single TFT 
Cardiac evaluation by 
ECG Intra myocardial 
ultrasonic techniques 
and colour (CDMI) 
 
Modified systolic and diastolic 
function however no left 
ventricular hypertrophy in 
Schyper  
Iqbal A 
129
  
2007 
Norway 
 
 
Population 
based health 
survey  
 
 
with 
 
 
 
 
Nested case 
control study 
 
Adults >24 yrs 
n= 2035 
52 TSH < 0.4,  
118 TSH 0.4-
5.25,  
66 TSH >5.25 
 
Known 
cardiovascular 
disease, receiving 
medication for 
hypertension 
Reference 
range 
statistically  
defined by 
sample TSH 
0.4- 5.25  
No FT4 
measured 
Echocardiographic 
parameters  
No association between TSH 
and LVMI, systolic blood 
pressure or heart rate after 
adjusting for age, BMI and 
systolic blood pressure 
Adults 
n=7954 
20 Schyper 
162 Euthyroid 
66 Schypo 
Patients with 
historical or active 
coronary infarction, 
angina pectoris, 
stroke, TF4 outside 
reference criteria, 
treatment of 
hypertension or TD, 
over 80 years 
TSH 0.5-3.49  
FT4 9-22  
Repeat TFT  
Echocardiographic 
and parameters  
pulse wave tissue 
Doppler indices 
 
LVMI similar, S and A wave 
velocities significantly 
increased in Schyper 
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Table 4.3 continued 
Author, 
publication 
date  
Design 
/setting 
Participants; 
age and 
thyroid status  
Exclusions  TSH and 
FT4 
reference 
criteria and 
frequency 
of TFT 
Measures 
 
Outcome 
Portella RB 
162  
2007 
Brazil 
 
Cross 
sectional, 
case 
control 
study 
Outpatient  
 
>60 years 
16 Schyper  
16 euthyroid 
controls similar 
socioeconomic 
status 
 
Those with Schyper 
for <6 months, 
concomitant illness or 
medication TFT or 
cardiovascular 
system 
 
TSH 0.4-4.0  
FT4 10.3-
24.4  
Heart rate variability using 
the tilt test (marker of CV 
autonomous function)  
Cardiovascular modulation 
significantly affected by 
Schyper 
Ertugrul DT 
134
 
2008 
Turkey 
 
Cross 
sectional,  
Case 
control 
Outpatient  
 
18-82 years 
47 Schyper 
33 euthyroid 
age/ gender/ 
BMI matched  
controls  
Pregnancy historical 
or concomitant 
systemic disease  
alcohol or drug abuse 
or malignancy 
TSH 0.45-
4.5 FT4 not 
explicit 
Single TFT 
Brain Natriuretic Peptide 
(BNP) concentration 
as marker of cardiac 
function produced by 
ventricular myocardium 
Significant increase in BNP 
in Schyper (31.2 ng/L vs 
23.0, p<0.0001)group 
compared to controls 
Rodondi N 
136
 
2008 
Switzerland 
 
Longitudin
al 
population 
cohort 
 
>65 years  
n=3044 
44 Schyper 
2526 Euth  
Receiving treatment 
for thyroid 
dysfunction, 
corticosteroids, 
amiodarone. Known 
heart failure at 
baseline  
TSH 0.4-4.5  
FT4 9-22  
Single TFT 
ECG at 5 yrs. Heart failure 
events 15 yrs follow-up 
(diagnosis or treatment of 
heart failure, and by 
consideration of symptoms, 
signs, chest radiographs 
Increased heart rate ( 69 vs 
64 p<0.05) Schyper not 
increased risk of heart 
failure 
 
Rosario PW
159
 
2008 
Brazil 
Case 
control  
Outpatient  
 
Women <65   
48 Schyper 
48 age, 
menopause, 
BMI matched 
controls 
Heart disease, 
hypertension, treated 
for osteoporosis or 
using oestrogen or 
corticosteroids 
TSH 0.3-5.0  
FT4 9.63-
23.17  
Repeat TFT 
 
Cardiac morphology and 
function 
Cardiac morphology and 
function significantly 
different in Schyper and 
controls. 
Dorr M 
163 
 
2010 
Germany 
Longitudin
al cohort 
>45 years 
3300 Euth 
107 schyper 
Known or possible 
thyroid disease 
TSH <0.3 
FT4 10-25 
 
Left ventricular function  No association with cardiac 
mass or development of left 
ventricular hypertrophy 
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4.3 Subclinical hyperthyroidism and mortality 
Biondi et al describe conflicting data related to increased cardiovascular mortality. 
91,137,165 One supplementary meta analysis of mortality data reported a modestly 
increased risk of mortality from all causes in individuals with subclinical hyperthyroidism 
compared with euthyroid controls (HR 1.41, 95% CI 1.12-1.79). 165 This meta analysis 
pooled mortality data for 290 individuals with subclinical hyperthyroidism originating from 
seven cohort studies exploring mortality from all causes. Excess mortality at 2, 5 and 10 
years after diagnosis of subclinical hyperthyroidism was reported by gender and age at 
the time of diagnosis. At any age, excess mortality after diagnosis was greater in men 
than women. Moreover, low excess mortality was described in both men and women 
until the age of 50, beyond which risk more than doubled with each decade. After the 
age of 80 years, however, excess risks started to decline suggesting a survival effect 
(Table 4.4). 165 The data related to excess mortality after diagnosis of subclinical 
hyperthyroidism are inherently limited by the fact that thyroid function may not be stable 
over time. Findings from another subsequent meta analysis of mortality data derived 
from five prospective population based cohorts demonstrated no significant impact of 
subclinical hyperthyroidism on total mortality (RR 1.12, 95% CI, 0.89-1.42) or 
cardiovascular mortality (RR 1.19, 95% CI, 0.81-1.76). Furthermore no differences by 
mean age were described. 158 These findings should be interpreted with caution since 
meta analyses of observational studies cannot prove that a risk does not exist and are 
subject to ecological fallacy as they are reliant upon aggregate rather than individual 
patient data. In contrast, a much more recent longitudinal study reported significantly 
higher hazard ratios for Japanese-Brazilian individuals with subclinical hyperthyroidism 
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in comparison with euthyroid subjects with respect to all cause mortality (HR 3.0, 95% 
CI, 1.5-5.9, n=14 (20.3%) versus n=52 (5.7%) respectively ) and cardiovascular mortality 
(HR 3.3, 95% CI 1.4-7.5, n=8 (11.6%) versus n=26 (2.8%) respectively). 166  Due to the 
small number of cardiovascular deaths (n=8) identified, it is possible that this study was 
not adequately powered to detect a meaningful association between subclinical 
hyperthyroidism and cardiovascular mortality. Furthermore, since thyroid function was 
only assessed at baseline, hazard ratios may be influence by development of overt 
hyperthyroidism and may not be exclusive to individuals with subclinical hyperthyroidism 
(Table 4.4). In summary, two meta analyses of mortality data describe conflicting results 
with respect to increased risk of all cause mortality in individuals with subclinical 
hyperthyroidism and with advancing age. Estimates of increased risk are generally 
modest or associated with wide confidence intervals due to the small number of events 
observed during the follow-up period.  
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Table 4.4 Subclinical hyperthyroidism and coronary heart disease and mortality 
Author and 
date  
Design 
/setting 
Participants Exclusions 
criteria 
TSH and FT4 
reference criteria 
and frequency of 
TFT confirming 
thyroid status 
Measure 
 
Outcomes 
Sgarbi A 
166
  
2010 
Brazil 
Cross 
sectional  
 
Adults >30yrs 
Schyper 69 
Euth 913 
Self reported 
TD, medication 
known to affect 
TFT 
TSH 0.45-4.5 
FT4 0.7-1.5 
Single TFT 
All cause and 
cardiovascular (CV) 
mortality 
All cause Schyper HR 3.0 
(1.5-5.9, n=14) and  
CV mortality HR 3.3 (1.4-7.5, 
n=8) 
Haentjens N
165
  
2008 
Belgium 
Systematic 
review and 
meta 
analyses on 
mortality 
 
 
Seven studies  
290 Schyper 
13039 Euth 
  All cause mortality Modestly increased risk in 
risk of death from all causes 
HR 1.41 (1.12-1.79) 
Ochs P 
158
 
2008 
Switzerland 
Systematic 
review and 
meta 
analyses on 
coronary 
heart disease 
and mortality 
 
Five prospective 
cohort studies  
  Coronary heart 
disease and 
mortality 
Modestly increased risk of 
coronary heart disease   
RR 1.54 (1.04-2.28)  
Total mortality RR 1.12 (0.89-
1.42)  
 
 103 
4.4 Bone mineral density and fracture risk   
Biondi et al describe conflicting results from the few small studies that have evaluated 
bone mineral density (BMD) in relation to endogenous subclinical hyperthyroidism. 91 
The primary reason for the scarcity of studies in this area, the small sample sizes and 
conflicting findings are the difficulties associated with establishing the duration of 
endogenous subclinical hyperthyroidism and recruitment of individuals with dissimilar 
disease duration. Despite these difficulties Biondi et al concluded that available data 
support the hypothesis that reduced bone mineral density can be induced by subclinical 
hyperthyroidism. Similarly, findings from all supplementary and subsequent studies 
support this hypothesis. In one supplementary case control study, reduced bone mineral 
density was shown in postmenopausal women with subclinical hyperthyroidism due to 
solitary autonomous thyroid nodule compared with age and menopause matched 
euthyroid controls. 5 Measurements of bone mineral density were, however, similar in 
premenopausal women with solitary autonomous thyroid nodule with subclinical 
hyperthyroidism compared to premenopausal age matched euthyroid women. In 
postmenopausal women, urinary markers of bone resorption (free and total 
deoxypyridinoline) were significantly higher. This study also demonstrated significantly 
lower serum concentrations of dehydroepiandosterone (DHEAS) in postmenopausal 
women with subclinical hyperthyroidism compared with euthyroid controls. Since 
DHEAS plays an important role in preservation of bone mass, the author suggested that 
insufficiency of DHEAS may be an additional risk factor for bone loss in postmenopausal 
subclinical hyperthyroidism (Table 4.5). 167 Likewise, a comparison of markers of bone 
turnover between 15 women with subclinical hyperthyroidism and 15 healthy age 
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matched controls described significantly higher serum concentrations of interleukin-6 (a 
cytokine thought to have a role in bone resorption) and alkaline phosphatase (a marker 
of bone formation). 142 Similarly, another supplementary study of 60 cases and 60 
controls demonstrated a significant increase in markers of bone turnover and a 
significant decrease in bone mass in pre- and post-menopausal women with subclinical 
hyperthyroidism due to toxic multinodular goitre.  167 Belaya et al further supported and 
extended these findings in a study of bone metabolism and bone mineral density in 
relation to aetiology of subclinical hyperthyroidism in postmenopausal women. 168 Four 
groups of postmenopausal women were studied; two groups of women with endogenous 
subclinical hyperthyroidism, a control group and a group with exogenous subclinical 
hyperthyroidism. Endogenous subclinical hyperthyroidism in one group of women was 
due to toxic multinodular goitre and the second group had stable subclinical 
hyperthyroidism for at least six months after antithyroid treatment for Graves disease. 
Only the two groups of women with endogenous subclinical hyperthyroidism had 
significantly lower bone mineral density and significantly higher concentrations of 
biochemical markers of bone turnover compared with the control group. Post hoc 
analysis demonstrated no differences in bone mass density between the two groups of 
postmenopausal women with endogenous subclinical hyperthyroidism. 168 Similarly, 
Rosario et al reported a significant increase in markers of bone formation and resorption 
in women with endogenous subclinical hyperthyroidism. 159 Additionally, in this 
evaluation of 48 women with endogenous subclinical hyperthyroidism with 48 age, BMI 
and menopause matched euthyroid controls bone mineral density in the femoral neck 
was significantly lower in pre- and post-menopausal women with endogenous subclinical 
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hyperthyroidism compared respectively with pre- and post-menopausal controls (Table 
4.5). Bone mineral density in the lumbar spine was significantly lower only in 
postmenopausal women with endogenous subclinical hyperthyroidism compared to 
controls. In terms of fracture risk, Biondi et al described few studies examining fracture 
risk in subclinical hyperthyroidism, none of which exclusively studied this in relation to 
endogenous subclinical hyperthyroidism. Furthermore, Biondi et al suggested that study 
findings may have been affected by inclusion of individuals with overt hyperthyroidism 
and confounding factors. No supplementary or subsequent studies of endogenous 
subclinical hyperthyroidism and fracture risk were identified.  
In summary, in accordance with the findings of Biondi et al, supplementary and 
subsequent studies consistently demonstrate an association between subclinical 
hyperthyroidism and parameters of bone metabolism and bone mineral density. 
However, the clinical significance of alterations in bone metabolism and bone mineral 
density remains uncertain. Since findings are generally derived from small studies of 
predominantly young and middle aged women, data require replication in prospective, 
population based studies. 
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Table 4.5 Bone metabolism and subclinical hyperthyroidism  
Author and date  Design 
/setting 
Participants, age and 
thyroid status  
TSH and FT4 
reference 
criteria and 
frequency of 
TFT 
Measures Outcome  
Foldes J 
5
 
1997 
Hungary 
Case 
control 
study  
Outpatients  
 
35-64 years  
63 Schyper (31 pre and 
31 post menopausal)  
41 age/ menopause 
matched controls 
TSH 0.3-4.0  
FT4 10-25  
Repeat TFT  
Markers of bone 
metabolism (DHEAS a 
marker of formation and 
Dpd resorption) and bone 
mass 
Bone mass and DHEAS 
significantly decreased and Dpd 
significant increased In 
postmenopausal women with 
Schyper compared with 
postmenopausal controls 
Tauchmanova L 
167 
 
2004 
Italy 
 
Cross-
sectional  
Secondary 
care  
 
 
Women ≥18 years 
60 SCHyper  
60 controls matched for 
age, menopausal status 
and duration and BMI 
 
TSH 0.3-3.5  
FT4 6.6-18.0  
Single TFT  
 
Bone mass density (BMD) 
using quantitative 
ultrasonometry (QUS) and 
dual energy x-ray 
absorptiometry DEXA and 
markers of bone 
metabolism 
Significant decrease in BMD and 
significant increase in markers of 
bone turnover in Schyper groups 
compared with controls 
Sekeroglu MR 
142
 
2006 
Turkey 
Case 
control  
Outpatients  
 
 
Women ≥18 years 
15 SCHyper,  
15 age matched controls 
TSH and FT4 
not explicit. 
Single TFT  
Markers of bone 
metabolism to include 
cytokines interleukin 6 (IL-
6) and tumour necrosis 
factor alpha (TNF-α) 
Schyper associated with higher 
Interleukin-6 and alkaline 
phosphatase supporting a role in 
bone turnover.  
Belaya ZE 
168
  
2007 
Russia 
Case 
control 
study 
Outpatients 
 
Postmenopausal women 
≥18 years 
20 Endo Schyper  
21 with Endo Schyper 6 
months after treatment  
22 age/ menopause 
matched controls  
TSH and FT4 
not explicit. 
Repeated TFT 
Bone mass density (BMD), 
biochemical markers of 
bone, calcium and 
phosphorous metabolism 
Some markers of bone turnover 
significantly higher and BMD 
significantly lower in endogenous 
Schyper, no difference in calcium or 
phosphorous metabolism  
Rosario PW 
159
 
2008 
Brazil 
 
Case 
control  
Outpatients  
 
Women <65 years  
48 Schyper 
48 age, menopause and 
BMI matched controls 
 
TSH 0.3-5.0 
FT4 9.63-
23.17  
Repeated TFT  
Bone abnormalities using 
biomarkers of bone 
turnover and dual energy x-
ray absorptiometry (DEXA)  
 
Significant increase in markers of 
bone turnover and lower BMD in 
the femoral neck in pre and 
postmenopausal women with 
Schyper. Significantly lower BMD in 
the post menopausal lumbar spine 
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4.5 Neuropsychological function 
Biondi et al suggested that good evidence exists to refute an association between 
subclinical hyperthyroidism and anxiety, depression or cognitive function in older adults. 
145 Despite these findings, based upon available data Biondi et al were unable to draw 
conclusions about the impact of subclinical hyperthyroidism upon mood and cognitive 
function in younger populations. Since these data are complicated by numerous 
confounding factors, it is difficult to determine whether subclinical hyperthyroidism is a 
causally associated with neuropsychological dysfunction.  
In one subsequent study, multiple confounders were evaluated alongside cognition and 
thyroid function in a large population based sample living in Italy (Table 4.6). 169 This 
study reported a significantly higher likelihood of cognitive impairment as defined by a 
Mini-Mental State Examination (MMSE) score of <24 in individuals with subclinical 
hyperthyroidism compared with euthyroid subjects (HR of 2.26, 95% CI 1.32-3.91). The 
cut offs used to define cognitive function may also explain the disagreement in findings 
related to cognitive function reported in this study 160 and the study described by Biondi 
et al. 145 In a random sample of 192 primary care based individuals aged 60 years or 
more, a similar prevalence of cognitive dysfunction, dementia, depression and anxiety 
disorders was described in individuals with subclinical hyperthyroidism compared with 
euthyroid individuals. However due to the inclusion of a small number of individuals with 
subclinical hyperthyroidism (n=3), individuals receiving treatment for thyroid dysfunction, 
and multiple testing, this study lacked adequate statistical power to detect meaningful 
differences between individuals with subclinical hyperthyroidism and euthyroid 
individuals. 170 In another supplementary study, Schlote et al examined short-term 
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memory, affective state, ability to concentrate and psychomotor performance in 35 
individuals with subclinical hyperthyroidism, 60 with overt hyperthyroidism and 28 
euthyroid controls. 171 Findings demonstrated no impairment in ability to concentrate or 
short term memory in any group, however self-ratings of affective state tended to be 
similar in patients with subclinical and overt hyperthyroidism (Table 4.6). In summary, 
data supplementary to Biondi et al are conflicting with respect to the impact of subclinical 
hyperthyroidism neuropsychiatric function. Studies in general are limited by a cross-
sectional design and multiple confounders. Clinical intervention on the basis of available 
evidence can not be justified.  
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Table 4.6 Neuropsychological function and subclinical hyperthyroidism  
Author and 
date  
Design 
/setting 
Participants Exclusions  TSH and FT4 
reference 
criteria and 
frequency of 
TFT confirming 
thyroid status 
Measures  
 
Outcome  
Ceresini G 
169 
 
2009 
Italy 
 
Cross 
sectional, 
community 
based 
 
Adults  
65 years or more = 
800 Euth 
71 schyper 
Under 65 = 
243 Euth 
1 schyper  
Dementia, 
treatment known 
to affect thyroid 
function 
TSH 0.46-4.68  
FT4 9.9-28.2  
Single TFT 
MMSE <24 indicative 
of cognitive 
impairment 
Schyper independently 
associated with cognitive 
impairment in older 
individuals (HR 2.26,95% 
CI p<0.003) 
Schlote B 
171
 
1992 
Germany 
Cross 
sectional, 
Outpatients 
 
>18 years  
35 Schyper 
28 controls  
 
History of 
psychiatric illness 
or disease known 
to effect thyroid 
function. 
Concomitant 
treatment for 
thyroid 
dysfunction  
TSH 0.2-3.5  
FT4 9-24  
Single TFT  
Affective state, short-
term memory, ability 
to concentrate and 
psychomotor 
performance 
Schyper increased self 
reported affective state and 
significantly impaired 
psychomotor skills. 
 
 
 
Sender 
Palacios MJ 
170
 
2004 
Spain 
Cross 
sectional 
descriptive 
Primary 
care  
192 randomly 
selected sample 4 
Schyper  
167 Euth  
21 Schypo 
 
Chronic illness TSH 0.25-6.70 
FT4 9-24 
Single TFT  
Schypo associated 
with dyslipidemia and 
increased lipid 
parameters 
Similar prevalence of 
cognitive dysfunction, 
dementia, depression and 
anxiety disorders in schyper 
and Euth 
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4.6 Natural history and progression to overt hyperthyroidism  
Biondi et al describe uncertainty with regard to the frequency with which subclinical 
hyperthyroidism progresses to overt hyperthyroidism. Initial lower serum thyrotrophin 
concentration and the underlying cause of thyroid dysfunction are considered predictive 
of rate of progression to overt hyperthyroidism. Accordingly, Biondi et al recommend 
regular monitoring to evaluate whether subclinical hyperthyroidism is persistent or 
progressive. Four subsequent studies examining the natural history of subclinical 
hypothyroidism were retrieved. 79, 172,173,174 One retrospective case note review reported 
a rate of progression to overt hyperthyroidism of 32% within four years in individuals with 
subclinical hyperthyroidism characterised by serum thyrotrophin concentrations lower 
than 0.1mIU/L. Survival analyses in this cohort of 75 individuals with no previous history 
of thyroid dysfunction also indicated that presence of symptoms of hyperthyroidism and 
level of baseline thyrotrophin are significant predictors of outcome. 173 The reported 
hazard ratios were 6.05 (95% CI; 2.18-16.84) for serum thyrotrophin concentration 
<0.10mIU/L and 2.08 (95% CI; 1.03-4.21) for subclinical hyperthyroidism with symptoms 
of overt hyperthyroidism (Table 4.7). The later supplementary study of 102 elderly 
women with subclinical hyperthyroidism defined by serum thyrotrophin between 0.1-
0.4mIU/L reported a lower rate of progression to over hyperthyroidism of only 1% per 
year. The authors of this study suggested that in this population spontaneous reversion 
to euthyroidism may occur, however persistent subclinical hyperthyroidism is more likely. 
172 These two supplementary studies report a much lower rate of spontaneous 
normalisation than earlier studies. 61,175 However, overestimation of spontaneous 
normalisation in the earlier studies may have occurred due to misclassification of non 
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thyroidal illness as subclinical hyperthyroidism, based upon one measurement of serum 
thyrotrophin concentration. Additionally, a supplementary retrospective examination of 
data from a large health care database suggested that approximately 51% of individuals 
with an initially decreased serum thyrotrophin concentration who are not treated with anti 
thyroid medications will revert to euthyroidism within five years. 79 Similarly low 
progression rates were reported in a more recent retrospective study evaluating 
progression to overt hyperthyroidism and regression to euthyroid state in a UK based 
adult population with subclinical hyperthyroidism. Classification of thyroid function five 
years after diagnosis demonstrated that 67.5% persisted with subclinical 
hyperthyroidism, 31.5% regressed to euthyroid status and 0.6% progressed to overt 
hyperthyroidism. Furthermore, the result suggested that older individuals and subjects 
with more severe subclinical hyperthyroidism (defined by a TSH of <0.1 mIU/L) at 
diagnosis were less likely to regression to euthyroid status (Table 4.7). 174 
In summary, the literature review identified four studies of the natural history of 
subclinical hyperthyroidism subsequent to the review by Biondi et al. Based upon 
available data, progression to overt hyperthyroidism from subclinical hyperthyroidism 
appears to be slow. In older individuals, progression is more likely than in younger 
individuals, however in general individuals are more likely to remain with subclinical 
hyperthyroidism than regress to euthyroid function or progress to overt hyperthyroidism.  
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Table 4.7 Natural history of subclinical hyperthyroidism  
Author and 
date 
Design 
/setting 
Participants Exclusions  TSH and FT4 reference 
criteria and frequency 
of TFT confirming 
thyroid status 
Outcomes  
Meyerovitch J 
79 
 
2007  
USA 
Retrospective  
survey health 
care database 
 
Adults 
n=422242 
 
Known thyroid 
dysfunction, treated 
with drugs known 
to interfere with 
thyroid dysfunction, 
pregnant 
TSH 0.35-5.5 
FT4 10.3-20  
 
Progression rate of 2.9% over 5 years 
follow-up 
Diez JJ
173
 
2009 
Spain 
Retrospective, 
case note 
review 
 
>24 years 
75 Schyper 
2 years follow-up 
TD other than 
schyper. 
Medication in the 
last 12 months 
known to interfere 
with TFT 
pregnancy 
TSH <0.5 
FTT not explicit  
Repeated TFT 
 
 
 
45% progressed to Ohyper. 
  
Rosario PW 
172
 
2009 
Brazil 
Prospective,  
Longitudinal  
 
>60 years  
Women  
102 Schyper 0.1-
0.4 
1-5 years follow-
up  
Concomitant or 
historical treatment 
for TD, pituitary 
disease and 
corticosteroids 
TSH 0.4-4.0 
FT4 9-23  
Repeat TFT assessed at 
3 monthly intervals  
Rate of progression to Ohyper, 1% per 
year 
 
Vadiveloo T 
174
 
2011 
UK 
 
Retrospective 
survey of a 
health care 
database 
 
Adults 
2024 Schyper 
Receiving thyroid 
medication or 
known to interfere 
with TFT, previous, 
pregnancy 
TSH <0.4  
FT4 10-25  
Repeated 4 month 
interval  
6.1% 1
st 
year after diagnosis. 
Older subjects less likely to revert than 
remain Schyper at 2 years (17.2% vs. 
81.2%) 
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Summary of chapter 4  
This chapter summarised evidence from a systematic review by Biondi et al and 
available supplementary data related to the clinical signs and pathophysiological 
consequences of subclinical hyperthyroidism. In general, the literature review 
contributed little additional, robust and generalisable data to further substantiate or 
significantly alter the conclusions made by Biondi et al. The most consistently reported 
adverse cardiac alteration of endogenous subclinical hyperthyroidism described is atrial 
fibrillation, but risk estimates vary and have yet to be fully established. There is 
consistent data to support the hypothesis that reduced bone mineral density can be 
induced by endogenous subclinical hyperthyroidism. Studies of bone mineral density in 
general have nevertheless been small, due to difficulties associated with establishing 
duration of endogenous subclinical hyperthyroidism and in the recruitment of individuals 
with similar disease duration. These data require confirmation in larger, population 
based studies.  
 
Four subsequent studies of the natural history of subclinical hyperthyroidism were 
identified. These data were contradictory with respect to the frequency of progression to 
overt hyperthyroidism. Subsequent data corroborate rather than significantly alter the 
conclusions of Biondi et al in this respect. The frequency with which subclinical 
hyperthyroidism becomes overt hyperthyroidism is uncertain, however older individuals 
and subjects with lower serum thyrotrophin concentrations have a higher risk of 
progression than young individuals with less severe subclinical hyperthyroidism. In 
 114 
general, studies were limited by a retrospective study design or recruitment of small 
selected samples. 
 
Despite the large body of literature, the clinical importance and adverse health 
consequences of endogenous subclinical hyperthyroidism remain unclear. Conflicting 
results have been reported in larger population based studies compared with those 
described in smaller studies of patient populations. The reasons for disagreement 
between studies are likely to be similar to those related to evaluation of 
pathophysiological consequences of subclinical hypothyroidism i.e. heterogeneity of the 
populations studied, the assays for measurement of serum thyrotrophin and reference 
criteria by which endogenous subclinical hyperthyroidism is defined. 
 
In conclusion, based upon evidence to date, the most likely pathophysiological effects of 
endogenous subclinical hyperthyroidism are AF and reduced bone mineral density. 
Whether intervention to treat underlying thyroid dysfunction is justified or beneficial in 
this regard remains unclear.  
 
In the next chapter, literature related to expression of symptoms in subclinical 
hypothyroidism will be presented.  
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 CHAPTER 5 SYMPTOMS AND SUBCLINICAL HYPOTHYROIDISM 
 
Overview of chapters 5-6 
Chapters 3 and 4 demonstrated that despite multiple studies there is little compelling 
evidence upon which screening and treatment for subclinical thyroid dysfunction can be 
justified. The clinical significance of subclinical thyroid dysfunction however cannot be 
fully realised until symptoms and perceived health status in individuals with subclinical 
hypothyroidism and euthyroid subjects have been explored. The following two chapters 
present and examine the evidence related to symptom manifestation and perceived 
health status in individuals with subclinical thyroid dysfunction. For the purposes of this 
thesis, symptoms are defined as clinical changes that are perceptible and apparent to 
the individual. In contrast, clinical signs are defined as clinical anomalies that are evident 
on physical examination or assessment by a clinician and include indicators of anxiety, 
depression and cognitive dysfunction. Data related to general well being, health status 
and quality of life will be considered alongside data on symptoms since these concepts 
deal with patient experiences and impact of disease on everyday life and are as such 
best assessed by patients themselves. Chapter 5 focuses upon subclinical 
hypothyroidism and chapter 6, on subclinical hyperthyroidism.  
 
Overview of chapter 5 
Chapter 5 reviews available evidence evaluating symptoms in individuals with subclinical 
thyroid dysfunction compared with euthyroid subjects. Since the systematic review by 
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Biondi et al also described studies evaluating the prevalence and diagnostic utility of 
symptoms and perceived health status in subclinical thyroid dysfunction the reviewers‟ 
findings and supplementary data will be presented in parallel.  
Another aim of this thesis is to characterise symptom expression and determine 
perceived health status in elderly individuals with subclinical thyroid dysfunction 
compared with euthyroid individuals. This chapter will also describe diagnostic indices 
and other validated instruments that have previously been used to evaluated symptoms 
or health status in individuals with subclinical hypothyroidism and euthyroid individuals.  
 
5.1 Results of the literature search 
The literature search strategy and results were reported in Chapters 3 and 4. Nine 
papers evaluating symptoms or perceived health status in individuals with subclinical 
hypothyroidism compared with euthyroid individuals were identified. Studies were 
excluded from review in this chapter if they involved individuals receiving treatment for 
thyroid dysfunction or only included individuals with subclinical hypothyroidism without a 
control comparison.  
 
5.2 Symptoms in individuals with subclinical hypothyroidism 
The majority of studies suggest that consideration of physical symptoms in isolation is 
associated with very poor diagnostic accuracy for overt hypothyroidism. This is therefore 
also likely to be true of subclinical hypothyroidism. However, there are a number of 
studies that have examined the possibility that subclinical hypothyroidism causes mild 
hypothyroid symptoms. Biondi et al report continuing controversy regarding the 
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presence of symptoms in subclinical hypothyroidism and suggest that symptoms alone 
cannot be used to distinguish individuals with subclinical hypothyroidism from euthyroid 
subjects. Based upon available data, Biondi et al concluded that symptom presentation 
is related to severity and duration of subclinical hypothyroidism and sensitivity to thyroid 
hormone deficiency. In the elderly, symptoms are likely to be less specific than in 
younger individuals.  
 
Using a new clinical scoring system designed to assess severity of thyroid failure, 
Zulewski et al demonstrated presence of symptoms suggestive of overt hypothyroidism 
in individuals with subclinical hypothyroidism. 37 In this study, 93 females with subclinical 
hypothyroidism scored significantly higher compared with 109 euthyroid females (3.4 
±2.0 versus 1.6±1.6, p<0.001). The Zulewski symptom scoring system was also used for 
investigation of symptoms in individuals with subclinical hypothyroidism in two other 
studies with variable results. 176,177 In one supplementary cross-sectional study, both 
clinical symptoms and health status were evaluated in 152 women with subclinical 
hypothyroidism, 14 with overt hypothyroidism and 66 euthyroid controls. 176 The 
prevalence of individual signs and symptoms in the groups are not reported. Based 
upon the number of signs and symptoms reported, individuals were classified as either 
having a normal symptom score (defined as three symptoms or less) or an abnormal 
symptom score (defined as more than three symptoms). The frequency of abnormal 
scores was significantly greater in individuals with subclinical hypothyroidism compared 
with euthyroid subjects (75% versus 32, p<0.05). Health status was also evaluated in 
this cohort using the SF36. The concept of perceived health status deals with patients 
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experiences and the impact of disease on everyday life and as such is best assessed by 
patients themselves. Poor health related quality of life or impaired health status may be 
important factors to consider when making decisions about management of subclinical 
hypothyroidism. The SF36 is a multi-purpose, generic measure of perceived health 
status comprising 36 items that make up eight domains. 178 The SF36 measures both 
negative and positive aspects of health and a range of health status and well being in 
terms of both physical and mental health. This instrument measures eight parameters of 
health status: role limitations due to physical problems, physical functioning, social 
functioning, pain, mental health, general health, energy and role limitations due to 
emotional problems. A physical health summary score can be derived from the domains 
of general health, physical functioning, role limitations due to physical problems and 
pain. The mental health summary score is derived from the energy, social functioning, 
and mental health and role limitations due to emotional problems domains. The results 
can be compared between different populations, specific treatments, and across 
different health care delivery systems. In comparison with euthyroid subjects, perceived 
health status scores were significantly different in individuals with subclinical 
hyperthyroidism with respect to three of the eight domains. Individuals with subclinical 
hyperthyroidism reported significantly reduced median scores for physical function (65 
versus 85, p<0.017), role physical (50 versus 100, p<0.017) and general health (62 
versus 82, p<0.017) compared with euthyroid individuals. Examination of the 
relationship between health status and clinical score demonstrated weak correlations 
(Spearman correlation coefficient ranging from -0.21 to -0.35). Significant negative 
correlations between clinical scores in individuals with subclinical hypothyroidism and 
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five domains of health status (physical function, bodily pain, general health, vitality and 
mental health) were reported. However, these correlations were lost following stratified 
analysis of serum thyrotrophin and serum free thyroxine according to the classification of 
clinical score as normal or abnormal. This suggests that serum thyrotrophin and free 
thyroxine concentration are not independently associated with reduced health status, 
and deterioration of health status is due to presence of signs and symptoms. 176 The 
representativeness of the population studied is restricted by the small sample size and 
inclusion of individuals without concomitant disease. In another recent supplementary 
case control study, the Zulewski scale was administered in 57 individuals with subclinical 
hypothyroidism and 37 euthyroid individuals recruited from the outpatient endocrinology 
clinic. 177 Compared with euthyroid subjects, significantly more individuals with 
subclinical hypothyroidism reported presence of the symptoms dry skin (14% versus 
33%, respectively p<0.05) puffy eyes (10.3% versus 36.7% respectively, p<0.05), 
thickened skin (6.9% versus 23.3% respectively, p<0.05) and hoarse voice (10.3 versus 
37% respectively, p<0.05). Furthermore a significantly greater proportion of individuals 
with subclinical hypothyroidism had a symptom score of ≥3 compared to euthyroid 
individuals (70% versus 38.7% respectively, p<0.04). 177 Again, however, these findings 
are restricted by recruitment of a small highly selected sample and as such are unlikely 
to be generalisbable to the general population.  
With the intention of evaluating the relationship between thyroid function and symptoms, 
Canaris et al administered the Colorado symptom survey to approximately 25000 
participants at a state-wide health fair in the USA. 56,59 The symptoms of hypothyroidism 
used in the survey were selected from findings of a previous study which demonstrated 
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a significant difference in prevalence of these symptoms between individuals with 
hypothyroidism and euthyroidism. 59 The survey evaluated current presence or absence 
of 20 symptoms and identified whether any of the symptoms were of recent onset (e.g. 
in the last 12 months). The response options for each item ranged from one to five with 
three being a neutral response and each extreme representing either complete absence 
or marked severity of the symptom. The results demonstrated that individuals with 
subclinical hypothyroidism reported a significantly greater percentage of recently 
changed symptoms compared with euthyroid individuals (15.4% versus 13.4% 
respectively, p<0.05). Furthermore, individuals with subclinical hypothyroidism reported 
a significantly greater mean percentage of total symptoms compared with euthyroid 
individuals (13.7% versus 12.1% respectively, p<0.05). Those with subclinical 
hypothyroidism were intermediate between the overt hypothyroidism and euthyroidism 
groups suggesting a positive association between number of symptoms and progressive 
thyroid failure. Low individual symptom sensitivities for higher serum thyrotrophin 
concentrations were also reported suggesting that the absence of a particular symptom 
did not rule out thyroid dysfunction. Accordingly, a high number of false positive 
individual symptoms were described. The authors also described derivation of a 
symptom scoring system to establish whether multiple symptoms better distinguish 
between overt hypothyroidism and euthyroidism than individual symptoms. The final 
symptom score utilised the most discriminatory current and changed symptoms (current 
symptoms; constipation, hoarse voice and deep voice and changed symptoms; 
constipation, hoarse voice, sensitivity to cold temperature, puffy eyes, and weak 
muscles) to calculate an accumulative score. Results further demonstrated a greater 
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likelihood of overt hypothyroidism with increasing symptom score. The effectiveness of 
the symptom score in distinguishing between individuals with subclinical hypothyroidism 
and euthyroidism however remains to be elucidated. The clinical utility of this symptom 
score is limited by the complex weighting system required for calculation of final 
symptom scores. This method of symptom assessment therefore may not be convenient 
or feasible in the primary care setting. Since only a third of the population were older 
than 65 years of age and the analysis of symptoms in the thyroid function groups was 
not stratified by age, additional studies are required to assess the external validity of this 
symptom scoring system in older age groups. Additionally, the study population was not 
strictly population based since participants were recruited from a health fair. These 
individuals are likely to be representative of healthier and potentially more affluent 
cohorts than the general population.  
Contradictory findings were reported by Bemben et al in a retrospective case note 
review of primary care geriatric clinic records. To determine the utility of 26 clinical signs 
and symptoms for diagnosis of subclinical hypothyroidism in elderly individuals with no 
known history of thyroid dysfunction, the records of 272 patients were reviewed. 179 
Irrespective of thyroid status, the symptoms lethargy and memory impairment were 
common in this population. A higher frequency of dry skin and dyspnoea was reported 
by the group with subclinical hypothyroidism compared with the euthyroid group, 
however the differences failed to reach significance (dry skin 40.5% versus 36.8% 
respectively and dyspnoea 42.9% versus 37.6% respectively). No relationship between 
thyroid function category and prevalence of any individual symptom was reported. 
Comparisons between the euthyroid and subclinical hypothyroidism groups stratified into 
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three subpopulations based upon total number of symptoms present (e.g. more than 
four symptoms, three to four symptoms and one to two symptoms) similarly failed to 
discriminate between the 230 euthyroid subjects and 42 individuals with subclinical 
hypothyroidism. Multivariate analysis used a cross validation strategy in which one 
subset of data was used to construct a logistic regression model, the results of which 
were then evaluated in the remaining subset of data. Logistic regression models had 
weak predictive power when applied to cases that were not used to build the model. The 
authors concluded that the classic clinical signs and symptoms individually or in 
combination are not present in elderly individuals with subclinical hypothyroidism and 
therefore do not aid active case finding in this population. The results are, of course, 
limited by the retrospective study design. Retrospective data collection from primary 
care records is likely to lead to poor correlation between clinical features and thyroid 
dysfunction because primary care clinicians do not routinely seek or record standard or 
specific clinical features in their patients. Another study investigated the presence of 44 
non thyroid specific symptoms in individuals with subclinical hypothyroidism compared 
with euthyroid individuals. 24 The most frequent symptoms in the subclinical 
hypothyroidism group were fatigue (27.9%), distress (20.9%) weight gain (14.0%) and 
nervousness (11.6%). These four symptoms were also the most frequently reported 
symptoms in the group with overt hypothyroidism. Discriminant analysis however failed 
to identify symptoms distinctive of subclinical hypothyroidism. The main aim of this study 
was to investigate the effects of thyroid dysfunction on quality of life as assessed using 
the SF36. 178 The 43 Individuals with subclinical hypothyroidism, scored significantly 
lower in the mental component summary scores than the 20 controls (43.8 versus 51.5 
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respectively, p<0.001).  24 Likewise physical component summary scores were 
significantly lower in individuals with subclinical hypothyroidism compared with euthyroid 
subjects (41.2 versus 46.7 respectively, p<0.02) The group with subclinical 
hypothyroidism scored more highly with respect to both component summary scores 
compared to those with overt hypothyroidism. These findings demonstrate that 
symptoms suggestive of overt hypothyroidism are present in individuals with subclinical 
hypothyroidism and suggest a graded effect of hypothyroid dysfunction on perceived 
health status. All subjects were aware of their thyroid function category before 
completion of the study questionnaire, therefore results could be subject to reporting 
bias. Furthermore, due to the relatively small size and limited age range of the 
participants these data are unlikely to be applicable to older populations. In contrast, a 
large community based cross-sectional study demonstrated that women with subclinical 
hypothyroidism have similar perceived health status as euthyroid women.  24 The SF36 
was also used to assess perceived health status in this study. 180 The mean mental 
component summary scores did not differ between 80 women with subclinical 
hypothyroidism and 240 age matched controls (51.5 versus 50.1 respectively). Likewise 
the mean physical component summary scores were similar between cases with 
subclinical hypothyroidism and age matched controls (49.1 versus 49.6 respectively). A 
key feature of this study was that the women were unaware of thyroid status, removing 
reporting biases. However the study sample may not be representative of the community 
from which they were recruited due to the low (11%) response rate (screened n=12544, 
participated n=1423). Razvi et al compared perceived health status assessed by the 
SF36 in 71 consecutively diagnosed community dwelling individuals with subclinical 
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hypothyroidism and age and gender matched UK normative data. 181 The findings 
demonstrated significantly lower absolute scores on all eight domains of the SF36 in 
individuals with subclinical hypothyroidism compared with the age and gender matched 
normative population. Due to limited availability of normative data for older age groups, 
absolute scores for older individuals with subclinical hypothyroidism (≥ 65 years of age) 
were compared with the younger group studied. The older group reported significantly 
lower scores for physical function, role limitations due to physical problems and pain 
than the younger group with a difference in mean absolute score of 17.72 (95%CI 6.4-
29.04) for physical function, 13.93 (95%CI 1.32-26.54) for role physical and 14.93 
(95%CI 2.97-26.89) for pain. Although the participants were recruited from the primary 
care setting the representativeness of the cohort is reduced because these individuals 
were all actively seeking medical attention and being investigated for thyroid 
dysfunction. These patients are therefore more likely to have symptoms and/or 
concomitant disease than the general primary care population. Furthermore, all 
individuals were aware of their thyroid function categorisation when completing the study 
questionnaire and this potential new, additional diagnosis may have impacted upon 
perceived health status.  181 In contrast, a similar study in Italy reported no difference in 
perceived health status between 45 individuals with subclinical hypothyroidism and age 
and gender matched Italian population norms as assessed by the Nottingham health 
profile (NHP) and the SF36. 15 The Nottingham Health profile is intended for use in the 
primary care setting and evaluates perceived emotional social and physical health 
problems. The questionnaire comprises two parts. Part one encompasses 38 questions 
that make up six domains (energy, pain, emotional reaction, sleep, physical abilities and 
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total isolation). Part two assesses which life areas are affected, work, hobbies, sex life, 
home life, social life, holidays and looking after the home. The individuals with 
subclinical hypothyroidism were all aware of their diagnosis and had been referred to a 
secondary care endocrinology clinic. The difference between these two final studies may 
be due to the different populations and normative data used in the analysis. 15   
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Table 5.0 Symptoms and health status and subclinical hypothyroidism  
Author, 
publication  
date 
Design Participants/ 
setting 
Exclusions Serum TSH ( 
mU/L) and FT4 ( 
pmol/L) reference 
criteria for 
Schypo 
Outcome 
measures 
(Instrument 
used) 
Summary of results 
Bemben 
DA
179 
 
1994  
USA 
Retrospectiv
e case note 
review 
Primary care   
 
Elderly >60 yrs 
86 Schypo 
230 Euth 
 
Previous thyroid 
dysfunction, referral 
by inpatient 
rehabilitation 
services 
TSH <5.0-14.9 
FT4 9.0-25.0 
26 classical signs 
and symptoms 
adapted from an 
endocrinology 
text book  
No association between 
Schypo and 26 individual 
symptoms attributed to overt 
hypothyroidism. No association 
between Schypo and totalled 
number of symptoms reported  
Zulewski  H
37
 
1997 
Switzerland 
Cross 
sectional 
study 
Outpatients 
Adults ≥18 years 
93 Schypo,  
189 Euth 
50 Ohypo  
 
Males 
 
TSH 0.1-4  
FT4 8.0-27 
14 symptoms and 
signs of 
hypothyroidism 
(Zulewski scale) 
Classical sign and symptoms 
are rare or absent in Schypo.  
Canaris GJ 
56
 
2002  
USA 
Cross 
sectional 
study 
Statewide 
health fair 
Adults ≥18 yrs  
2336 Shypo 
22842 Euth 
114 Ohypo 
 
Missing or 
inconsistent data  
TSH 0.3-5.1 
Total T4  
17 signs and 
symptoms of 
hypothyroidism 
and 3 thyroid 
neutral symptoms  
(Colorado 
symptom survey) 
Schypo group reported 
significantly more total 
symptoms than euthyroid 
group. Schypo 13.7% total 
symptoms vs 12.1% Euthyroid  
Bianchi GP
15
 
2004)  
Italy  
Consecutive, 
Community 
based  
Adults  
45 Schypo 
26 Ohyper 
2031 population 
norms 
Existing disease  TSH 0.35-4. 
FT4 8.0 -19 
Health status 
(SF-36) 
and Nottingham 
Health Profile 
Self reported 
All aware of diagnosis. Health 
status not significantly impaired 
in Schypo compared with 
population norms 
Razvi S 
181
 
2005 
UK 
Primary care 
based  
Adults 
100 consecutively 
diagnosed 
schypo 
Existing chronic 
disease, history of 
thyroid dysfunction 
TSH 0.4-4.0 
FT4 9-25  
Health status 
(SF-36) 
Self reported 
Perceived health status 
significantly impaired in Schypo 
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Table 5.0 Symptoms, health status and subclinical hypothyroidism continued 
Author, 
publication  
date 
Design Participants/ 
setting 
Exclusions Serum TSH ( 
mU/L) and FT4 ( 
pmol/L) reference 
criteria for 
Schypo 
Outcome 
measures 
(Instrument 
used) 
Summary of results 
Reuters VS
177
  
2006   
Brazil 
Case-control 
study 
Outpatients 
≥18 yrs 
57 Schypo  
37 Euth 
 
TSH >20mIU/L, 
treatment for 
thyroid dysfunction, 
chronic disease, 
medication known 
to interfere with 
TFT   
TSH 0.4-4.0 
FT4 10.2-23.0 
14 symptoms and 
signs of 
hypothyroidism 
(Zulewski scale) 
Self reported 
Schypo group presented with 
significantly higher clinical 
score compared with euthyroid 
group 
Gulseren S 
24
 
2006 
Turkey 
Prospective 
follow-up 
study 
Outpatients 
Women 18-75 yrs  
33 Schypo  
20 controls  
51 Ohypo  
 
Past psychiatric 
disorder, other 
chronic disease 
TSH 0.35-5.50  
FT4 11.45-23.2l 
Symptoms 
checklist 
developed by 
researchers  
Health status (SF 
36) 
Symptoms identical in Ohypo 
and Schypo. No individual 
symptoms distinctive of 
Schypo. Health status scores in 
Schypo group were significantly 
lower than Euth group 
Bell RJ 
180
 
2007  
Australia 
Community-
based cross-
sectional 
study. 
Women 18-75 yrs 
80 Schypo 
240 controls 
 
Pregnancy or 6 
weeks postpartum, 
chronic disease, 
concomitant 
treatment    
TSH  0.5-4.0 
FT4 10.0-19.0 
Health status 
(SF-36) 
Psychological 
General Well-
being Index 
(PGWI) 
Self reported 
No association with lower well-
being or impaired health-status 
Schypo compared with control 
Vigario P 
176
 
 2009 
Brazil 
Cross 
sectional 
study 
Outpatients 
Women ≥ 18 
years 
152 Schypo 
66 Euth  
14 Ohypo  
Medication known 
to affect thyroid 
function, current 
hospitalisation, 
chronic disease  
TSH ≥4.0 
FT4 10.3-24.5 
Repeat TFT 6 week 
interval 
Symptoms 
(Zulewski scale ) 
Health status 
(SF36)  
 
Frequency of abnormal clinical 
scores significantly different 
between 3 groups. Clinical 
exam, physicians blind to TF   
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Summary of chapter 5.0 
Nine relevant studies evaluating symptoms or perceived health status in individuals with 
subclinical hypothyroidism compared with euthyroid subjects were identified. In general, 
studies were conducted in adults of all ages with the exception of one retrospective 
study conducted in individuals aged >60 years. The populations sampled were sourced 
predominantly from the outpatient setting with little data being derived from community 
dwelling or primary care based study cohorts. Only two of the studies evaluated both 
symptoms and health status. The assays for measurement of thyrotrophin and the 
reference criteria upon which subclinical hypothyroidism was defined also varied 
between the studies. In terms of outcomes, tools employed for evaluation of symptoms 
were also varied. The available data provides some evidence for the presence of 
symptoms suggestive of overt hypothyroidism in individuals with subclinical 
hypothyroidism compared with euthyroid individuals. In general it seems that fewer signs 
and symptoms are observed in the general population compared with patient 
populations. Overall, findings are limited by small sample sizes, different outcome 
measures and heterogeneity of populations studied. There is also a lack of data related 
to symptoms in elderly individuals and it is unclear whether symptoms in older 
individuals with subclinical hypothyroidism are a pathophysiological consequence of 
thyroid dysfunction or merely a physiological alteration due to advancing age. Poor 
health related quality of life or impaired health status may be important factors to 
consider when making decisions about the management of subclinical hypothyroidism. 
More-over, the relationship between symptoms, impaired health status and thyroid 
function has yet to be fully elucidated since impaired health status may be an outcome 
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of subclinical hypothyroidism or a consequence of symptoms. In general, studies of 
outpatient populations demonstrate an association between subclinical hypothyroidism 
and symptoms and with impaired health status. These findings are unlikely to be 
applicable to the general population and as yet have not been confirmed in larger 
community based cohorts. In summary, on the basis of the available evidence, 
questions related to the presence of symptoms in subclinical hypothyroidism and the 
impact of subclinical hypothyroidism on perceived health status remain unanswered.  
 
In the current chapter, literature related to expression of symptoms in subclinical 
hypothyroidism was reviewed and summarised. In the next chapter, literature related to 
expression of symptoms in subclinical hyperthyroidism will be presented.  
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CHAPTER 6 SYMPTOMS AND SUBCLINICAL HYPERTHYROIDISM 
 
Overview of chapter 6  
As in the previous chapter the articles retrieved in the literature search will be presented 
and discussed alongside the systematic review by Biondi et al. Since another aim of this 
thesis is to characterise symptom expression and health status in subclinical 
hyperthyroidism, diagnostic indices and other instruments previously used for 
assessment of health status in individuals with subclinical hyperthyroidism and euthyroid 
subjects will be described in this chapter.  
As previously described in chapter 3 this thesis will focus solely upon endogenous 
subclinical hyperthyroidism since the clinical consequences and characteristics of this 
spontaneous form of thyroid dysfunction are less established and are more frequently 
encountered by primary care practitioners. The principal difference between these 
subgroups of subclinical hyperthyroidism is that the exogenous form has been induced 
either intentionally or unintentionally through administration of thyroxine replacement 
therapy. In this chapter, studies which exclusively include individuals with exogenous 
subclinical hyperthyroidism will not be reviewed because extrapolation of findings to 
individuals with endogenous subclinical hyperthyroidism may not be appropriate. This is 
particularly so in relation to symptom expression and perceived health status because 
individuals with exogenous subclinical hyperthyroidism may have previous experience of 
„thyroid symptoms‟ and as such may be more sensitive to changes in their health. 
Similarly, individuals receiving treatment for overt thyroid dysfunction may have greater 
health awareness due to frequent contact with the health services.  
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6.1 Results of the literature search 
The literature search strategy and results were reported in Chapters 3 and 4. Ten 
papers evaluating and symptoms or perceived health status in individuals with 
subclinical hyperthyroidism and euthyroid individuals were identified. Studies were 
excluded from review in this chapter if they involved individuals receiving treatment for 
thyroid dysfunction and only included individuals with subclinical hyperthyroidism without 
a control comparison.   
 
Biondi et al suggest that symptoms are less specific and less severe in endogenous 
subclinical hyperthyroidism than those observed in overt hyperthyroidism. This is 
particularly so in older individuals. Like subclinical hypothyroidism, the intensity of 
symptoms is likely to be related to the duration of subclinical hyperthyroidism and the 
individual‟s sensitivity to thyroid hormone excess.  
 
To asses whether individuals with subclinical hyperthyroidism selected from a non 
patient population exhibited similar signs and symptoms to those found in patients with 
subclinical hyperthyroidism Schlote et al measured serum thyrotrophin concentration in 
6884 workers. 182 Screening identified 228 (3.31%) with concentrations lower than the 
reference range (<0.21mIU/L), 65 (0.9%) with concentrations higher than the reference 
criteria and 6591 within the reference range. Further testing, application of 
exclusion/inclusion criteria and time constraints lead to the exclusion of approximately 
75%. The final sample comprised 16 individuals with exogenous subclinical 
hyperthyroidism, 15 individuals with exogenous subclinical hyperthyroidism and 27 age 
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and gender matched euthyroid controls. Signs and symptoms were evaluated in 
according to the Crooks index of hyperthyroidism. The Crooks clinical index is a 
diagnostic index developed in the 1950s to facilitate objectivity and improve accuracy of 
clinical assessment of overt hyperthyroidism. The index comprises eight symptoms 
(breathlessness on effort, palpitation, lethargy, sensitivity to heat, excessive sweating, 
nervousness, increased appetite and weight loss) and 11 signs (palpable thyroid, bruit 
over thyroid, lid retraction, lid lag, exophthalmos [bulging or protruding eyeballs], 
hyperkinetic movements, fine finger tremor, clammy hands, systolic and diastolic blood 
pressure and rapid pulse rate). 41,48  Schlote et al failed to demonstrate any significant 
differences between the three thyroid function groups with respect to total symptom 
score. A significant increase in the frequency of palpitation was observed in patients with 
endogenous subclinical hyperthyroidism compared with controls (28.6% versus 3.8% 
p<0.025). Although overall frequency of symptoms reported was low, symptoms of 
nervousness, excessive sweating and preference for the cold were present in around 
33% of subjects in each of the three thyroid function groups. In terms of signs of 
hyperthyroidism, fine finger tremor was the only clinical sign observed and again this 
sign was present in each of the thyroid function groups. These study findings are 
unlikely to be generalisable due to the fact that a large number of the population were 
excluded from the statistical analysis.  
In another study by Schlote et al, the Crooks index was administered to a patient 
population comprising 35 individuals with subclinical hyperthyroidism, 60 with overt 
hyperthyroidism and 28 euthyroid individuals. 171 The findings contradict the first study. A 
significantly greater proportion of the subclinical hyperthyroidism group compared with 
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the euthyroid group presented with palpitation (50% versus 0%, p<0.001), weight loss 
(42% versus 15%, p<0.01), breathlessness on effort (25% versus 15%, p<0.05) 
preference for cold (42% versus 8%, p<0.01) and excessive sweating (58% versus 15%, 
p<0.01). Three signs were also present in a significantly greater proportion of individuals 
with subclinical hyperthyroidism compared with euthyroid individuals. Palpable thyroid 
was observed in 75% of the subclinical hyperthyroidism group compared with 27% of the 
euthyroid group, p<0.001), fine finger tremor in 50% of those with subclinical 
hyperthyroidism compared with 15% of euthyroid subjects (p<0.001). Similarly, systolic 
blood pressure was significantly higher in the subclinical hyperthyroidism group 
compared with the euthyroid group (130 mmHg versus 120mmHg, p<0.05). Additionally 
total symptom score was significantly greater in individuals with subclinical 
hyperthyroidism compared with euthyroid individuals (6.0 versus -4.6; p<0.001). 182 
These two studies highlight the difference between patient and non-patient populations 
and further demonstrate that samples sourced from the outpatient setting are unlikely to 
be representative of the general population. 
The Crooks index was also administered in a prospective UK based study including 15 
consecutive elderly patients with subclinical hyperthyroidism, 10 elderly hyperthyroid 
patients and 10 euthyroid patients. Again, the total symptom score of the group with 
subclinical hyperthyroidism (-0.7 ±1.6) was significantly higher than the group with 
euthyroidism (-5.6 ±1.5; p <0.05). 183 Although all patients in the study were aware of 
their thyroid status, the examiner conducting the clinical assessment was blind to 
category of thyroid function limiting observer bias. Sgarbi et al reported similar clinical 
findings in accordance with the Crook index in a study of 10 individuals with subclinical 
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hyperthyroidism compared with 10 age, gender and BMI matched euthyroid controls. 184 
At baseline the Crooks clinical score was significantly higher in individuals with 
subclinical hyperthyroidism compared with euthyroid controls (12.0 versus -1.0 
respectively, p<0.001). The clinical index was significantly correlated with serum 
thyrotrophin but not free thyroxine concentration. The main symptoms present in 
individuals with subclinical hyperthyroidism were palpitation, tiredness, excessive 
sweating, nervousness, weakness and preference for cold. The findings of Sgarbi et al 
and Stott et al demonstrate a significant difference in the prevalence of symptoms in 
patient populations with endogenous subclinical hyperthyroidism. Patient populations 
are more likely than the general population to have severe symptoms and/or co-morbid 
conditions. It is also possible that these patients have different health seeking behaviour 
and/or better health education and awareness than the general population. Due to the 
small sample size and outpatient setting these study findings are unlikely to be 
generalisable.  
A more recent study of young and middle aged individuals with endogenous subclinical 
hyperthyroidism also described an increase in symptoms compared with age matched 
controls. 185 Biondi et al used the physician administered hyperthyroid symptom rating 
scale (HSRS) to assess symptoms in 23 patients with untreated, stable subclinical 
hyperthyroidism and 23 age and gender matched controls. The hyperthyroid symptom 
rating scale (HSRS) was developed and described in 1988 by Klein et al as an 
instrument intended for clinical assessment and management of patients with overt 
hyperthyroidism. 42 Symptom selection for inclusion in the HSRS was based upon two 
previous studies demonstrating a difference in prevalence of symptoms between 
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euthyroid and hyperthyroid subjects which used an established diagnostic index to score 
the presence and absence of symptoms of hyperthyroidism. 41,48 The HSRS scale 
comprises ten items that rate nervousness, diaphoresis, heat intolerance, motor activity, 
tremor, weakness, hyperdynamic precordium, diarrhoea, weight loss and appetite. The 
scale is an observer rated scale with information needed to rate each item obtained 
through review of medical history and physical examination. This scale has been widely 
used in studies to assess signs and symptoms of hyperthyroidism. 185, 186,187  Items are 
scored on a scale of 0-4 and summed to give a total score (0-40). A higher score 
indicates more severe symptoms suggestive of overt hyperthyroidism. Biondi et al 
described a significantly greater mean HSRS score in individuals with subclinical 
hyperthyroidism when compared with euthyroid controls (9.8±5.5 versus 4.3±2.2; p 
<0.001). As observed in other studies conducted in patient populations, a greater 
prevalence of palpitations, nervousness, tremor, heat intolerance and sweating was 
predominantly responsible for the difference in mean symptom score observed between 
the two groups. 188  
 
The hyperthyroid symptoms rating scale was also used to assess symptoms in 48 
women under the age of 65 years and 48 euthyroid women matched by age, body mass 
index and menopausal status. Similarly, the mean HSRS score was significantly higher 
in women with subclinical hyperthyroidism compared with euthyroid controls (9.0 versus 
4.2; p<0.01). 159 In contrast, a large cross-sectional study with 3790 participants with no 
previous thyroid dysfunction reported no association between subclinical 
hyperthyroidism and mental or physical complaints. 189 This study used Von Zersson‟s 
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complaints scale to evaluate 38 non thyroid specific symptoms in 61 individuals with 
subclinical hyperthyroidism and 2244 euthyroid individuals without evidence of goiter. 
Participants were asked to rate the degree to which they suffered each complaint using 
a scale of absent, mild, moderate or severe. The symptoms evaluated were back pain, 
joint pain, weakness, abdominal feeling of fullness, faintness, heartburn, irritability, 
nervousness, heavy legs, sleeplessness, dizziness, fatigue, headache, deafness, 
sudden difficulty breathing, feeling of suffocation, palpitation, anxiety, stomach ache, 
loss of energy, poor concentration, inner tension, sensitivity to weather, depression, 
numbness to hands or feet, globus sensation, breathlessness, difficulty swallowing, 
chest pain, nausea, rumination, nervous legs, hypersensitivity to warmth, 
hypersensitivity against cold, excessive need of sleep, tremor, neck and shoulder pain 
and loss of weight. Individuals with subclinical hyperthyroidism did not differ from 
controls with respect to total symptom score (mean symptoms score of 61.8 versus 64.7 
respectively; p<0.14). Significant differences between the two groups did however exist 
with respect to four single items with scores for back pain, depression and globus 
sensation being significantly lower in individuals with subclinical hyperthyroidism 
compared with controls and weight loss being significantly greater in individuals with 
subclinical hyperthyroidism compared with controls. The instrument used to evaluate 
symptoms in this study was not specifically designed to assess symptoms associated 
with thyroid dysfunction therefore the sensitivity of this tool for detection of symptoms is 
limited. Whilst all statistical analyses were controlled for age, gender and education 
further confounding variables associated with other co-morbid conditions were not 
considered. These findings should therefore be interpreted with caution. 189 In another 
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study, a 44 item symptoms checklist and the SF36 were administered to 13 patients with 
subclinical hyperthyroidism attending a hospital endocrinology clinic. 24 Twenty euthyroid 
patients were also evaluated. The most frequent symptoms in the subclinical 
hyperthyroidism group were excessive sweating (46.2%), palpitation (30.8%), 
nervousness (30.8%) and pain at extremities (23.1%). These symptoms were also the 
most frequent symptoms in the group with overt hyperthyroidism. However, compared 
with the subclinical hyperthyroidism group, these symptoms were more often present 
(excessive sweating 55%, palpitation 53%). 24  The frequency of presentation of these 
symptoms in the control group was not reported. In general, perceived health status was 
worse in the overt and subclinical hyperthyroidism groups than in the control group. In 
terms of mean mental component summary scores the subclinical hyperthyroidism 
group (48.8 ± 9.1) was intermediate between the euthyroid (51.5 ± 9.4) and overt 
hyperthyroidism groups (39.7 ± 12.9; ANOVA between groups p<0.001). Likewise, mean 
physical component summary score in the group with subclinical hyperthyroidism (46.6 ± 
7.9) was better that the group with overt hyperthyroidism (45.0 ± 8.9) however worse 
than the euthyroid group (50.2± 5.9; ANOVA between group p 0.02). These data are 
potentially limited because individuals were aware of thyroid function status when 
completing the symptom and perceived health status questionnaire. Response bias 
therefore cannot be ruled out. 24 
The mean mental component summary scores did not differ between 52 women with 
subclinical hyperthyroidism and 156 age matched controls (49.2 versus 49.6 
respectively). Likewise, the mean physical component summary scores were similar 
between cases with subclinical hyperthyroidism and age matched controls (49.2 versus 
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49.5 respectively). 180 A key feature of this study was that the women were unaware of 
thyroid status, removing reporting biases.  However, this study is limited by a low 
participation rate (11%) meaning the study sample are unlikely to be representative of 
the community from which they were sourced and data is unlikely to be generalisable.   
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Table 6.0 Symptoms and endogenous subclinical hyperthyroidism 
Author Design and 
setting 
Participants Exclusions Reference range for 
serum TSH (mIU/L) 
and FT4 (pmol/L) 
Instrument used/ no of 
items and completion  
Summary 
Stott DJ
183
 
1991  
UK 
Prospective, 
Case control,  
Outpatients  
 
61-93 yrs 
15 Schyper, 
10 Ohyper 
10 euthyroid 
controls 
No previous thyroid 
dysfunction 
TSH 0.2  
FT4 8.8-23.2  
Crooks index 
17 items (8 symptoms, 9 
signs) 
Physician completed  
 
Clinical score similar 
in subclinical and 
overt dysfunction and 
higher than euthyroid  
Sclote B 
182 
1992  
Germany 
Cross 
sectional,  
Community 
based  
43-52 yrs 
16 
EnSchyper, 
15 
ExSchyper, 
27 controls 
Hormonal, 
psychosomatic, 
psychiatric disease or 
chronic pain syndrome   
TSH 0.21-3.5 
 
Total T4, 45-130  
Crooks index Crooks index 
17 items (8 symptoms, 9 
signs) 
Physician completed  
 
No association 
between symptoms 
and endogenous 
subclinical 
hyperthyroidism 
Sclote B 
171 
1992  
Germany 
Cross 
sectional, 
Outpatients  
 
≥18 yrs 
60 Ohyper 
35 Schyper 
28 age 
matched, 
euthyroid 
controls 
History of psychiatric 
disease, drugs  or 
disease known to affect 
TFT  
TSH  0.2-3.55  
 
TotalT4 45-130  
Modified version of the 
Crooks index, 12 items (6 
symptoms, 6 signs). 
Physician completed 
Significantly greater 
prevalence of 5 
symptoms and 3 
signs in Schyper. 
Total modified score 
significantly greater in 
Schyper 
Biondi B 
188
 
2000  
Italy 
Case control, 
Outpatients  
 
30 -53yrs 
23 
subclinical, 
23 euthyroid 
controls 
Receiving medication 
without non thyroidal 
illness 
TSH 0.3-3.8  
 
FT4 7.7-20.6  
Hyperthyroid symptom 
rating scale (HSRS) 10 
items (9 symptoms, 1 sign) 
Physician completed 
Significantly higher 
symptom score 
Sgarbi JA
184
 
2003   
Brazil 
Prospective, 
Case control,  
Outpatients  
 
16-72 yrs  
10 
subclinical 
and 10 
euthyroid 
controls 
No history of thyroid 
dysfunction, 
respiratory, psychiatric, 
cardiovascular disease 
or drugs affecting TFT  
TSH 0.32-5.2  
 
FT4 10.3-24.5  
Crooks index 
17 items (8 symptoms, 9 
signs) 
Physician completed  
 
Clinical score 
significantly greater in 
Schyper 
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Table 7.0 Symptoms and endogenous subclinical hyperthyroidism continued 
Author Design and 
setting 
Participants Exclusions Reference range for 
serum TSH (mIU/L) 
and FT4 (pmol/L) 
Instrument used/ no of 
items and completion  
Summary 
Bianchi GP 
15
 
2004  
Italy  
Consecutive, 
Community 
based  
Adults  
45 Schypo 
26 Ohyper 
2031 
population 
norms 
Existing disease TSH 0.35-4. 
FT4 8.0 -19 
Health status (SF-36) 
and Nottingham Health 
Profile 
Self reported 
All aware of 
diagnosis. Health 
status not 
significantly impaired 
in Schyper compared 
with population 
norms 
Grabe HJ
189
 
2005  
Germany 
Cross 
sectional, 
Community 
based 
46-59 yrs 
61 Schyper 
3317 Euth 
16 Ohyper 
Known thyroid 
dysfunction 
TSH 0.3-3.0  
FT4 10-25  
Von Zerssen‟s complaints 
survey (31 mental and 
physical complaints). Self 
completion 
No association 
between symptoms 
and Schyper,  
non thyroid specific 
symptom measure  
Gulseren S
24
 
2006  
Turkey 
Prospective 
follow-up  
Outpatients  
 
Women ≥18 
yrs 
13 Schyper 
20 controls 
  
Past psychiatric 
disorder and other 
chronic disease, 
cancer  
TSH 0.35-5.50  
FT4 11.5-23.2  
44 item symptom checklist 
administered by 
researchers  
Health status (SF 36) 
Reduced mental and 
physical component 
scores in Schyper. 
Bell RJ
180
 2007 
 
Australia 
Cross 
sectional, 
Community 
based, 
 
Women  
<18-75 yrs 
52 Schyper 
156 controls 
Pregnant, post 
partum, history of 
chronic disease, 
malignancy or cancer 
treatment   
TSH 0.5-4.0  
FT4 10.0-19.0 
SF36- 36 items   
PGWI 22 items 
Self completion 
No significant 
differences in health 
status summary 
scores 
Rosario PW 
159
 
2008  
Brazil 
Case control,  
Outpatients  
 
Women ≤65 
yrs 
48 Schyper 
48 matched 
controls  
History of or 
treatment for thyroid 
dysfunction, drugs 
interfering with TFT, 
osteoporosis 
oestrogen, 
corticosteroids  
TSH  0.3-5.0  
FT4 9.63-23.17  
Hyperthyroid symptom 
rating scale (HSRS) 10 
items (9 symptoms, 1 sign) 
Physician completed 
Mean symptom score 
significantly higher in 
Schyper  
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Summary of chapter 6 
This chapter focused upon literature evaluating symptoms or perceived health status in 
individuals with endogenous subclinical hyperthyroidism compared with euthyroid 
subjects.  
Ten studies of symptoms or perceived health status in individuals with subclinical 
hyperthyroidism compared with euthyroid controls were identified and examined. In the 
main, thyroid specific instruments were used to assess symptoms, namely the Crooks 
diagnostic index and the hyperthyroid symptoms rating scale. One study used a reduced 
version of the Crooks index comprising 12 rather than 17 signs and symptoms 
suggestive of overt hyperthyroidism. Only one study employed a non thyroid specific 
symptom tool to measure prevalence of symptoms. The majority of studies were 
performed in outpatient endocrinology clinics with just two studies being conducted in 
the community setting, meaning findings are not generalisbable to the general 
population. In general the populations comprised mixed gender, middle aged adults 
however three studies comprised women only and two studies exclusively included 
individuals older than 60 years of age. Overall, studies report a greater prevalence of 
palpitations, excessive perspiration and preference for cold in individuals with subclinical 
hyperthyroidism compared with euthyroid individuals. The majority of studies 
investigating symptoms in individuals with endogenous subclinical hyperthyroidism using 
the Crooks index reported significantly higher symptom scores in individuals with 
subclinical hyperthyroidism compared with controls. Similarly, the case control studies 
conducted in the outpatient setting and employing the hyperthyroid symptoms rating 
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scale demonstrated significantly higher symptom scores in individuals with endogenous 
subclinical hyperthyroidism compared with euthyroid individuals. Community based 
studies failed to demonstrate any association between endogenous subclinical 
hyperthyroidism and symptoms or impaired health status. These findings are limited, 
however, by a low recruitment rate and use of a non thyroid specific and potentially 
insensitive instrument for assessment of symptoms. It is therefore difficult to know 
whether the cohort studied is representative of the population from which they were 
sourced and it is likely that important symptoms are not being measured.  
With respect to perceived health status, data are again generally derived from small 
studies of highly selected populations. Whilst these data do demonstrate impaired 
mental and physical health status, these findings are not corroborated in larger 
community based studies. An additional methodological issue with most of these studies 
is that participants are aware of their thyroid function status meaning that results may be 
subject to response bias. Similarly in studies where physical examination was required, 
the examiners were not always blind to the subjects‟ thyroid function status meaning that 
observer bias cannot be entirely ruled out.  
In summary, current data suggest that endogenous subclinical hyperthyroidism is 
associated with symptoms and impaired health status. On the whole, this evidence has 
been generated by small studies conducted in patient populations and there is a lack of 
data related to symptom expression and perceived health status in the general 
population or in older individuals with endogenous subclinical hyperthyroidism.  To 
further clarify the relationship between subclinical hyperthyroidism and symptoms and 
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health status, findings require replication in larger prospective community dwelling 
samples.  
In summary, on the basis of the available evidence uncertainty remains with respect to 
the presence of symptoms in subclinical hyperthyroidism and impact of subclinical 
hyperthyroidism on perceived health status.  
 
In the current chapter, literature related to the expression of symptoms in subclinical 
hyperthyroidism was reviewed and summarised. In the next chapter, the evidence 
presented so far in this thesis is reviewed and summarised. In addition the next chapter 
explores and clarifies the rationale for the cross-sectional study evaluating symptoms in 
individuals aged 65 years or more with and without subclinical thyroid dysfunction. 
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CHAPTER 7 STUDY RATIONALE 
 
Overview of chapter 7  
This chapter summarises the evidence presented so far in this thesis and clarifies the 
clinical relevance of subclinical hyperthyroidism and hypothyroidism in terms of 
pathophysiological consequences and physical signs and symptoms. An additional aim 
of this chapter is to explore the rationale for evaluating symptoms in community dwelling 
individuals aged 65 years or more with and without subclinical thyroid dysfunction, in 
order to further contextualise the thesis.  
 
Evidence presented in the initial two chapters demonstrates that overt thyroid 
dysfunction is a clinically important disorder commonly encountered in primary care. 
Biochemical evaluation of serum thyrotrophin and thyroxine concentrations allows 
further categorisation of thyroid dysfunction as either overt or subclinical thyroid 
dysfunction. The distinction made between these categories is based upon the 
concentration of serum free thyroxine (FT4), with concentrations of FT4 inside the 
reference range in the presence of elevated or depleted thyrotrophin defining subclinical 
dysfunction, and concentrations of both serum FT4 and thyrotrophin outside the 
reference range indicating overt dysfunction. In chapters 3 to 6, the large body of 
literature exploring the clinical presentation and pathophysiological impact of subclinical 
thyroid dysfunction was described and summarised. These chapters demonstrate that 
whilst exploration has been widely undertaken, research findings are inconsistent and 
the clinical importance of subclinical thyroid dysfunction remains largely unclear. This is 
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mainly attributable to the small sample sizes and heterogeneity of the outcomes studied. 
In addition to the wide ranging outcome measures, evaluation of the evidence is further 
complicated by heterogeneity of patient populations. Whilst many of the smaller studies 
demonstrate statistically significant differences between individuals with subclinical 
thyroid dysfunction and euthyroid subjects, the clinical significance of these differences 
is unclear. The use of different assays for measurement of serum thyrotrophin, different 
reference criteria used to define subclinical thyroid dysfunction and the reduced 
representativeness of the samples studied make interpretation and extrapolation of 
findings to community dwelling populations unfeasible. More robust data are needed to 
determine the clinical impact and relevance of subclinical thyroid dysfunction, especially 
in terms of impact in an elderly primary care population. Age seems to have significant 
impact upon both the clinical expression and biochemical profile of thyroid dysfunction. 
Data support an increase in the prevalence of subclinical thyroid dysfunction with 
advancing years. However, there is a lack of data related to the clinical consequence of 
subclinical thyroid dysfunction in the elderly community dwelling population and 
extrapolation of data derived from young or middle aged cohorts is inappropriate. There 
are data that demonstrate a decline in the frequency of classical signs and symptoms of 
thyroid dysfunction in older patients with overt thyroid dysfunction compared with 
younger subjects suggesting that age also modifies clinical presentation. Diagnosis of 
subclinical thyroid dysfunction based on symptom presentation is therefore likely to be 
more difficult in older individuals, not least because many of the traditional symptoms 
associated with overt thyroid dysfunction accompany normal ageing. Despite these 
difficulties, recent evidence demonstrates a low prevalence of undiagnosed overt thyroid 
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dysfunction in the UK community setting. This suggests that GPs have a high index of 
clinical suspicion and are adept at diagnosing thyroid dysfunction in this population. 
Some studies, however, suggest that GP knowledge is limited regarding the proper use 
of laboratory tools and describe variable practice with respect to both testing and 
treatment of subclinical thyroid dysfunction. Similarly, others report a large number of 
requests for thyroid function testing being generated by primary care physicians and 
suggest that thyroid dysfunction is increasingly a laboratory diagnosis. A lack of clear 
evidence related to which symptoms necessitate further investigation of thyroid function 
and guidance in relation to the frequency of thyroid function testing in individuals 
presenting with new or persistent symptoms may be responsible. Current guideline 
documents and expert opinion are also inconsistent with respect to management of 
subclinical thyroid dysfunction. The principal reason for this lack of consensus with 
respect to screening and management of subclinical thyroid dysfunction as chapters 3-6 
have shown is an insufficiency of good quality data demonstrating expression of 
symptoms and other pathophysiological manifestations of subclinical thyroid dysfunction. 
Evidently, symptoms typical of overt thyroid dysfunction accompany normal aging and 
are often present in individuals with normal thyroid function. Whether symptoms 
suggestive of overt thyroid dysfunction in elderly individuals are pathophysiological or 
physiological in origin therefore requires clarification. Further evidence of an adverse 
symptom profile in elderly individuals with subclinical thyroid dysfunction would support 
the need for screening and treatment in this population. Likewise, determination of an 
adverse impact on general health status may serve as an aid to treatment decision 
making and management in elderly individuals with subclinical thyroid dysfunction. 
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Although observation of clinical signs and symptoms alone seems to be neither sensitive 
nor specific for the diagnosis of thyroid dysfunction, guidance based upon symptom 
expression would further support GP decision making when ordering thyroid function 
testing. Characterisation of symptoms associated with subclinical hypothyroidism and 
subclinical hyperthyroidism in this population could improve GP detection of individuals 
most likely to benefit from testing and justify treatment. Additionally, unnecessary 
investigation and/or treatment of subclinical thyroid dysfunction in this population based 
upon presence of symptoms could be avoided.  
 
As previously stated, the aim of this thesis is to further clarify the pathophysiological 
consequences of subclinical hyperthyroidism and subclinical hypothyroidism and 
determine the association between symptoms suggestive of overt thyroid dysfunction 
and subclinical thyroid dysfunction in the elderly community dwelling population.  
 
In achieving this aim, there are four objectives which have been previously described. In 
evaluating the pathophysiology of subclinical thyroid dysfunction this thesis has so far 
reviewed a large body of existing evidence pertaining to the adverse clinical 
consequences and manifestation of symptoms in subclinical thyroid dysfunction. 
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CHAPTER 8 STUDY METHODOLOGY 
 
Overview of chapter 8 
In order to contextualise the methodology of this thesis, the first section of this chapter 
focuses on the historical setting and the methodology of the original Birmingham Elderly 
Thyroid Study (BETS I). After this, the full methodology of the current study; (BETS II 
follow-up study) is reported. This includes both the methodology of i) the longitudinal 
follow-up study and ii) the nested cross-sectional study which is the principal focus of 
this thesis.  
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8.1 Historical setting and methodology of the first BETS  
The first Birmingham Elderly Thyroid Study (BETS I) was conducted between 01/11/02 
and 30/11/04 to determine the prevalence of subclinical thyroid dysfunction and 
unidentified overt thyroid disease in a large (n=5881) UK community based elderly 
population. 63  In addition BETS I explored the relationship between thyroid function and 
i) prevalent atrial fibrillation (AF) 151 ii) cognitive function, 145 and subsequently the effect 
of thyroxine replacement therapy on cognitive function in subjects with subclinical 
hypothyroidism. 190 
The BETS I population was recruited from 20 general practices in the greater 
Birmingham area of the UK; this geographical area covers a range of socioeconomic 
backgrounds and is broadly representative of urban areas of England and Wales. At the 
time of this initial study, practice registers were searched to identify eligible individuals. 
To maximise generalisability to routine general practice, all patients aged 65 years or 
older were invited to participate. Individuals were excluded if they had an active 
diagnosis of thyroid disease, were receiving therapy for thyroid disease, had undergone 
thyroid surgery or treatment within the preceding 12 months, were unwilling or unable to 
give informed consent or if the GP considered contact to be inappropriate (e.g. recently 
bereaved, terminal illness). All eligible patients received an invitation letter, a study 
information sheet and an invitation reply slip. 
All patients indicating that they were willing to participate were offered a study 
appointment with the research nurse at their general practice. At the clinic session 
subsequent to obtaining written informed consent, a 12 lead Electrocardiograph (ECG) 
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was performed and blood was taken for thyroid function testing (TFT). Thyroid function 
tests comprised measurement of thyrotrophin (TSH) and FT4. Measurement of FT3 was 
also undertaken as dictated by the routine laboratory protocol, when levels of 
thyrotrophin below the lower limit of the reference range were detected. Table 8.0 
demonstrates the thyroid status of individuals screened during BETS I. At the time of this 
initial study, measurement of thyroid function was performed using chemiluminescent 
immunoassay (Advia Centaur assay produced by Bayer Diagnostics, Newbury, UK). 
Thyroid status was classified in accordance with standard reference range criteria for 
thyrotrophin, FT4 and FT3 used at the laboratory performing testing (Regional Endocrine 
Laboratory at the University Hospital Birmingham National Health Service Foundation) 
during the period 2002-2004 (Table 8.0).  
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Table 8.0 Categorisation of thyroid status  
Thyroid status n = 5881 
(%) 
Serum 
thyrotrophin 
(TSH) 
concentration 
mIU/L 
Serum 
thyroxine (FT4) 
concentration 
pmol/L 
Serum Tri- 
iodothyronine 
(FT3) 
concentration 
pmol/L 
Overt Hyperthyroidism 15 (0.3) < 0.40 > 20 >6.5 
Subclinical hyperthyroidism  128 (2.2) < 0.40 9 – 20 3.5-6.5 
Euthyroid total 5538 (94) 0.4 – 5.5 9 – 20 NA 
Subclinical hypothyroidism 168 (2.9) >5.50 9 – 20 NA 
Overt hypothyroidism  23 (0.4) >5.50 < 9.0 NA 
Unclassified 9 (0.2) NA NA NA 
 
 
Depression and anxiety and cognitive function were measured using previously 
validated instruments (Hospital Anxiety and Depression Scale) 191 and standardised 
tests of cognition (Mini Mental State Examination (MMSE) 192 and the Middlesex Elderly 
Assessment of Mental State (MEAMS) extensively used with elderly people. 193 In 
addition all participants completed the EQ5D to provide data on general health and well-
being. The research nurse reviewed the practice held medical notes and recorded 
concomitant disease and medication. 
 
8.1.1 Clinical follow-up as a result of thyroid screening during BETS I. 
Patients identified during BETS I screening as having either overt hyperthyroidism 
(n=15) or overt hypothyroidism (n=23) received treatment for thyroid dysfunction in 
accordance with routine treatment protocols. Ninety four individuals classified as 
subclinically hypothyroid gave written informed consent to participate in the BETS 
randomised controlled trial (RCT) to investigate the effect of thyroxine replacement 
therapy on cognitive function in subjects with subclinical hypothyroidism. Fifty one of 
those received the active replacement therapy with the remainder receiving a placebo. 
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Classification of thyroid status based upon measurements of thyrotrophin, FT4 and FT3 
for nine participants was not possible, and these individuals were referred to a 
thyroidologist for further clinical review. One further patient was excluded as subsequent 
validation confirmed age ineligibility. Overall, 5782 participants of the original study were 
classified as having euthyroid function, subclinical hyperthyroidism or subclinical 
hypothyroidism and did not require or receive further investigation or treatment in 
relation to thyroid status. This cohort forms the baseline population for the current study 
(Figure 8.0).  
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Figure 8.0 Clinical follow-up of the original cohort 
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8.1.2 Birmingham Elderly follow-up study (BETS II) 
The primary objective of the current and second Birmingham Elderly Thyroid Study 
follow-up study (BETS II) was to re-screen thyroid function in the original cohort and 
determine the proportion of patients with subclinical thyroid dysfunction in the BETS 
cohort who revert to a euthyroid state, experience persisting subclinical thyroid 
dysfunction or develop overt thyroid dysfunction. The principal focus of the thesis is the 
nested cross-sectional study, the aims and objectives of which have been previously 
described.  
 
8.1.3 Practice recruitment 
All twenty practices that had participated in the original study were invited to participate. 
One practice was unable to participate at the time of follow up. The other 19 practices 
expressing an interest were visited by a member of the research team for provision of 
information about the study to include study background, aims and methods and to 
discuss issues relating to study organisation. All nineteen practices agreed to participate 
in the follow-up study.  
 
8.1.4 Confirmation of patient eligibility  
A list of patients who participated in the original study was generated from the BETS I 
database held within the Department of Primary Care Clinical Science (PCCS) at the 
University of Birmingham. The BETS I database was developed during the original study 
and contains all previously recorded data including patient characteristics, address and 
155 
 
contact details, medication and disease history and thyroid function test results from the 
original screening study.  
 
8.1.5 Inclusion criteria  
The patient lists were sent to the general practitioners (GPs) for confirmation of eligibility 
and contained the names of; 
 Patients who were identified in the original screening study (BETS I) as having 
subclinical hyperthyroidism (defined by a TSH < 0.4 mIU/L, FT4 9-20 pmol/L and 
for FT3 3.5- 6.5 pmol/L) or subclinical hypothyroidism (characterised by a TSH 
>5.5 mIU/L and FT4 9-20 pmol/L) and who were untreated for thyroid dysfunction 
in BETS I. 
 Patients classified as euthyroid (defined by TSH 0.4 -5.5 mIU/L and FT4 9-20 
pmol/L) during the original BETS I study. 
 
8.1.6 Exclusion criteria  
The following individuals were excluded from the patient lists sent to GPs for 
confirmation of eligibility; 
 Individuals identified with overt hyperthyroidism (TSH <0.4 mIU/L, FT4 >20 
pmol/L and FT3 > 6.5pmol/L) or overt hypothyroidism (TSH >5.5 mIU/L and FT4 
< 9 pmol/L) during the original study. 
 Patients who received treatment such as thyroid surgery, radio-iodine therapy, 
anti thyroid medication and/or thyroxine for thyroid dysfunction during the original 
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study period either due to routine medical care or randomisation to the treatment 
arm of the BETS I randomised controlled trial.  
 Individuals in BETS I for whom classification of thyroid status based upon 
measurement of TSH and FT4 was not possible. 
 
The patient lists were verified by GPs who confirmed the patients‟ address, registration 
status (e.g. currently registered with the practice, no longer registered or deceased). 
GPs were also asked to make discretionary exclusions from the list if they judged 
contact with an individual to be inappropriate (e.g. individual recently bereaved, mentally 
impaired or terminally ill). 
 
GPs returned the patient lists to the research office. Those excluded by the GPs were 
removed from the list of individuals eligible to receive an invitation to participate in 
follow-up study. 
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8.2 Study procedure 
 
8.2.1 Recruitment 
All eligible patients were sent an invitation letter, patient information sheet, an invitation 
reply slip and a freepost envelope. Patients were asked to read the information sheet, 
and then to complete, sign and return the reply slip indicating whether they wished to 
participate. Patients willing to participate were asked to provide a contact telephone 
number. A second invitation letter was sent if no response was received within 3 weeks 
of the initial letter being sent.  
 
8.2.2 Arranging study appointments 
All patients indicating they were willing to participate were telephoned and offered a 30 
minute study appointment with a research nurse at their usual general practice. Those 
indicating that they were not willing to participate were not contacted further.  
 
8.2.2.1 Appointment confirmation  
Following the telephone call, patients agreeing to attend received a letter confirming 
their appointment date and time and a study questionnaire (Appendix 3 Symptoms 
questionnaire). Patients were asked to complete the study questionnaire prior to their 
appointment and return it to the research nurse during the clinic. Participants were not 
placed under any restrictions on eating or medication use before their study 
appointment.  
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8.2.3 Screening clinics 
All clinics were conducted between 06/02/08 and 17/10/08. Research nurses trained in 
good clinical practice and the study protocol conducted the screening clinics. At each 
clinic appointment the research nurse explained the study and patients‟ questions were 
answered and concerns discussed. Written informed consent was obtained from all 
patients willing to participate.  
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8.2.4 Outcome measures 
The principle outcomes were: 
 Proportions of participants categorised in accordance with current reference 
criteria defined by the testing laboratory as euthyroid, subclinically hyperthyroid 
and subclinically hypothyroid.  
 Prevalence of 12 current symptoms of overt hypothyroidism and 9 current 
symptoms suggestive of overt hyperthyroidism in thyroid function groups 
categorised in accordance with current laboratory reference criteria.  
 Prevalence of 12 symptoms of overt hypothyroidism and 9 symptoms suggestive 
of overt hyperthyroidism that have increased in intensity during the previous 12 
months in thyroid function groups categorised in accordance with current 
laboratory reference criteria.   
 Level of perceived health status in thyroid function groups categorised in 
accordance with current laboratory reference criteria.  
 Level of perceived health status in individuals reporting presence and absence of 
concurrent symptoms suggestive of overt thyroid dysfunction. 
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8.2.5 Ascertainment of outcomes  
8.2.5.1 Case note evaluation 
Initial recording of patient data was based upon patient reporting, with validation of data 
by inspection of medical records. All patients providing written informed consent to 
participate were asked about their current smoking status (to include the number of 
cigarettes or weight in grams of tobacco smoked per day) and their average alcohol 
intake each week. In addition, patients were asked whether they regularly consumed 
any products, supplementation or preparations of multi vitamins containing iodine or 
kelp. Details of first and second degree blood relatives who currently have or have 
previously had a diagnosis of thyroid dysfunction were also collected, including the 
relationship between them (i.e sibling, parent, or grandparent) and type of thyroid 
dysfunction if known. Routine general practice medical records were reviewed to collect 
data. To ensure full data capture for all patients irrespective of when they were screened 
in BETS I, the start date for the data collection period was defined as 01/11/02 (the start 
date of the BETS I screening study). All significant disease and major surgery occurring 
since 01/11/2002 were recorded (Table 8.1). These were diseases previously identified 
as potentially impacting on BETS I variables (thyroid function) or outcomes. Start dates 
and current status of treatment related to any of these diseases were recorded along 
with treatment end date where appropriate. Data related to thyroid surgery, radio-iodine 
therapy, anti thyroid drugs and thyroxine, start date and duration of treatment occurring 
since 01/11/02 were also recorded (Table 8.1) 
 
161 
 
Table 8.1 Concomitant diseases confirmed by review of case notes 
Diagnosis 
Anxiety 
Atrial Fibrillation 
Cancer 
Cerebrovascular disease / Stroke / TIA 
Dementia 
Depression 
Diabetes 
Heart failure / Valve disease 
Hypertension 
Ischemic or Coronary Heart Disease or Angina 
Irregular heart rhythm (other than AF which should be noted above) 
Peripheral vascular or artery disease 
Pituitary disease 
Pulmonary disease / COPD / Asthma 
Renal disease (Chronic and grade 3 or 4 only)  
 
 
Review of the medical records allowed collection of data on use of drug therapies known 
to influence tests of thyroid function or to be indicative of significant medical diagnoses; 
this included current use of medications listed in Table 8.2.  
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Table 8.2 Drug categories  
Drug / Drug Group 
Amiodarone 
Anti-depressant 
Anxiolytic 
Beta-adrenergic Blockers 
Lithium 
Major Tranquilizers 
Morphine or other opioid analgesics 
Glucocorticoids 
 
 
 
8.2.5.2 Demographic data 
Age was calculated using date of birth and either the date of the initial invitation to 
participate in screening (for non attendees) or the date of attendance at the screening 
clinic (for attendees). Socioeconomic status of an individual of retirement age may not 
be truly represented by measures that rely solely upon employment and education 
therefore the Index of Multiple Deprivation (IMD) 2004 was employed as a proxy 
measure of socioeconomic deprivation for this population. 194 IMD is a small area 
measure of neighbourhood deprivation calculated as the weighted average across 
seven domains of deprivation using data from the years 2000–2003 with lower scores 
indicating greater levels of deprivation. IMD scores are calculated at the level of Lower 
Super Output Areas (LSOAs), these being geographical units of varying size but 
containing a population of approximately 1500 at the time of the 2001 census which on 
average is smaller than the ward levels used in other indices such as Carstairs and 
Townsend (Table 8.3). 195 Furthermore, the use of multiple domains makes IMD a more 
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valid measure of deprivation in individuals of retirement age. IMD scores were converted 
into quartiles with quartile 1 representing the most affluent and quartile 4 the most 
deprived.  
 
Table 8.3 Seven domains of the Index of Multiple Deprivation 
Domains of the Index of Multiple Deprivation (IMD) 194 
Income 
Employment 
Health and disability  
Education, skills and training 
Barriers to housing and services 
Living environment  
Crime 
 
 
 
8.2.6 Clinical evaluation  
8.2.6.1 Venepuncture for thyroid function testing  
Venepuncture was undertaken to obtain a blood sample for thyroid function testing. 
Samples were collected in plastic vacuette 4ml serum separator clot activator tubes. The 
blood sample and accompanying laboratory request form were labelled with study 
specific sticky labels. Study labels included the following: the BETS II study logo and 
study Id number, the patients‟ unique study Id number, patient gender, date and time of 
sample collection. The venepuncture protocol dictated that two attempts to obtain a 
blood sample could be made during the screening appointment. Where the research 
nurse was unable to obtain blood during the first screening clinic, patients were offered a 
second appointment for venepuncture only. 
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8.2.6.2 Transportation of blood sample to the laboratory for testing 
Blood samples were collected, treated (gently inverted to activate clotting and stored at 
room temperature) and transported to the Regional Endocrine Laboratory at the 
University Hospital Birmingham National Health Service Foundation (UHB) for thyroid 
function testing in accordance with routine procedure for blood collection. Royal mail 
safeboxes™ were used to transport samples to the laboratory from general practices 
where UHB laboratory services were not routinely used (n=8 practices using 
safeboxesTM). The effectiveness of this system of delivery in terms of receipt of 
unspoiled samples by the laboratory has been previously demonstrated in other studies 
conducted in Primary Care Clinical Sciences and was used in BETS I (Personal 
communication with the authors). 
 
8.2.6.3 Measurement of thyroid function  
Measurement of serum thyrotrophin (TSH) and FT4 concentration was undertaken on all 
individuals that provided written informed consent to participate to include individuals 
that had received a diagnosis of thyroid dysfunction since the original BETS I screening 
study. In accordance with the routine laboratory protocol, FT3 measurements were 
performed only when levels of TSH were below the lower reference limit of 0.3mIU/L. 
Serum TSH, FT4, and FT3 were measured by electrochemiluminescent immunoassays 
on the Roche E170 (Roche Diagnostics, Burgess Hill, UK). The TSH assay was 
calibrated against the second International Reference Preparation 80/558. The lower 
limit of reporting for the TSH assay was 0.02 mIU/L and the manufacturer‟s quoted mean 
functional sensitivity was 0.014 mIU/L. Serum TSH and FT4 concentrations were 
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determined for all individuals; where a serum TSH below the lower limit of the reference 
range was identified, serum FT3 was also measured. Laboratory reference ranges for 
serum TSH, FT4 and FT3 concentration and the associated inter-assay coefficient of 
variation are shown in Table 8.4. 
 
 
Table 8.4 Reference range criteria  
 
 
 
 
8.2.7 Administration of the study questionnaire  
The study questionnaire was enclosed with participant appointment confirmation letters 
and included an instruction for self completion before attendance at the screening clinic. 
Study questionnaires comprised two parts with section one evaluating presence of 18 
current or recently changed symptoms suggestive of overt thyroid dysfunction and 
section two assessing perceived health status.  
 
8.2.7.1 Review of the study questionnaire 
The nurse reviewed each study questionnaire to ensure all questions had been fully 
completed, that only one response had been given per question and to ascertain 
symptoms that had not previously been reported to the GP and/or were considered 
indicative of other underlying disease. Research nurses received training in all aspects 
Thyroid parameter  UHB Reference 
Range 
Intra –assay co-efficient of 
variation (associated range)  
Thyrotrophin hormone  0.3-4.5 mlU/L 1.5% (0.5-33.0mlU/L) 
Free Thyroxine  10-22 pmol/L 2.0-2.5% (9.0-66.0pmol/L) 
Free Triiodothyronine  3.1-6.8 pmol/L 2.0-3.5% (4.0-21.0pmol/L) 
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of completion and inspection of the study questionnaire. Training emphasised the 
importance of self completion by participants and the nurses were reminded to refrain 
from selecting questionnaire responses at the request of participants. If for any reason a 
participant was unable to undertake this activity unaided or where items were incomplete 
the nurse assisted completion by reading the question to the participant and recording 
their answer on the questionnaire. Additional copies of the study questionnaire were 
available in each general practice for administration by the nurses in the event that 
participants had not received, were unable to complete, or had forgotten to bring the 
study questionnaire they had been previously allocated.  
 
8.2.8.1 Transfer and feedback of thyroid function test results  
Thyroid function test results were electronically transferred from the laboratory to the 
research office at the end of each day using an electronic transfer system that had been 
developed during the original study. This system allowed transfer of a file containing the 
thyroid function test results coded only by the unique patient identifier. Results were 
imported into the BETS II Microsoft access database, where anonymous TFT results 
were linked to individual participants based upon their unique study identification 
number. The TFT results were mail merged to the appropriate results letter and posted 
to participants and their GPs to be received within 28 days of the screening clinic. 
Participants with thyroid function tests that required consideration for treatment (with 
both TSH and FT4 levels outside the reference ranges) were referred back to their GP 
within 5 working days of results being received by the research office and patients were 
advised to make an appointment with their GP to discuss their results. Patients with test 
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results indicating subclinical thyroid dysfunction were advised to discuss their results 
with their GP at their next consultation. Where the laboratory reported that thyroid 
function testing had not been possible (due to insufficient or spoiled blood samples 
being received at the laboratory), patients were offered a second appointment for 
venepuncture only. 
 
8.3 Development of the study questionnaire 
Available tools for assessment of symptoms suggestive of overt hypothyroidism and 
overt hyperthyroidism and for evaluation of perceived health status were reviewed to 
identify appropriate instruments for use in the current study. Identification of one 
questionnaire comprising questions related to symptoms of both hypothyroidism and 
hyperthyroidism was unlikely therefore amalgamation of two instruments was necessary. 
The two principle characteristics of these instruments were determined to be suitability 
for self-completion by elderly individuals and administration to individuals with and 
without thyroid dysfunction. Additionally, because the thesis aimed to characterise 
symptoms associated with subclinical thyroid dysfunction as an aid to diagnosis, 
diagnostic indices specifically designed to distinguish between different grades of thyroid 
function were considered preferable to tools designed to assess change in symptoms 
before and after initiation of treatment. Furthermore, instruments that had been 
previously validated or widely utilised since the introduction of more sensitive third 
generation thyroid function assays in the 1980s were considered more relevant and 
therefore favourable.   
168 
 
Disease specific measures of health status and quality of life were excluded from further 
consideration because application of these tools to a population in which some 
individuals do not have the relevant disease is inappropriate and would not yield 
meaningful results. Only generic tools for assessment of perceived health status or 
health related quality of life were therefore explored.  
 
8.3.1 Review of instruments used to measure health status  
Two generic instruments that had previously been used to assess perceived health 
status in individuals with thyroid dysfunction were identified; the SF8 (a shortened 
version of the SF36) and the Nottingham Health profile (NHP). 196 The SF36 and the 
NHP have been extensively used in studies of chronic disease in the general population. 
The SF36 is also regarded as suitable for use with older adults. 178 More recently these 
tools were used by Bianchi et al to assess the burden of different grades of thyroid 
dysfunction on perceived health status. 15 The SF8 comprises eight items which are 
used to measure a range of health status to include mental and physical function and 
identifies both positive and negative aspects of health. The NHP comprises 45 items in 
two parts and measures only negative aspects. The NHP is therefore a less sensitive 
tool for measurement of how healthy individuals feel. The SF8 was therefore chosen for 
evaluation of perceived health status in the current study (Table 8.5). 
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Table 8.5 Evaluation of perceived health status  
Instrument/Tool Administration/ 
completion  
Number of 
items 
English 
language 
Comments   
Under active thyroid 
dependant quality of life 
questionnaire 198 
Questionnaire/ self 
completion 
18 Yes 
Disease specific measure of quality of life in 
hypothyroidism  
 
 
Thyroid treatment 
satisfaction 
questionnaire 
(ThyTSQ) 199 
Questionnaire/ self 
completion 
7  Yes 
Treatment satisfaction questionnaire suitable for 
routine clinical monitoring or use in clinical trials   
 
SF 36 178 
Questionnaire/ self 
completion 
36  Yes 
Generic measure of health,widely used, simple to 
administer, short completion time and assesses 
positive and negative aspects of health 
Nottingham health 
profile 197 
Questionnaire/ self 
completion 
45 in two 
parts 
Yes 
Generic measure of health status, acceptable, 
short completion time, less sensitive than SF36 in 
hypothyroidism, assesses only negative aspects of 
health 
Chronic Thyroid 
Questionnaire 14 
Interview/ clinician 
assisted 
104 Yes 
Disease specific measure of health status in 
hypothyroidism  
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8.3.2 Review of tools used for evaluation of symptoms  
Four instruments that evaluated symptoms of overt hypothyroidism were identified 
(Table 8.6). 37,39,56,200 The Thyroid Symptom Questionnaire (TSQ) was immediately 
excluded because it had been specifically designed for monitoring of residual complaints 
following treatment. 200 The three remaining tools were the Billewicz index, the Zulewski 
score and the Colorado symptom survey. 37,39 The Billewicz index was excluded 
because it is an older clinical index that has been shown to be of limited use for 
detection of early signs and symptoms of hyperthyroidism. 37 For this very reason the 
Billewicz index was recently modified, re-evaluated and updated by Zulewski et al and 
has been shown to be useful in distinguishing euthyroid individuals from individuals with 
overt hypothyroidism. However, the Zulewski score was considered inappropriate for 
use in the current study however because it requires administration by a trained 
clinician. 39 Moreover, the Colorado symptom survey fulfilled all of the inclusion criteria 
and was therefore the most suitable instrument for use in the current study. 56 This 
questionnaire was specifically designed to assess symptoms suggestive of overt 
hypothyroidism and has previously been administered for self completion in a large 
cross-sectional study comprising individuals with and without subclinical thyroid 
dysfunction. The tool comprises 17 symptoms of hypothyroidism and three other „thyroid 
neutral‟ symptoms. Selection of items was based upon the results of a previous study 
which demonstrated a difference in symptom prevalence between hypothyroid and 
euthyroid subjects. The survey is divided into two parts with part one assessing current 
presence or absence of each symptom and the second part determining whether the 
symptom is new compared with the previous year. The response option for each item is 
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1-5 with 3 being a neutral response and each extreme representing either complete 
absence or marked severity. The key features of this questionnaire are that it is 
convenient and easily administered and suitable for self-completion by an elderly 
population.  
Despite three instruments for assessing symptoms of overt hyperthyroidism being 
identified, none of them were diagnostic indices suitable for self completion by an elderly 
population. 41,42,201 The hyperthyroidism complaints questionnaire (HCQ) was not 
considered for use in the current study because it had been specifically designed for 
monitoring of residual complaints following replacement therapy.  201 The two remaining 
tools; the hyperthyroid symptoms rating scale (HSRS) and the Crooks‟ index, were both 
diagnostic indices that have recently been utilised in studies comparing individuals with 
subclinical hyperthyroidism and euthyroid individuals. 41,42 However, both indices, 
required administration by a clinician because physical examination is necessary for 
evaluation of clinical signs of hyperthyroidism.  
The Hyperthyroid symptoms rating scale (HSRS) has been widely used in studies to 
assess signs and symptoms of hyperthyroidism. 159,187,188 Klein et al developed this 
instrument to aid assessment of symptom severity in hyperthyroidism. 42 Selection of 
items from the HSRS was based upon two previous studies demonstrating a difference 
in prevalence of symptoms between individuals with overt hyperthyroidism and 
euthyroidism. 40,41 The HSRS scale comprises ten items that rate: nervousness, 
diaphoresis, heat intolerance, motor activity, tremor, weakness, hyperdynamic 
precordium, diarrhoea, weight loss and appetite. The scale is an observer rated scale 
with information needed to rate each item obtained through review of medical history 
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and physical examination. Items are scored on scale of 0-4 and summed to give a total 
score (0-40) with higher scores indicating more symptoms. Full use of this symptom 
rating scale was considered unfeasible in the current study due to the requirement for 
physical examination. Since this scale had been widely used in other studies and the 
fact that the majority of items it contains are common to other hyperthyroid symptom 
indices and literature related to symptoms, items were selected from it for use in the 
current research. 159, 188, 202    
Similarly, the Crooks index is a diagnostic index that was developed to improve 
accuracy of clinical assessment of overt hyperthyroidism. 41 Whilst it is an older clinical 
index it has been used recently to assess signs and symptoms that accompany 
subclinical hyperthyroidism. The index comprises eight symptoms (breathlessness on 
effort, palpitation, lethargy, sensitivity to heat, excessive perspiration, nervousness, 
increases in appetite, weight loss) and nine signs (palpable thyroid, bruit over thyroid, lid 
retraction, lid lag, exophthalmos and hyperkinetic movements, fine finger tremor, 
clammy hands and rapid pulse rate). A final clinical score of ≥19 is considered to be 
consistent with overt hyperthyroidism, ≤ 11 indicative of euthyroid status and between 
12-18 intermediate. 41 
It was therefore necessary to develop a specific questionnaire for ascertainment of data 
related to symptoms suggestive of overt hyperthyroidism. This was achieved by 
amending the Colorado symptom survey for hypothyroid symptoms to incorporate 
symptoms suggestive of hyperthyroidism as identified from the HSRS and Crook‟s 
index. The final questionnaire comprised items from the Colorado symptom survey, the 
hyperthyroid symptoms rating scale (HSRS) and the Crooks index. 41,42,59 Comparison of 
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items between these three indices and the literature informed selection of additional 
symptoms suggestive of hyperthyroidism for inclusion in the current study questionnaire. 
Since the Colorado symptom survey included six items assessing symptoms (body 
weight, sensitivity to temperature, speed of thinking, poor memory, muscle weakness 
and lethargy) which are also consistent with overt hyperthyroidism, it was necessary to 
add just three additional symptoms (trembling or shaking hands, excessive perspiration 
and palpitation).  
The three new items were inserted into the Colorado survey and arranged in order to 
preserve the original format of the survey. This format also enabled ascertainment of 
presence, absence and recent change in each of the three additional items.  
Eight items were removed from the Colorado symptom survey; these were depression, 
sleep, maths skill, coarser hair, irregular menses and three thyroid neutral items related 
to vision, cough and nausea. These items were removed from the current questionnaire 
as they had not previously been identified as important discriminators of thyroid 
dysfunction, were not considered to be clinically relevant or translatable to an elderly UK 
population and to minimise respondent burden. 59  Similarly, items of the HSRS and 
Crooks index requiring physical examination were not selected for use. Other items such 
as appetite, nervousness, hyperactivity, breathlessness on exertion, diarrhoea and daily 
function were not selected because they were not common to both indices and were not 
sufficiently supported in the literature to justify inclusion. Choice of questionnaire items 
for insertion and removal was affirmed by a consultant endocrinologist specialising in 
thyroid disease. The final symptom questionnaire therefore comprised 15 items, each 
with two parts relating to overall presence and recent onset of symptoms. 
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Table 8.6 Evaluation of symptoms and perceived health status  
Instrument/Tool Administration/ 
completion 
Number 
of items 
English 
language 
Comments 
 
 
 
Billewicz clinical index 39 Interview/clinical 
exam  
21 Yes Developed pre-1980 to aid diagnosis 
before availability of sensitive assays for 
TSH and FT4  
 
Zulewski scale 37  Interview/clinical 
exam 
14 Yes Updated version of the Billewicz index. 
Clinical score valuable for assessment of 
severity  
 
Thyroid Symptoms 
Questionnaire 200 
Questionnaire/ self 
completion 
12 Yes Specifically designed for monitoring 
residual complaints following initiation of 
therapy  
Colorado symptoms survey 56  Questionnaire/ self 
completion 
17 Yes Convenient and simple to administer. 
Clinical scoring system is complex  
Hyperthyroidism complaints  
questionnaire 201 
Questionnaire/ self 
completion 
31 Yes Designed for measurement of residual 
complaints following treatment for 
hyperthyroidism  
Hyperthyroid symptoms 
rating scale 42 
Interview/ clinical 
exam 
10 Yes Designed to aid assessment of symptom 
severity and response to therapy 
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8.3.3 Evaluation of symptoms  
The questionnaire utilised 15 items and enabled assessment of 18 symptoms 
suggestive of overt thyroid dysfunction. In particular, three questionnaire items were 
unique to assessment of symptoms suggestive of hyperthyroidism, six items to 
evaluation of symptoms suggestive of hypothyroidism and six items assessing 
symptoms which can be considered suggestive of either overt hyperthyroidism or overt 
hypothyroidism. Three of these items (activity, muscle weakness and memory) 
evaluated symptoms that have a similar clinical presentation in each form of thyroid 
dysfunction. In contrast, the final three items assess symptoms that exhibit an opposing 
clinical presentation in overt hyperthyroidism to that observed in overt hypothyroidism. 
As these three items generate data relevant to both forms of thyroid dysfunction, they 
are counted in both the total number of symptoms suggestive of overt hyperthyroidism 
and total number of symptoms suggestive of overt hypothyroidism. The questionnaire 
therefore enabled evaluation of a total of nine symptoms suggestive of overt 
hyperthyroidism and 12 symptoms suggestive of overt hypothyroidism (Table 8.7). 
 
Each item consisted of two components; the first to assess the presence of the symptom 
at the time of questionnaire completion (current symptom) and the second to evaluate 
change in symptom severity occurring during the previous 12 months (changed 
symptom). Both components encompassed a five point likert style response scale.  
In general, one end of each five point scale reflected the presence of a symptom 
suggestive of overt thyroid dysfunction and the other extreme exhibited the opposing 
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symptom not suggestive of overt thyroid dysfunction with a neutral option at the central 
position (Figure 8.1.1). The position of the symptom suggestive of overt thyroid 
dysfunction was changed throughout the questionnaire; in six items, the symptom 
occupied positions one and two and for all other items the symptom was located in 
positions four and five. The position of the neutral response option remained the same 
throughout. 
Overall, each questionnaire item evaluated only one symptom suggestive of overt 
thyroid dysfunction, however, for the items thinking, weight and temperature, both ends 
of the five point scale evaluated a symptom suggestive of overt thyroid dysfunction with 
location one and two representing high body weight, sensitivity to cold temperatures and 
slow thinking (symptoms suggestive of overt hypothyroidism) and positions four and five 
representing low body weight, sensitivity to heat and fast thinking (symptoms suggestive 
of overt hyperthyroidism) (Figure 8.1.2).  
For completion of component one of each questionnaire item (component to evaluate 
presence of current symptoms), participants were asked to consider their experience of 
each item, to compare their own experience with others in their age group and indicate 
the response within the five point scale which best represented them. The five point 
likert type scale provided two response options representing the presence of the 
symptom and three options indicated absence of the symptom. This five point scale also 
allowed severity of the symptom to be evaluated as either mild or severe in accordance 
with the likert point chosen. For example, hoarse voice at position four of the response 
scale was considered to be of mild severity whereas very hoarse voice located at point 
five of the scale was considered to be more severe (Figure 8.1.3).  
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The second component of each questionnaire item evaluated change in intensity of 
symptoms over the previous 12 months. Participants were asked to consider whether 
their current experience of each symptom was different from 12 months ago and to 
indicate what type of change had occurred, thus the response scale provided an option 
for no change, two options for an improvement in symptoms and a further two response 
options reflecting an increase in symptom severity. The five point scale enabled 
assessment of the level of increase in symptom severity for example the option „more 
hoarse now‟ was considered indicative of a mild increase in symptom severity and „much 
more hoarse now‟ was considered indicative of a severe increase in symptom severity 
during the previous 12 months (Figure 8.1.1- 8.1.3). 
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Table 8.7 Eighteen items of the symptoms questionnaire   
Item 
No.  
Questionnaire item Symptom number and 
type 
Symptom 
suggestive of 
hyperthyroidis
m 
Symptoms 
suggestive of 
hypothyroidism 
1 Perspiration/ 
sweating 
1 Excessive 
perspiration 
X  
2 Trembling/shaky 
hands 
2 Trembling hands 
X  
3 Palpitation 3 Frequent 
palpitation  
X  
4 Temperature* 
 
4 Sensitivity to heat * 
X  
5 Thinking * 5 Fast thinking* 
X 
 
 
6 Weight* 6 Weight loss* 
X 
 
 
7 Activity ** 
 
7 Lethargy** 
X X 
8 Muscles 1** 8 Weak muscles** 
X 
X 
 
9 Memory** 9 Poor memory** 
X 
X 
 
10 Voice 10 Hoarse voice 
 
X 
 
11 Tone of voice 11 Deep voice 
 
X 
 
12 Skin 12 Dry skin 
 
X 
 
13 Eyes 13 Puffy eyes 
 
X 
 
14 Muscles 2 14 Muscle cramps 
 
X 
 
15 Constipation 15 Constipation  
 
X 
 
4 Temperature* 
 
16 Sensitivity to cold*  
 X 
5 Thinking * 17 Slow thinking* 
 
X 
 
6 Weight* 18 Weight gain* 
 
X 
 
    9 symptoms 
 
12 symptoms 
 
* denotes symptoms suggestive of overt thyroid dysfunction that have a dissimilar and opposing clinical presentation 
in overt hyperthyroidism and overt hypothyroidism 
** indicates symptoms suggestive of overt thyroid dysfunction that have a similar presentation in both overt 
hyperthyroidism and overt hypothyroidism. 
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Figure 8.1 Questionnaire components 
  
8.1.1 Symptom suggestive of hypothyroidism  
 
 
 
8.1.2 Symptom suggestive of hypo and hyperthyroidism at likert position 4 and 5  
 
 
 
8.1.3 Symptoms of hypo and hyperthyroidism at opposite end of the likert scale 
 
Is your voice 
generally … 
Very clear Clear Average Hoarse Very hoarse 
Likert scale 
position 
1 2 3 4 5 
Symptom 
present or 
absent 
(absent) (absent) (absent) (present) (present ) 
Symptom 
intensity  
Absent   Absent Absent Mild intensity  Severe intensity 
Is your 
memory? 
Very good Good Average Poor Very poor 
Likert scale 
position 
1 2 3 4 5 
Symptom 
present or 
absent 
(absent/both) (absent/both ) (absent/both) (present/both ) (present/both ) 
Symptom 
intensity  
Absent   Absent Absent Mild intensity  Severe intensity 
Question: 
Are you 
generally … 
Very 
sensitive to 
cold 
Sensitive to 
cold 
Average 
Sensitive to 
heat 
Very sensitive 
to heat 
Likert scale 
position 
1 2 3 4 5 
Symptom 
present or 
absent 
(Present/Hypo) 
(Hyper/absent) 
(Present/Hypo) 
(Hyper/absent) 
(Both absent) 
(Present/Hyper) 
(Hypo/absent) 
(Present/Hyper) 
(Hypo/ absent) 
Symptom 
intensity  
Severe/Hypo Mild/Hypo Absent  Mild/Hyper Severe/Hyper 
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8.3.4 Evaluation of perceived health status 
Perceived health status was evaluated using the SF8 to enable comparison of disease 
burden between individuals with subclinical thyroid dysfunction and euthyroid 
individuals. The SF8 is a shortened version of the SF36 and as such is a multi purpose 
generic measure of perceived health status. The SF8 comprises 8 questions (one 
question to measure each of the eight SF36 domains), measures both negative and 
positive aspects of health and measures a range of health status and well being in terms 
of both physical and mental health. Table 8.9 demonstrates the single health measures 
and summary measures assessed using the SF8. The physical health summary 
measure comprises the four domains, general health, physical functioning, role physical 
and bodily pain and the mental health summary the four domains; vitality, social 
functioning, mental health and role emotional. (Table 8.8) 
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Table 8.8 Items and domains of the SF8 
SF8 single item health measures SF8 single item health measures 
General Health 
Physical component summary 
score 
Physical functioning 
Role Physical 
Bodily pain 
Vitality 
Mental component summary score 
Social functioning 
Mental health 
Role emotional 
 
 
 
8.3.5 Piloting of the symptoms questionnaire  
To evaluate face validity the questionnaire was piloted in 10 individuals over the age of 
65 years and was reviewed by a consultant endocrinologist specialising in thyroid 
dysfunction. The pilot population commented on the clarity of layout, format and content 
of the questionnaire as well as the relevance of the questions and appropriateness of 
the terminology used. The questionnaire design and content was refined in accordance 
with feedback obtained from piloting. 
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8.4 Management of data  
All data recorded on the case report forms during the screening clinics and all completed 
study questionnaires were returned to the study office for data entry. Data were entered 
onto a password protected Microsoft Access (2003) database, stored on the secure 
network within Primary Care Clinical Sciences, University of Birmingham. The database 
was constructed with restrictions on each field to limit entry of implausible data and aid 
data validation.  
 
8.4.1 Data validation 
Validation exercises were performed on all data fields to identify implausible values and 
conflicting data. Reference was made to source documents to resolve queries. A 
duplicate Access data base was set up to enable dual data entry of 10% of the 
symptoms questionnaires. Access database queries were set up to compare the two 
versions of the database (single and double data entry) and identify discrepancies 
arising from the double data entry. Discrepancies identified between the two data sets 
were checked against the paper questionnaires to verify the data. The database was 
amended as appropriate and error rates confirmed to be at acceptable levels (<5 errors 
per 1000 data points). The database was backed-up daily and once all data had been 
entered, cleaned and validated the study database was locked.  
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8.4.2 Transformation of symptoms data for analysis   
Data were subsequently transformed for the purposes of data analysis. Preliminary 
transformations were made to ensure that higher values represented symptom 
presence. Recoding of the items, weight, thinking and temperature was necessary, since 
these items represented symptoms that exist in overt hyperthyroidism and overt 
hypothyroidism, albeit with opposing clinical presentation. Two separate variables were 
created; one to reflect overt hyperthyroidism and another for overt hypothyroidism.  
A binary variable was created to reflect the presence or absence of each current and 
changed symptom, with a code of 1 indicating presence and 0 reflecting absence of the 
symptom.  A third variable was constructed for each item of component one and 
component two to reflect the severity of each symptom. The presence of a more severe 
symptom was allocated a value of 2 (e.g. very dry skin), a mild symptom a value of 1 
(dry skin) and all other options were coded as zero to reflect the absence of the 
symptom (i.e. response options; average skin, oily skin, very oily skin).  
 
8.4.3 Health status data entry and coding  
Data obtained using the SF8 were also transformed for the purposes of statistical 
analysis. The initial coding scheme assigned for items, general health and social 
function were coded 1 - 6 from left to right; and items physical functioning, role physical, 
bodily pain, vitality, mental health and role emotional were coded 1 - 5 from left to right. 
The first step in transformation of the ordinal scales to continuous data was application 
of scale means based upon the standard metrics of the SF36 to each of the eight 
domains. Each item of the SF8 was then assigned a regression co-efficient weight as 
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published in the SF8 user manual. An aggregate score for the physical and mental 
component summary scores was calculated by multiplying each SF8 item by its 
respective regression weight and summing all the products. Higher physical and mental 
compenent summary scores are indicative of greater perceived health status with scores 
ranging from 0–100). Data obtained using the case report forms were coded as detailed 
in Table 8.9. 
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Table 8.9 Coding schedule of the case report form 
Variable Coding 
Gender  1 Male, 2 Female 
Any current alcohol use 1 Yes, 0 No  
Current smoker  0 non smoker, 1 smoker 
Any current iodine intake  1 Yes; 0 No 
Family history of thyroid dysfunction 1 Present; 0 Absent 
     Amiodarone  
     Anti-depressant 
     Anxiolytic 
     Beta-adrenergic Blockers  
     Lithium  
     Major Tranquilisers  
     Morphine or other opioid analgesics 
     Glucocorticoids  
0; treatment not prescribed   
1;treatment prescribed 
 
   Anxiety 
   Atrial Fibrillation 
   Cancer  
   Cerebrovascular disease / Stroke / TIA 
   Dementia 
   Depression 
   Diabetes 
   Heart failure / Valve disease 
   Hypertension 
   Ischaemic or Coronary Heart Disease or   Angina 
   Irregular heart rhythm 
   Peripheral vascular or artery disease 
   Pituitary disease 
   Pulmonary disease / COPD / Asthma 
   Renal disease (Chronic and grade 3 or 4 only)  
   Rheumatoid arthritis  
   Neurological disease 
   Knee replacement 
   Hip replacement 
   Osteoarthritis 
   Anaemia 
   Goitre 
0; no diagnosis,   
1; disease diagnosed  
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8.4.4 Ethical approval  
Ethical approval for the study was obtained from the North Staffordshire Local Research 
Ethics Committee; reference number: 07/H1204/136, approval date; 19/12/2007 prior to 
commencement of the research. R&D approval was obtained from the Birmingham and 
Solihull PCT Consortium (Ref: 153/1108/P) and Coventry Teaching PCT (Ref: 
COV100907).  
 
8.4.5 Sample size   
Formal sample size (power) calculations were not undertaken during protocol 
development due to this research being nested within a longitudinal study design and 
therefore limited to follow-up of an existing cohort. However the large nature of the initial 
cohort (n=5881) and the anticipated loss to follow-up (10%) suggested that 5293 
individuals would be available to the study.  
 
8.4.6 Categorisation of thyroid function 
The results of the thyroid function tests (TFT) conducted at screening were used to 
categorise thyroid function in accordance with the algorithm detailed in Figure 8.2. 
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Figure 8.2 Algorithm used to categorise thyroid status  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thyroid 
Function 
Testing  
 
 
TSH  
<0.3  
 
TSH  
0.3-4.5 
 
TSH 
>4.5 
T4 
<10 
T4 
<10 
Euthyroid  
T4 
<10 
OHypo 
T4 
10-22 
Schypo 
T4 
10-22 
Euthyroid  
T4 
10-22 
T4 
>22 
Euthyroid  
T4 
>22 
T4 
>22 
Unclassified 
T3 
<3.1 
Unclassified 
T3 
<3.1 
Schyper 
T3 
<6.8 
Unclassified 
 
T3 
3.1-6.8 
Schyper 
T3 
>3.1 
Shyper 
T3 
>6.8 
OHyper 
T3 
>6.8 
OHyper 
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 8.5 Statistical analysis  
The focus of this thesis is the characterisation of symptoms suggestive of overt thyroid 
dysfunction in individuals with subclinical hyperthyroidism and subclinical 
hypothyroidism. The statistical analysis plan was designed to allow exploration of the 
relationships between i) category of thyroid function and symptoms, ii) category of 
thyroid function and health status, iii) symptoms and health status, iv) symptoms and 
serum thyrotrophin (thyroid stimulating hormone [TSH]) concentration and v) symptoms 
and serum free thyroxine concentration. 
 
In its evaluation of the clinical impact of subclinical thyroid dysfunction this study collated 
thyroid function test results and self reported data on the presence of current symptoms 
suggestive of hyperthyroidism and hypothyroidism as well as data on recent change in 
severity of these symptoms and current health status. Demographic data collated 
comprised age, gender and deprivation score as well as medical history and 
concomitant medication pre-specified as likely to be associated with thyroid function, 
recorded symptoms or to interfere with tests of thyroid function.  
  
Descriptive and statistical analyses were undertaken using SPSSv15. In general, 
descriptive analysis included mean (with standard deviation) for data that followed a 
normal distribution or median with inter quartile range for data that did not follow a 
normal distribution and confidence intervals for proportions in categorical data where 
appropriate.   
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Details of statistical tests used at each stage of analysis are provided in chapters 9-15 
along with the results obtained. The Kolmogorov-Smirnov test for normality was applied 
to establish if data were normally distributed, where relevant. Appropriate statistical tests 
were determined after assessment of data distribution. Given the fact that multiple 
testing was used, Bonferroni adjusted alpha values were used to control for type 1 error 
where appropriate and are reported where relevant in the results chapters (Chapters 9-
15).  
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 8.5.1 Representativeness of the study population  
A consort diagram was constructed to describe the cohort in terms of eligibility, response 
rate, loss to follow-up and participation in screening of thyroid function. The full 
characteristics of the study population are described and demographic factors explored 
(Figure 8.3).   
 
8.5.2 Symptom expression and health status of the cohort  
To further characterise the study cohort with respect to expression of individual 
symptoms suggestive of overt thyroid dysfunction, the prevalence of symptoms reported 
was calculated and tabulated. To determine the relationship between individual 
symptoms suggestive of overt thyroid dysfunction and health status, the Mann Whitney 
U test was used to compare distribution of mental and physical component summary 
scores between groups reporting presence and absence of individual current and 
changed symptom (Figure 8.3). 
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Figure 8.3 Statistical analysis; description of the cohort  
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8.5.3 Categorisation and description of subgroups 
Participants were categorised into three groups indicative of thyroid function in 
accordance with the standard reference criteria used by the Regional Endocrine 
Laboratory University Hospital Birmingham. Descriptive statistics were used to describe 
the thryoid function groups with respect to age, gender, IMD 2004 score, lifestyle 
characteristics, medical history, concomitant medication, serum concentration of 
thyrotrophin, TF4 and FT3 and mental and physical component summary scores. 
(Figure 8.4) 
 
8.5.4 Expression of symptoms in the thyroid function groups  
Initially exploratory univariate analyses were undertaken to examine the relationship 
between thyroid function category and expression of symptoms and to identify 
potentially clinically important symptoms for inclusion in the multivariate analysis (Figure 
8.4). To evaluate the potential clinical importance of pairs of symptoms, each possible 
combination of two symptoms was defined. The purpose of defining a new variable for 
each pair of symptoms was two-fold. Firstly, to enable comparison of the prevalence of 
symptom pairs across thyroid function groups. Secondly, to allow examination of 
interactions between symptoms; that is to determine whether the relationship between 
category of thyroid function (as the dependent variable) and each individual symptom 
(as an independent explanatory variable) was modified by the presence or absence of 
another symptom. Interactions between pairs of symptoms were examined using binary 
logistic regression analysis. Individual and pairs of symptoms were selected for inclusion 
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in the multiple logistic regression analyses if a statistically significant difference in 
symptom prevalence existed between the thyroid function groups (e.g. euthyroid versus 
subclinical hyperthyroidism and euthyroid versus subclinical hypothyroidism). Similarly, 
where a statistically significant interaction between two symptoms was identified, the 
interaction term and individual symptoms were selected for inclusion in the logistic 
regression model.  
Since the univariate analysis was exploratory in nature and intended to enable selection 
of potentially important symptoms appropriate for inclusion in the multivariate analysis, 
where necessary the Bonferroni adjusted alpha level was substituted for a more 
conventional and less conservative alpha level of 5%. 
 
 
8.5.4.1 Multivariate analyses and thyroid function category  
Binary logistic regression analysis was undertaken to determine if cases of subclinical 
thyroid function could be predicted from individual symptoms, combinations of 
symptoms, interactions between symptoms and from other demographic variables 
(medical history, concomitant medication, age and deprivation score) (Figure 8.4). 
Demographic variables were excluded from the logistic regression analysis if there were 
data missing for 1.0% or more of the population or where the outcome of interest was 
present in less than 1.0% of the population. Two separate models were constructed. 
One model was constructed to identify factors predictive of subclinical hypothyroidism 
and incorporated all individuals with subclinical hypothyroidism and euthyroid function. 
The second model was constructed for identification of factors predictive of subclinical 
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hyperthyroidism and comprised all individuals with subclinical hyperthyroidism and 
euthyroid function. The final model employed the forward Likelihood Ratio (LR) method 
of variable selection with a significance level of 5% for variable inclusion and 10% for 
variable removal. Tests for multicolinearity were conducted to confirm absence of high 
levels of intercorrelation between explanatory variables. Using this approach to model 
construction, each of the explanatory variables and each of the statistically significant 
two way interactions were entered sequentially. The significance of each variable 
already in the model was reviewed at each step and variable removal was based upon 
the likelihood ratio test statistic which indicated whether or not a variable was significant 
in explaining some of the variability in the response. Non significant variables were 
removed. The final model was selected based upon the highest fulfilment of goodness to 
fit as indicated by Nagelkerke R2 (range of 0 to 1, with 1 indicating that the model fully 
explains the variation in the dependant variable) and the greatest ability to predict the 
correct category for each case compared with step 0 (i.e the initial model constructed 
before entry of any of the independent variables). Logistic regression analysis provided 
co-efficients to indicate the effect of each explanatory variable upon the response 
variable when controlling for all other variables entered in to the model. 
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8.5.5 Symptom expression in the incident cases   
Characterisation of symptoms in individuals with new and persistent subclinical thyroid 
dysfunction was undertaken because it is possible that incident cases experience a 
greater symptom burden than those with persistent subclinical thyroid dysfunction. To 
enable categorisation of the incident and persistent thyroid dysfunction subgroups it was 
necessary to draw upon historical study data. All study participants were categorised as 
either persisting within their baseline thyroid function category or changing from baseline 
thyroid function category during the interval period. Individuals remaining within the 
baseline thyroid function category during the interval period were categorised to either, 
persistent euthyroidism (defined by a baseline and follow-up categorisation of 
euthyroidism) or persistent subclinical thyroid dysfunction (defined by a baseline and 
follow-up classification of subclinical thyroid dysfunction). Those that changed from 
baseline thyroid function category were similarly categorised to one of two groups, with 
group one comprising those that reverted to euthyroid function (defined by a baseline 
classification of subclinical thyroid dysfunction and a follow-up classification of 
euthyroidism) and group two comprising incident cases of subclinical thyroid dysfunction 
(defined by a baseline classification of euthyroidism and a follow-up classification of 
subclinical thyroid dysfunction). The prevalence of individual and totalled hyperthyroid 
and hypothyroid symptoms reported in subgroups of the study population with incident 
and persistent thyroid function were compared. The proportion of the incident and 
persistent subclinical thyroid dysfunction groups reporting presence of each individual 
symptom were compared using the chi squared test for independence or the Fisher‟s 
exact test where appropriate (Figure 8.4). Given the fact that multiple comparisons were 
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being made between groups, a Bonferroni adjusted alpha value of p<0.003 was used to 
control for type 1 error. The prevalence of symptoms reported by cases with persistent 
euthyroid and persistent subclinical thyroid dysfunction were explored and compared in 
an identical manner. 
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Figure 8.4 Statistical analysis; symptoms in the subgroups  
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8.5.6 Symptom expression and serum thyrotrophin concentration 
Univariate analyses were undertaken to explore the relationship between serum 
thyrotrophin concentration and individual symptoms, combinations of symptoms and 
interactions between symptoms and to enable selection of variables for inclusion in the 
multivariate analyses (Figure 8.5). Since serum thyrotrophin concentrations did not 
follow a normal distribution and transformations (including logarithmic) failed to achieve 
normal distribution, non-parametric tests were employed. Multiple linear regression 
analysis (forward stepwise) was performed to establish models for predicting serum 
thyrotrophin concentration. As an extension of simple linear regression, multiple linear 
regression aims to find a linear relationship between a response variable and a 
combination of several possible explanatory variables, thereby enabling prediction of a 
value of the response variable from knowledge of the explanatory variables. The linear 
regression model incorporated all individuals in the final cohort. Variables were selected 
for inclusion in the linear regression model if the univariate analysis had demonstrated a 
statistically significant difference in serum thyrotrophin concentration between groups 
reporting presence and absence of individual symptoms, combination of symptoms or 
where a statistically significant interaction between symptoms had been observed. 
Demographic variables were excluded from the linear regression analysis if there were 
data missing for 1.0% or more of the population or where the outcome of interest was 
present in less than 1.0% of the population. Multiple linear regression analysis provided 
co-efficients to indicate the average effect of each explanatory variable upon the 
response variable when controlling for all other variables entered in to the model. The 
final model was selected based upon goodness to fit as indicated by the R-squared 
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coefficient (range from 0 to 1) with larger R-squared values indicating better fit of the 
model to the data and therefore a greater ability of the model for prediction of serum 
thyrotrophin concentration (the dependant variable).   
 
8.5.7 Symptom expression and serum free thyroxine concentration 
Serum FT4 concentration in the cohort demonstrated a normal distribution, however for 
reasons of consistency (and since mean and median values of normally distributed data 
are similar), non parametric statistical tests were employed for analysis of serum FT4 
concentrations between groups reporting the presence and absence of individual and 
pairs of symptoms. Multiple linear regression analysis was performed to establish a 
model for predicting serum FT4 concentration as previously described. 
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Figure 8.5 Statistical analysis; symptoms and biochemical parameters  
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This chapter of the thesis has described the methodology of the cross-sectional survey 
evaluating symptoms, perceived health status and thyroid function in a large UK based 
community dwelling cohort of individuals aged 65 years and over. In this chapter full 
details of the statistical data analysis were also provided.   
The results of the study are presented and summarised in the next seven chapters. 
Details of statistical tests used at each stage of analysis are provided in Chapters 9-15 
along with the results obtained.  
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 CHAPTERS 9-16 RESULTS OF THE CROSS-SECTIONAL STUDY  
 
Overview of chapters 9-16 
Although the longitudinal data do not address the aims of this thesis, it is nevertheless 
necessary to present these data in the current chapter to aid description of the cohort. 
The current chapter begins with a consort diagram with accompanying text to describe 
the cohort in terms of eligibility, response rate, loss to follow-up and participation in 
screening of thyroid function. To further enable consideration of the representativeness 
of the study cohort, the findings from comparisons between the study population and the 
general populations of two regions of the UK in terms of demography and presence of 
common co-morbidities are presented. Thereafter the results will be divided into six 
chapters in accordance with the statistical analysis plan presented in chapter 8. 
 
Chapter 10: Symptom expression of the cohort  
This chapter aims to characterise the study population with respect to reported 
presence, intensity and change during the previous 12 months in 18 symptoms 
suggestive of overt thyroid dysfunction and health status. 
 
Chapter 11: Categorisation and description of subgroups  
Chapter 11 focuses upon characterisation of the thyroid function subgroups with respect 
to demography, lifestyle, medication use, medical history and health status.  
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Chapter 12: Symptoms expression in subgroups  
Chapter 12 further explores the thyroid function subgroups with respect to prevalence of 
current and changed individual symptoms, pairs of symptoms and total number of 
symptoms.  
 
Chapter 13: Symptoms in incident cases of subclinical thyroid dysfunction 
This chapter explores symptoms expression in individuals that developed subclinical 
thyroid dysfunction during the interval period between baseline and follow-up thyroid 
function screening.  
 
Chapter 14: Symtpoms and serum thyrotrophin concentration 
The aim of chapter 14 is to present the findings of the univariate and multivariate 
analyses exploring the relationship between serum thyrotrophin concentration and 
symptom expression.  
 
Chapter 15: Symptoms and serum free thyroxine concentration 
Lastly, chapter 15 describes the findings of the univariate and multivariate analyses 
exploring the relationship between serum thyroxine concentration and symptom 
expression.  
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CHAPTER 9 DEMOGRAPHICS OF THE COHORT 
The aim of the current chapter is to consider the representiveness of the study cohort. 
 
9.1 Implication of the changes during the interval period  
As described in chapter 8, reclassification of the baseline thyroid function test results 
and subsequent classification of thyroid function were undertaken before data were 
reviewed. In terms of the cross-sectional study, these changes had no impact. 
Correction of the BETS I thyroid function test results (TFT) led to reclassification of 
thyroid status in 139/5881(2.4%) of the BETS I participants. A consequence of the 
reclassification was that four individuals were recategorised as overtly hypothyroid (two 
previously classified as having subclinical hypothyroid status at BETS I and two 
euthyroid) and were therefore no longer eligible for inclusion and were excluded from 
statistical analyses.  
 
9.2 Follow-up 
Of the original cohort of 5881 BETS I participants, 103 individuals did not fulfil the 
inclusion criteria for the follow-up study. As described in section 9.1, reclassification of 
baseline thyroid function category due to changes in assays and reference criteria led to 
the exclusion of four individuals. A further 38 had received a diagnosis of overt thyroid 
dysfunction during the original study (15 with a diagnosis of overt hyperthyroidism and 
23 with overt hypothyroidism) and 51 had been allocated to the treatment arm of the 
BETS randomised controlled trial (RCT). Thyroid function was unclassifiable for a further 
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nine individuals and one individual was excluded following identification of an error in the 
data pertaining to date of birth.  
Overall, 98.2% (n=5778) fulfilled the inclusion criteria and were eligible for follow-up. 
Follow-up of 184/5778 (3.2%) of the potentially eligible cohort was not possible because 
the general practice with which they were registered was unable to participate. Status 
verification by GPs led to the exclusion of a further 1151/5778 (20%); 501 were 
unavailable for follow-up because they were deceased and 453 because they were no 
longer registered with the practice. GPs considered a further 197 to be inappropriate for 
follow-up; therefore 4443 individuals were invited to participate (Figure 9.1). 
 
9.2.1 Response rate  
After invitation a further 68 (1%) individuals were excluded as not known at address or 
deceased. A further 793/4443 (18%) declined the invitation to participate and no 
response was received from 353/4443 (8%). The remaining 3229/4443 (73%) agreed to 
participate and appointments were arranged for 96% of these individuals (3104/3229). 
Of the 3104 individuals accepting a screening clinic appointment, 99 (3.2%) were lost to 
follow-up with 87/3104 (2.8%) not attending and 12/3104 (0.4%) being unable or not 
wishing to provide written informed consent to participate. An additional 124/3229 
(3.8%) individuals expressing an interest in taking part in the screening clinics were lost 
to follow-up because the screening clinic times were inconvenient for them (n=28), they 
were too unwell to attend (n=24) or changed their minds about participating (n=72) 
(Figure 9.1). Overall, 68% (3005/4443) of those invited to participate attended a study 
clinic and consented to screening of thyroid function.  
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A further 4.5% (135/3005) of those that attended screening were excluded, 64/3005 
(0.02%) had missing thyroid function tests results either because venepuncture was 
unsuccessful or the blood sample received by the laboratory was insufficient or not 
viable for testing and 0.002% (7/3005) failed to return a fully completed questionnaire 
and therefore had missing symptoms data. A further 58/135 were excluded from the final 
analysis population; 57/135 due to receiving treatment for thyroid dysfunction and a 
further one because thyroid status could not be determined (TFT results were 
unclassifiable most likely due to assay artefacts and/or drug interactions). The thyroid 
function test results for six individuals indicated overt thyroid dysfunction, with four 
individuals being categorised with overt hypothyroidism and two with overt 
hyperthyroidism. The final population available for analysis therefore comprised 2870 
individuals.  
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Figure 9.1 Consort diagram 
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9.3 Demographics of the cohort  
The age range of the final study population was 68.7 – 96.4 years with a mean of 76.9 
years (SD 5.01). The socioeconomic status of the final population ranged from 3.2 (least 
deprived) to 74.4 (most deprived) giving a mean IMD score of 21.67 SD (15.06) (Table 
9.1). 
 
Table 9.1 Characteristics of the final cohort  
Variable  
n 2870 Mean (SD) Median (IQR)  
Age ( years ) 
2870 76.90 (5.01) 76.10 (7.48) 
IMD score 2004 
2869 21.67 (15.06) 17.70 (18.70) 
 
 
Individuals aged between 65 and 74 years made up 42.3% of the final population with 
49.8% (n= 1429) of the final cohort being aged between 75-84 years of age and 8.0% 
aged 85 years or more (Table 9.2). 
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Table 9.2 Age and gender distribution of the cohort  
 
 
 
The age and gender distribution of the final cohort was compared with the census data 
2001 for England and Wales and the West Midlands region. 203  The age and gender 
distribution of the final population were significantly different to the age and gender 
distribution of England and Wales and of the West Midlands region (χ2 263.37; df 3; 
p<0.001). The study population comprised a greater proportion of individuals aged 
between 75 -84 years (49.8 %) than England and Wales (35.3%) and the West Midlands 
region (35.2%). A smaller proportion of individuals in the final cohort were aged between 
65-74 years compared with these age groups in the West Midlands region and England 
and Wales (42.3) versus 53.7 and 52.5 respectively. In part this is an artefact of the 
study inclusion criteria (minimum age of 65 years in the initial study of 2002-2003). This 
Variable 
 
England and Wales 
n (%) 
West Midlands 
n (%) 
Expected 
frequency in 
accordance with 
census data 
2001 
n (%)  
Study 
population  
n (% )  
χ
2  
test for 
goodness 
to fit,  
p value 
Male 25,325,926 (48.7) 1,095,207 (48.6) 1406.3 (49.0) 1485 (51.6) χ
2 
= 8.636,  
df 2, 
 p <0.003 Female 26,715,990 (51.3) 1,159,537 (51.4) 1463.7 (5.10) 1391 (48.4) 
≥65 yrs 8,316,298 (15.98) 353,769 (15.69) 
 
2870 (100) 
 
65-74 years 4,366,316 (52.5) 190,075 (53.7) 1536.5 (53.0) 1214 (42.3) 
χ
2 
=263.37, 
df 3, 
p <0.001 
 
75-84 years 2,935,164 (35.3) 124,687 (35.2) 1014.6 (35.0) 1429 (49.8) 
≥ 85 yrs 1014816.0 (12.1) 390007 (11.0) 1429 (11.0) 227 (8.0) 
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data should be taken into account by anyone wishing to apply findings at a population 
level (Table 9.2). 
In terms of gender distribution, the final cohort was significantly different (χ2  8.636; df 1; 
p<0.003) to that of the other two groups and comprised a significantly smaller proportion 
of women (48.4%) than the West Midlands region (51.4%) and England and Wales 
(51.3%) (Table 9.2). Given that this thesis aims to explore the association between 
thyroid function and symptom expression at the individual level, these dissimilarities are 
unlikely to be of great importance but are presented for completeness and to allow 
representativeness to be determined by any reader wishing to extrapolate this data. 
To further demonstrate the nature of the study population and report upon the 
representativeness of the cohort, the study population were subdivided in accordance 
with the published IMD quartiles for England and Wales and for the West Midlands 
(Table 9.3). The chi squared goodness of fit test was used to explore the proportion of 
study cases that fell into the published IMD quartiles for these two regions and compare 
these proportions with the expected value of 25%. The study population were 
significantly different to the population of England (χ2 75.68; 3 df, p<0.001) and the 
population of the West Midlands (χ2 85.66; df 3, p<0.001). The study population was 
significantly more deprived than the general population of England and significantly 
more affluent than the population of the West Midlands (Table 9.3). Again, this should 
not impact on the association with symptoms reported but may require further 
consideration by anyone wishing to translate overall symptom burden to a population 
level.  
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Table 9.3 Representativeness in terms of deprivation  
Study population stratified in accordance with IMD quartiles for England % (n= 2869) 
IMD quartile  Range of IMD 
scores within 
each quartile 
Expected 
frequency (%) 
Frequency in 
study population 
2869 (%) 
χ
2;  
df, 
p value  
1 Least deprived 1-9.62 
717.3 (25.0) 
664 (23.1)  
75.7 
df 3 
 <0.001 
2 9.63-17.0 632 (22.0)  
3 17.01-30.0 918 (32.0) 
4 Most deprived 30.01-85.0 655(22.8) 
Study population stratified in accordance with IMD quartiles for the West Midlands 
IMD quartile  Range of IMD 
scores within 
each quartile 
Expected 
frequency (%) 
Frequency in 
study population 
2869 (%) 
χ
2  
df, 
p value 
1 Least deprived 1-11.20 
717.3 (25.0) 
841 (29.3) 
85.7 
df 3 
<0.001 
2 11.21-19.2 768 (26.8) 
3 19.21-35.1 749 (26.1) 
4 Most deprived 35.11-78.8 511 (17.8) 
*1 missing IMD score 2004 
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9.4 Clinical characteristics of the study cohort  
In terms of thyroid function test (TFT) results, the mean serum concentration of 
thyrotrophin was 2.1mIU/L, median 1.8mIU/L and ranged from <0.01-19.30mIU/L. 
Serum free thyroxine concentrations of the study population demonstrated normal 
distribution and as such the mean and median free thyroxine concentration was 
14.9pmol/L, ranging from 9.1-30.1pmol/L. Likewise, free tri-idothyronine concentrations 
demonstrated a normal distribution in this population with a mean and median of  
5.1pmol/L and range from 3.9- 7.0pmol/L (Table 9.4).  
 
 
Table 9.4 Thyroid function test results for the cohort  
Variable  n  Mean (SD)  Median 
 
Thyrotrophin  
(mIU/L) 2870 2.1 (1.4) 1.8 
Free thyroxine 
(pmol/L)  2870 14.9 (2.1) 14.9 
Tri –idiothyronine  
(pmol/L) 37 5.1 ( 0.7) 5.1 
 
 
 
 
Review of the medical records held by the general practice enabled collection of medical 
history and co morbidities. The most prevalent co-morbidity was hypertension, with 
51.2% (n=1470) of the cohort having a diagnosis of hypertension documented in their 
medical records. Approximately 18% (n=525) of the cohort had a diagnosis of renal 
disease or a glomerular filtration rate of between 15-59 ml/min/1.73m2 documented in 
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their medical records. This finding may in part be due to the introduction of the 2008 
National Service Framework for chronic kidney disease, which advocates routine 
primary care measures of glomerular filtration rate as an indicator of renal status (with 
chronic renal disease defined by a glomerular filtration rate of between 15-59 
ml/min/1.73m2). 204 Approximately 11% (n=300) of the final cohort had a known history of 
cancer and 202 (7.0%) a previous diagnosis of AF (Table 9.5). 
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Table 9.5 Medical history of the cohort 
Disease category  Present 
%, 95% CI (n) 
Absent 
%, 95% CI (n) 
Missing data 
% 
(n) Hypertension 51.2,49.9-53.0 
(1470) 
48.8,47.0-50.6 
(1400) 
0 
Renal disease 18.3, 16.9-19.7 
(525) 
2345, 80.3-83.1 
(81.7) 
0 
Ischaemic heart disease 12.6,11.5-13.9 
(363) 
87.4, 86.1-88.5 
(2507) 
0 
Pulmonary disease 12.4,11.2-13.6 
(355) 
87.6, 86.4-88.8 
(2515) 
0 
Diabetes 11.7, 10.6-12.9 
(336) 
88.3, 87.1-89.4 
(2534) 
0 
Cancer 10.5,9.4-11.6 
(300) 
89.1, 87.9-90.2 
(2558) 
(12)0.4 
Depression 7.8, 6.9-8.8 
(224) 
92.2,91.2-93.1 
(2646) 
0 
Atrial Fibrillation 7.0, 6.2- 8.0 
(202) 
93.0,92.0-93.8 
(2668) 
0 
Anxiety 6.0, 5.2-6.9 
(172) 
94.0,93.1-94.8 
(2698) 
0 
Stroke/TIA 5.5, 5.0-6.8 
(157) 
94.5,93.6-95.3 
(2713) 
0 
Heart failure 4.4, 3.7-5.2 
(126) 
95.6, 94.8-96.3 
(2744) 
0 
Peripheral vascular disease 3.4, 2.8-4.1 
(98) 
96.6,95.9-97.2 
(2772) 
0 
Irregular heart rhythm 3.4,2.8-4.1 
(97) 
96.6, 95.9-97.2 
(2773) 
0 
Knee replacement 3.1, 2.5-3.8 
(89) 
96.9, 96.2-97.5 
(2781) 
0 
Rheumatoid Arthritis 2.4,1.9-3.0 
(69) 
97.6,96.2-97.5 
(2801) 
0 
Hip replacement 2.3,1.8-2.9 
(66) 
97.7,97.1-98.2 
(2804) 
0 
Osteoarthritis 1.8,1.4-2.4 
(53) 
98.2, 97.1-98.6 
(2817) 
0 
Neurological disease 0.9, 0.6-1.3 
(26) 
99.1, 98.7-99.4 
(2844) 
0 
Dementia 0.7, 0.4-1.0 
(19) 
99.3, 99.0-99.6 
(2851) 
0 
Anaemia 0.5, 0.3-0.8 
(13) 
99.5, 99.2-99.7 
(2857) 
0 
Pituitary disease 0.3, 0.1-0.5 
(8) 
99.7, 99.7-100 
(2867) 
0 
Goitre 0.2, 0.1-0.4 
(5) 
99.8,99.6-99.9 
(2865) 
0 
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When compared with the general population of England and the West Midlands, a 
greater proportion of the current study cohort were identified with atrial fibrillation (5% 
versus 7% respectively) χ2 25.1, df 1, p<0.001. 205 Additionally, the chi squared 
goodness of fit test indicated a significant difference in the proportion of the study cohort 
with a history of hypertension (51%) as compared with the value of 38% for England (χ2 
212.9, df 1, p<0.001) and 42% for the West Midlands (χ2 100.1, df, p<0.001) that was 
obtained in the Health survey for England 2005. 206 There were, however, no significant 
differences in the proportion of individuals identified in the current sample with a history 
of diabetes (11.7%) as compared with the health survey obtained value of 11.5% for 
England and the West Midlands (χ2 0.12, df 1, p<0.728). The publication of evidence 
based guidance for identification and diagnosis of AF and for hypertension in adults in 
primary care in 2006 may be responsible for the larger proportions of hypertension and 
atrial fibrillation identified in the current study cohort compared with previously published 
data. 207,208 Clinical guidelines for diabetes were published by the Department of Health 
in 2001 and published data is likely to be more complete. It is therefore likely that the 
disease burden of the cohort is largely representative of the population. 
 
In terms of lifestyle characteristics of the study population, approximately 64% (n=1844) 
of the final population reported that they currently and regularly consume alcohol and 
6.2% (n=175) reported that they were current smokers. Around 15% (n=421) reported 
having a family history of thyroid dysfunction and 6.2% reported taking kelp or iodine 
supplementation (Table 9.6). 
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Table 9.6 Self-reported lifestyle characteristics and family history   
Characteristic Characteristic 
present 
n (%, 95%CI) 
Characteristic 
absent 
n (%, 95%CI) 
Missing data  
n (%) 
Regular alcohol intake  1844  
(64.3,62.5-66.0) 
999  
(34.8, 33.1-36.6) 
27 (0.9) 
Current smoker  
175  
(6.1, 5.1-7.0) 
2675  
(93.2, 92.2-94.2) 
20 (0.7) 
Kelp or iodine supplementation 
179 
 (6.2, 5.4-7.2) 
2624  
(91.4, 90.3-92.4) 
67 (2.3) 
Family history of TD 
421  
(14.7, 13.4-16.0) 
2409 
 (83.9, 82.5- 85.2) 
40 (1.4) 
 
 
With regard to medication prescribed by the GP, beta-adrenergic blockers were being 
prescribed to around 14% of the cohort, 5% were receiving glucocorticoids and 5% 
antidepressants. A small number of individuals in the final cohort were being prescribed 
major tranquilisers (n=13; 0.5%) and a smaller proportion (0.1%) were receiving 
treatment with lithium. (Table 9.7)  
 
Table 9.7 Prescription medication use within the cohort 
Medication Characteristic present 
n (%, 95%CI) 
Characteristic absent 
n (%,95%CI) 
Amiodarone 11 (0.4, 0.2-0.7) 2859 (99.6, 99.3-99.8) 
Antidepressant 151 (5.3, 4.5-6.1) 2719 (94.7, 93.9-95.5) 
Anxiolytic 57 (2.0, 1.5-2.6) 2813 (98.0, 97.0-98.5) 
Beta-adrenergic blocker  397(13.8,12.6-15.1) 2473 (86.2, 84.9-87.4) 
Lithium 4 (0.1, 0.1-0.4) 2866 (99.9, 99.6-99.9) 
Major tranquiliser 13 (0.5, 0.3-0.8) 2857 (99.5, 99.2-99.7) 
Morphine or other opioid 25 (0.9, 0.6-1.3) 2845(99.1, 98.7-99.4) 
Glucocorticoids 145 (5.1, 4.3-5.9) 2725(94.9, 94.1-95.7) 
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Summary of chapter 9 
The aim of this chapter was to demonstrate the nature of the study cohort and report 
upon the representativeness of the sample for readers wishing to utilise symptom 
prevalence data. This chapter demonstrates a good response rate with 68% of those 
invited taking part in screening of thyroid function. The final cohort available for analysis 
comprised 2870 individuals for whom data collection had been fully completed and 
thyroid categorisation was possible. 
Compared with the general population of England and Wales and the West Midlands, 
the study cohort had a larger proportion of 75-84 year olds, a smaller proportion of 
women and a greater prevalence of AF and hypertension. Additionally, whilst being 
more deprived then the general population of England and Wales, the study cohort was 
less deprived than the population of the West Midlands. In terms of medical history and 
co-morbidity the populations were similar with respect to the prevalence of diabetes. 
These differences are largely an artefact of historical cohort establishment and 
inaccuracy of published data which is outdated in the light of recent changes in policy 
and guidelines. These difference do not impact upon the cross-sectional study results 
which are the primary aim of this thesis but are worthy of consideration if extrapolating 
findings to other populations.  
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CHAPTER 10 SYMPTOM EXPRESSION AND HEALTH STATUS OF THE COHORT 
 
Overview of chapter 10  
Initially, this chapter describes the prevalence and intensity of symptoms present at the 
time of questionnaire completion (current symptoms), followed by a description of the 
prevalence and intensity of symptoms that have changed in the preceding 12 months 
(changed symptoms).   
In addition, this chapter presents data related to perceived health status of the study 
population and reports upon the relationship between both the mental and physical 
components of health status and symptom expression. The effect of total number of 
symptoms on mental and physical health status summary scores is presented 
graphically and the findings from comparisons of median physical component and 
mental component summary scores between groups reporting presence and absence of 
each individual symptom are presented.    
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10.1 Symptom expression of the cohort 
The final cohort of 2870 individuals self reported presence, intensity and recent change 
in 15 symptoms suggestive of overt thyroid dysfunction. Weight gain was the most 
prevalent current symptom, with 48.6% (n=1396) of the cohort reporting presence of this 
symptom at the time of questionnaire completion. The most prevalent symptom 
suggestive of hyperthyroidism reported by 22.8% (305/2870) of the cohort was fast 
thinking and the most prevalent symptom suggestive of hypothyroidism other than 
weight gain was sensitivity to cold temperatures. Dry skin was reported by 32% (n=924) 
of the cohort (Table 10.1). 
 
10.1.1 Intensity of current symptoms  
Severe symptoms were reported less frequently than mild symptoms with 42.3% of the 
cohort (1213/1398) reporting mild weight gain and just 6.4% (n=185) severe weight gain. 
Severe dry skin was reported by 5.0% (n=143) of the final population and mild dry skin 
by 27.2% (n=781) of the cohort. Prevalence of severe symptoms ranged from 0.1% to 
6.4% whereas the prevalence of mild symptoms ranged from 2.5% to approximately 
42.2% (Table 10.1) 
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Table 10.1 Prevalence of current symptoms reported by the cohort  
 Intensity of current symptoms  
 
Classification symptom  Missing 
data  
n (%) 
Absent 
n  
(%,95%CI) 
Present 
n  
(%,95%CI) 
Mild 
n 
(%,95%CI) 
Severe 
n 
(%,95%CI) 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
e
rth
y
ro
id
is
m
 
Excessive perspiration 
2 (0.1) 
2778  
(96.9,96.1-97.4) 
90  
(3.1,2.6-3.8) 
73 
(2.5,2.0-3.2) 
17 
(0.6,0.4-0.9) 
Trembling hands 
1 (0) 
2749  
(95.8,95.0-96.5) 
120  
(4.2, 3.5-5.0) 
90 
(3.1,2.6-3.8) 
30 
(1.0,0.7-1.5) 
Frequent palpitation  
6 (0.2) 
2693  
(93.8,93.1-94.8) 
171  
(6.0, 5.1-6.9) 
145 (5.1,4.3-
5.9) 
26 
(0.9,0.8-1.3) 
Sensitivity to heat  
48 (1.7) 
2518  
(87.7,86.5-88.9) 
304 
(10.6,9.5-11.8) 
277 
(9.7,8.6-10.8) 
27 
(0.9,0.6-1.4) 
Fast thinking 
4 (0.1) 
2211  
(77.0,75.5-78.5) 
655  
(22.8,21.2-24.4) 
595 
(20.7,19.3-22.3) 
60 
(2.1,1.6-2.7) 
Weight loss 
4 (0.1) 
2660  
(92.7,91.0-93.6) 
206  
(7.2, 6.3-8.2) 
190 (6.6,5.8-
7.6) 
16 
(0.6,0.3-0.9) 
E
ith
e
r fo
rm
 o
f 
T
D
 
Lethargy /lethargy 
2 (0.1) 
2408  
(83.9,82.5-88.2) 
460  
(16.0,14.2-17.4) 
380 
(13.2,12.0-14.5) 
80 
(2.8,2.2-3.5) 
Weak muscles 
4 (0.1) 
2458 
(85.6,84.3-86.9) 
408  
(14.3,13.0-15.5) 
375 
(13.1,11.9-14.3) 
33 
(1.1,0.8-1.6) 
Poor memory 
1 (0) 
2596 
(90.5,89.3-91.5) 
273  
(9.5,8.6-10.7) 
253 
(8.8,7.8-9.9) 
20 
(0.7,0.5-1.1) 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 
5 (0.2) 
2688  
(93.7,92.7-94.5) 
177  
(6.2,5.3-7.1) 
170 
(5.9,5.1-6.8) 
7 
(0.2,0.1-0.5) 
Deep voice 
8 (0.3) 
26794 
(93.2,92.4-94.2) 
188  
(6.6,5.7-7.5) 
184 
(6.4,5.6-7.4) 
4 
(0.1,0.1-0.4) 
Dry skin 
6 (0.2) 
1940  
(67.6,65.9-69.3) 
924  
(32.2,30.5-33.9) 
781 
(27.2,25.6-28.9) 
143  
(5.0,4.2-5.8) 
Puffy eyes 
5 (0.2) 
2475 
(86.2,84.9-87.4) 
390  
(13.2,12.4-14.9) 
373 
(13.0,11.8-14.3) 
17 
(0.6,0.4-0.6) 
Muscle cramps 
3 (0.1) 
2434  
(84.8,83.4-86.1) 
433  
(15.1,13.8-16.4) 
368 
(12.8,11.6-14.1) 
65 
(2.3,1.8-2.9) 
Constipation  
7 (0.2) 
2485  
(86.6,85.3-87.8) 
378  
(13.1,12.0-14.5) 
288 
(10.0, 9.0-11.2) 
90 
(3.1,2.6-3.8) 
Sensitivity to cold  
48 (1.7) 
1837 
(64.0,62.2-65.7) 
985  
(34.3,32.6-36.1) 
849 
(30.0,27.4-31.3) 
136 (4.7,4.0-
5.6) 
Slow thinking 
4 (0.1) 
2638 
(91.9,90.0-92.9) 
228  
(7.9,7.0-9.0) 
215 
(7.5,6.6-8.5) 
13 
(0.5,0.3-0.8) 
Weight gain 
4 (0.1) 
1470 
(51.3,49.4-53-0) 
1396  
(48.6,46.8-50.5) 
1211 
(42.2,40.4-44.0) 
185  
(6.4,5.6-7.4) 
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10.1.2 Prevalence of changed symptoms reported by the cohort  
In terms of change in presence and intensity of symptoms during the preceding 12 
months, the most frequently reported changed symptom was lethargy with 19% 
reporting that they were less active now than they were 12 months ago. Around 16% of 
the cohort reported having weaker muscles and 16% poorer memory than 12 months 
before. The most frequently reported „changed‟ symptom suggestive of hyperthyroidism 
was weight loss (12.7%) and weight gain (15.3%) the most prevalent changed symptom 
suggestive of hypothyroidism (Table 10.2).  
  
10.1.3 Intensity of changed symptoms 
In terms of intensity of symptoms, a minimum of 0.1% and a maximum of 2.0% of the 
cohort reported presence of a severe change in symptom intensity during the previous 
12 months whereas a mild change was reported by between 0.4% and 16.6% of the 
cohort. Overall, severe changes in individual symptoms were reported less frequently 
than mild changes in symptoms, with respect to the changed symptom lethargy, 2.0% 
(n=57) reported experiencing a severe change and 16.5% (n=475) of the cohort 
reported a mild change. (Table 10.2) 
 
 
 
 
 
  222 
 
 
Table 10.2 Prevalence of changed symptoms reported by the cohort 
 
 
 
 
 Intensity of changed symptom 
 
 Symptom 
classification 
Missing 
data  
n (%) 
Absent 
n (%,95%CI) 
Present 
n (%,95%CI)  
Mild 
n (%,95%CI)  
Severe 
n (%,95%CI)  
S
u
g
g
e
s
tiv
e
 o
f 
h
y
p
e
rth
y
ro
id
is
m
 
Excessive perspiration 8  
(0.3) 
2802 
(97.6,97.0-98.1) 
60 
(2.1,1.6-2.7) 
56  
(2.0,1.5-2.5) 
4  
(0.1,0.1-0.4) 
Trembling hands 11  
(0.4) 
2719  
(94.7,93.9-95.8) 
140 
(4.9,4.1-5.7) 
129  
(4.5,2.8-8.3) 
11  
(0.4,0.2-0.7) 
Frequent palpitation 14  
(0.5) 
2728  
(95.0,94.2-95.8) 
128 
(4.5,3.8-5.3) 
122  
(4.3,3.6-5.1) 
6  
(0.2,0.1-0.5) 
Sensitivity to heat  13  
(0.5) 
2798  
(97.5,96.9-98.0) 
59 
(2.1,1.6-2.6) 
48  
(1.7,1.3-2.2) 
11  
(0.4,0.2-0.7) 
Fast thinking 8 
 (0.3) 
2847  
(99.2,98.8-99.5) 
15 
(0.5,0.3-0.9) 
12  
(0.4, 0.2-0.7) 
3  
(0.1,0-0.3) 
Weight loss 2 
 (0.1) 
2489 
(86.7,85.4-87.9) 
379 
(13.2,12.0-14.5) 
362 
(12.7,11.4-13.9) 
17  
(0.6,0.4-0.9) 
E
ith
e
r fo
rm
 
o
f T
D
 
Lethargy 8  
(0.3) 
2330  
(81.2,79.7-82.6) 
532 
(18.5,17.2-20.0) 
475  
(16.5,15.2-18.0) 
57  
(2.0,2.1-3.3) 
Weak muscles 8  
(0.3) 
2397 
(83.5,82.184.8) 
465 
(16.2,14.9-17.6) 
443  
(15.5,14.2-16.8) 
22  
(0.8,0.5-1.2) 
Poor memory 3  
(0.1) 
2394  
(83.4,82.0-84.7) 
473 
(16.4,15.2-17.9) 
457  
(15.9,14.6-17.3) 
16  
(0.6,0.3-0.9) 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 37  
(1.3) 
2692  
(93.8,92.8-94.6) 
141 
(4.9,4.2-5.8) 
134  
(4.7,4.0-5.5) 
7  
(0.2,0.1-0.5) 
Deep voice 24  
(0.8) 
2789  
(97.2,96.5-97.7) 
57 
(2.0,1.5-2.6) 
55  
(1.9,1.5-2.5) 
2  
(0.1,0-0.3) 
Dry skin 7  
(0.2) 
2495  
(86.9,85.7-88.1) 
368 
(12.8,11.6-14.1) 
337  
(11.7,10.7-13.0) 
31  
(1.1,0.8-1.5) 
Puffy eyes 12  
(0.4) 
2685  
(93.6,92.6-94.4) 
173 
(6.0,5.2-7.0) 
164  
(5.7,4.9-6.6) 
9  
(0.3, 0.2-0.6) 
Muscle cramps 5  
(0.2) 
2488  
(86.7,85.4-87.9) 
377 
(13.1,11.9-14.1) 
347  
(12.1,10.9-13.3) 
30  
(1.0, 0.7-1.5) 
Constipation  14  
(0.5) 
2662  
(92.8,91.7-93.6) 
194 
(6.7,5.9-7.7) 
168  
(5.9, 5.1-6.8) 
26  
(0.9,0.6-1.3) 
Sensitivity to cold  13 
 (0.5) 
2492  
(86.8,85.5-88.0) 
365 
(12.7,11.5-14.0) 
339  
(11.8,10.7-13.0) 
26  
(0.9,0.6-1.3) 
Slow thinking 8 
 (0.3) 
2529  
(88.0,88.6-89.3) 
337 
(11.7,10.6-13.0) 
327  
(11.4,10.3-12.6) 
10  
(0.3,0.2-0.6) 
Weight gain 2 
 (0.1) 
2405  
(83.8,82.4-85.1) 
465 
(16.1,14.9-17.6) 
440  
(15.3,14.1-16.7) 
23  
(0.8, 0.5-1.2) 
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Figure 10.1 - 10.2 Prevelance of multiple hypothyroid symptoms reported by the cohort 
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Figure 10.3 - 10.4 Prevelance of multiple hyperthyroid symptoms reported by the cohort 
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10.2 Health status of the cohort 
Health status was measured using the SF8 which is a multi purpose generic measure of 
health status that includes both a physical and mental health component. The physical 
health component score is a summary score of four measures of physical health, 
(general health, physical functioning, role physical and bodily pain) and the mental 
health component score is a summary score of four measures of mental health, (vitality, 
social functioning, mental health and role emotional). Mental and physical component 
summary scores range from 0-100, with 0 reflecting worst possible health status and 
100, the best possible health status.  Overall health status data were available for 
2817/2870 (98%) of the study population with 53 individuals failing to return fully 
completed SF8 questionnaires. In general, the population demonstrated better overall 
mental health status than physical health status, scoring higher for the mental 
component summary score with an overall median of 51.86 compared with a median 
physical component summary score of 46.55.  
 
Physical and mental health status at an individual symptom level was examined in order 
to identify those symptoms with the greatest impact upon health status. The Mann 
Whitney U test was used to compare median health status summary scores between 
two subgroups with group 1 representing those reporting presence of the symptom and 
group 2 defined by those reporting an absence of the symptom.  
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10.2.1 Impact of individual symptoms and health status  
A significant difference in median physical component score between the two subgroups 
existed for 16 of the 18 symptoms (p<0.001 for all 16 symptoms). With respect to 15 of 
these 16 symptoms, a significantly lower median physical component summary score 
was attained by those expressing symptom presence compared with those stating 
absence of the symptom (p<0.001 in all 15 cases). In contrast those reporting current 
presence of the symptom fast thinking attained significantly higher physical component 
summary score compared with those that reported an absence of current fast thinking 
(48.8 versus 46 respectively, p<0.001). There were no significant differences in physical 
component summary score observed between groups with respect to current symptoms 
deep voice or weight gain (Table 10.3).  
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Table 10.3 Presence versus absence of current symptoms; comparison of physical 
component summary scores 
Symptom classification Median physical component summary score 
Absence of 
symptom 
%,95%CI 
 (n) 
Presence of 
symptom 
%,95%CI 
 (n) 
Z* 
(p value) 
S
u
g
g
e
s
tiv
e
 o
f 
h
y
p
e
rth
y
ro
id
is
m
 
Excessive perspiration 46.7,46.2-47.6 
(2727) 
38.8,35.4-42.6 
 (88) 
-5.6 (<0.001) 
Trembling hands 47.0,46.3-47.7 
(2697) 
38.0,35.4-48.7 
(119) 
-6.4 (<0.001) 
Frequent palpitation 47.3,44.9-46.4 
(2643) 
37.0, 23.9-24.6 
(168) 
-9.9 (<0.001) 
Sensitivity to heat  47.0,46.3-47.7 
(2470) 
45.0,43.3-46.4 
(300) 
-3.0 (<0.001) 
Fast thinking 46.0,44.9-46.6 
(2174) 
48.8,46.4-50.0 
(639) 
-3.9 (<0.001) 
Weight loss 46.6,45.9-47.8 
(2609) 
46.0,44.4-46.7 
(204) 
-0.2 (0.754) 
E
ith
e
r 
fo
rm
 
o
f T
D
  
Lethargy 49.1,48.6-49.7 
(2367) 
32.7,31.6-34.0 
(448) 
-24.5 (<0.001) 
Weak muscles 48.7,48.0-49.2 
(24.4) 
35.8,34.5-37.3 
(399) 
 -18.8 
(<0.001) 
Poor memory 47.4,46.5-47.9 
(2550) 
41.1,39.1-43.0 
(267) 
-6.9 (<0.001) 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 47.0,46.3-47.7 
(2638) 
41.7,38.2-44.2 
(174) 
-5.7 (<0.001) 
Deep voice 46.5,45.8-47.4 
(2624) 
47.0,45.1-50.5 
(185) 
-.07 ( 0.577) 
Dry skin 48.2,47.5-48.9 
(1901) 
44.0,43.2-44.9 
(910) 
-8.1 (<0.001) 
Puffy eyes 47.2,46.4-47.9 
(2426) 
43.8,42.1-45.1 
(386) 
-4.6 (<0.001) 
Muscle cramps 48.1,47.5-48.8 
(2386) 
39.1,37.6-40.5 
(428) 
-12.9 (<0.001) 
Constipation  47.6,45.3-48.2 
(2438) 
40.8,39.2-42.3 
(372) 
-8.8 (<0.001) 
Sensitivity to cold  48.4,47.7-49.2 
(1799) 
44.4,43.3-45.0 
(971) 
-8.1 (<0.001) 
Slow thinking 47.2,46.4-47.9 
(2589) 
39.7,37.9-42.7 
(224) 
-7.4 (<0.001) 
Weight gain 48.2,47.1-49.3 
(1436) 
45.0,44.3-45.6 
(1377) 
-5.6 (<0.001) 
 
* associated with the Mann Whitney U test  
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In terms of mental component summary score a significant difference was observed 
between the two subgroups with respect to 15 of the 18 symptoms. The median 
mental component summary score was significantly lower in the group reporting 
current symptom presence compared with the group reporting absence of the 
symptoms for 14 of the symptoms (Table 10.4). A significantly higher median mental 
component score however was observed in those reporting current presence of fast 
thinking compared with those not reporting presence of this symptom. No significant 
differences were observed between the groups with respect to presence of current 
symptoms deep voice or weight gain (Table 10.4).  
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Table 10.4 Presence versus absence of current symptoms; comparison of mental 
component summary scores  
Symptom classification 
 
Median mental component summary score 
Absence of 
symptom  
%,95%CI 
(n) 
Presence of 
symptom  
%,95%CI 
 (n) 
Z 
(p value) 
S
u
g
g
e
s
tiv
e
 o
f 
h
y
p
e
rth
y
ro
id
is
m
 
Excessive perspiration 52.0,51.5-52.5 
(2727) 
46.3,33.4-51.4 
(88) 
-3.9 (<0.001) 
Trembling hands 52.1,51.6-53.1 
(2698) 
47.5,44.7-49.5 
(119) 
-5.5 (<0.001) 
Frequent palpitation  52.2,51.7-52.8 
(2643) 
44.0,41.4-46.9 
(168) 
-8.0 (<0.001) 
Sensitivity to heat  52.2,51.7-52.8 
(2470) 
51.0,48.5-51.4 
(300) 
-3.1 (0.001) 
Fast thinking 51.2,50.6-51.7 
(2174) 
53.6,52.9-54.8 
(639) 
-5.8 (<0.001) 
Weight loss 52.0,51.5-52.5 
(2609) 
51.2,49.5-52.2 
(204) 
-2.2 (0.030) 
E
ith
e
r 
fo
rm
 
o
f T
D
  
Lethargy 52.1,51.3-53.3 
(2367) 
45.5,44.3-47.3 
(448) 
-11.9 (<0.001) 
Weak muscles 52.9,52.3-53.3 
(2414) 
45.2,44.1-47.3 
(399) 
-11.9 (<0.001) 
Poor memory 52.4,51.8-53.1 
(2550) 
47.2, 44.8-
49.2(267) 
-8.5 (<0.001) 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 52.1,51.6-52.7 
(2624) 
48.9,46.9-50.7 
(174) 
-4.4 (<0.001) 
Deep voice 51.9,51.5-52.5 
(2624) 
51.2,50.1-52.0 
(185) 
-0.9 (0.717) 
Dry skin 52.8,52.2-53.4 
(1901) 
50.8,49.8-51.3 
(910) 
-7.0 (<0.001) 
Puffy eyes 52.4,51.9-53.1 
(2426) 
49.4,48.2-50.9 
(386) 
-6.0 (<0.001) 
Muscle cramps 52.5,51.9-53.1 
(2386) 
48.3,46.9-49.6 
(428) 
-8.0 (<0.001) 
Constipation  52.5,52.0-53.2 
(2438) 
47.6,45.5-49.1 
(372) 
-8.7 (<0.001) 
Sensitivity to cold  53.1,52.2-53.4 
(1799) 
51.1,50.5-51.4 
(971) 
-5.9 (<0.001) 
Slow thinking 52.4,52.0-52.8 
(2589) 
45.0,34.6-37.2 
(224) 
-9.6 (<0.001) 
Weight gain 51.7,51.5-52.5 
(1436) 
52.0,51.5-52.6 
(1377) 
-0.4 (0.874) 
 
* associated with the Mann Whitney U test  
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Mann Whitney U tests were similarly used to compare median health status summary 
scores between groups reporting changed symptoms suggestive of overt thyroid 
dysfunction. In terms of physical component summary score and prevalence of 
individual changed symptoms reported by the cohort, a significant difference in 
median physical component summary score between groups reporting presence and 
absence of symptoms was observed for 17 symptoms. In each case, those reporting 
recent change in the symptom attained a significantly lower median physical 
component summary score than those reporting no change in the symptom (p<0.001 
in all cases). The differences in median component summary score observed 
between groups reporting recent change and no change in fast thinking however 
failed to reach significance (Table 10.5). 
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Table 10.5 Presence versus absence of changed symptoms; comparison of physical 
component summary scores 
Symptom classification 
 
Median physical component summary score 
Absence of 
symptom  
%,95%CI 
(n) 
Presence of 
symptom  
%,95%CI 
 (n) 
Z 
(p value)  
S
u
g
g
e
s
tiv
e
 
o
f 
h
y
p
e
rth
y
ro
id
is
m
 
Excessive perspiration 46.6,45.5-47.5 
(2750) 
39.3,35.0-45.1 
(59) 
-3.3 (<0.001) 
Trembling hands 47.0,46.5-47.8 
(2670) 
38.2,37.2-41.3 
(136) 
-6.5 (<0.001) 
Frequent palpitation 47.0,46.4-47.1 
(2675) 
39.0,35.1-41.9 
(128) 
-6.9 (<0.001) 
Sensitivity to heat  46.6,46.1-47.6 
(2745) 
41.1,37.6-44.5 
(59) 
-3.6 (<0.001) 
Fast thinking 46.5,45.9-47.3 
(2796) 
44.8,38.8-56.51 
(14) 
-0.54 (0.396) 
Weight loss 47.0,46.3-47.6 
(2443) 
44.2,42.3-45.9 
(373) 
 -3.6 (<0.001) 
E
ith
e
r 
fo
rm
 
o
f T
D
 
Lethargy 49.1,48.5-49.7 
(2284) 
36.5,35.5-37.6 
(525) 
-20.0 (<0.001) 
Weak muscles 48.4,47.7-49.1 
(2354) 
38.0,36.8-39.1 
(455) 
-15.4 (<0.001) 
Poor memory 47.5,46.6-48.2 
(2347) 
43.2,42.2-44.8 
(467) 
-6.5 (<0.001) 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 47.0,46.3-47.7 
(2647) 
41.2,37.6-42.4 
(136) 
-5.8 (<0.001) 
Deep voice 46.6,46.1-47.6 
(2739) 
38.2,34.7-44.7 
(55) 
-3.5 (<0.001) 
Dry skin 47.7,47.0-48.4 
(2446) 
41.1,34.6-42.0 
(364) 
-9.3 (<0.001) 
Puffy eyes 47.1,46.4-47.8 
(2634) 
41.1,39.2-43.7 
(171) 
-6.1 (<0.001) 
Muscle cramps 47.8,47.0-48.6 
(2440) 
39.8,38.3-41.4 
(373) 
-11.1 (<0.001) 
Constipation  47.0,46.3-48.9 
(2612) 
41.1,39.2-43.6 
(191) 
-5.4 (<0.001) 
Sensitivity to cold  47.7,46.8-48.0 
(2443) 
42.0,40.0-43.0 
(361) 
-8.1 (<-0.001) 
Slow thinking 47.6,46.6-48.2 
(2477) 
42.2,39.6-43.8 
(333) 
-7.5 (<0.001) 
Weight gain 47.5,46.5-48.0 
(2361) 
43.8,42.4-44.9 
(455) 
-5.0 (<0.001) 
* associated with the Mann Whitney U test  
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Similarly, a significant difference in median mental component summary score 
between the groups existed for 17 (p<0.001) of the 18 changed symptoms. (Table 
10.6). 
Table 10.6 Presence versus absence of changed symptoms; comparison of mental 
component summary scores 
 
* associated with the Mann Whitney U test  
Symptom classification Median mental component summary score 
Absence of 
symptom  
%,95%CI 
(n) 
Presence of 
symptom  
%,95%CI 
 (n) 
Z 
(p value) 
S
u
g
g
e
s
tiv
e
 o
f 
h
y
p
e
rth
y
ro
id
is
m
 
Excessive perspiration 52.0, 51.6-52.5 
(2750) 
43.6,39.2-48.7 
(59) 
-5.1 
(<0.001) 
Trembling hands 52.1,51.6-52.7 
(2670) 
47.6,45.0-50.5 
(136) 
-5.1 
(<0.001) 
Frequent palpitations 52.1, 51.7-52.7 
(2675) 
44.7,42.1-46.8 
(128) 
-6.9 
(<0.001) 
Sensitivity to heat  52.1,51.6-52.6 
(2745) 
44.0,40.5-47.8 
(59) 
-5.6 
(<0.001) 
Fast thinking 51.9,51.5-52.4 
(2796) 
50.8,34.4-58.1 
(14) 
-0.4 (0.71) 
Weight loss 52.3,51.6-52.4 
(2443) 
49.2,48.1-50.9 
(373) 
-6.1 
(<0.001) 
E
ith
e
r 
fo
rm
 
o
f T
D
  
Lethargy 53.2,53.6-53.4 
(2284) 
45.5,44.8-47.3 
(525) 
-13.9 
(<0.001) 
Weak muscles 52.0,52.4-52.3 
(2354) 
46.1,44.9-47.3 
(455) 
-11.9 
(<0.001) 
Poor memory 52.7,52.1-53.3 
(2347) 
49.0,47.7-49.9 
(467) 
-8.9 
(<0.001) 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 52.1,51.7-52.7 
(2647) 
47.0,45.0-49.3 
(136) 
-4.9 
(<0.001) 
Deep voice 52.0,51.6-52.5 
(2739) 
46.5,42.2-49.3 
(55) 
-3.7 
(<0.001) 
Dry skin 52.5,51.9-53.1 
(2446) 
48.2,46.4-49.8 
(364) 
-8.4 
(<0.001) 
Puffy eyes 52.1,51.7-52.7 
(2634) 
48.2,45.3-50.2 
(171) 
-5.1 
(<0.001) 
Muscle cramps 52.5,51.9-53.1 
(2440) 
48.2,46.9-49.6 
(373) 
-7.6 
(<0.001) 
Constipation  52.2,51.7-53.1 
(2612) 
48.3,45.5-49.6 
(191) 
-6.1 
(<0.001) 
Sensitivity to cold  52.5,51.9-53.1 
(2443) 
48.1,46.3-49.2 
(361) 
-7.6 
(<0.001) 
Slow thinking 52.6,52.1-53.2 
(2477) 
47.4,45.2-50.0 
(333) 
-9.6 
(<0.001) 
Weight gain 52.1,51.7-52.8 
(2361) 
51.0,49.8-51.5 
(455) 
-3.2 
(<0.001) 
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10.2.2 Summary of findings related to individual symptoms and health status  
In general, individual symptoms appear to have a statistically significant impact upon 
health status of the cohort. The size of the changes in health status observed were, 
in general, small (<10 units) and are unlikely to be clinically meaningful.  
 
  234 
10.3 Multiple symptoms and health status  
10.3.1 Multiple hyperthyroid symptoms and health status  
The impact of individual symptoms on health status was relatively small and unlikely 
to be of clinical significance. It is possible that multiple symptom presentation 
increases the magnitude and clinical significance of changes in health status. 
Therefore, the impact of multiple symptoms on health status was examined. To 
further explore the relationship between symptoms expression and health status, 
totalled number of symptoms reported was plotted against median physical and 
mental component summary scores. As the totalled number of reported current 
symptoms suggestive of overt hyperthyroidism increased, median physical 
component summary scores decreased (Figure 10.5).  
 
Figure 10.5 Relationship between multiple current hyperthyroid symptoms and health 
status summary scores 
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A Kruskal Wallis test revealed a statistically significant difference in physical and 
mental component summary score across the four totalled current hyperthyroid 
symptom groups (group 1; n=1187: no symptoms reported, group 2; n=1395: one to 
two symptoms reported, group 3; n =216, three to four symptoms reported and group 
4; n= 19: five or more symptoms reported) χ2 (df3, n=2817) = 355.26, p<0.001 and χ2 
(df3, n=2817) = 175.55, p>0.001, respectively). Group four reporting the greatest 
number of totalled symptoms suggestive of hyperthyroidism recorded a lower median 
physical component summary score (28.0) than the other three groups (median 
score group 1; 50.2, group 2; 45.3 and group 3; 34.4 respectively) (Table 10.7). With 
respect to mental component summary scores, the results demonstrated a similar 
trend with group four reporting the greatest number of totalled symptoms suggestive 
of hyperthyroidism attaining the lower median mental component summary score 
(33.30) than the other three groups (median score group 1; 53.3, group 2; 51.9 and 
group 3; 43.2, respectively). 
 
Table 10.7 Effect of multiple current hyperthyroid symptoms on health status 
summary scores  
Totalled 
current 
hyperthyroid 
symptoms  
Median physical 
component 
summary score  
χ
2
 (p) 
df = 3 
 
Median mental 
component 
summary score  
χ
2
 (p) 
df = 3 
 
None (n=1187) 50.2 
 
355.3 
(<0.001) 
53.3 
175.6 
(<0.001) 
1-2 (n=1395) 45.3 
 
51.9 
3-4 (n=216) 34.4 
 
43.2 
5 or more 
(n=19) 
28.0 
 
33.3 
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10.3.2 Multiple changed hyperthyroid symptoms and health status 
As the totalled number of reported changed symptoms suggestive of overt 
hyperthyroidism increased, median physical component summary scores decreased. 
In the same way, as the totalled number of changed symptoms suggestive of overt 
hyperthyroidism increased median physical component summary score decreased 
(Figure 10.6) 
 
 
Figure 10.6 Relationship between multiple changed hyperthyroid symptoms and 
health status summary scores 
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In terms of changed symptoms suggestive of hyperthyroidism, a significant difference 
in median mental and physical component summary score also existed between the 
four totalled hyperthyroidism symptom groups. Again, the group with the highest 
number of totalled symptoms reported significantly lower levels of physical and 
mental health than any of the other three groups (Table 10.8). 
 
 
 
Table 10.8 Impact of multiple changed hyperthyroid symptoms on health status 
summary scores   
Totalled 
changed 
hyperthyroid 
symptoms  
Median physical 
component 
summary score  
χ
2
 (p) 
df = 3 
 
Median mental 
component 
summary score  
χ
2
 (p) 
df = 3 
 
None (n=1563) 
50.5 
349.7 
(<0.001) 
53.9 
275.2 
(<0.001) 
1-2 (n=1005) 
43.6 50.7 
3-4 (n=221) 
36.7 43.6 
5 or more 
(n=28) 34.2 34.7 
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10.3.3 Multiple current hypothyroid symptoms and health status  
The impact of multiple current and changed hypothyroid symptoms on mental and 
physical component summary scores was similar to that observed due to multiple 
hyperthyroid symptoms (Figures 10.7 and 10.8).  
As the totalled number of reported current symptoms suggestive of overt 
hypothyroidism increased, median physical component summary scores decreased. 
(Figure 10.7) 
 
 
Figure 10.7 Relationship between multiple current hypothyroid symptoms and health 
status scores score 
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Likewise, as the totalled number of changed symptoms suggestive of overt 
hypothyroidism increased, median physical component summary score decreased 
(Figure 10.8). 
 
 
 
 
Figure 10.8 Relationship between multiple changed hypothyroid symptoms and 
health status score 
 
 
 
 
Total number of changed symptoms 
suggestive of  hypothyroidism reported
11.0010.009.008.007.006.005.004.003.002.001.00.00
M
e
d
ia
n
60.00
50.00
40.00
30.00
20.00
10.00
0.00
Mental component summary score
Physical component summary score 
 
Total number of changed symptoms suggestive of 
hypothyroidism reported 
  240 
 
Kruskal Wallis tests also revealed a statistically significant difference in median 
mental and physical component summary score between the four totalled current 
hypothyroidism symptom groups, ( p<0.001) (Table 10.9). 
 
Table 10.9 Effect of multiple current hypothyroid symptoms on health status summary 
scores 
Totalled current 
hypothyroid 
symptoms  
Median physical 
component 
summary score  
χ
2
 (p) 
df = 3 
 
Median mental 
component 
summary score  
χ
2
 (p) 
df = 3 
 
None (n=447) 
53.7 
509.3 
 (<0.001) 
53.6 
248.0 (<0.001 ) 
1-2 (n=1434) 
48.8 53.4 
3-4 (n=670) 
41.9 50.4 
5 or more 
(n=266) 34.2 42.5 
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In terms of multiple changed hypothyroid symptoms and health status summary 
scores, those reporting the highest number of symptoms suggestive of 
hypothyroidism scored significantly lower on both the physical and mental component 
summary scores (p <0.001 in each case). (Table 10.10) 
 
 
Table 10.10 Impact of multiple changed hypothyroid symptoms on health status 
summary score 
 
Totalled 
changed 
hypothyroid 
symptoms  
Median physical 
component 
summary score  
χ
2
 (p) 
df = 3 
 
Median mental 
component 
summary score  
χ
2
 (p) 
df = 3 
 
None  (n=1259) 
51.8 
392.3 (<0.001) 
54.2 
255.6 
(<0.001) 
1-2 (n=973) 
44.9 51.5 
3-4 (n=387) 
40.6 48.2 
5 or more 
(n=198) 37.5 42.7 
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Summary of chapter 10 
In this chapter, symptom expression and health status of the cohort was explored 
and described. The most prevalent current symptom suggestive of hypothyroidism 
reported by the cohort was weight gain. Lethargy, poorer memory and weaker 
muscles were the most prevalent changed symptoms reported by the cohort. Fast 
thinking was the most frequently reported symptom suggestive of overt 
hyperthyroidism. In terms of intensity of current and changed symptoms the cohort 
reported a higher prevalence of mild intensity symptoms than severe intensity 
symptoms.  
At the individual symptom level, median physical component summary score was 
significantly lower in those reporting presence of 16 current symptoms and 17 
changed symptoms suggestive of overt thyroid dysfunction. The presence of current 
fast thinking, changed weight loss or changed dry skin were not associated with 
lower median physical component summary scores. Mental component summary 
scores were significantly lower in individuals reporting presence of 15 current and 17 
changed symptoms. Those reporting presence of current symptoms weight gain and 
deep voice did not score significantly lower in terms of median component summary 
score. Individuals reporting current presence of fast thinking scored significantly 
higher with respect to median mental component summary score than those 
reporting absence of fast thinking. The difference between those reporting changed 
fast thinking compared with those reporting an absence of changed fast thinking 
however failed to reach significance. In general, mental health status of the cohort 
was better than physical health status. An inverse relationship between totalled 
number of symptoms suggestive of overt thyroid dysfunction reported and median 
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physical and mental component summary scores was observed. Reduced physical 
and mental component summary scores are associated with presence of current and 
changed individual symptoms suggestive of overt thyroid dysfunction. Furthermore, 
physical and mental component summary scores declined as the totalled number of 
current and changed symptoms suggestive of overt thyroid dysfunction increased.  
These results suggest that symptoms suggestive of overt thyroid dysfunction are 
prevalent in individuals aged 65 years or more and appear to have a significant 
impact upon health status. Whilst individual symptoms do have a statistically 
significant influence upon heath status the impact is generally small (<10 units) and 
unlikely to be clinically meaningful. The results related to multiple symptoms however 
demonstrate that presence of five or more symptoms leads to clinically important 
changes in health status.  
This chapter explored symptom expression and health status in the study cohort. The 
next chapter explores and describes the characteristics of the thyroid function 
groups.   
 
  244 
CHAPTER 11 DESCRIPTION OF THE SUBGROUPS 
 
 
Overview of chapter 11 
The current chapter introduces the thyroid function groups and presents the 
characteristics and demographics of the subgroups.  This chapter commences with a 
description of how the study population was divided into three subgroups according 
to the results of the thyroid function tests. The characteristics of the subgroups are 
then presented and findings of comparisons between the euthyroid and subclinical 
hyperthyroidism groups and the euthyroid and subclinical hypothyroidism groups 
reported. This chapter concludes with a summary of the main findings.   
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11.1 Expression of symptoms in accordance with thyroid function category  
Using standard reference criteria for classification of thyroid function, patients were 
divided into three subgroups: group 1 with subclinical hyperthyroidism (n=29), group 
2; euthyroid (n=2703) and group 3; subclinical hypothyroidism (n=138).  
 
11.2 Categorisation and description of the subgroups  
The euthyroid group were significantly younger than the subclinical hyperthyroidism 
group (mean age 76.83 versus 79.06 years respectively; p<0.02) and the subclinical 
hypothyroidism group (mean age 76.83 versus 77.70 years respectively; p<0.05). 
There was no significant difference in mean age of the subclinical hyperthyroidism 
group compared with the subclinical hypothyroidism group (79.06 versus 77.70 years 
respectively; p<0.21). In terms of socioeconomic status, the subclinical 
hyperthyroidism group was the most affluent with a mean IMD score of 22.16 and the 
subclinical hypothyroid group the least affluent (mean IMD score 21.72) no significant 
difference existed between these groups when compared with the euthyroid group 
(Table11.1). 
 
The median serum thyrotrophin concentration was 5.39mIU/L in the subclinical 
hypothyroidism group, 0.15 mIU/L in the subclinical hyperthyroidism group and in the 
euthyroid group 1.78mIU/L. The lower limit of reporting serum thyrotrophin 
concentration was 0.02mIU/L, therefore concentrations below this threshold were 
undetectable. For analysis purposes,  all five individuals with an undetectable 
thyrotrophin concentration were allocated a value of 0.02 mIU/L. Serum thyrotrophin 
concentration ranged from 0.02-0.29mIU/L in the subclinical hyperthyroidism group, 
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0.30- 4.50 mIU/L euthyroid and 4.53-19.30 mIU/L subclinical hypothyroidism. Serum 
free thyroxine concentration ranged from 9.1-30.10pmol/L in the euthyroid group, 
12.60-21.20pmol/L in the subclinical hyperthyroidismgroup and 10.50–17.90pmol/L 
subclinical hypothyroidism group. 
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Table 11.1 Euthyroid versus subclinical thyroid dysfunction; comparison of 
demographic and clinical variables 
Variable  Euthyroid  
n=2703 
Subclinical 
hyperthyroid  
 n =29 
(Euth vs 
SChyper)  
(p) 
df = 1 
Subclinical 
hypothyroid 
n=138 
(Euth vs 
SChypo) 
(p) 
df = 1 
Male  
n (%, 95% CI) 
1414 (52.3) 10 (34.5) 
χ
2
 3.7 
(0.06) 
61 (44.2) 
χ
2
3.5 
(0.06) Female 
n (%, 95% CI) 
1289 (47.7) 19 (65.5) 77 (55.8) 
Age  
 
n=2703 n=29  n=138  
Mean,95% CI 
(SD) 
76.8,76.6-77.0 
(4.9) 
79.1,77.6-81.1 
(5.5) 
(0.02)# 
77.7,76.8-78.6 
(5.3) 
(0.05)# 
Median, 
95%CI (IQR) 
76.0,75.8-76.3 
(7.50) 
79.6,74.9-82.3 
(9.80) 
Z-2.26 
(0.02)* 
76.2,75.5-77.7 
(7.30) 
Z-1.84 (0.07)* 
IMD score  
 
n=2702 n=29  n=138  
Mean, 95% CI 
(SD) 
21.7,21.2-22.3  
(15.2) 
22.2,17.3-27.0 
(13.3) 
(0.88)# 
20.4,18.3-22.5 
(12.5) 
(0.23)# 
Median 95%CI 
(IQR) 
17.2,17.4-18.3 
(18.7) 
17.8,14.3-23.4 
(14.8) 
Z-0.65 
(0.52)* 
18.1,15.5-19.3 
(18.4) 
Z-0.12 (0.90)* 
TSH  
 
n=2703 n=29  n=138  
Mean,95% CI 
(SD) 
1.94, 1.91-1.97 
(0.90) 
0.14, 0.1-0.18 
(0.10) 
(<0.001)# 
6.28, 5.87-6.69 
(2.48) 
(<0.001)# 
Median, 
95%CI (IQR) 
1.80,1.75-1.82 
(1.24) 
0.2,0.06-0.21 
(0.20) 
Z-9.28 
(<0.001)* 
5.4,5.20-5.63 
(1.49) 
Z-9.84 (<0.001)* 
FT4 
 
n=2703 n=29  n=138  
Mean,95% CI 
(SD) 
15.1,15.0-15.2 
(2.04) 
16.3,15.6-17.0 
(1.94) 
 (<0.001)# 
13.6,13.4-13.9 
(1.74) 
 (<0.001)# 
Median,95%CI 
(IQR) 
15.0,14.8-15.0 
(2.5) 
16.0,15.5-17.2 
(2.3) 
Z-3.45 
(<0.001)* 
13.5,13.2-13.9 
(2.40) 
Z-7.90 (<0.001)* 
* associated with the Mann Whitney U test, # associated with the t test
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Comparison of lifestyle characteristics reported by the subgroups revealed that a 
significantly greater proportion of the subclinical hypothyroidism group had a family 
history of thyroid dysfunction compared with euthyroid group (21.7% versus 14.2% 
respectively, χ2 6.03, df 1, p<0.01). The subclinical hypothyroidism group was also 
significantly different to the euthyroid group in terms of alcohol intake (56.2% versus 
65.5% respectively, χ2 4.91, df 1, p 0.03) and use of iodine supplementation (χ2 4.15, 
df 1, p 0.042). No significant difference existed between the euthyroid and subclinical 
hyperthyroidism groups with respect to any of the self reported lifestyle 
characteristics (Table 11.2).   
 
Table 11.2 Euthyroid versus subclinical thyroid dysfunction; comparison of self-
reported lifestyle characteristics and family history of thyroid dysfunction  
Lifestyle 
characteristics 
and family history 
of TD 
Euthyroid 
n 
(%, 95% CI) 
Subclinical 
hyperthyroid 
n 
(%, 95% CI) 
χ
2
  
(p value) 
df = 1 
(Euth vs 
SChyper) 
Subclinical 
hypothyroid 
n 
(%, 95% CI) 
χ
2
  
(p value) 
df = 1 
(Euth vs 
SChypo) 
Alcohol intake 1753 
(65.5,63.0-66.6) 
14 
(50.0,31.4-65.6) 
2.92 
(0.09) 
77 
(56.2,47.2-63.8) 
4.91 
(0.03) 
Current smoker 165 
(6.1,5.3-7.1) 
2 
(7.1,1.9-22.0) 
 
(0.69)* 
8 
(5.8,3.0-11.0) 
0.02 
(0.90) 
Kelp/iodine 
supplementation 
175 
(6.6,5.6-7.5) 
1 
(3.7,0.6-17.2) 
 
(1.0)* 
3 
(2.2,0.7-6.2) 
4.15 
(0.042) 
Family history of TD 384 
(14.2,12.9-15.6) 
7 
(24.1,12.2-42.1) 
 
(0.10)* 
30 
(21.7,15.7-29.3) 
6.03 
(0.01) 
*associated with the Fisher exact test  
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In terms of the frequency of prescription medication, there were no significant 
differences between these with euthyroid compared with the subclinical 
hyperthyroidism or subclinical hypothyroidism groups. Beta-adrenergic blockers were 
the most frequently prescribed concomitant medication with 24% of the subclinical 
hyperthyroid group, 13.9% of the euthyroid group and 10.1% of the subclinical 
hypothyroid group receiving this treatment (Table 11.3). 
 
 
Table11.3 Euthyroid versus subclinical thyroid dysfunction; comparison of medication 
prescribed by the GP 
Prescribed 
medication 
Euthyroid 
n  
(%,95% CI) 
Subclinical 
hyperthyroid 
n  
(%,95% CI)  
(Euth vs 
SChyper) 
χ
2
  
(p value) 
df = 1 
 
Subclinical 
hypothyroid 
n  
(%,95% CI) 
(Euth vs 
SChypo) 
χ
2
  
(p value) 
df = 1 
 
Amiodarone 11  
(0.40,0.2-0.7) 
0 
(0-11.7) 
(1.00)* 
0 
(0-2.7) 
 
(1.00)* 
Antidepressant 145  
(5.40,4.6-6.3) 
0 
(0-11.7) 
(0.40)* 
6  
(4.3,2.0-9.2) 
0.27 
(0.60) 
Anxiolytic 56  
(2.10,1.6-2.7) 
0 
(0-11.7) 
(1.00)* 
1  
(0.7,0.1-4.0) 
 
(0.53)* 
Beta-adrenergic 
blocker  
376  
(13.90,12.7-15.3) 
7  
(24.1,12.2-42.1) 
(0.17)* 
14  
(10.1-6.1-16.3) 
1.57 
(0.21) 
Lithium 4  
(0.10,0.1-0.4) 
0 (1.00)* 
0 
(0.2-2.7) 
 
(1.00)* 
Major tranquiliser 12  
(0.40,0.3-0.8) 
1 (3.4,0.6-17.2) (0.13)* 
0 
(0.2-2.7) 
 
(1.00)* 
Morphine or other 
opioid 
25  
(0.90,0.6-1.4) 
0 
(0-11.7) 
(1.00)* 
0 
(0.2-2.7) 
 
(0.63)* 
Glucocorticoids 136  
(5.0, 4.3-5.9) 
1 (3.4, 0.6-17.2) (1.00)* 
8  
(5.8, 3.0-11.0) 
0.16 
(0.69) 
   *associated with the Fishers exact test  
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There were no significant differences between the euthyroid and subclinical 
hyperthyroidism groups with respect to prevalence of co-morbidity. However, a 
significant difference between the euthyroid and subclinical hypothyroidism groups 
was observed with respect to the prevalence of pulmonary disease. A significantly 
greater proportion of the euthyroid subjects had a diagnosis of pulmonary disease 
compared with the individuals with subclinical hypothyroidism (12.9% versus 3.6 
respectively; p<0.001. These two groups were otherwise similar with respect to all 
other co-morbidities (Table 11.4).  
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Table 11.4 Euthyroid versus subclinical thyroid dysfunction; comparison of co-morbidity  
Medical history 
Euthyroid 
 
n  
(%,95% CI) 
Subclinical 
hyperthyroid  
n  
(%,95% CI) 
(Euth vs 
SChyper) 
χ
2
  
(p value) 
df = 1 
Subclinical 
hypothyroid 
n  
(%,95% CI) 
(Euth vs 
SChypo 
χ
2
  
(p value) 
df = 1 
Anaemia  13  
(0.50,0.3-0.8) 
0 
(0-11.7) 
(1.00) 
0 
(0.9-2.7) 
(1.00) 
Anxiety present  163  
(6.00,5.2-7.0) 
0 
(0-11.7) 
(0.41)* 
9  
(6.50,3.5-11.9) 
0.07  
(0.81) 
Atrial Fibrillation 195  
(7.20,6.3-8.3) 
1  
(3.40,0.6-17.2) 
(0.72)* 
6  
(4.30,2.0-9.2) 
1.64  
(0.20) 
Cancer 280 
(10.40,9.3-11.6) 
2  
(6.90,1.9-22.0) 
(0.76) 
18  
(13.00,8.4-19.7) 
0.97  
(0.33) 
Dementia 18  
(0.70,6.9-8.9) 
1  
(3.40,0.6-17.2) 
(0.18) 
0 
(0.9-2.7) 
(1.00) 
Depression 211  
(7.80,6.9-8.9) 
0 
(0-11.7) 
(0.61) 
13  
(9.40,5.6-15.5) 
0.47  
(0.49) 
Diabetes 315  
(11.70,10.5-12.9) 
4  
(13.80,5.5-30.6) 
(0.77) 
17  
(12.30,7.8-18.8) 
0.06  
(0.81) 
Goitre 5  
(0.20,0.1-0.4) 
0 
(0-11.7) 
(1.00) 
0 
(0.9-2.7) 
(1.00) 
Heart failure 123  
(4.60,3.8-5.4) 
0 
(0-11.7) 
(0.64) 
3  
(2.20,0.7-6.2) 
1.75  
(0.19) 
Hip Replacement  66  
(2.40,1.9-3.1) 
0 
(0-11.7) 
(1.00) 
0 
(0.9-2.7) 
(0.08) 
Hypertension 1379  
(51.0,49.7-52.9) 
14  
(48.30,31.4-65.6) 
(0.85) 
77  
(55.80,47.5-63.8) 
1.20  
(0.27) 
Ischemic heart 
disease  
339 
(12.50,11.3-13.8) 
1  
(3.40,0.6-17.2) 
(0.25) 
23  
(16.70,11.4-23.8) 
2.01  
(0.16) 
Irregular heart 
rhythm 
95  
(3.50,2.9-4.3) 
1  
(3.40,0.6-17.2) 
(1.00) 
1  
(0.70,0.1-4.0) 
(0.09) 
Knee Replacement  80  
(3.00,2.4-3.7) 
2  
(6.90,1.9-22.0) 
(0.22) 
7  
(5.10,2.5-10.1) 
(0.20) 
Neurological 
disease 
26  
(1.00,0.7-1.4) 
0 
(0-11.7) 
(1.00) 
0 
(0.9-2.7) 
(0.64) 
Osteoporosis 51  
(1.90,2.7-4.1) 
0 
(0-11.7) 
(1.00) 
2  
(1.40,0.4-5.1) 
(1.00) 
Peripheral 
vascular disease 
90  
(3.30,2.7-4.11) 
2  
(6.90,1.9-22.0) 
(0.16) 
6  
(4.30,2.0-9.2) 
(0.47) 
Pituitary disease 8  
(0.30,0.2-0.6) 
0 
(0-11.7) 
(1.00) 
0 
(0.9-2.7) 
(1.00) 
Pulmonary disease 348  
(12.90,11.7-14.2) 
2 (6.90) (0.57) 
5  
(3.60,1.6-8.2) 
10.23 
(0.001) 
Renal disease 497  
(18.40-17.0-19.9) 
5  
(17.20,7.6-34.5) 
(1.00) 
23  
(16.70,11.4-6.2) 
0.260 
(0.61) 
Rheumatoid 
Arthritis 
66  
(2.40,1.9-3.1) 
0 
(0-11.7) 
(1.00) 
3  
(2.20,0.7-6.2) 
(1.00) 
Stroke  148  
(5.50,4.7-6.4) 
3  
(10.30,3.6-26.4) 
(0.21) 
6  
(4.30,2.0-9.2) 
0.33 (0.57) 
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11.3 Health status in the thyroid function groups 
The euthyroid and subclinical hyperthyroidism groups were similar with respect to both 
mental and physical component scores. Likewise, the euthyroid and subclinical 
hypothyroidism groups were similar in terms of median mental and physical component 
summary scores (Table 11.5).  
 
Table 11.5 Euthyroid versus subclinical thyroid dysfunction; comparison of mental and 
physical health status summary scores  
Median component 
summary score  
Euthyroid 
n=2653 
 
Subclinical 
hyperthyroid 
n=27 
 
Euth vs 
Schyper 
Z score* 
(p value) 
 
Subclinical 
hypothyroid 
n=137 
 
 
Euth vs 
ScHypo  
Z Score* 
(p value)  
 
Median physical 
component summary 
score, 95% CI  
(IQR) 
46.5, 45.8-47.4 
(16.52) 
45.8,35.6-54.5 
 (21.77) 
-0.72 
(0.47) 
47.0,44.5-49.3 
(13.32) 
 
-0.17 
(0.87) 
 
Median mental 
component summary 
score, 95% CI  
(IQR) 
51.8,51.5-52.3 
(11.46) 
49.2,44.6-54.1 
(9.95) 
-1.66 
(0.09) 
53.1,51.5-54.9 
(8.32) 
 
-1.15 
(0.25) 
 
* associated with the Mann Whitney U test 
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Summary of chapter 11 
The subclinical hyperthyroidism group was significantly older than the euthyroid group 
(79.0 versus 76.8 years respectively, p<0.017). These groups were nevertheless similar 
with respect to gender, socioeconomic status, lifestyle characteristics, prescription 
medication, co-morbidities and physical and mental health status.  
The subclinical hypothyroidism and euthyroid groups were significantly different in terms 
of age, alcohol intake, family history of thyroid dysfunction and prevalence of pulmonary 
disease. Similarly, the subclinical hypothyroidism group were older than the group with 
euthyroid (77.7 versus 76.8 years respectively, p<0.049). Additionally, a larger 
proportion of the subclinical hypothyroidism group self reported having a family history of 
thyroid dysfunction. The euthyroid group had a significantly greater proportion of 
individuals self reporting regular alcohol intake (65.5% versus 56.2%, p<0.03) and a 
greater prevalence of pulmonary disease (12.9% versus 10.2% respectively, p <0.001). 
These groups were, however, similar with respect to gender, socioeconomic status, 
lifestyle characteristics, prescription medication and physical and mental health status.  
The findings from comparisons of physical and mental component summary scores 
across the thyroid function groups in the current chapter suggest that neither subclinical 
hyperthyroidism or subclinical hypothyroidism are associated with reduced health status. 
In combination with the previous results demonstrating a significant difference in 
physical and mental component summary scores between groups reporting presence 
and absence of individual symptoms, these findings suggest that it is the presence of 
individual symptoms rather than subclinical thyroid dysfunction itself that is responsible 
for impaired health status.  
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This chapter introduced the thyroid function subgroups and described lifestyle, co-
morbidity, concomitant medication and perceived health status in euthyroid subjects and 
individuals with subclinical hyperthyroidism and subclinical hypothyroidism. In the next 
chapter, symptom expression in the thyroid function groups is further explored.  
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CHAPTER 12 SYMPTOMS IN THE SUBGROUPS 
 
Overview of chapter 12 
The aim of this chapter is to present the findings of univariate and multivariate analyses 
exploring the relationship between thyroid function category and expression of 
symptoms. Results of the univariate analyses are tabulated and summarised to clarify 
which individual symptoms and combinations of symptoms are potentially important 
predictors of thyroid function and were included in the multivariate analysis.  
Binary logistic regression models constructed to identify those symptoms or 
combinations of symptoms that are independent predictors of subclinical thyroid 
dysfunction while controlling for lifestyle characteristics, demographics, concomitant 
medication and medical history are then presented.  
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12.1 Prevalence of hypothyroid symptoms  
To enable characterisation of symptoms reported in the euthyroid and subclinical 
hypothyroidism groups, the prevalence of individual hypothyroid symptoms reported by 
each group was calculated. The chi squared test of independence was used to compare 
the prevalence of current and changed individual symptoms between the euthyroid and 
subclinical hypothyroidism groups. Where appropriate the Fishers exact test was used. 
A Bonferroni adjusted alpha value of p<0.004 was used to control for type I error for 
each comparison between euthyroid and subclinical hypothyroidism groups.  
 
At the individual symptoms level there were no significant differences between the 
euthyroid and subclinical hypothyroidism groups with respect to any of the twelve current 
symptoms suggestive of hypothyroidism. Likewise there were no significant differences 
in the prevalence of changed symptoms reported by these two groups (Table 12.1). 
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Table 12.1 Euthyroid versus subclinical hypothyroidism; comparison of the prevalence of 
individual current and changed hypothyroid symptoms  
 Current symptoms reported Changed symptoms reported 
 
Symptom  Euthyroid 
%, 
95% CI, 
(n) 
Subclinical 
hypothyroid 
%, 
95% CI 
(n) 
χ
2
  
(p value) 
df = 1 
 
 
Euthyroid 
%, 
95% CI, 
(n) 
Subclinical 
hypothyroid 
%, 
95% CI 
(n) 
χ
2
  
(p value) 
df = 1 
 
Lethargy 
16.40, 
15.0-17.8 
(442) 
10.90, 
6.7-17.3 
(15) 
2.83  
(0.09) 
18.70, 
17.3-20.2 
(505) 
16.10, 
10.9-23.1 
(22) 
 
0.62 
(0.43) 
Weak muscles 
14.30, 
13.0-15.7 
(386) 
14.50, 
9.6-21.3 
(20) 
0.04  
(0.95) 
16.40, 
15.0-17.8 
(442) 
13.90, 
9.1-20.6 
(19) 
0.61 
(0.44) 
Poor memory 
9.70, 
8.6-10.9 
(262) 
8.00, 
4.5-13.7 
(11) 
0.45 
(0.50) 
16.50, 
15.2-18.0 
(446) 
15.90, 
10.8-23.0 
(22) 
0.03  
(0.86) 
Hoarse voice 
6.00, 
5.2-7.0 
(163) 
8.00, 
4.5-13.8 
(11) 
0.90 
(0.34) 
4.80, 
4.1-5.7 
(128) 
6.50, 
3.5-11.9 
(9) 
0.83  
(0.36) 
Deep voice 
6.40, 
5.5-7.4 
(172) 
9.50, 
5.6-15.6 
(13) 
2.07 
(0.15) 
2.00, 
1.5-2.6 
(54)  
1.40, 
0.4-5.1 
(2) 
 
(1.00)* 
Dry skin 
32.20, 
30.4-34.0 
(868) 
33.30, 
26.0-41.6 
(46) 
0.08  
(0.78) 
13.10, 
11.8-14.4 
(352) 
9.50, 
5.6-15.6 
(13) 
1.48  
(0.23) 
Puffy eyes 
13.30, 
12.1-14.7 
(360) 
15.90, 
10.8-23.0 
(22) 
0.76  
(0.38) 
6.00, 
5.2-7.0 
(162) 
5.80,  
3.0-11.0 
(8) 
0.12 
(0.91) 
Muscle 
cramps 
15.10, 
13.8-16.5 
(408) 
15.20, 
10.2-22.1 
(21) 
0.01 
(0.97) 
13.10, 
11.9-14.4 
(354) 
13.80,  
9.0-20.5 
(19) 
0.05 
(0.83) 
Constipation  
13.20, 
11.9-14.5 
(355) 
14.50, 
9.6 -21.3 
(20) 
0.20 
(0.65) 
6.70, 
5.8-7.7 
(181) 
8.00, 
4.5-13.8 
(11) 
0.35 
(0.56) 
Sensitivity to 
cold  
34.80, 
33.0-36.7 
(925) 
37.20, 
29.6-45.6 
(51) 
0.33 
(0.57) 
12.80, 
11.6-14.1 
(345) 
10.90, 
6.7-17.2 
(15) 
0.45  
(0.50) 
Slow thinking 
7.90, 
6.9-8.9 
(212) 
11.60, 
7.3-18.9 
(16) 
2.48  
(0.12) 
11.70, 
10.6-13.0 
(316) 
13.80, 
9.0-20.5 
(19) 
0.53  
(0.47) 
Weight gain 
48.50, 
46.7-50.4 
(1310) 
53.60, 
45.3-61.7 
(74) 
1.36 
(0.24) 
15.90, 
14.6-17.3 
(429) 
20.30, 
14.4-27.8 
(28) 
1.88 
(0.17) 
Bonferroni adjustment p<0.004 * associated with the Fishers exact test  
 
 
  258 
12.2 Intensity of hypothyroid symptoms reported by subgroups 
Comparisons between the groups with respect to the reported intensity of current and 
changed symptoms were also undertaken. Again, a Bonferroni adjusted alpha value of 
p<0.004 was applied to control for type I error for each comparison between the 
euthyroid and subclinical hypothyroidism groups. No significant differences in 
prevalence of mild intensity current or changed symptoms suggestive of hypothyroidism 
existed between the euthyroidism and subclinical hypothyroidism groups (Table 12.2). 
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Table 12.2 Euthyroid versus subclinical hypothyroidism; comparison of the prevalence of 
individual current and changed mild intensity hypothyroid symptoms  
 Current mild intensity symptoms Changed mild intensity symptoms  
 
Symptom  Euthyroid 
%, 
95%CI 
 (n) 
Subclinical 
hypothyroid 
%, 
95%CI 
 (n) 
χ
2
  
(p value) 
df 1 
 
 
Euthyroid 
%, 
95%CI 
 (n) 
Subclinical 
hypothyroid 
%, 
95%CI 
 (n) 
χ
2
  
(p value) 
df 1 
 
Lethargy  
13.90, 
12.6-15.2 
(364) 
10.30, 
6.2-16.5  
(14) 
1.4 
(0.23) 
17.00 
15.6-18.5  
(449) 
16.10, 
10.9-20.1 
(22) 
0.08 
(0.77) 
Weak 
muscles 
13.30, 
12.0-14.6 
(354) 
14.50, 
9.6-21.3  
(20) 
0.17 
(0.68) 
15.80 
14.4-17.2 
 (422) 
13.2, 
8.5-20.0 
(18) 
0.63 
(0.43) 
Poor memory 
9.00, 
8.0-10.2  
(242) 
8.00, 
4.5-13.7  
(11) 
0.18 
(0.67) 
16.00, 
14.7-17.5  
(430) 
15.9, 
10.8-23.0 
(22) 
0.001 
(0.98) 
Hoarse voice 
5.80, 
5.0-6.70  
(156) 
8.00, 
4.5-13.7  
(11) 
1.17 
(0.28) 
4.50, 
3.8-5.4  
(121) 
6.5, 
3.5-11.9 
(9) 
1.15 
(0.28) 
Deep voice 
6.20, 
5.4-7.2  
(168) 
9.5, 
5.6-15.6  
(13) 
2.29 
(0.13) 
1.90, 
1.5-2.5 
 (52) 
1.4, 
0.4-5.1 
(2) 
0.17 
(0.68) 
Dry skin 
28.50, 
26.8-30.3 
(730) 
31.30, 
24.1-39.6  
(42) 
0.49 
(0.48) 
12.10, 
10.9-13.4  
(322) 
9.5, 
5.6-15.6 
(13) 
0.83 
(0.36) 
Puffy eyes 
12.90, 
11.7-14.2 
(346) 
14.1, 
 9.2-20.9  
(19) 
0.16 
(0.69) 
5.70, 
4.9-6.7  
(154) 
5.1, 
2.5-10.2 
(7) 
0.09 
(0.76) 
Muscle 
cramps 
13.10 
11.8-14.4 
(344) 
15.2, 
10.2-22.1  
(21) 
0.54 
(0.46) 
12.20, 
11.0-13.5  
(326) 
13.1, 
8.5-19.8 
(18) 
0.11 
(0.75) 
Constipation  
10.20 
9.1-11.5 
(267) 
13.9, 
9.1-20.6 
 (19) 
1.83 
(0.18) 
5.90, 
5.0-6.8  
(156) 
8.0, 
4.5-13.8 
(11) 
1.10 
(0.29) 
Sensitivity to 
cold  
31.60  
29.8-33.4 
(798) 
34.4, 
26.8-42.8 
(45) 
0.45 
(0.50) 
12.10, 
10.9-13.4  
(322) 
10.9, 
6.7-17.2 
(15) 
0.18 
(0.67) 
Slow thinking 
7.40  
6.5-8.5 (200) 
10.9, 
6.7-17.3 
(15) 
2.28 
(0.13) 
 
11.40, 
10.3-12.7  
(307) 
13.1, 
8.5-19.8 
(18) 
0.37 
(0.54) 
Weight gain 
45.00  
43.1-47.0 
(1137) 
49.6, 
41.1-58.2  
(65) 
1.03 
(0.31) 
15.20, 
13.9-16.6  
(408) 
20.3, 
14.4-27.8 
(28) 
2.58 
(0.11) 
 
Bonferroni adjusted p value < 0.004. * associated with the Fishers exact test 
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Similarly, there were no significant differences observed between the euthyroid and 
subclinical hypothyroidism groups with respect to the prevalence of severe current or 
changed symptoms suggestive of hypothyroidism (Table 12.3)  
 
Table 12.3 Euthyroid versus subclinical hypothyroidism; comparison of the prevalence of 
individual current and changed severe intensity hypothyroid symptoms  
 Current severe intensity symptom 
 
Changed severe intensity symptom 
Symptom  Euthyroid 
%, 
95% CI (n) 
Subclinical 
hypothyroid 
%, 
95% CI (n) 
χ
2
 (p) 
df = 1 
 
 
Euthyroid 
%, 
95% CI (n) 
Subclinical 
hypothyroid 
%, 
95% CI (n) 
χ
2
 (p) 
df = 1 
 
Lethargy  3.30, 
2.7-4.1 (78) 
0.80, 
0.1-4.5 (1) 
 
(0.18)* 
2.50, 
1.9-3.2 (56) 
0 
(0-3.2) 
 
(0.11)* 
Weak muscles 1.40, 
1.0-1.9 (32) 
0 
(0-3.2) 
 
(0.40)* 
0.90, 
0.6-1.4 (20) 
0.80 (1) 
 
(1.00)* 
Poor memory 0.80, 
0.5-1.3 (20) 
0 
(0-2.9) 
 
(0.62)* 
0.70, 
0.4-1.1 (16) 
0 
(0-3.2) 
 
(1.00)* 
Hoarse voice 0.30, 
0.1-0.6 (7) 
0 
(0.3.0) 
 
(1.00)* 
0.30, 
0.1-0.6 (7) 
0 
(0-2.9) 
 
(1.00)* 
Deep voice 0.20, 
0.1-0.4 (4) 
0 
(0.3.2) 
 
(1.00)* 
0.10, 
0.1-0.3 (2) 
0 
(0.27) 
 
(1.00)* 
Dry skin 7.00, 
6.0-8.2 (138) 
4.20, 
2.6-10.2 (4) 
1.16 
(0.28) 
1.30, 
0.9-1.8 (30) 
0 
(0-30) 
 
(0.40)* 
Puffy eyes 0.60, 
0.4-1.0 (14) 
2.50, 
0.9-7.2 (3) 
 
(0.05)* 
0.30, 
0.2-0.6 (8) 
0.80, 
0.1-4.2 (1) 
 
(0.37)* 
Muscle cramps 2.70, 
2.1-3.5 (64) 
0 
(0-3.2) 
 
(0.07)* 
1.20, 
0.8-1.7 (28) 
0.80, 
0.1-4.6 (1) 
 
(1.00)* 
Constipation  3.60, 
2.9-4.4 (88) 
0.80, 
1.0-4.6 (1) 
 
(0.15)* 
1.00, 
0.7-1.5 (25) 
0 
(0-3.0) 
 
(0.63)* 
Sensitivity to cold  6.80, 
5.8-81 (127) 
6.50, 
3.0-13.5 (6) 
0.01 
(0.91)* 
1.00, 
0.6-1.5 (23) 
0 
(0-3.0) 
 
(0.63* 
Slow thinking 0.50, 
0.3-0.8 (12) 
0.80, 
0.1-4.5 (1) 
 
(0.47)* 
0.40, 
0.2-0.7 (9) 
0.80, 
0.1-4.6 (1) 
 
(0.39)* 
Weight gain 11.10, 
9.6-12.7 (173) 
14.70, 
8.4-24.4 (11) 
0.93 
(0.34) 
0.90, 
0.6-1.4 (21) 
0 
(0.3.4) 
 
(0.62)* 
Bonferroni adjusted p value < 0.004. * associated with the Fishers exact test  
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12.3 Totalled number of hypothyroid symptoms  
Whilst few individual symptoms exhibited differing prevalence in the subclinical 
hypothyroidism and euthyroid groups, it is possible that subclinical dysfunction manifests 
in a multiple symptom presentation. To enable further exploration of the relationship 
between symptoms and category of thyroid function, the cohort was divided into groups 
in accordance with totalled number of hypothyroid symptoms reported. The proportion of 
each thyroid function group reporting hypothyroid symptoms was plotted against the 
totalled number of symptoms reported. 
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No clear trends between totalled numbers of current hypothyroid symptoms and thyroid 
function group were observed (Figure 12.1).  
 
 
 
Figure 12.1 Totalled current hypothyroid symptoms reported 
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Similarly, no clear relationship between thyroid function category and total number of 
changed hypothyroid symptoms reported was observed (Figure 12.2). 
 
 
 
Figure 12.2 Totalled changed hypothyroid symptoms reported 
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The chi squared test for independence was used to compare the proportions of each 
thyroid function group with respect to the category of total number of hypothyroid 
symptoms reported. No association between thyroid function and category of total 
number of current or changed hypothyroid symptoms was observed (Table 12.4). 
 
Table 12.4 Euthyroid versus subclinical hypothyroidism; comparison of the prevelance of 
multiple hypothyroid symptoms 
Category Current hypothyroid symptoms   Changed hypothyroid symptoms 
 
Totalled 
symptoms  
Euthyroid 
n (%) 
Subclinical 
hypothyroid 
n (% )  
χ
2
  
(p value) 
df = 3 
 
Euthyroid 
n (%) 
Subclinical 
hypothyroid 
n (%)  
χ
2
  
(p value) 
df = 3 
 
None  439  
(16.20) 
18  
(13.00) 
2.19 
(0.54) 
1212 
(44.80) 
62  
(44.90) 
0.22  
(0.98) 
1-2 1362 
(50.40) 
76  
(55.10) 
934  
(34.60) 
49  
(35.50) 
3-4 648  
(24.00) 
29 
 (21.00) 
368  
(13.60) 
17  
(12.30) 
5 or more 254 
(9.40) 
15  
(10.90) 
189 
(7.00) 
10  
(7.20) 
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12.3.1 Totalled number of mild hypothyroid symptoms reported 
Since no clear trends between totalled number of current or changed hypothyroid 
symptoms and thyroid function group were observed, bar charts were not employed to 
further describe data related to intensity of symptoms.  
With respect to hypothyroid symptoms, no significant differences in totalled number of 
current or changed mild intensity symptoms were observed between the euthyroid and 
subclinical hypothyroidism groups (Table 12.5). 
 
 
Table 12.5 Euthyroid versus subclinical hypothyroidism; comparison of the prevelance of 
multiple mild intensity hypothyroid symptoms 
 Current mild intensity symptoms   Changed mild intensity symptoms  
 
Totalled 
symptoms  
Euthyroid 
% (n) 
Subclinical 
hypothyroid 
% (n)  
χ
2
  
(p value) 
df = 3 
 
Euthyroid 
% (n) 
Subclinical 
hypothyroid 
% (n)  
χ
2
  
(p value) 
df = 3 
 
None  17.80  
(481) 
15.20 
 (21) 
1.42 
(0.70) 
45.50 
 (1229) 
44.90 
 (62) 
0.86 
(0.84) 
1-2 
50.20 (1357) 
48.60 
 (67) 
35.50 
 (960) 
37.00 
 (51) 
3-4 25.00 
 (675) 
27.50 
 (38) 
13.00 
 (351) 
10.90 
 (15) 
5 or more 7.00 
 (190) 
8.70 
 (12) 
6.00 
 (163) 
7.20 
 (10) 
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12.3.2 Totalled number of severe hypothyroid symptoms 
The relationship between totalled number of severe intensity hypothyroid symptoms and 
thyroid function group was also examined. No significant differences between thyroid 
function groups were observed with respect to symptoms of severe intensity (Table 
12.6).  
 
Table 12.6 Euthyroid versus subclinical hypothyroidism; comparison of the prevelance of 
multiple severe intensity hypothyroid symptoms 
 Current severe intensity symptoms  Changed severe hypothyroid symptoms 
 
Totalled 
symptoms  
Euthyroid 
% (n) 
Subclinical 
hypothyroid 
% (n)  
 χ
2
  
 (p value) 
df = 1 
 
Euthyroid 
% (n) 
Subclinical 
hypothyroid 
% (n)  
χ
2
 
(p value) 
df = 1 
 
None  79.40 
(2145) 
82.60 
 (114) 0.85 
(0.36) 
93.50 
(2526) 
97.10 
 (134) 2.93 
(0.09) 1-2 20.60 
 (558 ) 
17.40 
 (24) 
6.50 
 (177) 
2.90 
 (4) 
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12.4 Combination of current symptoms suggestive of overt hypothyroidism 
To evaluate the potential clinical importance of combinations of current symptoms, each 
possible pair of symptoms was determined. The purpose of this was two-fold, firstly to 
enable calculation and comparison of prevalence of symptom pairs across the thyroid 
function groups and, secondly, to allow examination of interactions between symptoms.  
 
12.4.1 Combinations of current symptoms suggestive of overt hypothyroidism  
Prevalence of each pair of current symptoms suggestive of overt hypothyroidism was 
compared between the euthyroid and subclinical hypothyroidism groups (Table 12.7-
12.8). At the Bonferroni adjusted alpha level (p<0.0014) no statically significant 
differences were observed between these groups for any of the 66 possible symptom 
pairs. At the more conventional significance level of 5%, however, a significant 
difference between groups existed with respect to the prevalence of two pairs of 
symptoms. The combination of weak muscles with slow thinking was significantly more 
prevalent in the subclinical hypothyroidism group than the euthyroid group (6.5% versus 
2.9% respectively; p<0.036). Additionally dry skin with slow thinking was significantly 
more prevalent in those with subclinical hypothyroidism (7.2% versus 3.7% respectively, 
p<0.038).  
 
.  
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Table 12.7 Euthyroid versus subclinical hypothyroidism; comparison of the prevalence of 66 possible pairs of current 
hypothyroid symptoms  
 Weak muscles 
 %  
n 
Poor memory 
%  
n 
Hoarse voice 
%  
n 
Deep voice 
%  
n 
Dry skin 
%  
n 
Puffy eyes 
%  
n 
 
Euth 
SC 
Hypo 
Euth 
SC 
Hypo 
Euth 
SC 
Hypo 
Euth 
SC 
Hypo 
Euth 
SC 
Hypo 
Euth 
SC 
Hypo 
Lethargy  7.2 
194 
3.6 
5 
3.6 
96 
3.6 
5 
1.9 
51 
2.9 
4 
1.2 
32 
1.4 
2 
7.2 
194 
5.8 
8 
3.0 
81 
1.4 
2 
Weak 
muscles 
  
3.2 
86 
3.6 
5 
1.9 
5.1 
2.2 
3 
1.0 
28 
1.4 
2 
7.4 
200 
8.0 
11 
3.1 
83 
1.4 
2 
Poor 
memory 
    
1.3 
36 
0.7 
1 
0.8 
22 
1.4 
2 
4.4 
118 
4.3 
6 
2.4 
66 
1.4 
2 
Hoarse 
voice 
      
1.4 
38 
2.2 
3 
2.8 
77 
2.2 
3 
1.6 
42 
1.4 
2 
Deep  
voice  
 
        
2.4 
65 
 
0.7 
1 
1.5 
40 
2.9 
4 
Dry  
skin 
          
5.7 
155 
5.8 
8 
Puffy  
eyes 
            
Bonferroni adjusted alpha level of <0.0014 
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Table 12.8 Euthyroid versus subclinical hypothyroidism; comparison of the prevalence of 66 possible pairs of current 
hypothyroid symptoms continued 
 Muscle cramps 
%/n 
 
Constipation 
%/n 
Sensitivity to cold 
%/n 
Slow thinking 
%/n 
 
Weight gain 
  %/n 
 
Euth 
SC 
Hypo 
Euth 
SC 
Hypo 
Euth 
SC 
Hypo 
Euth 
SC 
Hypo 
Euth 
SC 
Hypo 
Lethargy  4.5 
122 
2.9 
4 
3.6 
98 
4.3 
6 
7.3 
198 
6.5 
9 
3.1 
84 
3.6 
5 
9.5 
257 
7.2 
10 
Weak 
muscles 
4.7 
128 
3.6 
5 
3.7 
100 
4.3 
6 
7.0 
190 
8.0 
11 
2.9* 
78 
6.5* 
9 
7.2 
195 
5.8 
8 
Poor memory 2.2 
59 
0.7 
1 
2.6 
70 
4.3 
6 
4.8 
130 
3.6 
5 
4.3 
117 
5.8 
8 
4.5 
121 
3.6 
5 
Hoarse voice 2.0 
55 
1.4 
2 
1.3 
36 
2.9 
4 
2.6 
70 
3.6 
5 
1.3 
35 
0.7 
1 
3.1 
85 
2.2 
3 
Deep voice  
 
1.4 
37 
1.4 
2 
0.7 
20 
2.2 
3 
2.3 
64 
2.2 
3 
0.6 
17 
1.4 
2 
3.8 
104 
5.8 
8 
Dry skin 7.3 
197 
6.5 
9 
5.8 
157 
6.5 
9 
13.8 
373 
18.1 
25 
3.7
#
 
101 
7.2
#
 
10 
16.1 
434 
15.9 
22 
Puffy eyes 3.2 
86 
5.8 
8 
2.2 
60 
4.3 
6 
5.5 
150 
6.5 
9 
1.8 
49 
2.2 
3 
7.2 
194 
8.7 
12 
Muscle 
cramps 
  
3.7 
99 
2.2 
3 
7.0 
189 
8.7 
12 
1.6 
42 
2.9 
4 
8.1 
219 
10.1 
14 
Constipation  
 
    
6.2 
167 
7.4 
10 
2.0 
54 
4.3 
6 
6.2 
167 
7.2 
10 
Sensitivity to 
cold 
      
4.1 
111 
7.2 
10 
15.0 
405 
15.9 
22 
Slow thinking 
 
      
  3.7 
99 
6.5 
9 
Weight gain  
      
    
*Weak muscles with slow thinking p<0.036, #Dry skin with slow thinking p<0.03, Bonferroni adjusted alpha level of <0.0014 
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In terms of interactions between hypothyroid symptoms, a significant interaction 
between the symptoms deep voice and dry skin was observed (p<0.04) (Table 12.9). 
The odds ratio associated with presence of deep voice was 2.44 and statistically 
significant (p<0.01). The OR for presence of dry skin however was 1.22 and not 
satistically significant (p<0.29). The interaction term however, produced an OR 0.11 and 
a negative and statistically significant co-efficient (-2.19, p<0.04). This model therefore 
suggests that subclinical hypothyroidism is 0.11 times less likely in the presence of the 
hypothyroid symptoms deep voice and dry skin than in the presence of either deep voice 
or dry skin alone. Due to the large numbers of interactions tested, it of of course possible 
that this is a spurious finding and does not make clinical sense.  
 
Table 12.9 Euthyroid versus subclinical hypothyroidism; Interactions between 
hypothyroid symptoms 
Variable  Co- efficient p value OR 
Deep Voice (DV) 0.89 <0.01 2.44 
Dry Skin (DS) 0.20 0.29 1.22 
Interaction term DVDS -2.19 0.04 0.11 
Constant -3.08 0.00 0.05 
 
 
 
 
12.5 Summary of the univariate analysis related to hypothyroid symptoms  
Initial exploratory univariate analyses were undertaken to determine the relationship 
between individual symptoms suggestive of overt hypothyroidism and thyroid function 
category and to select variables for inclusion in the multivariate analysis. Due to multiple 
testing, a Bonferroni adjusted alpha level (p<0.004) was applied. At the Bonferroni 
significance level, no differences were observed between the euthyroid and subclinical 
hypothyroidism groups with respect to the prevalence of any of the 12 current or 
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changed individual symptoms suggestive of overt hypothyroidism. Further exploratory 
analysis to determine whether combinations of two symptoms were associated with 
subclinical hypothyroidism or to identify interactions between symptoms also failed to 
demonstrate any differences between the thyroid function groups at the Bonferroni 
adjusted alpha level.  
 
To further enable selection of appropriate symptoms for inclusion in multivariate logistic 
analysis, it was necessary to apply a more conventional statistical significance level.  
At the 5% level, no significant differences between the euthyroid and subclinical 
hypothyroidism groups were observed with respect to prevalence of individual current 
hypothyroid symptoms. A significant difference was, however, observed between the 
euthyroid and subclinical hypothyroidism groups with respect to two combinations of 
symptoms. A significantly greater proportion of the subclinical hypothyroidism group 
reported presence of the combination; weak muscles with slow thinking (6.5% versus 
2.9% respectively; p<0.036) and dry skin with slow thinking (7.2% versus 3.7% 
respectively; p<0.038) compared with the euthyroid group.  
 
A significant interaction between the hypothyroid symptoms deep voice and dry skin was 
also observed (p<0.04). 
 
Comparison of totalled number of symptoms reported by thyroid function groups failed to 
demonstrate any differences between groups with respect to current or changed 
symptoms suggestive of overt hypothyroidism. Likewise, no clear relationship existed 
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between category of thyroid function and total number mild or severe intensity current or 
changed hypothyroid symptoms reported.  
 
Further exploration of combinations of more than two hypothyroid symptoms was not 
performed due to the low frequency of reported pairs of hypothyroid symptoms and 
similarities between euthyroid and subclinical hypothyroidism groups with respect to the 
prevalence of symptom pairs. Similarly, further examination of interactions between 
more than two hypothyroid symptoms was not undertaken because results are difficult to 
interpret and apply in a clinical setting and are therefore of limited clinical utility.  
 
Likewise, additional exploration of changed hypothyroid symptoms with respect to 
prevalence of pairs of symptoms and interactions was not conducted. The main reason 
for not undertaking this analysis again was the low frequency of changed hypothyroid 
symptoms reported. Additionally, since this data relies upon patient recall of the time of 
onset of symptoms within the previous 12 months it is likely to be less convenient, 
accurate and meaningful in a clinical setting than data on current symptoms. 
 
Overall, these findings suggest that no single symptom is associated with subclinical 
hypothyroidism. Two possible combinations of symptoms and a pair of interacting 
symptoms suggestive of overt hypothyroidism may however be important indicators of 
subclinical hypothyroidism (Table 12.10).  
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Table 12.10 Hypothyroid symptoms for the multivariate analysis 
Symptoms suggestion  of overt hypothyroidism 
Significant individual symptoms  None 
Significant combinations of two symptoms 
Weak muscles with slow thinking 
Dry skin with slow thinking 
Significant interaction between symptoms 
Interaction term and composite symptoms 
Deep voice with dry skin  
Deep voice 
Dry skin 
 
 
Binary logistic regression was performed to construct a model to determine which 
symptoms best predict subclinical hypothyroidism. The symptoms listed in table 12.10 
and the additional explanatory variables age, gender, IMD 2004 score, prescription 
medication and medical history were used to construct this model. 
 
12.6 Predictors of subclinical hypothyroidism  
The final subclinical hypothyroidism model was statistically significant (p<0.001) 
indicating an ability to distinguish between groups with euthyroidism and subclinical 
hypothyroidism. The final model correctly predict 95.1% of cases. However, this was 
similar to the baseline model (block 0) which was also able to correctly predict 95.1% of 
cases without consideration of any independent explanatory variables and assuming 
that subclinical hypothyroidism was not present. The final subclinical hypothyroidism 
model was able to explain 20% (Nagelkerke R square) of the variance in the dependent 
variable. Two variables made a unique statistically significant contribution to the final 
model which suggested that not having a history of pulmonary disease and presence of 
the symptom combination weak muscles with slow thinking were associated with 
subclinical hypothyroidism. In terms of the symptom combination weak muscles with 
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slow thinking, those reporting presence of this symptom pair were almost three times as 
likely as those not reporting presence of this symptom combination to have subclinical 
hypothyroidism (OR 2.46; 95% CI 1.20-5.05) (Table 12.11).  
 
 
Table 12.11 Subclinical hypothyroidism model (n=2872) 
Variable 
Co-
efficient 
p-
value 
OR 
Lower 
95 % CI 
for OR 
Upper 95 
% CI for 
OR 
Pulmonary disease -1.37 0.003 0.26 0.10 0.63 
Current weak muscles with slow thinking 0.90 0.014 2.46 1.20 5.05 
Constant  -2.92  
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12.7 Summary of the main findings related to hypothyroid symptoms  
The adjusted (multivariate) analysis demonstrated an association between subclinical 
hypothyroidism and the symptom pair weak muscles with slow thinking. These 
associations however are weak, with the model being able to explain only 20% of the 
variance in the dependent variable. Furthermore, whilst the final logistic regression 
model was able to correctly classify 95% of cases suggesting an ability to distinguish 
between cases of euthyroid subjects and individuals with subclinical hypothyroidism, the 
model was only able correctly classify euthyroid subjects. 
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12.8 Prevalence of hyperthyroid symptoms  
To enable characterisation of symptoms in the subclinical hyperthyroidism and euthyroid 
groups, the prevalence of individual symptoms reported by each group was calculated. The 
chi squared test of independence was used to compare the prevalence of current and 
changed individual hyperthyroid symptoms between the euthyroid and subclinical 
hyperthyroidism groups. A Bonferroni adjusted alpha value of p<0.005 was used to control 
for type I error.   
At the individual symptom level there were no significant differences between the euthyroid 
and subclinical hyperthyroidism groups with respect to any of the nine current symptoms 
suggestive of overt hyperthyroidism.  Likewise, there were no significant differences in the 
prevalence of changed hyperthyroid symptoms reported by these two groups (Table 12.12). 
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Table 12.12 Euthyroid versus subclinical hyperthyroidism; comparison of the prevalence 
of individual hyperthyroid symptoms  
 
Bonferroni adjusted p value <0.005, * associated with the Fishers exact test 
 Current symptoms  Changed symptoms  
Symptom Euthyroid 
%,95% CI  
(n) 
Subclinical 
hyperthyroid 
%,95% CI  
(n) 
χ
2
 (p) 
df =1 
Euthyroid 
%,95% CI (n) 
Subclinical 
hyperthyroid 
%,95% CI  
(n) 
χ
2
 (p) 
df =1 
Excessive 
perspiration 
3.1,2.5-3.8 
(84) 
3.4,0.6-17.2 
(1) 
 
(0.60)* 
2.1,1.6-2.7 
(57) 
6.9,1.9-22.0 
(2) 
 
(060)* 
Trembling hands 4.3,3.6-5.1 
(115) 
3.4,0.6-17.2 
(1) 
 
 
(1.00)* 
4.9,4.2- 5.8 
(133) 
0 
 
(1.00)* 
Frequent 
palpitation 
6.0,5.2-7.0 
(163) 
6.9,1.9-22.0 
(2) 
 
(0.69)* 
4.4,3.7-5.3 
(119) 
10.3,3.6-26.4 
(3) 
 
(0.69)* 
Sensitivity to heat 10.7,9.6-11.9 
(284) 
13.8,5.5-30.4 
(4) 
 
(0.54)* 
1.9,1.5-2.5 
(52) 
6.9,1.9-22.0 
(2) 
 
(0.54)* 
Fast thinking 22.7,21.1-24.3 
(612) 
31.0,17.3-
49.2 (9) 
 
1.14 
(0.27) 
0.5,0.3-0.8 
(13) 
3.4,0.2-17.2 
(1) 
1.14 
(0.29) 
Weight loss 7.4,7.0-9.1 
(200) 
3.4,0.6-17.2 
(1) 
 
(0.72)* 
13.3,12.1-14.7 
(360) 
20.7,9.8-38.4 
(6) 
 
(0.70)* 
Lethargy 16.4,15.0-17.8 
(442) 
10.3,3.6-26.4 
(3) 
 
 
(0.61)* 
18.7,17.3-20.2 
(505) 
17.2,7.6-34.5 
(5) 
 
(0.61)* 
Weak muscles 14.3,13.0-15.7 
(386) 
6.9,1.9-22.0 
(2) 
 
(0.42)* 
16.4,15.0-17.8 
(442) 
13.8,5.5-30.6 
(4) 
 
(0.42)* 
Poor memory 9.7,8.6-10.9 
(262) 
 
0 
 
(0.11)* 
16.5,15.2-18.0 
(446) 
17.2,7.6-34.5 
(5) 
 
(0.11)* 
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12.9 Intensity of hyperthyroid symptoms  
Comparisons between the groups with respect to the reported intensity of current and 
changed hyperthyroid symptoms were also undertaken. Again, Bonferroni adjusted 
alpha values of p<0.005 were used to control for type one error for each comparison 
between the euthyroid and subclinical hyperthyroidism groups. No significant differences 
in the prevalence of mild intensity current or changed hyperthyroid symptoms existed 
between the euthyroid and subclinical hyperthyroidism groups (Table 12.13). 
 
Table 12.13 Euthyroid versus subclinical hyperthyroidism; comparison of the prevalence 
of individual mild intensity hyperthyroid symptoms  
 Current mild intensity symptoms Changed mild intensity symptoms  
Symptom  Euthyroid 
%,95% CI 
(n) 
Subclinical 
hyperthyroid 
%,95% CI 
(n) 
χ
2
 (p) 
df = 1 
 
 
Euthyroid 
%,95% CI 
(n) 
Subclinical 
hyperthyroid 
%,95% CI 
(n) 
χ
2
 (p) 
df = 1 
 
Excessive 
perspiration 
2.6,2.0-3.2 
(69) 
0,0.12.1 
0.74 
(0.39) 
 
2.0,1.5-2.6 
(53) 
6.9,1.9-22.0 
(2) 
3.52 
(0.06) 
Trembling 
hands 
3.2,2.6-3.9 
(85) 
3.4,0.6-17.2 
(1) 
0.007 
(0.94) 
 
4.6,3.8-5.4 
(122) 
0,0-11.7  
(0) 
1.38 
(0.24) 
Frequent 
palpitation  
5.2, 4.4-6.1 
(138) 
3.4,0.6-17.2 
(1) 
0.14 
(0.70) 
4.2,3.5-5.0 
(113) 
10.3,3.6-26.4 
(3) 
2.64 
(0.10) 
Sensitivity to 
heat  
9.8,8.8-11.0 
(259) 
10.7,3.7-27.2 
(3) 
0.24 
(0.88) 
1.6,1.2-2.2  
(43) 
3.4,0.6-17.2  
(1) 
0.67 
(0.41) 
Fast thinking 
21.0,19.5-22.6 
(555) 
28.6,15.3-47.0 
(8) 
0.95 
(0.33) 
0.4,0.2-0.7 
(10) 
3.4, 0.6-17.2 
(1) 
6.75 
(0.01) 
Weight loss 
6.9,6.0-7.9 
(184) 
3.4,0.6-17.2 
(1) 
2.53 
(0.47) 
12.8,11.6-14.1 
(343) 
20.7,9.8-38.4 
(6) 
1.60 
(0.21) 
Lethargy  
13.9,12.2-13.5 
(364) 
10.3,7.1,2.0-22.6 
(2) 
0.55 
(0.30) 
17.0,15.6-18.5 
(449) 
14.3,5.7-31.5 
(4) 
0.15 
(0.70) 
Weak 
muscles 
13.3,12.0-14.5 
(354) 
3.6,0.6-17.7 
(3) 
2.28 
(0.13) 
15.8,14.4-17.2 
(422) 
10.7,3.6-26.4 
(3) 
0.54 
(0.47) 
Poor memory 
9.0,8.0-10.2 
(242) 
0,0-11.7 
(0) 
2.87 
(0.09) 
16.0,14.7-17.5 
(430) 
13.8,5.5-30.6 
(5) 
0.03 
(0.86) 
Bonferroni adjusted p value <0.005  
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The euthyroid and subclinical hyperthyroidism groups were similar with respect to the 
prevalence of severe intensity hyperthyroid symptoms reported (Table 12.14). 
 
Table 12.14 Euthyroid versus subclinical hyperthyroidism; comparison of the prevalence 
of individual severe intensity hyperthyroid symptoms  
 Current severe intensity symptoms Changed severe intensity symptoms  
Symptom  Euthyroid 
%,95% CI 
(n) 
Subclinical 
hyperthyroid 
%,95% CI 
(n) 
χ
2
 (p) 
df = 1 
 
 
Euthyroid 
%,95% CI 
(n) 
Subclinical 
hyperthyroid 
%,95% CI 
(n) 
χ
2
 (p value) 
df = 1 
 
Excessive 
perspiration 
0.6, 0.3-0.9 
(15) 
3.4,0.6-17.2 
(1) 
 
(0.16)* 
0.2,0.1-0.4 
(4) 
0,0-12.1  
(0) 
 
(1.00)* 
Trembling 
hands 
1.1,0.8-1.6 
(30) 
0,0-12.1 (0) 
 
(1.00)* 
0.4,0.2-0.8 
(11) 
0,0-12.1  
(0) 
 
(1.00)* 
Frequent 
palpitation  
1.0,0.7-1.4 
(25) 
3.6,0.6-17.7 
(1) 
 
(0.25)* 
0.2,0.1-0.5 
(6) 
0,0-12.1  
(0) 
 
(1.00)* 
Sensitivity 
to heat  
1.0,0.7-1.5 
(25) 
3.8,0.7-18.9 
(1) 
 
(0.25)* 
0.3,0.2-0.6 
(9) 
3.6,0.6-17.7 
(1) 
 
(0.10)* 
Fast 
thinking 
2.7,2.1-3.4 
(57) 
4.8,0.8-22.7 
(1) 
 
(0.44)* 
0.1,0-0.3 (3) 
0,0-12.1  
(0) 
 
(1.00)* 
Weight loss 0.6,0.4-1.0 
(16) 
0, 0-12.1 (0) 
 
(1.00)* 
0.7,0.5-1.2 
(17) 
0,0-12.1  
(0) 
 
(1.00)* 
Lethargy 3.3,2.7-4.1 
(78) 
3.7,0.7-18.3 
(1) 
 
(0.60)* 
2.5,1.9-3.2 
(56) 
4.0,0.7-19.5 
(1) 
 
(0.47)* 
Weak 
muscles 
1.4,1.0-1.9 
(32) 
3.6,0.6-17.7 
(1) 
 
(0.33)* 
0.9,0.6-1.4 
(20) 
3.8,0.7-18.9 
(1) 
 
(0.21)* 
Poor 
memory 
0.8, 0.5-1.3 
(20) 
0,0-17.0 (0) 
 
(1.00)* 
0.7,0.4-1.1 
(16) 
0,0-12.1  
(0) 
 
(1.00)* 
Bonferroni adjusted pvalue <0.005, * associated with the Fishers exact test  
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Whilst few individual symptoms exhibited different prevalence in the subclinical 
hyperthyroidism and euthyroid groups, it is possible that subclinical hyperthyroidism 
manifests with multiple symptom presentation. To enable further exploration of the 
relationship between symptoms and category of thyroid function, the cohort was divided 
into groups in accordance with totalled number of hyperthyroid symptoms reported. The 
proportion of each thyroid function group reporting hyperthyroid symptoms was plotted 
against the totalled number of symptoms reported. 
 
 
Figure 12.3 Totalled current hyperthyroid symptoms 
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Figure 12.4 Totalled changed hyperthyroid symptoms 
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The chi squared test for independence suggested that there was no association 
between category of thyroid function and totalled number of current or changed 
symptoms suggestive of overt hyperthyroidism (Table 12.15). 
 
 
Table 12.15 Euthyroid versus subclinical hyperthyroidism; comparison of the prevalence 
of multiple hyperthyroid symptoms  
 Current multiple symptoms  Changed multiple symptoms  
Totalled 
number of 
symptoms 
Euthyroid 
% (95% CI) 
Subclinical 
hyperthyroid 
% (95% CI) 
χ
2
 (p) 
df = 3 
Euthyroid 
% (95% CI) 
Subclinical 
hyperthyroid 
% (95% CI) 
χ
2
 (p) 
df = 3 
 
None 1130 
(41.90) 
13 
(44.80) 
1.85 
(0.40) 
1502 
(55.70) 
13 
(46.40) 
1.27 
(0.53) 
1 symptom  914 
(33.90) 
12 
(41.40) 
639 
(23.70) 
9 
(32.10) 
2 or more 656 
(24.30) 
4 
(13.80) 
558 
(20.70) 
6 
(21.40) 
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12.10 Totalled number of mild intensity hyperthyroid symptoms  
The chi squared test for independence was used to compare the proportions of the 
euthyroid and subclinical hyperthyroidism groups with respect to total number of mild 
and severe intensity hyperthyroid symptoms reported. No significant differences in 
totalled number of current or changed mild intensity symptoms suggestive of 
hyperthyroidism existed between the euthyroid and subclinical hyperthyroidism groups 
(Table 12.16).   
 
Table 12.16 Euthyroid versus subclinical hyperthyroidism; comparison of the prevalence 
of multiple mild intensity hyperthyroid symptoms 
 Current mild intensity symptoms  Changed  mild intensity symptoms   
 
Totalled 
number of 
symptoms  
Euthyroid 
% (n) 
Subclinical 
hyperthyroid 
% (n)  
χ
2
 (p) 
df = 1 
 
Euthyroid 
% (n) 
Subclinical 
hyperthyroid 
% (n)  
χ
2
 (p) 
df = 1 
 
None  45.00 
(1215) 
51.70  
(15) 
0.53 
(0.47) 
56.50  
(1528) 
44.80  
(13) 
1.60 
(0.20) 1-2 55.00 
(1487) 
48.30 
(14) 
43.50  
(1175) 
55.20 
 (16) 
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The relationship between total number of severe intensity symptoms and thyroid function 
group was also examined. There were no significant differences observed between the 
euthyroid and subclinical hyperthyroidism groups with respect to prevalence of 
hyperthyroid symptoms of severe intensity (Table 12.17).  
 
Table 12.17 Euthyroid versus subclinical hyperthyroidism; comparison of the prevalence 
of multiple severe intensity hyperthyroid symptoms  
 Current severe intensity symptoms  Severe changed symptoms  
Totalled 
number of 
Symptoms  
Euthyroid 
% (n) 
Subclinical 
hyperthyroid 
% (n)  
Fisher 
exact p 
value 
df = 1 
 
Euthyroid 
% (n) 
Subclinical 
hyperthyroid 
% (n)  
Fisher 
exact (p) 
df = 1 
 
None  
91.2 (2464) 86.2 (25) 
0.321 
95.7(2587) 96.6 (28) 
1.00 
1-2 
8.8 (239) 13.8 (4) 4.3 (116) 3.4 (1) 
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12.11 Combination of current hyperthyroid symptoms  
To evaluate the potential clinical importance of combinations of current hyperthyroid 
symptoms, each possible combination of two symptoms was defined.  
 
12.12 Combinations of current hyperthyroid symptoms  
The prevalence of each pair of symptoms suggestive of overt hyperthyroidism was 
compared between the euthyroid and subclinical hyperthyroidism groups using the Chi 
squared test for independence.   
At a Bonferroni adjusted alpha level of p<0.0014, no significant differences were 
observed between the euthyroid and subclinical hyperthyroidism groups with respect to 
the prevalence of any of the 36 possible pairs of symptoms. 
At a significance level of 5%, however, a significant difference between the euthyroid 
and subclinical hyperthyroidism groups existed with respect to the combination of 
symptoms sensitivity to heat with fast thinking. A significantly greater proportion of 
individuals with subclinical hyperthyroidism than euthyroid reported presence of this 
symptom combination (10.3% versus 2.7% respectively; p<0.045) (Table12.18)  
 
No interactions between symptoms suggestive of hyperthyroidism were identified.  
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Table 12.18 Euthyroid versus subclinical hyperthyroidism; comparison of the prevalence of 36 pairs of current hyperthyroid 
symptoms 
 Trembling 
hands 
%  
n 
Frequent 
palpitations 
% 
n 
Sensitivity 
to heat 
% 
n 
Fast 
thinking 
% 
n 
Weight loss 
% 
n 
Lethargy 
% 
n 
Weak 
muscles 
% 
n 
Poor 
memory 
% 
n 
 
Euth 
SC 
Hyper 
Euth 
SC 
Hyper 
Euth 
SC 
Hyper 
Euth 
SC 
Hyper 
Euth 
SC 
Hyper 
Euth 
SC 
Hyper 
Euth 
SC 
Hyper 
Euth 
SC 
Hyper 
Excessive 
perspiration 
0.1 
4 
0 
0.4 
12 
0 
1.4 
37 
0 
0.8 
22 
0 
0.1 
1 
0 
1.0 
26 
0 
1.0 
27 
0 
0.4 
12 
0 
Trembling  
hands 
  
0.5 
14 
0 
10.5 
284 
4.0 
13.8 
22.6 
612 
31.0 
9 
7.4 
200 
1 
3.4 
16.4 
442 
10.3 
3 
15.1 
408 
13.8 
4 
9.7 
262 
0 
Frequent 
palpitation 
    
0.9 
24 
3.4 
1 
1.2 
33 
3.4 
1 
0.5 
14 
0 
2.1 
57 
3.4 
1 
1.8 
48 
0 
1.0 
27 
0 
Sensitivity to heat       
2.7* 
73 
10.3* 
3 
0.1 
4 
0 
2.1 
58 
3.4 
1 
1.6 
43 
3.4 
1 
0.8 
22 
0 
Fast  
thinking 
        
2.0 
53 
0 
2.8 
75 
3.4 
1 
2.4 
64 
3.4 
1 
0.7 
18 
0 
Weight  
loss 
          
1.3 
36 
0 
1.8 
48 
0 
0.9 
23 
0 
Lethargy             
7.2 
194 
3.4 
1 
3.6 
96 
0 
Weak 
muscles 
              
3.2 
86 
0 
Poor  
memory 
                
* Sensitivity to heat with fast thinking p<0.045 
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Further exploration of combinations of three or more symptoms was not warranted 
because few significant differences in the prevalence of individual symptoms existed 
between the euthyroid and subclinical hyperthyroidism groups. Similarly, further 
examination of changed hyperthyroid symptoms was not undertaken due to the low 
frequency of changed symptoms reported. 
 
12.13 Summary of univariate analysis of hyperthyroid symptoms  
Initially, exploratory univariate analyses were undertaken to determine the 
relationship between individual symptoms suggestive of overt hyperthyroidism and 
thyroid function category and to select variables for inclusion in the multivariate 
analysis. Due to multiple testing, a Bonferroni adjusted alpha level (p<0.005) was 
applied. At this level no significant differences were observed between the euthyroid 
and subclinical hyperthyroidism groups with respect to reported prevalence of any of 
the nine current or changed individual hyperthyroid symptoms. Further exploratory 
analysis to determine whether combinations of two symptoms were associated with 
subclinical hyperthyroidism or to identify interactions between symptoms also failed 
to demonstrate any differences between the thyroid function groups at the Bonferroni 
adjusted alpha level.  
 
To further enable selection of appropriate and potentially important hyperthyroid 
symptoms for inclusion in the multivariate logistic regression analysis it was therefore 
necessary to apply a less conservative and more conventional significance level of 
5%.  
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At the 5% level, no differences between the euthyroid and subclinical hyperthyroid 
groups were observed with respect to the prevalence of individual current 
hyperthyroid symptoms. At a significance level of 5%, however, a significant 
difference between the euthyroid and subclinical hyperthyroidism groups existed with 
respect to the combination of symptoms sensitivity to heat with fast thinking. A 
significantly greater proportion of individuals with subclinical hyperthyroidism than 
euthyroidism reported presence of this symptom combination (10.3% versus 2.7% 
respectively; p<0.045). 
 
Investigation of potential interactions between symptoms suggestive of 
hyperthyroidism failed to demonstrate any significant interactions between pairs of 
symptoms.  
 
Overall, these findings suggest that no single symptom is associated with subclinical 
hyperthyroidism. However, in terms of combinations of symptoms, one possible 
combination of two symptoms suggestive of overt hyperthyroidism may be an 
important indicator of subclinical hyperthyroidism (Table 12.19).  
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Table 12.19 Hyperthyroid symptoms for the multivariate analysis  
Symptoms suggestion of overt hyperthyroidism 
Significant individual symptoms  None 
Significant combinations of two symptoms Sensitivity to heat with fast thinking 
Significant interaction between symptoms None 
 
 
12.14 Predictors of subclinical hyperthyroidism  
Binary logistic regression was performed to construct a model to determine which 
symptoms best predict subclinical hyperthyroidism. The subclinical hyperthyroidism 
model included the symptoms listed in Table 12.19 and the additional explanatory 
variables age, gender, IMD 2004 score, prescription medication and medical history. 
 
The final subclinical hyperthyroidism model was statistically significant, indicating an 
ability to distinguish between euthyroid subject and individuals with subclinical 
hyperthyroidism (p<0.016). Whilst this model was able to correctly classify 99% of 
cases, it failed to demonstrate any improvement upon the baseline model (block 0) 
which was also able to correctly classify 99% of cases without consideration of any of 
the independent explanatory variables and under the assumption that the event of 
interest; subclinical hyperthyroidism was not present (Table 12.20). Furthermore, the 
final subclinical hyperthyroidism model was only able to explain 28% (Nagelkerke R 
square) of the variance. Two variables made a unique statistically significant 
contribution to the model which suggested that age, and the symptom combination 
sensitivity to heat with fast thinking were associated with subclinical hyperthyroidism. 
The model indicated that with each year increase in age subclinical hyperthyroidism 
was 1.08 times more likely than euthyroidism. Furthermore, the final subclinical 
hyperthyroidism model suggested that individuals reporting presence of sensitivity to 
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heat with fast thinking were over four times more likely to have subclinical 
hyperthyroidism than those not reporting presence of this pair of symptoms (OR 4.69; 
95% CI 1.37-16.01).  
 
Table 12.20 Subclinical hyperthyroidism model  
Variable 
Co-
efficient 
p-
value 
OR 
Lower  
95% CI 
for OR 
Upper  
95% CI 
for OR 
Age 0.077 0.032 1.08 1.01 1.16 
Current sensitivity to heat with fast thinking 1.55 0.014 4.69 1.37 16.01 
Constant -10.60  
 
12.15 Summary of multivariate analyses of hyperthyroid symptoms   
At the less stringent significance level of 5%, significant differences between the 
thyroid function groups were observed, therefore enabling selected of potentially 
important symptoms for inclusion in the multivariate analyses.  
 
In terms of symptoms suggestive of overt hyperthyroidism the symptom pair 
sensitivity to heat with fast thinking was significantly more prevalent in the subclinical 
hyperthyroidism group than the euthyroid group (2.7 % versus 10.3% respectively, 
p<0.045). Likewise, the adjusted (multivariate) analysis demonstrated an association 
between subclinical hyperthyroidism and sensitivity to heat with fast thinking.  
However, these associations are weak since the model was not able to explain more 
than 28% of the variance in the dependent variable. Furthermore, whilst the final 
logistic regression models were able to correctly classify over 95% of cases 
suggesting an ability to distinguish between cases of with subclinical hyperthyroidism 
and euthyroid subjects, the model did not correctly classify any of the cases with 
subclinical hyperthyroidism.  
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Summary of chapter 12  
The results of the univariate analysis suggest that there is no association between 
category of thyroid function and individual symptoms or combinations of symptoms 
suggestive of overt thyroid dysfunction.  
To enable selection of individual symptoms and combinations of symptoms for 
inclusion in the multivariate analyses it was necessary to relax the Bonferroni 
adjusted alpha level used to control for type 1 error. At a less stringent significance 
level of 5%, significant differences between the thyroid function groups were 
observed, therefore enabling selection of potentially important symptoms for inclusion 
in the multivariate analyses.  
The results of the univariate and adjusted (multivariate) analysis were consistent and 
demonstrated an association between subclinical hyperthyroidism and sensitivity to 
heat with fast thinking and subclinical hypothyroidism with weak muscles and slow 
thinking. However, these associations were weak and neither model was able to 
explain more than 28% of the variance in the dependent variable. Furthermore, whilst 
the final logistic regression models were able to correctly classify over 95% of cases, 
suggesting an ability to distinguish between euthyroid subjects and individuals with 
subclinical thyroid dysfunction, neither model correctly classified any of the cases 
with subclinical thyroid dysfunction (sensitivity 0, specificity 100%).  
The final subclinical hyperthyroid model suggested that a subject reporting presence 
of sensitivity to heat with fast thinking is 4.5 times more likely to have subclinical 
hyperthyroidism than to have normal euthyroid function. The final subclinical 
hypothyroidism model suggested that an individual reporting presence of weak 
muscles with slow thinking is twice as likely to have subclinical hypothyroidism as 
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normal thyroid function. From a clinical perspective, these findings do not aid GPs in 
distinguishing between an elderly individual who is more likely to have subclinical 
thyroid dysfunction and who would benefit from further investigation of thyroid 
function from an individual less likely to have subclinical disease. The clinical utility of 
these findings is further restricted by the fact that these symptom pairs are not 
exclusive to individuals with subclinical thyroid dysfunction and may also be reported 
by euthyroid subjects. Additionally, the difference in the prevalence of these symptom 
pairs between euthyroid subjects and individuals with subclinical thyroid function, 
although statistically significant, is relatively small and unlikely to be clinically useful 
at the individual patient level. Sensitivity to heat with fast thinking was reported by 
2.7% of the euthyroid group compared with 10.3% of the subclinical hyperthyroidism 
group and weak muscles with slow thinking was reported by 2.9% of the euthyroid 
group and 6.5% of the subclinical hypothyroidism group. Since the Bonferroni 
corrected alpha level was substituted for a more conventional significance level of 
5%, these may be spurious findings and as such should be interpreted with caution.  
An alternative explanation for failure to identify an association between symptoms 
and thyroid function category is that important determinants of subclinical thyroid 
dysfunction have not been measured within the current study. Indeed, it has been 
suggested that the clinical profile of subclinical thyroid dysfunction has changed since 
the advent of more sensitive serum thyrotrophin assays. As such, it is possible that 
thyroid dysfunction is being identified earlier and those symptoms previously 
considered indicative of thyroid abnormalities reflect longer standing thyroid 
dysfunction and are no longer relevant.   
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In this chapter, symptom expression in the thyroid function subgroups was explored 
and described. In the next chapter, symptom expression in incident cases of 
subclinical thyroid dysfunction occurring during the interval period is examined and 
compared with cases of persistent thyroid dysfunction. 
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CHAPTER 13 SYMPTOMS IN THE INCIDENT CASES 
 
Overview of chapter 13  
It is possible that incident cases experience a greater symptom burden than those 
with persistent subclinical thyroid dysfunction who may be more accustomed to 
and/or tolerant of symptoms. This chapter aims to characterise symptoms in 
individuals that developed subclinical thyroid dysfunction during the interval period 
between baseline and follow-up thyroid function screening. Symptom expression in 
subgroups of the study population with incident and persistent thyroid function are 
compared.  
Although not reported in this chapter, for completeness the prevalence of symptoms 
reported by cases with persistent euthyroid and persistent subclinical thyroid 
dysfunction were explored. These data are reported in Appendix 6 and 7.  
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Thyroid function category remained unchanged between baseline follow-up for 
94.6% (n=2715) of the cohort with 91.9% (n=2638) being categorised as having 
persistent euthyroidism and 2.7% with persistent subclinical thyroid dysfunction. 
During the interval period, thyroid function category changed from euthyroid to 
subclinical thyroid dysfunction in 90 (3.1%) individuals (incident cases) and in 65 
individuals (2.3%) thyroid function reverted to euthyroid status from subclinical 
thyroid dysfunction. (Table 13.1) 
 
Table 13.1 Description of longitudinal thyroid function groups 
Group  Type of change between baseline and follow-up  n (%) 
1  Persistent Euthyroidism (PEuth) 2638 (91.9) 
2 Persistent Subclinical Thyroid Dysfunction (PSCTD) 77 (2.7) 
3 Incident Subclinical Thyroid Dysfunction (NSCTD)  90 (3.1) 
4 Reverted to Euthyroidism (RevEuth) 65 (2.3) 
 Total 2870 (100.0) 
 
 
The proportion of the incident and persistent subclinical thyroid dysfunction groups 
reporting presence of each individual symptom was compared using the χ2 test for 
independence or the Fisher‟s exact test where appropriate. Given the fact that 
multiple comparisons were being made between groups, a Bonferroni adjusted alpha 
value of p<0.003 was used to control for type I error. The results are presented in 
Table 13.1-13.2. In the tables, NSCTD is indicative of incident/new cases of 
subclinical thyroid dysfunction and PSCTD relates to persistent cases of subclinical 
thyroid dysfunction. 
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Table 13.2 Incident subclinical thyroid dysfunction versus persistent subclinical 
thyroid dysfunction; comparison of the prevalence of current symptoms  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bonferroni adjusted alpha level p<0.003 *associated with the Fisher Exact test  
 
 
 
Changed symptom  NSCTD 
%,95%CI (n) 
PSCTD 
%,95%CI (n) 
χ
2
 (p) 
df=1 
Excessive perspiration 3.3,1.1-9.3 (3) 3.9, 1.3-10.8 (3) (1.0)* 
Trembling hands 3.4,1.1-9.3 (3) 2.6,0.7-9.0 (2) (1.0)* 
Frequent palpitations 5.6,2.4-12.4 (5) 3.9,1.3-10.8 (3) (0.73)* 
Sensitivity to heat 14.4,8.6-23.2 (13) 9.2,4.5-17.6 (7) 1.07 (0.30) 
Fast thinking 27.8,19.6-37.8 (25) 23.4,15.3-34.0 (18) 0.42 (0.52) 
Weight loss 2.2,0.6-7.7 (2) 5.2,2.0-12.6 (4) (0.42)* 
Lethargy 14.6,8.6-23.2 (13) 6.5,2.8-14.3 (5) 2.81 (0.09) 
Weak muscles 14.4,8.6-23.2 (13) 11.7, 6.3-20.7 (9) 0.28 (0.60) 
Poor memory 8.9,4.6-16.6 (8) 3.9, 1.3-10.8 (3) 1.68 (0.10) 
Hoarse voice 5.5,2.4-12.4 (5) 11.7,6.3-20.7 (9) 1.97 (0.16) 
Deep voice 12.4,7.0-20.6 (11) 6.5,2.8-14.4 (5) 1.63 (0.20) 
Dry skin 35.6,26.4-45.9 (32) 31.2, 21.9-42.2 (24) 0.36 (0.55) 
Puffy eyes 15.6,7.8-21.9 (12) 20.0,15.3-34.0 (18) 0.55 (0.46) 
Muscle cramps 20.0,13.0-29.4 (18) 9.1, 4.5-17.6 (7) 3.88 (0.05) 
Constipation 
 
15.6,9.5-24.4 (14) 11.7,6.3-20.7 (9) 0.52 (0.47) 
Sensitivity to cold 37.8,28.5-48.1 (34) 34.2, 24.4-44.9 (26) 0.23 (0.63) 
Slow thinking 13.3,7.8-21.9 (12) 5.2, 2.0-12.6 (4) 3.17 (0.08) 
Weight gain 54.4,44.2-64.3 (49) 48.1,37.3-59.0 (37) 0.68 (0.41) 
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Table 13.3 Incident subclinical thyroid dysfunction versus persistent subclinical 
thyroid dysfunction; comparison of the prevalence of changed symptoms  
Bonferroni alpha level p <0.003. *associated with the Fisher Exact test  
 
Changed symptom 
NSCTD 
%,95%CI (n) 
PSCTD 
%,95%CI (n) 
χ
2
 (p) 
df=1 
Excessive perspiration 1.1, 0.2-6.0 (1) 2.6,0.7-9.0 (2) (0.59)* 
Trembling hands 3.31.1-9.3 ( 3) 5.2,2.0-12.6 (4) (0.71)* 
Frequent palpitations 7.8,3.8-15.2 (7) 2.5,0.7-9.0 (2) (0.18)* 
Sensitivity to heat 4.4,1.7-10.9 (4) 3.9,1.3-10.8 (3) (1.00)* 
Fast thinking 0,0-4.1 (0) 2.6, 0.7-9.0(2) (0.21)* 
Weight loss 11.1,6.1-19.3 (10) 11.7,6.3-20.7 (9) 0.01 (0.91) 
Lethargy 14.6,8.6-23.2 (13) 18.2,11.2-28.2 (14) 0.39 (0.53) 
Weak muscles 12.4,7.0-20.6 (11) 15.6,9.1-25.3 (12) 0.36 (0.55) 
Poor memory 16.7,10.4-25.7 (15) 15.6,9.1-25.3 (12) 0.36 (0.55) 
Hoarse voice 6.7,3.1-13.8 (6) 9.2,4.5-17.6 (7) 0.37 (0.54) 
Deep voice 0, 0.4.1 (0) 3.9,1.3-10.8 (3) (0.10)* 
Dry skin 10.0,5.4-17.9 (9) 9.2,4.5-17.6 (7) 0.03 (0.86) 
Puffy eyes 7.8, 3.8-15.2 (7) 5.2,2.0-12.6 (4) 0.45 (0.502) 
Muscle cramps 14.4,8.6-23.2 (13) 13.0,7.2-22.3 (10) 0.07 (0.79) 
Constipation 
 
6.7,3.1-13.8 (6) 9.1,4.5-17.6 (7) 0.32 (0.79) 
Sensitivity to cold 13.3,7.8-21.9 (12) 10.4,5.4-19.2 (8) 0.34 (0.56) 
Slow thinking 14.4,8.6-23.2 (13) 10.4,5.4-19.2 (8) 0.62 (0.43) 
Weight gain 24.4,16.7-34.2 (22) 15.6,11.2-28.2 (12) 2.0 (0.16) 
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To enable further exploration of the totalled number of symptoms reported by the 
incident and persistent subclinical thyroid function groups, individuals in each 
subgroup were further categorised in accordance with the total number of symptoms 
reported. The Chi squared test for independence was used to compare the 
proportions in each of the totalled symptom categories between the incident and 
persistent subclinical thyroid dysfunction subgroups. 
 
The incident and persistent subclinical thyroid dysfunction groups were similar with 
respect to the total number of current symptoms suggestive of hypothyroidism. A 
significant difference in total number of changed hypothyroid symptoms was however 
observed with the persistent subclinical thyroid dysfunction group reporting a greater 
prevalence of 1-2 symptoms than the incident subclinical thyroid dysfunction group 
(46.8% versus 27.8% respectively, p<0.036) (Table 13.4).  
 
 
Table 13.4 Incident subclinical thyroid dysfunction versus persistent subclinical 
thyroid dysfunction; comparison of the prevelance of multiple hypothyroid symptoms 
 
 Current hypothyroid symptoms  Changed hypothyroid symptoms 
Totalled 
number of 
symptoms 
NSCTD 
n=90 
PSCTD 
n=77 
χ
2
 (p) 
df = 2 
 
NSCTD 
n=90 
PSCTD 
n=77 
χ
2
 (p) 
df = 2 
 
None 
10 (11.10) 12 (15.60) 
2.68 (0.26) 
43 (47.80) 29 (37.70) 
6.68 (0.04) 
1-2  
49 (54.40) 47 (61.00) 25 (27.80) 36 (46.80) 
3 or more  
31 (34.40) 18 (23.40) 22 (24.40) 12 (15.60) 
  299 
Since only four individuals with persistent subclinical thyroid dysfunction reported 
presence of three or more symptoms, amalgamation of individuals reporting two or 
more symptoms was necessary to enable analysis. No significant difference between 
the thyroid function groups was observed (Table 13.5). 
 
 
Table 13.5 Incident subclinical thyroid dysfunction versus persistent subclinical 
thyroid dysfunction; comparison of the prevalence of multiple hyperthyroid symptoms  
 Current hyperthyroid symptoms  Changed hyperthyroid symptom  
Totalled 
number of 
symptoms 
NSCTD 
n=90 
PSCTD 
n=77 
χ
2
 (p) 
df = 2 
NSCTD 
n=90 
PSCTD 
n=77 
χ
2
 (p) 
df = 2 
 
None 
36 (40.0 38 (49.4) 
2.60 (0.27) 
52 (57.8) 39 (50.6) 
0.85 (0.65) 
1  
36 (40.0) 30 (39.0) 23 (25.6) 23 (29.9) 
2 or more 
18 (20.0) 9 (11.7) 15 (16.7) 15 (19.5) 
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Figures 13.1 - 13.2 Incident subclinical thyroid dysfunction versus persistent subclinical thyroid dysfunction; comparison of the 
prevalence of multiple hypothyroid symptoms  
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Figure 13.3 - 13.4 Incident subclinical thyroid dysfunction versus persistent subclinical thyroid dysfunction; comparison of the 
prevalence of multiple hyperthyroid symptoms  
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Summary of chapter 13 
In this chapter, the prevalence of symptoms reported by individuals with incident 
subclinical thyroid dysfunction was compared with individuals with persistent subclinical 
thyroid dysfunction. No significant differences between the incident and persistent 
subclinical thyroid dysfunction groups existed with respect to the prevalence of 18 
individual current or changed symptoms suggestive of overt hyperthyroidism or 
hypothyroidism. Similarly, no clear relationship between the thyroid function subgroups 
and total number of symptoms was observed.  
 
A significant difference in total number of changed hypothyroid symptoms was observed 
which could warrant further analysis. However, since there were no other significant 
differences observed between the groups with respect to totalled number of changed 
hypothyroid symptoms this finding is likely to be spurious. In general, these results 
corroborate the findings presented in Chapter 12 and, as such, further demonstrate that 
subclinical thyroid dysfunction in this population is not associated with symptoms 
suggestive of overt thyroid dysfunction.  
In conclusion, incident cases of subclinical thyroid dysfunction do not experience a 
greater symptom burden than those with persistent subclinical thyroid dysfunction. 
These findings further demonstrate that the presence of symptoms either alone or in 
combination with previous thyroid function test results are of limited clinical utility and do 
not aid decision making with regard to management of subclinical thyroid dysfunction.  
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This chapter explored and compared prevalence of symptoms in individuals with incident 
subclinical thyroid dysfunction with individuals with persistent subclinical thyroid 
dysfunction. The next chapter explores the relationship between symptoms and serum 
thyrotrophin concentration.  
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CHAPTER 14 SYMPTOMS AND SERUM THYROTROPHIN CONCENTRATION 
Overview of chapter 14  
It is possible that symptoms are manifested at specific concentrations of serum 
thyrotrophin. This chapter will therefore examine the relationship between symptoms 
and serum thyrotrophin concentration.  
Univariate analyses were undertaken to explore the relationship between serum 
thyrotrophin concentration and individual symptoms, combinations of symptoms and 
interactions between symptoms and to enable selection of variables for inclusion in the 
multivariate analyses. In this chapter, the results of the univariate analyses are 
summarised and the findings of the multiple linear regression analysis (forward 
stepwise) performed to establish models for predicting serum thyrotrophin concentration 
are presented and discussed. The full findings of the univariate analyses are presented 
in Appendix 8. 
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14.1 Summary and justification for selection of symptoms  
At the Bonferroni adjusted alpha level, no significant differences in serum thyrotrophin 
concentration were observed between groups with respect to individual symptoms or 
pairs of symptoms. The significance level was therefore relaxed to 5% to enable 
selection of symptoms for inclusion in the multiple linear regression analysis.  
At the 5% significance level, the groups were significantly different with respect to one of 
the 18 individual symptoms and nine of the 98 possible symptom pairs. Four interacting 
pairs of symptoms were also identified. These interaction variables alongside the 
corresponding composite symptoms were selected for inclusion in the multivariate 
analysis (Table 14.1). 
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Table 14.1 Summary and justification for selection of symptoms for inclusion in the TSH 
model 
Type of symptom Symptom/ pair of symptoms 
Symptom 
present
#
 
Symptom 
absent
#
 
Z score* 
p value 
Hyperthyroid pair 
Excessive perspiration with 
trembling hands 
3.13 1.82 
Z-2.010 
p<0.044 
Hyperthyroid pair 
Frequent palpitations with 
sensitivity to heat 
1.38 1.83 
Z-2.370 
p<0.018 
Hyperthyroid pair 
Frequent palpitations with 
weak muscles 
1.45 1.83 
Z-2.067  
p<0.039 
Hypothyroid individual Weight gain 1.89 1.78 
Z-2.906 
p<0.004 
Hypothyroid pair Lethargy with constipation 1.83 1.55 
Z-2.513 
p<0.012 
Hypothyroid pair 
Poor memory with deep 
voice 
1.32 1.83 
Z-2.181 
p<0.029 
Hypothyroid pair Hoarse voice with puffy 
eyes 
1.39 1.82 
Z-1.998 
p<0.046 
Hypothyroid pair Puffy eyes with weight gain 2.00 1.81 
Z-2.070 
p<0.038 
Hypothyroid pair 
Sensitivity to cold with 
weight gain 
1.91 1.81 
Z-2.322 
p< 0.020 
Either hypo or hyper pair Lethargy with poor memory 1.72 1.82 
Z-2.262 
p<0.024 
Type of interaction  Interaction term and p value Interacting symptoms 
Hypothyroid  
Muscle cramps and 
sensitivity to cold p<0.043 
Muscle cramps 
Sensitivity to cold 
Hypothyroid  
Hoarse voice and weight 
gain p<0.012 
Hoarse voice 
Weight gain 
Hypothyroid 
Hoarse voice and 
constipation p<0.002 
Hoarse voice 
Constipation 
Hypothyroid 
Hoarse voice and puffy eyes 
p<0.038 
Hoarse voice 
Puffy eyes 
* associated with the Mann Whitney test, 
#
 median TSH concentration - mIU/L 
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14.3 Multiple linear regression to predict thyrotrophin concentration   
Eight independent variables made a unique and statistically significant contribution to 
the final TSH model. The final model was able to explain only 16% (R Squared) of the 
variance in serum thyrotrophin concentration and indicated that presence of current 
symptoms, weight gain, hoarse voice with constipation and excessive perspiration with 
trembling hands were associated with an increase of 0.167 units, 1.160 units and 1.348 
units in serum thyrotrophin concentration respectively. Furthermore, the model 
suggested age was associated with serum thyrotrophin concentration with each year 
increase being associated with a 0.012 unit increase in serum thyrotrophin 
concentration. Four variables were independently associated with a decrease in serum 
thyrotrophin with history of irregular heart rhythm other than AF being associated with a 
0.292 unit decrease in serum thyrotrophin. The symptom combination of hoarse voice 
with puffy eyes, hoarse voice with weight gain and lethargy with constipation were 
associated with a decrease of 0.448 units, 0.336 units and 0.381 units of serum 
thyrotrophin respectively (Table 14.2)  
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Table 14.2 TSH model - predictors of serum TSH concentration  
Variable Co- 
efficient 
Standard 
error 
t p value 
Constant  1.115 0.420 2.6574 0.008 
Hoarse voice with constipation  1.160 0.258 4.486 0.001 
Hoarse voice with puffy eyes -0.448 0.228 -1.965 0.050 
Weight gain 0.167 0.055 3.048 0.002 
Lethargy with constipation -0.381 1.46 -2.067 0.009 
Age 0.012 0.005 2.308 0.021 
Excessive perspiration with trembling hands 1.348 0.627 2.150 0.032 
Other Irregular heart rhythm  -0.292 0.147 -1.984 0.047 
Hoarse voice with weight gain -0.336 0.171 -1.965 0.049 
Standardised residuals: > ± 2.5 =2%; >± 2.0 = 4% 
 
Exploration of the distribution of the standardised residuals for outliers indicated that 
only 4% of the standardised residuals were more than 2 standard deviations away from 
the mean (i.e. larger than 2.0 and smaller than -2.0). However, more than 1% were 
greater than 2.5 standard deviations away from the mean (> ± 2.5 =2%) suggesting that 
for these cases the model fits rather poorly.  
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Summary of chapter 14 
Only six of the 19 symptoms identified in the univariate analysis contributed to the final 
serum thyrotrophin model. It is possible of course that the findings of the univariate 
analysis were spurious and multiple testing is responsible for inclusion of symptoms in 
the adjusted analysis that are not associated with serum thyrotrophin. 
Multiple linear regression analysis suggested that six symptoms are independently 
associated with serum thyrotrophin concentration. The observed relationships between 
higher serum thyrotrophin concentration and the symptoms hoarse voice with 
constipation and weight gain were consistent with the biochemical profile of overt 
hypothyroidism. Furthermore, these relationships were consistent with the classification 
of these symptoms as those suggestive of hypothyroidism. In contrast, the association 
between excessive perspiration with trembling hands and lower concentrations of serum 
thyrotrophin was not consistent with either the symptom classification or the biochemical 
profile of overt hyperthyroidism. Similarly, the associations between serum thyrotrophin 
concentration and the symptoms hoarse voice with puffy eyes, lethargy with constipation 
and hoarse voice with weight gain did not concur with the biochemical profile or 
symptom classification of overt hypothyroidism. The final TSH model also suggested 
that age and irregular heart rhythm other than AF were independently associated with 
serum thyrotrophin concentration. Age was associated with a higher serum thyrotrophin 
concentration and history of irregular heart rhythm other than AF with lower serum 
thyrotrophin concentration. Whilst a statistically significant association between serum 
thyrotrophin concentration and a number of symptoms has been identified, these 
findings are unlikely to be clinically significant given that presence of symptoms is 
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associated with small (range 0.16-1.34 units) changes in serum thyrotrophin 
concentration. Furthermore, given that most of these results are contradictory and no 
significant differences between the groups were observed after adjustment for multiple 
testing it is likely that all significant findings are spurious.  
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CHAPTER 15 SYMPTOMS AND SERUM THYROXINE CONCENTRATION 
 
Overview of chapter 15 
In the previous chapter, the relationship between symptoms and serum thyrotrophin 
concentration was examined. The analyses did not demonstrate a strong association 
between serum concentration of thyrotrophin and symptom expression. It is possible that 
symptoms are expressed at specific concentrations of serum thyroxine. In the current 
chapter, the relationship between serum thyroxine concentration and symptoms is 
explored. The full results of the univariate analyses are presented in Appendix 9. 
 
15.1 Summary of the univariate analysis and symptoms selection 
Since no significant differences in serum free thyroxine concentration were observed at 
the Bonferroni adjusted alpha level of p<0.0005, relaxation of the significance level to 
5% was necessary to enable symptom selection.  
This resulted in selection of three individual symptoms, 14 symptom pairs and six 
symptom interaction terms with associated composite symptoms for inclusion in the 
multivariate linear regression model (Table 15.1). 
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Table 15.1 Summary and justification for selection of symptoms for inclusion in the FT4 
model 
Type of symptom Symptom/ pair of symptoms  Symptom 
present
#
 
Symptom 
absent
#
  
Z score* p value 
Hyperthyroid  
Weight loss 15.30 14.80 Z-3.778 p<0.001 
Hypothyroid   
Weight gain  14.80 15.00, Z-3.494, p<0.001 
Either  
Lethargy 15.30 14.80 Z-3.906, p<0.001 
Hyperthyroid pair Excessive perspiration with heat 
sensitivity 
14.00 14.90 Z-2.245, p<0.025 
Hyperthyroid pair 
Frequent palpitation with weight loss   16.75 14.90 Z-2.922, p<0.003 
Hyperthyroid pair  
Frequent palpitation with poor memory  15.60 14.90 Z-2.070, p<0.038 
Hyperthyroid pair  
Fast thinking with weight loss   15.60 14.90 Z-2.357, p<0.018 
Hypothyroid pair  
Lethargy with dry skin  15.20 14.80 Z-2.398, p<0.016 
Hypothyroid pair  
Lethargy with sensitivity to cold   15.30 14.90 Z-3.054, p<0.020 
Hypothyroid pair  
Lethargy with muscle cramp 15.50 14.90 Z-3.714, p <0.001 
 Hypothyroid pair 
Lethargy with slow thinking  15.30 14.90 Z-2.248, p <0.025 
Hypothyroid pair 
Dry skin with puffy eyes   14.50 14.90 Z 2.120, p <0.034 
Hypothyroid pair 
Dry skin with constipation  14.60 14.90 Z-3.037, p <0.002 
Hypothyroid pair 
Puffy eyes with weight gain  14.70 14.90 Z-2.025, p<0.043 
Hypothyroid pair 
Constipation with weight gain   14.40 14.90 
Z- 3.307, p< 
0.001 
Either  
Lethargy with weak muscles  15.30 14.90 Z-2.770, p<0.006 
Either  
Lethargy with poor memory 15.30 14.90 Z -2.222, p<0.020 
Interaction type Interaction term Interacting symptoms 
Hypothyroid  
Fast thinking * lethargy, p<0.015 Fast thinking/Lethargy 
Hypothyroid  
Deep voice * muscle cramp, p<0.044 Deep voice/Muscle cramp 
Hypothyroid 
Dry skin * constipation, p <0.017 Dry skin/Constipation 
Hypothyroid 
Lethargy * muscle cramp, p <0.004 Lethargy/Muscle cramp 
Hypothyroid 
Lethargy * weight gain, p <0.038 Lethargy/Weight gain 
Hypothyroid 
Hoarse voice*constipation,p<0.048 Hoarse voice/Constipation 
* associated with the Mann Whitney test, # median FT4 concentration, pmol/l 
  313 
 
15.2 Multiple linear regression to predict free thyroxine  
Twelve independent variables made a unique statistically significant contribution to FT4 
model. This model was able to explain 37% (R Squared) of the variance in free thyroxine 
and indicated that each one unit decrease in IMD score 2004 was associated with an 
increase of 0.008 units in serum FT4. Gender was also associated with serum 
concentration of free thyroxine with female gender being associated with a 0.196 unit 
decrease in free FT4 concentration. The presence of the current symptoms weight loss 
and lethargy were associated with 0.3112 unit and 0.687 unit increases in FT4 
concentration respectively. Similarly, the symptom combinations lethargy with muscle 
cramps and frequent palpitation with weight loss were associated with an increase in 
serum thyroxine concentration of 0.495 units and 1.257 units respectively. Alcohol and 
smoking status were also associated with serum thyroxine concentration with regular 
alcohol intake and current smoking being associated with a decrease in serum FT4 of 
0.219 and 0.382 units respectively (Table 15.2). One individual symptom and three 
symptom pairs were associated with decreased serum FT4 concentration. Presence of 
the symptom weight gain was associated with a 0.165 unit decrease in serum thyroxine 
concentration and presence of the symptom pairs dry skin with constipation, hoarse 
voice with constipation and lethargy with weight gain were associated with a 0.523, 
0.759 and 0.495 unit decrease in serum FT4 concentration respectively. Female gender 
was associated with a 0.196 unit increase in serum FT4 concentration and each unit 
increase in IMD score 2004 was associated with a 0.08 unit decrease in serum FT4 
concentration (Table 15.2). 
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Table 15.2 FT4 model - predictors of serum TF4 concentration 
Variable Co- 
efficient 
Standard 
error 
t p=value 
Constant  15.307 0.163 93.807 0.000 
Lethargy 0.687 0.171 4.015 0.000 
Weight gain -0.165 0.086 -1.911 0.056 
Alcohol 0.219 0.084 2.613 0.009 
Dry skin with constipation -0.523 0.170 -3.078 0.002 
IMD score 2004 -0.08 0.003 -3.166 0.002 
Frequent palpitations with weight loss 1.257 0.565 2.225 0.026 
Gender  -0.196 0.079 -2.479 0.013 
Smoking 0.382 0.163 2.346 0.019 
Hoarse voice with constipation  -0.759 0.340 -2.233 0.026 
Lethargy with muscle cramps 0.495 0.216 2.294 0.022 
Lethargy with weight gain -0.433 0.213 -2.034 0.042 
Weight loss 0.312 0.159 1.968 0.049 
        Standardised residuals: > ± 2.5 =2%; >± 2.0 = 5% 
 
 
 
Exploration of the distribution of the standardised residuals for outliers indicated that 5% 
of cases were more than two standard deviations away from the mean (i.e. larger than 
2.0 and smaller than -2.0 standard deviations). Furthermore, this model was a poor fit for 
more than 1% of the cases (>±2.5 =2%) that were greater than 2.5 standard deviations 
away from the mean (i.e. larger than 2.5 and smaller than -2.5 standard deviations). 
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Summary of chapter 15  
Given that some findings of the univariate analyses are discordant with the biochemical 
profile of overt hypothyroidism or overt hyperthryroidsm and the corresponding symptom 
classification, it is reasonable to suggest that all findings are spurious. Multiple linear 
regression analysis demonstrated that the symptoms weight gain, weight loss, lethargy 
and the symptom pairs lethargy with weight gain, lethargy with muscles cramps, 
frequent palpitations with weight loss, hoarse voice with constipation and dry skin with 
constipation were independently associated with serum free thyroxine concentration. 
Again, however, the relationship between the symptom pair lethargy with muscle cramps 
and lower concentrations of FT4 was discordant with the biochemical profile of overt 
hypothyroidism and the corresponding symptom classification. The most consistent 
finding was the association between serum FT4 concentration and the symptoms 
lethargy and weight change. The association of weight gain with lower concentrations of 
FT4 is consistent with the biochemical profile and symptom classification of overt 
hypothyroidism. Similarly, the association between weight loss and higher serum FT4 
concentration is in agreement with the biochemical definition and symptom classification 
of overt hyperthyroidism. The symptom combination lethargy with weight gain is also 
independently associated with FT4 concentration with presence of weight modifying the 
relationship between lethargy and serum free thyroxine. Whilst statistically significant, 
these findings are unlikely to be clinically relevant due to the presence of symptoms 
being associated with such small (between 0.08 and 1.257 units) changes in serum 
thyroxine concentration.   
  316 
CHAPTER 16 DISCUSSION 
 
16.1 Statement of principal findings from the literature review  
The literature review comprised evidence from a recent systematic review by Biondi et al 
which compiled data published between 1970 and April 200792 supplemented by 
subsequently published articles retrieved from electronic searches. The literature review 
demonstrated that whilst there is a wealth of research related to investigation of the 
pathophysiological consequences of subclinical thyroid dysfunction the findings are 
inconsistent. Furthermore, there is a lack of good quality data to confirm or refute 
expression of symptoms and other pathophysiological consequences associated with 
overt thyroid dysfunction other than AF in community dwelling individuals with subclinical 
thyroid dysfunction.  
 
16.2 Statement of principal findings of the cross-sectional study  
In terms of symptoms, the large cross-sectional survey provides comprehensive data on 
the prevalence of self reported symptoms suggestive of overt thyroid dysfunction and 
perceived health status in an unselected, community dwelling elderly cohort with and 
without subclinical thyroid dysfunction. The results indicate that symptoms suggestive of 
overt thyroid dysfunction are not associated with subclinical hypothyroidism or 
subclinical hyperthyroidism. Additionally, the findings demonstrate that subclinical 
thyroid dysfunction is not associated with impaired health status in this population. As 
expected, perceived health status is independently associated with presence of 
individual symptoms. The current study provides further evidence to demonstrate that 
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subclinical hypothyroidism and subclinical hyperthyroidism are not clinically relevant or 
important in this population in terms of symptom burden, and as such, routine screening 
and/or treatment of subclinical thyroid dysfunction is not justified in this population.  
 
16.3 Discussion of the results of the literature review  
In general, the literature review contributed little additional, robust and generalisable 
data to further substantiate or significantly alter the conclusions made by Biondi et al. 91 
Subsequent data do nevertheless, provide good evidence to refute an association 
between subclinical hypothyroidism and increased risk of coronary heart disease, heart 
failure or cardiovascular mortality. 138,139 With respect to subclinical hyperthyroidism, 
subsequent data corroborate the findings of Biondi et al and provide good evidence for 
an increased risk of AF in older individuals with severe subclinical hyperthyroidism 
characterised by serum thyrotrophin concentrations of less than 0.1mIU/L. 151 However, 
risk estimates for AF in subclinical hyperthyroidism are still to be established. Whether 
treatment for subclinical thyroid dysfunction is more beneficial or preferential than 
treatment for AF likewise requires further investigation. There is also consistent data to 
support the hypothesis that reduced bone mineral density can be induced by 
endogenous subclinical hyperthyroidism, 5,167,168 although these data require 
confirmation in larger, population based studies.  
In terms of symptoms, the literature review identified evidence suggesting that 
individuals with subclinical thyroid dysfunction experience symptoms suggestive of overt 
thyroid dysfunction. 24,37,171 However, these data are derived from small studies of 
patient populations and findings have not been corroborated in larger, population based 
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cohorts. On the whole, few studies evaluate symptoms and findings related to symptom 
prevalence are limited by small sample sizes, different outcome measures and 
heterogeneity of populations studied. Furthermore, in studies where physical 
examination was required for evaluation of signs and symptoms, the examiners were not 
always blind to the subjects‟ thyroid function status meaning that observer bias cannot 
be entirely ruled out. With respect to perceived health status, data are again generally 
derived from small studies within highly selected populations and therefore data are not 
widely generalisable. An additional methodological issue with these studies is that 
participants are often aware of their thyroid function category, meaning that results may 
be subject to response bias. 
With respect to perceived health status, whilst data derived from smaller studies 
demonstrate impaired mental and physical health status in individuals with subclinical 
thyroid dysfunction, these findings are limited by the cross-sectional design meaning 
that cause and effect can not be established. Few studies investigate both symptom 
expression and perceived health status in relation to subclinical thyroid dysfunction 
therefore it is difficult to comment upon whether symptoms or thyroid dysfunction are 
responsible for impaired health status. 15,176,188 
 Multiple reasons for the inconsistencies in study findings have been proposed. In 
general, studies differ with respect to the assays used to measure serum thyrotrophin 
concentration and the reference criteria against which subclinical thyroid dysfunction is 
defined. 91 Other possible explanations for the discrepancies in study findings are 
differences in inclusion/exclusion criteria employed with regard to individuals with known 
thyroid disease. Furthermore, heterogeneity of underlying cause and duration of 
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subclinical hypothyroidism may lead to disparate findings. Similarly, differential definition 
of outcome measures and identification of and adjustment for confounders may 
contribute to the conflicting results.  
 
16.4 Discussion of results of the cross-sectional study  
 
16.4.1 Representativeness 
Compared with the general population of England and Wales and the West Midlands, 
the study cohort had a larger proportion of 75-84 year olds and a higher prevalence of 
AF and hypertension. 205, 207 These disparities are however likely to be artefacts of the 
study methodology since the inclusion criteria for the original cohort established in 2002 
stipulated 65 years of age and above. Similarly, screening for AF and hypertension in 
the original study may be responsible for a higher prevalence of these conditions in the 
study cohort compared with the general populations of the West Midlands and 
England.205 
In addition, the cohort was dissimilar to these populations in terms deprivation score, 
being more deprived than the general population of England and Wales and less 
deprived than the population of the West Midlands. Given that this thesis aimed to 
explore the association between thyroid function category and symptom expression at 
the individual patient level, these dissimilarities are unlikely to impact upon the validity of 
primary findings. As such, there is no foreseeable reason why these findings should not 
be extrapolated to other similarly aged populations. Iodine status of the population is 
often cited as a reason for caution with respect to extrapolation of findings to other 
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populations. 169 The current study was conducted in an iodine sufficient area however 
with respect to symptoms this is unlikely to be of significant clinical note. 
 
16.4.2 Symptoms in the thyroid function groups 
The euthyroid and subclinical hypothyroidism groups were similar with respect to 
gender, socioeconomic status, lifestyle characteristics, prescription medication and 
physical and mental health status. A greater proportion of the euthyroid group self 
reported regular alcohol intake and had a history of pulmonary disease compared with 
the subclinical hypothyroidism group. This finding is potentially spurious due to the fact 
that multiple testing was conducted, although the use of a Bonferroni corrected alpha 
level was designed to minimise the effects of multiple statistical testing. The groups with 
subclinical hypothyroidism and subclinical hyperthyroidism were significantly older than 
the euthyroid group. As expected, symptoms suggestive of overt thyroid dysfunction 
were relatively prevalent in this elderly cohort. In agreement with other community based 
studies evaluating symptoms, the results of the univariate analysis suggest that there is 
no association between subclinical thyroid dysfunction and any individual symptom or 
total number of symptoms suggestive of overt thyroid dysfunction in an elderly 
community dwelling population. 179, 189  In agreement with other studies, the hyperthyroid 
symtoms excessive perspiration, palpitation, sensitivity to heat 171,184 and the 
hypothyroid symptoms hoarse voice, dry skin and weight gain were more prevalent in 
individuals with subclinical thyroid dysfunction than in euthryoid subjects. 24,37  In the 
current study however these differences failed to reach statistical significance.  
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In terms of combinations of symptoms, at the conventional significance level of 5%, an 
association between subclinical hyperthyroidism and presence of sensitivity to heat with 
fast thinking was noted. Similarly, an association between subclinical hypothyroidism 
and weak muscles with slow thinking and dry skin with slow thinking was observed. 
Although a statistically significant difference in the prevalence of these symptom pairs 
existed between the euthyroid and subclinical thyroid function groups, the differences 
were small and therefore unlikely to be clinically useful at the individual patient level. 
Sensitivity to heat with fast thinking was reported by 2.7% of the euthyroid group 
compared with 10.3% of the subclinical hyperthyroidism group. Weak muscles with slow 
thinking were reported by 2.9% of the euthyroidism group and 6.5% of the subclinical 
hypothyroidism group. Additionally, these findings are likely to be spurious and as such 
should be interpreted with caution.  
The results of the univariate and adjusted (multivariate) analyses were consistent with 
respect to the association between subclinical hyperthyroidism and sensitivity to heat 
with fast thinking, and, similarly, with respect to the association between subclinical 
hypothyroidism and presence of weak muscles with slow thinking. The association 
between subclinical hypothyroidism and dry skin with slow thinking however did not 
remain in the adjusted analysis. The findings further suggest that subclinical 
hyperthyroidism is 4.5 times more likely in an elderly individual presenting with sensitivity 
to heat and fast thinking than in an elderly individual without these symptoms. Likewise 
the odds of an elderly individual having subclinical hypothyroidism increases two-fold if 
the patient presents with weak muscles and slow thinking. Again however, the clinical 
utility and diagnostic value of these observations at the individual patient level is limited.  
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Furthermore, these associations were weak with neither logistic regression model being 
able to explain more than 28% of the variance in the dependent variables. Additionally, 
whilst both models had a specificity of 100% and were able to correctly classify all 
euthyroid cases (true negatives), neither model was able to correctly classify any cases 
of subclinical hyperthyroidism or subclinical hypothyroidism (true positives). These 
findings support previous observations in community based populations 182,189 and in 
older individuals 179 and further demonstrate that symptoms are poor predictors of 
subclinical thyroid dysfunction in an elderly population.  
The availability of historical data provided an opportunity for further subgroup analysis 
and allowed exploration of symptom expression in new cases of subclinical thyroid 
dysfunction compared with persistent cases of subclinical thyroid dysfunction. The 
results demonstrated a similar symptom burden in individuals with incident subclinical 
thyroid dysfunction compared with individuals with persistent subclinical thyroid 
dysfunction. These findings further demonstrate that the presence of symptoms either 
alone or in combination with a previous thyroid function test results are of limited clinical 
utility and do not aid decision making with regard to management of subclinical thyroid 
dysfunction. These data are however limited because the date of onset of subclinical 
thryoid dysfunction is unknown and may have occurred at any point during the five year 
interval period.  
 
16.4.3 Perceived health status and symptoms  
Perceived health status was examined with respect to presence and absence of 
individual symptoms and in relation to category of thyroid function. Physical and mental 
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component summary scores were explored at an individual symptom level in order to 
identify those symptoms with the greatest impact upon health status. The results 
demonstrate a statistically significant difference between groups reporting presence and 
absence of the majority of current and changed individual symptoms with respect to both 
physical and mental component summary scores. Furthermore, in accordance with 
another community based study, the current study observed a decrease in median 
physical and mental component summary score as the total number of reported current 
or changed symptoms increased. 180 The group reporting the highest total number of 
symptoms described significantly lower levels of physical and mental health compared 
with the groups reporting fewer symptoms. Furthermore, similar levels of mental and 
physical health were described by the euthryoid and subclinical hypothyroidism and 
subclinical hyperthyroidism groups. The findings of the current study therefore do not 
support an association between subclinial thyroid dysfunction and impaired health 
status. 24, 181 In contrast, the current study findings suggest that reduced health status is 
independently associated with the presence of symptoms suggestive of overt thyroid 
dysfunction.  
 
16.4.4 Symptoms and biochemical parameters of thyroid function 
Multiple linear regression analysis demonstrated an association between serum TSH 
and weight gain and also the symptom pair hoarse voice with constipation. Both were 
associated with higher serum TSH which is consistent with the biochemical profile and 
symptom classification of overt hypothyroidism. Serum TSH was also associated with 
hoarse voice with puffy eyes, lethargy with constipation and hoarse voice with weight 
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gain. However, these associations were not consistent with the biochemical profile or 
symptom classification of overt hypothyroidism. Similarly, presence of the symptom 
combination excessive perspiration with trembling hands was associated with higher 
serum TSH which is contrary to the biochemical profile and symptom classification of 
overt hyperthyroidism. Given that many findings are contradictory it is reasonable to 
suggest that all findings are spurious. 
In agreement with other studies, multiple linear regression analysis also demonstrated 
an association between higher serum thyrotrophin concentrations and advancing age 
and lower serum thyrotrophin levels and irregular heart rhythm other than AF. 151 Serum 
TF4 concentration was associated with five symptom combinations, three individual 
symptoms, smoking and alcohol status, gender and deprivation score. The relationship 
between higher FT4 concentration and weight loss and frequent palpitation with weight 
loss was consistent with the biochemical profile and symptom classification of overt 
hyperthyroidism. Equally, the association between lower serum TF4 concentration and 
the symptoms weight gain, hoarse voice with constipation and dry skin with constipation 
was in agreement with the symptom classification of overt hypothyroidism. Lethargy and 
lethargy with muscle cramps which are symptoms that have been observed in both overt 
hyperthyroidism and in overt hypothyroidism were associated with higher FT4 
concentration whereas lethargy with weight gain was associated with lower FT4 
concentration. This suggests that presence of weight gain modifies the relationship 
between lethargy and FT4 concentration. A higher FT4 concentration was associated 
with being of female gender and less affluent. Smoking and regularly consuming alcohol 
was associated with lower FT4 concentrations. These associations were weak though, 
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with neither the TSH or FT4 regression model explaining more than 37% of the variance. 
It is possible of course, that important determinants of serum TSH and FT4 were not 
assessed in the current study. The most consistent finding was the association between 
serum FT4 and the symptoms lethargy and weight change. With respect to the 
relationship between serum TSH and symptoms suggestive of overt thyroid dysfunction 
the results were less consistent. Although statistically significant differences in the 
distribution of serum FT4 and TSH concentration were observed, the differences were 
small and are unlikely to be clinically meaningful. These data further support the earlier 
results demonstrating that symptoms are not associated with subclinical hyperthyroidism 
or subclinical hypothyroidism.  
  326 
16.5 Comparison with other published works 
Several investigators support the use of multiple symptoms or symptom scores as 
diagnostic aids for the identification of individuals in whom subsequent testing would be 
most appropriate. 37,38,39 Symptom scores were not investigated in the current study 
because the prevalance of more than two symptoms was low and no clear relationship 
existed between category of thyroid function and total number of current or changed 
symptoms suggestive of overt thyroid dysfunction reported. Furthermore, derivation of a 
symptom score often requires allocation of arbitrary values to individual symptoms and 
is frequently difficult to calculate and interpret. Symptom scores are therefore of limited 
clinical utility and are unlikely to be convenient or feasible in the primary care setting. 
Community based studies generally have failed to demonstrate differences between 
thyroid function groups with respect to total number of symptoms. 180 One exception to 
this is the Colorado symptoms study in which individuals with subclinical hypothyroidism 
reported a significantly higher mean percentage of symptoms compared with euthyroid 
individuals. 56 The possible explanations for these disparate findings include the 
heterogeneity in the populations studied in terms of age, study inclusion criteria, assays 
and reference criteria for definition of serum TSH. The possibility that concomitant 
medication was responsible for the presence of symptoms could also cannot be entirely 
ruled out because data related to medication use in this population was not recorded or 
controlled for in the analysis.  
Few previous studies of symptoms or perceived health status have been conducted in 
community based populations. 180,189 The majority of studies demonstrating an 
association between subclinical thyroid dysfunction and symptoms or impaired health 
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status have been conducted in the hospital setting. In the outpatient environment, 
symptoms and impaired health status are likely to be more frequently observed than in 
non health seeking community dwelling populations and are likely to be affected by 
reporting times.  
Differences in perceived health status between thyroid function groups have been 
previously demonstrated. However, in general, the participants have been aware of their 
thyroid function category at the time of questionnaire completion. 176 It is possible that 
medicalisation or labelling of abnormal biochemical profiles as subclinical thyroid 
dysfunction is responsible for impaired health status in these individuals. A key feature 
of the current study is that all participants were blind to their thyroid function 
categorisation at the time of completion of the symptom and health status 
questionnaires. In accordance with Bell et al, the current study failed to demonstrate any 
differences in perceived health status between thyroid function groups, thereby 
demonstrating that subclinical thyroid function is not associated with impaired health 
status. 180 
Two investigators have explored the relationship between thyroid function category and 
symptoms and thyroid function category and perceived health status. 24,176 However, 
only one additionally evaluated the relationship between perceived health status and 
presentation of symptoms. Similar to the findings of the current study, the investigators 
suggested that deterioration in perceived health status was associated with the 
presence of symptoms. In contrast to the current study, however, this relationship was 
not independent of category of thyroid function.  
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16.6 Strengths  
The strengths of this research are the large number of unselected elderly individuals 
studied and the simultaneous and detailed evaluation of thyroid function, self reported 
symptoms and perceived health status, concomitant disease, medical history and 
lifestyle characteristics. Additionally, current data is not subject to response bias 
because all participants were unaware of their thyroid function status at the point of 
completion of the symptoms and health status questionnaire. Another strength of this 
study is that all participants self completed the study questionnaire therefore researcher 
bias can be entirely ruled out. 
 
16.7 Weaknesses and study limitations  
An alternative explanation for not identifying an association between symptoms and 
thyroid function category is that important determinants of subclinical thyroid dysfunction 
have not been measured within the current study. Indeed, it has been suggested that 
the clinical profile of subclinical thyroid dysfunction has changed since the advent of 
more sensitive serum thyrotrophin and free thyroxine assays. As such, it is possible that 
thyroid dysfunction is being identified earlier and those symptoms previously considered 
indicative of thyroid abnormalities reflect longer standing thyroid dysfunction and are no 
longer relevant. Equally, since the final logistic regression models only explained 
between 20-28% of the variance it is possible that important determinants of thyroid 
dysfunction were not measured in the current study. Evidence based development of the 
symptoms questionnaire was employed to ensure that the most relevant and sensitive 
symptoms were selected and included. It is therefore unlikely that known determinants 
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were not measured. It is of course possible that there is no “one size fits all” with respect 
to presentation of symptoms in subclinical thyroid dysfunction. Expression of symptoms 
may be unique to the individual based upon sensitivity to alterations in thyroid 
parameters outside of the reference range and the duration of subclinical thyroid 
dysfunction. Investigation of the prevalence of 18 individual symptoms reflecting a 
variety of metabolic processes involving a range of organ systems nevertheless failed to 
establish an association between subclinical thyroid dysfunction and any symptoms that 
the literature suggests indicate overt thyroid dysfunction. 
Cross-sectional study designs that categorise thyroid function based upon measurement 
at one point in time face the possibility of detecting a transient abnormality in 
thyrotrophin concentration due to a non thyroidal illness. Thus, it is conceivable that 
individuals with transient changes in serum thyrotrophin were misclassified as having 
subclinical thyroid dysfunction. Due to the large sample size, however, misclassification 
of thyroid function category is unlikely to be of significance in this study. Furthermore, 
the prevalence of subclinical thyroid dysfunction was similar to that observed in similar 
community dwelling elderly populations in iodine sufficient areas. The thyroid function 
groups were similar with respect to prevalence of prescription medication and medical 
history with the exception of pulmonary disease which was significantly greater in the 
euthyroid group than the subclinical hyperthyroidism group. The adjusted analysis 
however controlled for these potential confounders. Similarly, due to the cross-sectional 
nature of this study, the impact of duration of subclinical thyroid dysfunction on 
expression of symptoms is unknown and is another limitation of this study. It is possible 
that incident cases experience a greater symptom burden than those with persistent 
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subclinical thyroid dysfunction who may be more accustomed to and/or tolerant of 
symptoms. In the current study, exploration of symptom expression in individuals that 
developed subclinical thyroid dysfunction (incident cases) during the interval period was 
possible due to the availability of historical thyroid function test results. The results 
demonstrated a similar symptom burden in individuals with incident subclinical thyroid 
dysfunction compared with individuals with persistent subclinical thyroid dysfunction.  
Furthermore, data related to symptoms were self reported and therefore it is not possible 
to entirely rule out acquiescence and social desirability bias. This of course is inevitable 
due to the subjective nature of the outcome measures. Participants did however self 
complete the study questionnaires at home before attending the research clinic 
therefore their answers were not influenced by the research nurse. Additionally, in an 
attempt to reduce bias, the position of symptom suggestive of thyroid dysfunction was 
varied through out the symptom questionnaire. However, since the original format of the 
Colorado survey was maintained, the neutral option remained in a central position for 
each questionnaire item. Participants‟ responses were not influenced by category of 
thyroid function since they were unaware of thyroid function categorisation at the time of 
questionnaire completion. Furthermore, the analysis predominantly focused upon 
current symptoms as this data is likely to be more accurately reported than data related 
to symptoms that have changed during the previous 12 months.  
A final limitation of the study is the relatively small number of individuals identified with 
subclinical hyperthyroidism (n=29). This is an artefact of the low prevalence of 
subclinical hyperthyroidism in the general population. Due to the large sample of 
euthyroid individuals included in the univariate analysis, all outcomes related to 
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subclinical hyperthyroidism have large confidence intervals. The precise nature of the 
outcomes related to the euthyroid subjects (due to the large sample size) in the same 
way offsets this. The estimates of the logistic regression analysis should be interpreted 
more cautiously since these are based upon 29 cases and 25 predictor variables and 
generally at least 10 times as many cases as predictor variables are recommended for 
stable and reproducible results.  
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CHAPTER 17 CONCLUSIONS 
This thesis aimed to characterise symptoms and further clarify the pathophysiological 
consequences of subclinical thyroid dysfunction in community dwelling individuals aged 
65 years of more. In fulfilment of the aim of this thesis there were four objectives. This 
chapter will demonstrate how each of these objectives has been met. 
 
The first objective of this thesis was: 
To further clarify the pathophysiological consequences of subclinical thyroid 
dysfunction in community dwelling individuals aged 65 years of more. 
In fulfilment of this objective, a systematic literature review was undertaken. The findings 
of the review of existing evidence pertaining to the pathophysiological consequences of 
subclinical hypothyroidism and subclinical hyperthyroidism are presented in chapters 3 
and 4 respectively. Current evidence related to expression of symptoms in individuals 
with subclinical hypothyroidism and subclinical hyperthyroidism is reported in chapters 5 
and 6 respectively. 
 
The second objective of the thesis was: 
To determine the relationship between symptoms and subclinical thyroid 
dysfunction in an elderly community dwelling population.  
This objective was successfully completed by means of a cross-sectional survey 
designed to evaluate biochemical parameters of thyroid function (enabling classification 
of thyroid function) and self reported symptoms suggestive of overt thyroid dysfunction in 
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a large elderly, community dwelling cohort. The methodology for this survey is detailed 
in chapter 8 and the results in chapters 9-12.  
 
The third objective of the thesis was: 
To establish the impact of symptoms and the effect of subclinical thyroid 
dysfunction upon perceived health status in this population.  
This objective was also met by means of the cross-sectional survey which allowed 
collection of data related to perceived health status alongside data relating to symptoms. 
The full methodology is described in chapter 8 and the results are presented in chapters 
10-11.  
 
The final objective of this thesis was:  
To explore the relationship between symptoms and serum concentration of 
serum thyrotrophin and free thyroxine in this population.  
To address this objective, it was necessary to compare the distribution of the 
biochemical thyroid function parameters, serum thyrotrophin and free thyroxine in 
individuals reporting presence of symptoms with subjects reporting absence of 
symptoms. The methodology for this is detailed in chapter 8 and the results are 
presented in chapters 14 and 15 respectively. 
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17.1 Summary of the main findings of the thesis  
This thesis examined a large body of research related to the pathophysiological 
consequences of subclinical thyroid dysfunction and demonstrated that there is a lack of 
robust data to confirm or refute that subclinical thyroid dysfunction is associated with 
similar adverse pathophysiological consequences or physical signs and symptoms to 
overt thyroid dysfunction. The findings of the cross-sectional study provide further 
evidence to suggest that subclinical thyroid dysfunction is not clinically relevant or 
important in elderly individuals in terms of impaired health status and symptom burden. 
Although symptoms suggestive of overt thyroid dysfunction were relatively prevalent in 
this elderly cohort and statistically significant differences in the prevalence of symptoms 
and in the distribution of serum thyrotrophin and thyroxine were observed, these 
differences were small and unlikely to be clinically meaningful at the individual patient 
level.  The clinical utility of these observations is therefore limited and does not aid 
clinical decision making with regard to management of subclinical thyroid dysfunction in 
elderly individuals. Whilst this study suggests that elderly individuals with and without 
subclinical thyroid dysfunction have symptoms traditionally associated with overt thyroid 
dysfunction, the question as to whether these symptoms maybe reversible with 
treatment for thyroid dysfunction remains unanswered. Since symptoms are likely to be 
a consequence of „healthy‟ ageing however, interventions which aim to restore euthyroid 
function are unlikely to resolve symptoms or greatly impact health status. Other non 
thyroidal causes and/or solutions should be sought to help improve general health 
status. 
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17.2 Recommendations  
Based upon the findings of the literature review and cross-sectional study, repeated 
thyroid function testing and/or intervention in elderly individuals on the basis of 
symptoms suggestive of overt thyroid dysfunction alone can not be justified. Caution is 
therefore recommended when requesting repeat thyroid function tests or initiating 
treatment for an elderly individual based upon only the presence of symptoms 
suggestive of overt thyroid dysfunction.  
 
17.3 Further work  
The results of this study further challenge the traditional picture of thyroid dysfunction in 
older individuals. To confirm or refute the pathophysiology and profile of symptoms 
associated with overt and subclinical thyroid dysfunction in this population; further 
population based, longitudinal work, employing repeated measures of thyroid function 
and symptoms over an extended follow-up period (i.e middle to older age) are required. 
Then depending upon the outcome of the longitudinal work, a randomised controlled trial 
of treatment in subclinical thyroid dysfunction may be required to further clarify the 
benefits of treatment and aid clinical decision making with respect to primary care 
management of subclinical thyroid dysfunction.  
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Appendix 1 Electronic search strategies 
 
No: Search limits  
1 Humans 
2 Adult 19-44 years 
3 Middle aged 45-64 years  
4 Middle aged 
+aged:45+years  
5 Aged: 65+years 
6 80+over: 80+ years 
 
No: Individual search terms MeSH term 
1 Subclinical hypothyroidism Subclinical- all fields, hypothyroidism- MeSH  
2 Atrial fibrillation Atrial fibrillation   
3 Cardiovascular risk Cardiovascular and risk  
4 Cardiovascular disease Cardiovascular diseases 
5 Cardiac status Heart  
6 Cardiac function Heart and physiology (Subheading) 
7 Cardiac morphology Heart (anatomy and histology-Subheading) 
8 Bone fracture Fractures, bone 
9 Bone Bone and bones 
10 Osteoporosis Osteoporosis 
11 Cognitive function Physiology( cognitive - all fields) 
12 Dementia Dementia 
13 Anxiety Anxiety  
14 Neuropsychiatric All fields  
15 Neuromuscular All fields 
16 Adverse consequences All fields  
17 Clinical manifestation All fields  
18 Clinical importance All fields  
19 Progression  
20 Symptoms  
21 Quality of life  
22 Health status  
23 1&2  
24 1&3  
25 1&4  
26 1&5  
27 1&6  
28 1&7  
29 1&8  
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30 1&9  
31 1&10  
32 1&11  
33 1&12  
34 1&13  
35 1&14  
36 1&15  
37 1&16  
38 1&17  
39 1&18  
40 1&19  
41 1&20  
42 1&21  
43 1&22  
44 Subclinical hyperthyroidism Subclinical – all fields, hyperthyroidism - MeSH 
45 44&1  
46  44&2  
47 44&3  
48 44&4  
49 44&5  
50 44&6  
51 44&7  
52 44&8  
53 44&9  
54 44&10  
55 44&11  
56 44&12  
57 44&13  
58 44&14  
59 44&15  
60 44&16  
61 44&17  
62 44&18  
63 44&19  
64 44&20  
65 44&21  
66 44&22  
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Fair 
 
Appendix 2 SF-8 Health Survey 
 
This survey asks for your views about your health. This information will help you to keep track of how you 
feel and how well you are able to do your usual activities.  
Answer every question by selecting the answer as indicated. If you are unsure about how to 
answer a question, please give the best answer you can. For each of the following questions, 
please circle the option which best describes your answer, for example 
 
 
Q1. Overall, how would you rate your health during the past 4 weeks? 
Excellent Very good Good Fair Poor Very poor 
Q2. During the past 4 weeks, how much did physical health problems limit your usual physical 
activities (such as walking or climbing the stairs)? 
Not at all Very little Somewhat Quite a lot 
Could not do 
physical 
activities 
Q3. During the past 4 weeks, how much difficulty did you have doing your daily work, both at home 
and away from home, because of your physical health? 
Not at all A little bit Some Quite a lot 
Could not do 
daily work 
Q4. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild  Moderate Severe Very severe 
Q5. During the past 4 weeks, how much energy did you have? 
Very much Quite a lot Some A little None 
Q6. During the past 4 weeks, how much did your physical health or emotional problems limit your 
usual social activities with family and friends? 
Not at all Very little Somewhat Quite a lot 
Could not do social 
activities 
Q7. During the past 4 weeks, how much have you been bothered by emotional problems (such as 
feeling anxious, depressed or irritable)? 
Not at all Slightly Moderately Quite a lot Extremely 
Q8. During the past 4 weeks, how much did personal or emotional problems keep you from doing 
your usual work or other daily activities? 
Not at all Very little Somewhat Quite a lot 
Could not do daily 
activities 
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Appendix.3 Symptoms questionnaire 
This questionnaire is designed to help us understand more about the type of symptoms people in your age group 
experience. We are sending this questionnaire to people with and without thyroid disease.  
Each question has two parts: 
 Part A asks you to think about yourself compared to others in your age group  
 Part B asks you to think about whether you have experienced any change over the 
previous 12 months. 
Please read each item and circle the response which best answers the question for you, for example 
 
Q1  
Voice 
A) Is your voice 
generally (compared 
with others in your age 
group)…… 
Very 
hoarse 
Hoarse Average Clear Very clear 
B) Is this different from 
12 months ago? 
Much more 
hoarse now 
More 
hoarse 
Unchanged 
More clear 
now 
Much more 
clear now 
 
Q2  
Tone of 
voice 
A) Is the tone of your 
voice (compared with 
others in your age 
group)…… 
Very high High Average Deep Very deep 
B) Is this different from 
12 months ago? 
Much 
higher now 
Higher now Unchanged 
Deeper 
now 
Much 
deeper now 
 
Q3 
Skin 
A) Is your skin 
(compared with others in 
your age group)…… 
Very dry Dry Average Oily Very oily 
B) Is this different from 
12 months ago? 
Much more 
dry now 
More dry 
now 
Unchanged 
More oily 
now 
Much more 
oily now 
 
Q4    
Eyes 
A) Is the area around 
your eyes (compared with 
others in your age 
group)…… 
Very puffy Puffy Average Sunken 
Very 
sunken 
B) Is this different from 12 
months ago? 
Much more 
puffy now 
More puffy 
now 
Unchange
d 
More 
sunken 
now 
Much more 
sunken 
now 
 
Q5 
Weight 
A) For your height is your 
current weight…… Very high  A little high  Average 
A little 
low 
Very low 
B) Is this different from 12 
months ago? 
Much 
heavier now 
Heavier 
now 
Unchanged 
Lighter 
now 
Much 
lighter now 
 
Q6 
Activity 
A) Are you generally 
(compared with others in 
your age group)….. 
Much more 
active than 
others 
More active 
than others 
Average 
Less 
active 
than 
others 
Much less 
active than 
others 
Dry 
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12 months ago? 
Much more 
active now 
More active 
now 
Unchanged 
Less 
active 
now 
Much less 
active now 
 
Q7 
Muscles 
A) Are your muscles 
generally (compared 
with others in your age 
group)…… 
Very weak Weak Average Strong Very strong 
B) Is this different from 
12 months ago? 
Much 
weaker 
now 
Weaker 
now 
Unchanged 
Stronger 
now 
Much 
stronger 
now 
 
Q8 
Muscles 2 
A) Do your muscles 
cramp (compared with 
others in your age 
group)…… 
Very rarely Rarely 
Average 
amount 
Often Very often 
B) Is this different from 
12 months ago? 
Cramp 
much less 
often now 
Cramp less 
often now 
Unchanged 
Cramp 
more often 
now 
Cramp 
much more 
often now 
 
Q9 
Thinking 
A) Is your thinking 
(compared with 
others in your age 
group)…… 
Very slow Slow Average Fast Very fast 
B) Is this different 
from 12 months 
ago? 
Much 
slower now 
Slower now Unchanged Faster now 
Much faster 
now 
 
Q10 
Temperature 
A) Are you 
generally 
(compared with 
others in your age 
group)…… 
Very 
sensitive to 
cold 
Sensitive to 
cold 
Average 
Sensitive to 
heat 
Very 
sensitive to 
heat 
 
B) Is this different 
from 12 months 
ago? 
Much 
colder now 
Colder now Unchanged 
Warmer 
now 
Much 
warmer 
now 
 
Q11 
Memory 
A) Is your memory 
(compared with 
others in your age 
group)…… 
Very good Good Average Poor Very poor 
B) Is this different 
from 12 months 
ago? 
Much 
better now 
Better now Unchanged Poorer now 
Much 
poorer now 
 
Q12 
Perspiration 
and sweating 
A) When you are 
NOT in a warm or 
hot place and 
NOT exercising do 
you perspire or 
sweat…… 
Excessively 
or very 
heavily 
Heavily 
Average 
amount 
Only slightly Not at all 
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B) Is this different 
from 12 months 
ago? 
 
Sweat much 
more 
heavily now 
Sweat more 
heavily now 
Unchanged 
Sweat less 
now 
Sweat 
much 
less now 
 
Q13  
Trembling or 
shaky hands 
A) Do your hands 
tremble or 
shake…… 
Very 
obviously 
Obviously 
Average 
amount 
Slightly but 
not 
obviously 
Not at all 
B) Is this different 
from 12 months 
ago? 
 
Much more 
obviously 
now 
More 
obviously 
now 
Unchanged 
Less 
obviously 
now 
Much less 
obviously 
now 
 
 
Q14 
Palpitations 
(heart races, 
flutters or skips 
a beat) 
A) When you are 
sitting quietly or 
lying in bed do you 
feel that your heart 
races, flutters or 
skips a beat…… 
Very rarely Rarely 
Average 
amount 
Often Very often 
B) Is this different 
from 12 months 
ago? 
Much less 
often now 
Less often 
now 
Unchanged 
More often 
now 
Much more 
often now 
 
 
Q15 
Constipation 
A) Are you 
constipated  Very rarely Rarely 
Average 
amount 
Often Very often 
B) Is this different 
from 12 months 
ago? 
Much less 
often now 
Less often 
now 
Unchanged 
More often 
now 
Much more 
often now 
 
 
Please return this questionnaire to your BETS II nurse. If you have any problems completing any of the questions the 
BETS II nurse will help you during your study appointment. 
 
Thank you for taking time to complete this questionnaire. 
 
Please note: 
All information provided will be held in accordance with the Data Protection Act 1998 
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Appendix 4 Participant Consent Form 
 
 
 
 
Title of Study:  BETS II - Birmingham Elderly Thyroid Study Follow-up 
Are current reference ranges appropriate for identification of thyroid dysfunction in the 
elderly? 
 
Centre ID: <GP Practice> 
Patient Identification Number: <Patient ID> 
Patient Initials: <Patient Initials> 
 
Name of Researcher:  Dr Lesley Roberts 
Please initial inside each applicable box 
 
1. I confirm that I have read and understand the BETS II information sheet  
dated 09/11/07 version 3 for the above study and have had the       opportunity to 
ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw       
at any time, without giving any reason, without my medical care or  legal rights 
being affected. 
 
3. I agree for a blood sample to be taken for the purposes of BETS II. 
 
4. I understand that my medical notes may be looked at by members of the           
BETS II research team, but understand that strict confidentiality will be        
maintained.  I give permission for these individuals to access my records. 
 
5. I agree for my contact details to be retained on the BETS II Database so that I 
can be contacted in the future and invited to participate in further research in this 
area.  
 
6. I agree to take part in the above BETS II study  
 
 
 
 
 
 
 
---------------------------------------- -----------------       --------------------------------------- 
Name of Patient   Date        Signature 
 
---------------------------------------- -----------------       --------------------------------------- 
Name of person taking consent Date        Signature 
 
 
 
 
 
(White original for researcher site file, yellow copy for the patient; pink copy to be kept in medical notes)  
For The Attention of  
 
……………………….… 
(GP Name) 
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Appendix 5 Changes to assay and reference criteria  
 
This section details the changes in laboratory methodologies for thyroid function testing 
occurring between the two studies (BETS I and BETS II). In addition, the impact of these 
changes is reported and the methods used to resolve problems encountered are 
described and justified. Whilst not of direct relevance to the cross-sectional element of 
this thesis an appreciation of laboratory changes is essential for the reader to fully 
understand the inclusion criteria.  
 
Changes in the assay used to measure serum thyrotrophin, FT4 and FT3 occurred 
between the two studies with the Avida Centaur assay used during BETS I being 
replaced by the Roche E170. In parallel with this, a change to the standard reference 
ranges for TSH and the thyroid hormones FT4 and FT3 occurred at the UHB endocrine 
laboratory during the period between the baseline and follow-up studies. Table A5.1 
shows the standard reference ranges for serum thyrotrophin, FT4 and FT3 in use by the 
laboratory at the two time points. Table A5.2 details the reference criteria upon which 
classification of thyroid status was based in BETS I and BETS II. 
 
Table A5.1 References criteria used for during BETS I and BETS II 
 
 
Assay BETS I reference range BETS II reference range 
Thyrotropin (TSH) 0.4-5.5 mlU/L 0.3-4.5 mlU/L 
Free Thyroxine (FT4) 9-20 pmol/L 10-22 pmol/L 
Free Triiodothyronine (FT3) 3.5-6.5 pmol/L 3.1-6.8 pmol/L 
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For the longitudinal study these changes meant that the planned comparison of 
individuals‟ TFT results and thyroid status across the two time points was no longer 
appropriate without prior correction. Reclassification of the BETS I TFT results and 
subsequent classification was therefore undertaken before data were reviewed. The 
methodology used for correction and reclassification is fully described. The changes had 
no impact in terms of the cross-sectional study, however, reclassification of baseline 
thyroid status inevitably meant that a number of individuals no longer fulfilled the 
eligibility criteria for the study and were therefore excluded from this nested research.  
 
 
Table A5.2 reference criteria for classification of thyroid status  
Thyroid status Thyrotrophin 
(TSH) mlU/L 
Free 
thyroxine 
(FT4) pmol/L 
Free 
Tri- iodothyronine 
(FT3) pmol/L 
 BETS I BETS II BETS I BETS II BETS I BETS II 
Overt Hyperthyroidism < 0.4 < 0.3 > 20 > 22 >6.5 >6.8 
Subclinical hyperthyroidism  < 0.4 < 0.3 9 – 20 10 - 22 3.5-6.5 3.1-6.8 
Euthyroid  0.4 – 5.5 0.3 - 4.5 9 – 20 10 - 22 NA NA 
Subclinical hypothyroidism  >5 5 > 4.5 9 – 20 10 - 22 NA NA 
Overt hypothyroidism  >5 5 > 4.5 < 9 < 10 NA NA 
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Correction of baseline TFT results 
To enable the comparison of individuals TFT results and thyroid status across the two 
time points (BETS I and BETS II) as proposed in the longitudinal study protocol, a 
correction factor was applied to the baseline TFT results. Table A5.3 details the 
correction factors provided by the regional endocrine laboratory and applied to baseline 
(BETS I) TFT results.  
 
Table A5.3 Correction factors applied to serum TSH and FT4 measurements 
Parameter Correction factor 
TSH correction factor  1.0729 x baseline (Avida centaur) TSH +0.0381 
FT4 correction factor 1.1943 x baseline FT4 (Avida Centaur) -2.1128 
FT3 correction factor 1.0680 x baseline (Avida Centaur) TSH -0.3866 
 
 
The Regional Endocrine Laboratory UHB calculated the correction factors necessary to 
allow comparison of TFT results across the two time points in June 2006. In order to 
calculate the thyrotrophin correction factor, the thyrotrophin concentrations of 130 
samples were measured using the Avida Centaur assay and then measured using the 
Roche E170 assay. The results obtained were plotted against one another and 
regression analysis conducted to define a line of best fit. The slope and intercept of the 
line of best fit were calculated with corresponding 95% confidence intervals (CI). 
Correlation analysis was used to test the null hypothesis that there was no relationship 
between the two assays. The findings from assessment of thyrotrophin did not confirm 
the null hypothesis and review of the confidence intervals for the slope of line of best fit 
indicated that a multiplication factor equal to the slope of the graph should be applied to 
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the thyrotrophin measurements obtained using the Avida Centaur assay. In addition 
review of the 95% CIs for the intercept indicated addition of the value of the intercept 
was also necessary to enable comparison. These methods were also employed for 
calculation of the FT4 and FT3 correction factors with 145 samples being measured on 
each assay for calculation of the FT4 correction factor and 52 samples to obtain the FT3 
correction factor (Figures A5.1-A5.3). 
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Figure A5.1 Serum thyrotrophin concentration (mIU/L) 
 
N= 130; Correlation r=0.9932, t = 96.801, p<0.0001 
Roche E170 TSH = 1.0729 x Avida Centaur + 0.0381 
Slope   se=0.0111  95% CI = 1.0509-1.0948 
Intercept se=0.1198 95%CI= -0.1989-0.2752 
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Figure A5.2 Serum free thyroxine concentration (pmol/L) 
 
N=145, r=0.9676, t=45.794, p<0.0001 
Roche E170=1.1943 x Avida Centaur -2.1128 
Slope   se=0.0261  95% CI = 1.1428-1.2459 
Intercept se=0.4538 95%CI= -3.0099-1.2158 
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Column 5 [Cent_FT4]
Column 6
[RocheFT4]
0
5
10
15
20
25
30
35
40
0 5 10 15 20 25 30 35 40
  350 
Figure A5.3 Serum free T3 concentration (pmol/L) 
 
N=52; r=0.9407, t=19.614, p<0.0001 
Roche E170=1.0680 x Avida Centaur -0.3866 
Slope   se=0.0545  95% CI = 0.9586-1.1773 
Intercept se=0.2990 95%CI= -0.9871-0.2139 
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Appendix 6 Symptom expression in the incident subclinical thyroid dysfunction 
and persistently euthyroid subgroups 
 
The proportion of the incident subclinical thyroid dysfunction and persistent euthyroid 
subgroups reporting presence of each individual symptom was compared using the χ2 
test for independence or the Fisher‟s exact test where appropriate. Given the fact that 
multiple comparisons were being made between groups, a Bonferroni adjusted alpha 
value of p<0.003 was used to control for type I error. The results are presented in Tables 
A6.1-A6.4. In the following tables and bar charts, the acronym NSCTD is used in 
reference to the incident subclinical thyroid dysfunction subgroup and PEuth is used to 
denote the persistently euthyroid subgroup. 
 
The prevalence of 18 current symptoms suggestive of overt thyroid dysfunction was 
similar in the incident subclinical thyroid dysfunction and persistently euthyroid 
subgroups (Table A6.1). Similarly, there were no significant differences in the 
prevalence of individual changed symptoms reported by the thyroid function subgroups 
(Table A6.2). 
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Table A6.1 Incident subclinical thyroid dysfunction versus persistent euthyroidism; 
comparison of the prevalence of current symptoms  
 
Bonferroni alpha level p<0.003, * p value associated with the Fisher exact test
Current symptom  NSCTD 
%, 95% CI (n) 
PEuth 
%, 95%CI (n) 
χ
2
 (p) 
df=1 
Excessive perspiration  3.3,1.1-9.3 (3) 3.0,2.4-3.7 (7.9) (0.75)* 
Trembling hands 3.4,1.1-9.3 (3) 4.2,3.5-5.1 (112) (1.00)* 
Frequent palpitations  5.6,1.1-9.3 (5) 5.9,5.0-6.8 (155) 0.02 (0.90) 
Sensitivity to heat  14.4,2.4-23.2 (13) 10.7,9.4-11.7 (277) 1.27 (0.26) 
Fast thinking 27.8,10.9-37.8 (25) 22.7,21.1-24.3 (598) 1.27 (0.26) 
Weight loss 2.2,0.6-7.7 (2) 7.5,6.6-8.6 (198) 3.59 (0.06) 
Lethargy 14.6,8.6-23.2 (13) 16.5,15.1-17.9 (434) 0.22 (0.64) 
Weak muscles 14.4,8.6-23.2 (13) 14.4,12.9-15.6 (375) 0.003 (0.96) 
Poor memory 8.9,4.6-16.6 (8) 9.7,8.7-10.9 (257) 0.073 (0.79) 
Hoarse voice  5.6,2.4-12.4 (5) 5.8,4.9-6.7 (152) 0.004 (0.95) 
Deep voice 12.4,7.0-20.6 (11) 6.3,5.4-7.2 (165) 5.27 (0.02) 
Dry skin 35.6,26.4-45.9 (32) 32.2,30.4-33.9 (847) 0.45 (0.50) 
Puffy eyes 20.0,13.0-29.4 (18) 13.1,11.8-14.4 (344) 3.64 (0.06) 
Muscle cramps 20.0,13.0-29.4 (18) 14.9,13.6-16.3 (392) 1.79 (0.18) 
Constipation 15.6,9.5-24.4 (14) 13.0,11.7-14.3 (342) 0.50 (0.48) 
Sensitivity to cold  37.8,28.5-48.1 (34) 34.8,32.4-36.0 (902) 0.24 (0.56) 
Slow thinking 13.3,7.8-21.9 (12) 7.8,6.8-8.9 (205) 0.34 (0.56) 
Weight gain 54.4,44.2-64.3 (49) 48.3,46.3-50.1 (1272) 1.31 (0.25) 
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Table A6.2 Incident subclinical thyroid dysfunction versus persistent euthyroidism; 
comparison of the prevalence of changed symptoms  
Bonferroni alpha level p <0.003. *p value associated with the Fisher Exact test 
 
Changed  
symptom  
NSCTD 
%,95%CI (n) 
PEuth 
%,95%CI (n) 
χ
2
 (p) 
df=1 
Excessive perspiration  1.1,0.2-6.0 (1) 2.1,1.6-2.7 (54) (1.0)* 
Trembling hands 3.3,1.1-9.3 (3) 4.9,4.1-5.8 (129) (0.80)* 
Frequent palpitations  7.8,3.8-15.2 (7) 4.4,3.6-5.2 (115) (0.12)* 
Sensitivity to heat  4.4,1.7-10.9 (4) 1.8,1.4-2.4 (48) (0.09)* 
Fast thinking 0, 0-4.1 (0) 1.8,1.4-2.4 (48) (0.09)* 
Weight loss 11.1,6.1-19.3 (10) 13.3,12.1-14.7 (351) 0.368 (0.544) 
Lethargy 14.6,8.6-23.2 (13) 18.7,17.2-20.2 (492) 0.954 (0.329) 
Weak muscles 12.4,7.0-20.6 (11) 16.3,14.9-17.7 (429) 0 (0.320) 
Poor memory 16.7,10.4-25.7 (15) 16.6,15.2-18.1 (438) 0 (0.991) 
Hoarse voice  6.7,3.1-13.8 (6) 4.6,3.9-5.5 (121) (0.314)* 
Deep voice 0, 0.4.1 (0) 2.0,1.5-2.6 (52) (0.42)* 
Dry skin 10.0,5.4-17.9 (9) 13.1,11.8-14.4 (344) 0.727 (0.394) 
Puffy eyes 7.8,3.8-15.2 (7) 5.7,4.9-6.6 (150) 0.682 (0.409) 
Muscle cramps 14.4,8.6-25.2 (13) 13.0,11.7-14.3 (342) (1.00)* 
Constipation 
  
6.7,3.1-13.8 (6) 6.7,5.8-7.7 (177) 0.33 (0.856) 
Sensitivity to cold  13.3,7.8-21.9 (12) 12.7,11.4-13.9 (333) 0.33 (0.856) 
Slow thinking 14.4,8.6-23.2 (13) 11.6,10.4-12.9 (306) 0.663 (0.415) 
Weight gain 24.4,16.7-34.2 (22) 16.1,14.7-17.5 (424) 4.44 (0.035) 
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No clear relationship between the longitudinal thyroid function subgroups and total 
number of current or changed, hypothyroid or hyperthyroid symptoms was observed. 
(Figure A6.1 and Figure A6.2).  
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Figure A6.1 and A6.2 Incident subclinical thyroid dysfunction versus persistent euthyroidism; comparison of the prevalence of multiple 
hypothyroid symptoms  
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Figure A6.3 and A6.4 Figure A6.1 and A6.2 Incident subclinical thyroid dysfunction versus persistent euthyroidism; comparison of the 
prevalence of multiple hyperthyroid symptoms  
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No significant difference between the longitudinal thyroid function subgroups existed 
with respect to total number of current or changed symptoms suggestive of 
hyperthyroidism or hypothyroidism (Table A6.3 and table A6.4). 
 
Table A6.3 Incident subclinical thyroid dysfunction versus persistent euthyroidism; comparison of 
the prevalence of multiple hypothyroid symptoms  
 Current hypothyroid symptom  Changed hypothyroid symptom  
Totalled 
number of 
symptoms 
NSCTD 
n=90 
PEuth 
n=2637 
χ
2
 (p) 
df = 2 
 
NSCTD 
n=90 
PEuth 
n=2637 
χ
2
 (p) 
df = 2 
 
None 10 (11.1) 432 (16.4) 
1.80 (0.41) 
43 (47.3) 1186 (45.0) 
1.95 (0.38) 
1-2 
  
49 (54.4) 1334 (50.6) 25 (27.8) 910 (34.5) 
3 or more 31 (34.4) 871 (33.0) 22 (24.4) 541 (20.5) 
 
 
 
Table A6.4 Incident subclinical thyroid dysfunction versus persistent euthyroidism; comparison of 
the prevalence of multiple hyperthyroid symptoms  
 Current hyperthyroid symptoms Changed hyperthyroid symptom  
Totalled 
number of 
symptoms 
NSCTD 
n=90 
PEuth 
n=2637 
χ
2
 (p) 
df = 2 
 
NSCTD 
n=90 
PEuth 
n=2637 
χ
2
 (p) 
df = 2 
 
None 36 (40.0) 1102 (41.8) 
0.65 
(0.721) 
52 (57.8) 1465 (55.5) 
1.266 
(0.531) 
1-2 
 
48 (53.3) 1311 (49.7) 33 (36.7) 936 (35.5) 
3 or more 6 (6.7) 222 (8.5) 5 (5.6) 237 (9.0) 
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Appendix 7 Symptom expression in the persistent subclinical thyroid dysfunction 
and persistently euthyroid subgroups 
The proportion of the persistent subclinical thyroid dysfunction and persistent euthyroid 
subgroups reporting presence of each individual symptom was compared using the χ2 
test for independence or the Fisher‟s exact test where appropriate. Given the fact that 
multiple comparisons were being made between groups, a Bonferroni adjusted alpha 
value of p<0.003 was used to control for type 1 error. The results are presented in 
Tables A7.1-A7.4. In the tables and bar charts the acronym PSCTD is used in reference 
to the persistent subclinical thyroid dysfunction subgroup and PEuth is used to denote 
the persistently euthyroid subgroup. 
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Table A7.1 Persistent subclinical thyroid dysfunction versus persistent euthyroidism; 
comparison of the prevalence of current symptoms  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* p value associated with the Fishers Exact test 
Current 
symptom  
PSCTD 
%,95%CI (n) 
PEuth 
%,95%CI (n) 
χ
2
 (p) 
df=1 
Excessive perspiration  
3.9,1.3-10.8 
 (3) 
3, 2.4-3.7  
(79) 
(0.51) 
Trembling hands 
2.6,0.7-9.0 
 (2) 
4.2,3.5-5.1 
 (112) 
(0.77) 
Frequent palpitations  
3.9,1.3-10.8 
 (3) 
5.9,5.0-6.8 
 (155) 
(0.62) 
Sensitivity to heat  
9.2,4.5-17.6 
 (7) 
10.7,9.4-11.7 
 (277) 
0.17 (0.68) 
Fast thinking 
23.4,15.3-34.0 
(18) 
22.7,21.1-24.3 
(598) 
0.02 (0.89) 
Weight loss 
5.2,2.0-12.6 
 (4) 
7.5,6.6-8.6 
 (198) 
0.59 (0.44) 
Lethargy 
6.5,2.8-14.3 
 (5) 
16.5,15.1-17.9 
(434) 
5.48 (0.02) 
Weak muscles 
11.7,6.3-20.7 
 (9) 
14.2,12.9-15.6 
(375) 
0.40 (0.53) 
Poor memory 
3.9,1.3-10.8 
 (3) 
9.7,8.7-10.9 
(257) 
2.96 (0.09) 
Hoarse voice  
11.7,6.3-20.7 
(9) 
5.8,4.9-6.7 
 (152) 
(0.05) 
Deep voice 
6.5,2.8-14.3 
 (5) 
6.3,5.4-7.2 
 (165) 
(0.81) 
Dry skin 
31.2,21.9-42.2 
(24) 
32.2,30.4-33.9 
 (847) 
0.04 (0.85) 
Puffy eyes 
15.6,9.1-25.3 
(12) 
13.1,11.8-14.4 
(344) 
0.42 (0.52) 
Muscle cramps 
9.1,4.5-17.6 
 (7) 
14.9,13.6-16.3 
(392) 
2.00 (0.16) 
Constipation 
11.7,6.3-20.7 
(9) 
13.0,11.7-14.3 
(342) 
0.11 (0.74) 
Sensitivity to cold  
34.2,24.3-44.9 
(26) 
34.8,32.4-36.0 
(902) 
0.01 (0.92) 
Slow thinking 
5.2,2.0-12.6 
 (4) 
7.8,6.8-8.9 
 (205) 
0.70 (0.40) 
Weight gain 
48.1,37.3-59.0 
(37) 
48.3,46.3-50.1 
(1272) 
0.002 (0.97) 
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Table A7.2 Persisent subclinical thyroid dysfunction versus persistent euthyroidism; 
comparison of the prevalence of changed symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 * p value associated with the Fishers Exact test
Changed 
symptom  
PSCTD 
%,95%CI  
(n) 
PEuth  
%,95%CI  
(n) 
χ
2
 (p) 
df=1 
Excessive 
perspiration  
2.6.0.7-9.0  
(2) 
2.1, 1.6-2.7 
 (54) 
(0.67)* 
Trembling hands 
5.2,2.0-12.6 
 (4) 
4.9,4.1-5.8 
 (129) 
(0.79)* 
Frequent 
palpitations  
2.6,0.7-9.0  
(2) 
4.4,3.6-5.2 
 (115) 
(0.77)* 
Sensitivity to heat  
3.9,1.3-10.8  
(3) 
1.8,1.4-2.4 
 (48) 
(0.18)* 
Fast thinking 
2.6,0.7-9.0  
(2) 
0.5,0.3-0.8 
 (13) 
(0.07)* 
Weight loss 
11.7,6.3-20.7 
(9) 
13.3,12.1-14.7 
(351) 
0.17 (0.68) 
Lethargy 
18.2,11.2-28.2 
(14) 
18.7,17.2-20.2 
(492) 
0.01 (0.91) 
Weak muscles 
15.6,9.1-25.3 
(12) 
16.3,14.9-17.7 
(429) 
0.03 (0.87) 
Poor memory 
15.6,9.1-25.3 
(12) 
16.6,15.2-18.1 
(438) 
0.06 (0.81) 
Hoarse voice  
9.2,4.5-17.6 
 (7) 
4.6,3.9-5.5 
 (121) 
(0.09)* 
Deep voice 
3.9 ,1.3-10.8 
(3) 
2.0,1.5-2.6 
 (52) 
(0.21)* 
Dry skin 
3.9,1.3-10.8  
(3) 
13.1,11.8-14.4 
(344) 
1.00 (0.39) 
Puffy eyes 
5.2,2.0-12.6  
(4) 
5.7,4.9-6.6 
 (150) 
(1.00)* 
Muscle cramps 
13.0,7.2-22.3 
 (10) 
13.0,11.7-14.3 
(342) 
 (1.00)* 
Constipation 
9.1,4.5-17.6  
(7) 
6.7,5.8-7.7 
 (177) 
0.65 (0.04) 
Sensitivity to cold  
10.4,5.4-19.2  
(8) 
12.7,11.4-13.9 
(333) 
0.36 (0.55) 
Slow thinking 
10.4,5.4-19.2  
(8) 
11.6,10.4-12.9 
(306) 
0.11 (0.74) 
Weight gain 
15.6,9.1-25.3 
(12) 
16.1,14.7-17.5 
(424) 
0.014 (0.91) 
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Figures A7.1 and A7.2 Persisent subclinical thyroid dysfunction versus persistent euthyroidism; comparison of multiple hypothyroid 
symptoms reported 
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Figure A7.3 and A7.4 Total number of current and changed hyperthyroid symptoms reported 
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Table A7.3 Persistent subclinical thyroid dysfunction versus persistent euthyroidism; comparison 
of the prevalence of multiple hypothyroid symptoms 
 
 
These groups were similar also with respect to total number of current and changed 
symptoms suggestive of overt hypothyroidism and overt hyperthyroidism. (Table A7.3) 
 
 
Table A7.4 Persistent subclinical thyroid dysfunction versus persistent euthyroidism; comparison 
of the prevalence of multiple hyperthyroid symptoms  
 Current hyperthyroid symptom  Changed hyperthyroid symptom  
Totalled 
number of 
symptoms 
PEuth PSCTD χ
2
 (p) 
df = 2 
 
PEuth PSCTD χ
2
 (p) 
df = 2 
 
None 1102 (41.8) 38 (49.4) 
2.281 
(0.320) 
1465 (55.5) 39 (50.6) 
3.108 
(0.21) 
1-2 
symptom  
1311 (49.7) 35 (45.5) 936 (35.5) 34 (44.2) 
3 or more 225 (8.5) 4 (5.2) 237 (9.0) 4 (5.2) 
 
 
 Current hypothyroid symptoms Changed hypothyroid symptoms 
Totalled 
number of 
symptoms 
PEuth 
n=2637 
PSCTD  
n=77 
χ
2
 (p) 
df = 2 
 
PEuth 
n=2637 
PSCTD 
n=77 
χ
2
 (p) 
df = 2 
 
None 
432 (16.4) 12 (15.6) 
3.76 (0.15) 
1186 (45.0) 29 (37.7) 
5.01 (0.08) 
1-2  
1334 (50.6) 47 (61.0) 910 (34.5) 36 (46.8) 
3 or more  
871 (33.0) 18 (23.4) 541 (20.5) 12 (15.6) 
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Appendix 8 Results of univariate exploration of symptoms and serum TSH 
concentration 
 
The Mann Whitney U test was used to compare median serum thyrotrophin 
concentration between groups reporting presence and absence of individual symptoms 
and between those reporting a recent change and no change in intensity of individual 
symptoms during the preceding 12 months.  
 
At the Bonferroni adjusted alpha level of p<0.003 there were no significant differences in 
median serum thyrotrophin concentration between those reporting presence and 
absence of symptoms. Since the univariate analysis was explanatory in nature and 
aimed to identify appropriate symptoms for inclusion in the multivariate analysis the 
significance level was relaxed to 5% to enable selection of symptoms. At a level of 5% 
significance, a significant difference existed with respect to the current symptom weight 
gain. A significantly higher serum thyrotrophin concentration was observed in those 
reporting presence of current weight gain than in those reporting absence of this 
symptom (1.89mIU/L versus 1.78mIU/L, p<0.004) (Table A8.1).  
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Table A8.1 Presence versus absence of individual sysmptoms; comparison of serum TSH 
concentration  
  Current symptom  Changed symptom   
 Symptom  Symptom 
absent 
Median, 
95%CI (n) 
Symptom 
present 
  Median, 
95%CI (n) 
Z Score 
(p value) 
Symptom 
absent 
Median, 
95%CI (n) 
Symptom 
present 
Median, 
95%CI (n)   
Z Score  
(p value)  
S
u
g
g
e
s
tiv
e
 o
f 
h
y
p
e
rth
y
ro
id
is
m
 
Excessive 
perspiration 
1.82,1.78-
1.87 (2778) 
1.74,1.49-
2.04 (90) 
- 0.43 
(0.67) 
1.82,1.78-
1.87 
(2802) 
1.78,1.43-
2.03 (60) 
-0.43 
(0.67) 
Trembling hands 1.81,1.78-
1.86 (2749) 
1.81,1.27-
1.91 (120) 
-1.02 
(0.31) 
1.82,1.78-
1.87 (2719) 
1.91,1.70-
2.05 (140) 
- 0.55 
(0.58) 
Frequent 
palpitations  
1.83,1.78-
1.88 (2693) 
1.72,1.31-
175 (171) 
0.27 
(0.27) 
1.82,1.71-
1.87 (2728) 
1.78,1.56-
1.97 (128) 
-0.29 
(0.77) 
Sensitivity to 
heat  
1.84,1.78-
1.89 (2518) 
1.84,1.65-
1.92 (304) 
-0.75 
(0.46) 
1.83,1.78-
1.88  (2798) 
1.64,1.36-
2.27 (59) 
-0.41 
(0.68) 
Fast thinking 1.82,1.78-
1.88 (2211) 
1.82,1.73-
1.93 (655) 
-0.05 
(0.96) 
1.82,1.78-
1.87(2847) 
1.42,0.84-
3.46 (15) 
-0.87 
(0.38) 
Weight loss 1.84,1.79-
1.89 (2660) 
1.71.1.46-
1.51 (206) 
-1.75 
(0.08) 
1.83,1.78-
1.88 (2489) 
1.80,1.12-
1.30 (179) 
-0.72 
(0.47) 
E
ith
e
r 
fo
rm
 
o
f T
D
  
Lethargy 1.83,1.79-
1.89 (2408) 
1.77,1.69-
1.89 (460) 
-1.12 
(0.26) 
1.83, 1.79-
1.89 (2330) 
1.77,2.12-
2.49 (512) 
- 1.59 
(0.11) 
Weak muscles 1.82,1.78-
1.89 (2458) 
1.85,1.70-
1.94 (408) 
-0.31 
(0.76) 
1.83,1.78-
1.87 (2397) 
1.82,1.70-
1.89 (465) 
- 0.82 
(0.42) 
Poor memory 1.83,1.78-
1.93 (2596) 
1.79,1.65-
1.90 (273) 
-0.99 
(0.32) 
1.84, 1.79-
1.91 (2394) 
1.75,1.62-
1.83 (473) 
- 1.90 
(0.06) 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 1.82,1.78-
1.87 (2688) 
1.78,1.64-
1.97 (177) 
-0.08 
(0.93) 
1.82,1.78-
1.87 (2692) 
1.82,1.56-
2.11 (141) 
-0.09 
(0.93) 
Deep voice 1.83,1.78-
1.88 (2674) 
1.73,1.57-
1.93 (188) 
-1.41 
(0.16) 
1.82,1.76-
1.86 (2789) 
1.67, 1.30-
2.28 (57) 
-0.39 
(0.69) 
Dry skin 1.79,1.76-
1.85 (1940) 
1.88,1.80-
1.95 (924) 
-1.11 
(0.27) 
1.83,1.83-
1.97 (2495) 
1.78, 1.61-
2.99 (368) 
-1.41 
(0.16) 
Puffy eyes 1.81,1.77-
1.87 (2475) 
1.86,1.77-
2.00 (390) 
-0.03 
(0.98) 
1.82,1.78-
1.86 (2685) 
1.94,1.75-
2.40 (173) 
-1.39 
(0.16) 
Muscle cramps 1.83,1.79-
1.89 (2434) 
1.76,1.68-
1.87 (433) 
-0.84 
(0.40) 
1.83,1.78-
1.88 (2488) 
1.78,1.65-
1.93 (377) 
-0.94 
(0.35) 
Constipation  1.82,1.78-
1.87 (2485) 
1.79,1.36-
1.57 (373) 
-0.31 
(0.76) 
1.82, 1.78-
1.87 (2662) 
1.82,0.77-
1.67 (194) 
-0.13 
(0.90) 
Sensitivity to 
cold  
1.82,1.76-
1.88 (1837) 
1.86,1.78-
1.92 (985) 
0.27 
(0.27) 
1.82,1.78-
1.88 (2492) 
1.83,1.74-
1.96 (365) 
- 0.14 
(0.89) 
Slow thinking 1.82, 1.77-
1.86 (2638) 
1.90,1.77-
1.95 (228) 
-0.10 
(0.30) 
1.83,1.78-
1.89 (2525) 
1.77,1.65-
1.89 (337) 
-0.62 
(0.54) 
Weight gain 1.76,1.72-
1.83 (1470) 
1.89,1.82-
1.96 (1396) 
-2.91 
(0.004) 
1.83,1.78-
1.88 (2525) 
1.79, 1.73-
1.94 (463) 
-0.75 
(0.75) 
* associated with the Mann Whitney U test 
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The Kruskal Wallis test was used to compare median serum TSH concentration between 
participants divided into three groups based upon intensity of reported symptoms (e.g 
absent, mild or severe). A Bonferroni adjusted alpha value was used to control for type I 
error. No associations between serum TSH concentration and presence of reported 
current symptoms suggestive of overt hyperthyroidism and overt hypothyroidism where 
observed at the Bonferroni adjusted level of significance. (Table A8.2)  
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Table A8.2 Presence versus absence of individual current mild and severe intensity symptoms; 
comparison of serum TSH concentration  
   Median serum TSH concentration 
 Current symptom  Symptom 
absent  
%,95%CI (n) 
Mild symptom 
present  
%,95%CI (n) 
Severe intensity 
symptom 
 %,95%CI (n) 
p 
value*  
S
u
g
g
e
s
tiv
e
 o
f 
h
y
p
e
rth
y
ro
id
is
m
 
Excessive perspiration 1.82,1.78-1.87 
(2778) 
1.72,1.55-2.07 
(73) 
1.76,1.39-3.13 
(17) 
0.50 
Trembling hands 1.81,1.78-1.86 
(2749) 
2.00,1.69-2.39 
(90) 
1.96,1.36-2.60 
(30) 
0.22 
Frequent palpitations  1.83,1.78-1.88 
(2693) 
1.75,1.47-1.94 
(145) 
1.59,1.36-2.42 
(26) 
0.27 
Sensitivity to heat  1.84,1.78-1.89 
(2518) 
1.75,1.63-1.89 
(277)  
1.98, 1.44-2.66 
(27) 
0.20 
Fast thinking 1.82,1.78-1.88 
(2211) 
1.81,1.72-1.93 
(595) 
1.89,1.48-2.32 
(60) 
0.95 
Weight loss 1.84,1.79-1.89 
(2660) 
1.70,1.51-1.73 
(190) 
1.86,1.33-2.76 
(16) 
0.46 
E
ith
e
r 
fo
rm
 
o
f T
D
  
Lethargy 1.83,1.79-1.89 
(2408) 
1.78,1.69-
1.94(380) 
1.74,1.46-1.93 
(80) 
0.58 
Weak muscles 1.82,1.78-1.89 
(2458) 
1.85,1.7-1.9 
(375) 
1.97,1.42-2.60 
(33) 
0.91 
Poor memory 1.83,1.78-1.93 
(2596) 
1.79,1.61-1.89 
(253) 
1.98,1.53-3.16 
(20) 
0.47 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 1.82,1.78-1.87 
(2688) 
1.79,1.64-2.03 
(170) 
1.77,0.2-3.75 
(7) 
0.73 
Deep voice 1.83,1.78-1.88 
(2674) 
1.73,1.57-1.93 
(184) 
1.69,1.35-2.41 
(4) 
0.21 
Dry skin 1.79,1.76-1.85 
(1940) 
1.86,1.78-1.95 
(781) 
1.92,1.81-2.16 
(143) 
0.25 
Puffy eyes 1.81,1.77-1.87 
(2475) 
1.84,1.73-2.00 
(373) 
2.28, 1.44-3.35 
(17) 
0.57 
Muscle cramps 1.83,1.79-1.89 
(2434) 
1.78,1.69-1.90 
(368) 
1.75,1.50-204 
(65) 
0.29 
Constipation  1.82,1.78-1.87 
(2485) 
1.78,1.61-1.94 
(288) 
1.88,1.64-2.12 
(90) 
0.56 
Sensitivity to cold  1.82,1.76-1.88 
(1837) 
1.85,1.77-1.94 
(849) 
1.88,1.77-2.17 
(136) 
0.64 
Slow thinking 1.82, 1.77-1.86 
(2638) 
1.89,1.72-207 
(215) 
1.96,0.88-3.29 
(13) 
0.19 
Weight gain 1.76,1.72-1.83 
(1470) 
1.86,1.78-1.94 
(1211) 
2.09,1.85-2.33 
(185) 
0.08 
   Bonferroni adjusted alpha level, p<0.003 (0.05/18), * associated with Kruskal Wallis test 
 
Likewise the two groups were similar with respect to the prevalence and intensity of 
changed symptoms suggestive of overt thyroid dysfunction at a Bonferroni adjusted 
alpha level of p<0.003. (Table A8.3) 
  368 
 
Table A8.3 Presence versus absence of individual changed mild and severe intensity 
sysmptoms; comparison of serum TSH concentration    
   Median serum TSH concentration 
 Changed symptom  Symptom 
absent  
%,95%CI (n) 
Mild symptom 
present  
%,95%CI (n) 
Severe intensity 
symptom 
 %,95%CI (n) 
p value* 
S
u
g
g
e
s
tiv
e
 o
f 
h
y
p
e
rth
y
ro
id
is
m
 
Excessive perspiration 1.82,1.78-1.87 
(2802) 
1.80,1.95-2.04 
(56) 
1.38,1.22-1.46 
(4) 
0.70 
Trembling hands 1.82,1.78-
1.87(2719) 
1.91,1.70-2.05 
(129)  
1.91,0.86-2.90 
(11) 
0.36 
Frequent palpitations  1.82,1.71-1.87 
(2728) 
1.79,1.57-1.99 
(122) 
1.57,0.86-2.26  
(6) 
0.79 
Sensitivity to heat  1.83,1.778-1.88 
(2798) 
1.61,1.30-2.26 
(48) 
2.66,0.06-3.41 
(11) 
0.47 
Fast thinking 1.82,1.78-1.87 
(2847) 
1.45,0.87-3.46 
(12) 
0.84,0.62-3.92 
(3) 
0.78 
Weight lose 1.83,1.78-1.88 
(2489) 
1.80,1.68-1.88 
(362) 
1.64,1.04-2.33  
(17) 
0.55 
E
ith
e
r fo
rm
 o
f 
T
D
 
Lethargy 1.83, 1.79-1.89 
(2330) 
1.77,1.69-1.88 
(475) 
1.49,1.34-1.86 
(57) 
0.43 
Weak muscles 1.83,1.78-1.87 
(2397) 
1.83, 1.70-1.93 
(443) 
1.68, 0.88-2.55 
(22) 
0.95 
Poor memory 1.84, 1.79-1.91 
(2394) 
1.74,1.62-1.83 
(457) 
1.82,0.86-2.50 
(16) 
0.49 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 1.82,1.78-1.87 
(2692) 
1.84, 1.55-2.08 
(134) 
1.21,0.88-3.51 
(2) 
0.95 
Deep voice 1.82,1.76-1.86 
(2789) 
1.76, 1.38-2.28 
(55) 
1.39,1.35-1.42 
(2) 
0.79 
Dry skin 1.83,1.83-1.97 
(2495) 
1.78,1.60-1.88 
(337) 
1.78,1.33-2.15 
(31) 
0.32 
Puffy eyes 1.82,1.78-1.86 
(2685) 
1.95,1.73-2.41 
(164) 
1.83,0.86-3.78 
(9) 
0.21 
Muscle cramps 1.83,1.78-1.88 
(2488) 
1.83,1.69-1.96 
(347) 
1.44,1.20-1.76 
(30) 
1.00 
Constipation  1.82, 1.78-1.87 
(2662) 
1.94,1.70-2.18 
(168) 
1.17,1.05-1.88 
(26) 
0.57 
Sensitivity to cold  1.82,1.78-1.88 
(2492) 
1.87,1.76-2.03 
(339) 
1.19,0.79-1.57 
(26) 
0.57 
Slow thinking 1.83,1.78-1.89 
(2525) 
1.77,1.64-1.88 
(327) 
2.02, 0.52- 3.29 
(10) 
0.67 
Weight gain 1.83,1.78-1.88 
(2525) 
1.80,1.73-1.93 
(327) 
1.77,1.05-2.28 
(23) 
0.83 
Bonferroni adjusted alpha level,p<0.003, * associated with Kruskal Wallis test 
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Serum TSH concentration and combinations of current symptoms  
To further investigate the relationship between expression of symptoms and serum 
thyrotrophin concentration each possible pair of current symptoms was defined. As 
previously described in Chapter 8 the purpose of this was two-fold, firstly to enable 
comparison of median serum thyrotrophin concentration between the groups reporting 
the presence and absence of symptoms and secondly to allow examination and 
identification of interactions between symptoms. Comparisons between groups were 
made using the Mann Whitney U Test. A Bonferroni adjusted alpha level was used to 
control for type I error. Since this analysis was exploratory in nature and aimed to 
identify appropriate individual symptoms and pairs of symptoms for inclusions in the 
multivariate analysis the analysis plan allowed for application of a significance level of 
5% if necessary.  
 
Serum TSH concentration and symptom interactions  
Investigation of interactions between symptoms suggestive of overt hyperthyroidism 
failed to identify any significant interactions. Examination of interactions between 
symptoms suggestive of hypothyroidism identified a significant interaction between; 
hoarse voice with weight gain (p<0.012) (Table A8.4), hoarse voice and puffy eyes 
(p<0.038 (Table A8.5), hoarse voice and constipation (p<0.002) (Table A8.6) and 
muscle cramps and sensitivity to the cold (p<0.043) (Table A8.7).  
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TSH and combinations of current hyperthyroid symptoms  
At the Bonferroni adjusted alpha level of p<0.001 no significant differences in median 
serum TSH concentration was observed between the groups with respect to the 
prevalence of any of the 36 possible pairs of current symptoms suggestive of 
hyperthyroidism (Table A8.8). 
At a significance level of 5% however, a significant difference between the groups 
existed with respect to the prevalence of four symptom pairs; excessive perspiration with 
trembling hands, frequent palpitation with sensitivity to heat, frequent palpitations with 
weak muscles and lethargy with poor memory. Serum TSH concentration was 
significantly lower in those reporting presence of frequent palpitations with sensitivity to 
heat (1.38mIU/L versus 1.83mIU/L, Z-2.370, p<0.018), frequent palpitation with weak 
muscles (1.45mIU/L versus 1.83mIU/L, Z-2.067, p<0.039) and lethargy with poor 
memory (1.61mIU/L versus 1.83mIU/L, Z-2.262, p<0.024) than in those not reporting 
presence of these symptoms pairs. In contrast serum TSH concentration in those 
reporting presence of excessive perspiration with trembling hands was significantly 
higher than median serum concentration in the group reporting an absence of one or 
both of these symptoms (3.13mIU/L versus 1.82mU/L, Z-2.010, p<0.010). (Table A8.8) 
 
Serum TSH and combinations of current hypothyroid symptoms  
At the Bonferroni adjusted alpha level of p<0.0008, no significant differences in median 
serum thyrotrophin concentration were observed between the groups with respect to the 
prevalence of any of the 63 possible pairs of current symptoms suggestive of 
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hypothyroidism (Table A8.9). At a significance level of 5% however, a significant 
difference was observed with respect to the prevalence of five symptom pairs, lethargy 
with constipation, poor memory with deep voice, puffy eyes with weight gain, sensitivity 
to cold with weight gain and hoarse voice with puffy eyes. Serum TSH concentration 
was significantly greater in those reporting presence of puffy eyes with weight gain 
(2.00mIU/L versus 1.81mIU/L, Z- 2.070, p<0.038) and sensitivity to cold with weight gain 
(1.91mIU/L versus 1.81mIU/L, Z-2.322, p<0.020) than in those reporting absence of 
these symptoms. In contrast, serum TSH concentration was significantly lower in those 
reported presence compared with those reporting absence of hoarse voice with puffy 
eyes (1.39mIU/L versus 1.83mIU/L, Z-1.998, p<0.046), poor memory with deep voice 
(1.32mIU/L versus 1.83mIU/L, Z-2.181, p<0.029) and lethargy with constipation 
(1.55mIU/L versus 1.83mIU/L, Z- 2.513, p<0.012) (Table A8.9). 
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Table A8.4 TSH interaction model 1- Hoarse voice and weight gain 
Model Co-efficient Std. Error t p value 
Constant 2.058 .038 54.707 .000 
Hoarse voice .330 .155 2.137 .033 
Weight gain  .141 .054 2.615 .009 
Interaction term HVWG -.548 .217 -2.524 .012 
 
 
Table A8.5 TSH interaction model 2- Hoarse voice and puffy eyes 
Model Co-efficient Std. Error t p value 
Constant 2.118 .029 73.254 .000 
Hoarse voice .187 .126 1.486 .137 
Puffy eyes .052 .081 .643 .520 
Interaction term HVPE -.525 .253 -2.077 .038 
 
 
Table A8.6 TSH interaction model 3- Hoarse voice and constipation 
Model Co-efficient Std. Error t p value 
Constant 2.130 .029 73.795 .000 
Hoarse voice -.136 .123 -1.104 .270 
Constipation -.032 .081 -.399 .690 
Interaction term HVC .827 .264 3.129 .002 
 
 
Table A8.7 TSH interaction model 4- Muscle cramps and sensitivity to the cold 
Model Co-efficient Std. Error t p value 
Constant 2.124 .035 61.324 .000 
Muscle cramps -.148 .101 -1.464 .143 
Sensitivity to cold  .028 .061 .467 .640 
Interaction term MCSC .302 .149 2.023 .043 
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Table A8.8 Presence versus absence of pairs of hyperthyroid symptoms; comparison of serum TSH concentration 
 
Excessive perspiration with trembling hands Z*=-2.010, p 0.044, frequent palpitations with sensitivity to heat Z* =-2.370, p 0.018, frequent 
palpitations with weak muscles Z*=-2.067 p 0.039, lethargy with poor memory Z*=-2.262, p 0.024, * associated with the Mann Whitney U test 
 
 Trembling hands Frequent 
palpitation 
Sensitivity to 
heat 
 
Fast thinking Weight loss Lethargy Weak muscles Poor memory 
 Absent Present Absent Present Absent Present Absent Present Absent Present Absent Present Absent Present Absent Present 
 Median 
n 
Median 
n 
Median 
n 
Median 
n 
Median 
n 
Median 
n 
Median 
n 
Median 
n 
Excessive 
perspiration  
1.82 
2865 
3.13 
5 
1.82 
2857 
1.79 
12 
1.82 
2829 
1.76 
41 
1.82 
2844 
1.85 
24 
1.82 
2869 
1.45 
1 
1.82 
2843 
1.72 
26 
1.82 
2841 
1.63 
29 
1.82 
2846 
1.85 
24 
Trembling 
hands   
1.82 
2855 
1.58 
15 
1.82 
2857 
1.56 
13 
1.82 
2856 
1.97 
14 
1.82 
2856 
1.98 
14 
1.82 
2822 
2.03 
48 
1.82 
2825 
1.92 
45 
1.82 
2856 
1.97 
14 
Frequent 
palpitation     
1.83 
2844 
1.38 
26 
1.82 
2834 
1.56 
36 
1.82 
2856 
1.37 
14 
1.82 
2811 
1.53 
59 
1.83 
2820 
1.45 
50 
1.82 
2842 
1.67 
28 
Sensitivity 
to heat        
1.83 
2793 
1.63 
77 
1.82 
2866 
1.07 
4 
1.82 
2810 
1.76 
60 
1.82 
2822 
1.76 
48 
1.82 
2845 
1.67 
25 
Fast 
thinking          
1.83 
2819 
1.66 
54 
1.82 
2791 
1.84 
79 
1.82 
2802 
2.00 
68 
1.82 
2852 
1.73 
18 
Weight lose 
          
1.82 
2831 
1.42 
39 
1.82 
2819 
1.89 
51 
1.82 
2846 
1.85 
24 
Lethargy  
            
1.82 
2670 
1.82 
200 
1.83 
2769 
1.61 
101 
Weak 
muscles               
1.82 
2779 
1.72 
91 
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Table A8.9 Presence versus absence of pairs of hypothyroid symptoms; comparison of serum TSH concentration 
 Hoarse voice  
Median ( n) 
Deep voice  
Median ( n) 
Dry skin  
Median ( n) 
Puffy eyes  
Median ( n) 
 
Absent  Present  Absent  Present  Absent  Present  Absent Present  
 Median 
n 
Median 
n 
Median 
n 
Median 
n 
Lethargy 
1.82 
2815 
1.85 
55 
1.82 
2836 
1.92 
34 
1.82 
2667 
1.78 
203 
1.82 
2787 
2.00 
83 
Weak muscles 
1.84 
2816 
1.74 
54 
1.82 
2840 
1.96 
30 
1.81 
2659 
1.89 
211 
1.82 
2785 
1.94 
85 
Poor memory 
1.82 
2833 
1.79 
37 
1.83 
2846 
1.32 
24 
1.83 
2746 
1.71 
124 
1.82 
2802 
1.85 
68 
Hoarse voice   
1.82 
2827 
1.76 
43 
1.82 
2790 
1.78 
80 
1.82 
2824 
1.39 
46 
Deep voice     
1.83 
2804 
1.93 
66 
1.82 
2823 
1.73 
47 
Dry skin       
1.82 
2705 
1.95 
165 
Poor memory with deep voice Z*=-2.181, p<0.029, hoarse voice with puffy eyes Z*=-1.998, p 0.046, * assoacited with Mann Whitney U test 
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Table A8.9 Presence versus absence of pairs of hypothyroid symptoms; comparison of serum TSH concentration continued 
 Muscle cramps 
Median ( n) 
Constipation  
Median ( n) 
Sensitivity to cold 
Median ( n) 
Slow thinking  
Median ( n) 
Weight gain  
Median ( n) 
 Absent Present Absent  Present Absent  Present Absent  Present Absent  Present 
 Median  
n 
Median  
n 
Median  
n 
Median  
n 
Median  
n 
Lethargy 1.84 
2742 
1.70 
128 
1.83 
2765 
1.55 
105 
1.82 
2662 
1.81 
208 
1.81 
2781 
1.77 
89 
1.82 
2601 
1.84 
29 
Weak muscle 1.83 
2736 
1.72 
134 
1.84 
2763 
1.60 
107 
1.82 
2668 
1.87 
202 
1.82 
2783 
1.88 
87 
1.82 
2666 
188 
204 
Poor memory  1.83 
2810 
1.68 
60 
1.82 
2794 
1.76 
76 
1.82 
2735 
1.81 
135 
1.83 
2745 
1.89 
125 
1.82 
2744 
1.78 
126 
Hoarse voice 1.83 
2813 
1.71 
57 
1.82 
2830 
2.32 
40 
1.83 
2794 
1.63 
76 
1.82 
2834 
1.88 
36 
1.82 
2780 
1.76 
90 
Deep voice 
 
1.82 
2831 
1.57 
39 
1.82 
2847 
1.76 
23 
1.82 
2802 
1.73 
68 
1.84 
2851 
1.62 
19 
1.83 
2756 
1.79 
114 
Dry skin 1.83 
2661 
1.76 
209 
1.82 
2703 
1.94 
167 
1.82 
2469 
1.89 
401 
1.82 
2759 
1.89 
111 
1.81 
2410 
1.90 
460 
Puffy eyes 1.84 
2774 
1.74 
96 
1.82 
2802 
1.83 
68 
1.82 
2707 
1.75 
163 
1.82 
2818 
1.85 
52 
1.81 
2662 
2.00 
208 
Muscle cramps   1.84 
2766 
1.69 
104 
1.82 
2660 
1.90 
204 
1.82 
2824 
2.24 
46 
1.82 
2636 
1.83 
234 
Constipation     1.84 
2692 
1.77 
178 
1.82 
2810 
1.89 
60 
1.82 
2692 
1.85 
178 
Sensitivity to 
cold 
      1.82 
2749 
1.98 
121 
1.81 
2441 
1.91 
429 
Lethargy with constipation Z*=-2.513, p 0.012, p<0.029, puffy eyes with weight gain Z*=-2.070, p<0.038,  
sensitivity to cold with weight gain Z*=-2.322,p<0.020, * associated with Mann Whitney U test
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Appendix 9 Results of univariate exploration of symptoms and serum FT4 
concentration 
 
FT4 in groups reporting presence of symptoms  
The Mann Whitney U test was used to compare median serum FT4 concentration 
between groups reporting presence and absence of individual current and changed 
symptoms. In terms of current symptoms, a significantly greater median serum FT4 
concentration was observed in the group reporting presence of weight loss compared 
with the group reporting absence of this symptom (15.30pmol/L versus 14.80pmol/L 
respectively, Z-3.778, p<0.001). Likewise, the group reporting presence of lethargy had 
a significantly greater median FT4 concentration compared with the group reporting 
absence of lethargy (15.30pmol/L versus 14.80pmol/L respectively, Z-3.905, p<0.001). 
To further corroborate this relationship between symptoms and serum thyroxine 
concentration, a significantly lower median FT4 concentration was observed in the group 
reporting presence of weight gain compared with the group reporting absence of this 
symptom suggestive of overt hypothyroidism (14.80pmol/L versus 15.00pmol/L 
respectively, p<0.001). Despite suggesting dissimilar relationships between symptoms 
and serum FT4 concentration these findings are consistent and in keeping with the 
symptom classification as suggestive of overt hyperthyroidism or hypothyroidism. An 
example of this is the association between weight loss, a symptom suggestive of overt 
hyperthyroidism and higher concentrations of FT4 and the association between weight 
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gain, a symptom suggestive of hypothyroidism and lower concentrations of FT4 
concentration.  
In terms of changed symptoms suggestive of overt hyperthyroidism and overt 
hypothyroidism, no significant differences in serum FT4 concentration were observed 
between groups (Table A9.1).  
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Table A9.1 Presence versus absence of individual sysmptoms; comparison of FT4 concentration  
  Current symptom  Changed symptom  
Symptom  Symptom 
absent 
Median, 
95%CI (n) 
Symptom 
present 
  Median, 
95%CI(n) 
Z scores  
(p value) 
Symptom 
absent 
Median, 
95%CI (n) 
Symptom 
present 
  Median, 
95%CI (n) 
Mann 
Whitney 
test  
Z scores 
(p value)  
S
u
g
g
e
s
tiv
e
 o
f h
y
p
e
rth
y
ro
id
is
m
 
Excessive 
perspiration 
14.9,14.8-15.0 
(2778) 
14.75,13.8-
15.5 (90) 
-0.46 
(0.64) 
14.9,14.8-
15.0 (2802) 
14.9,14.3-
15.7 (60) 
-0.22 
(0.82) 
Trembling 
hands 
14.9, 14.8-
1.86 (2749) 
15.1,14.6-15.6 
(120) 
-1.47 
(0.14) 
14.9,14.8-
15.0 (2719) 
14.8,14.5-
15.1 (140) 
-0.05 
(0.96) 
Frequent 
palpitation 
14.9,14.8-15.0 
(2693) 
15.2,14.3-15.2 
(171) 
-2.33 
(0.02) 
14.9,14.8-
15.0 (2728) 
15.2,14.5-
15.7 (128) 
-1.09 
(0.28) 
Sensitivity to 
heat  
14.9,14.8-15.0 14.7,14.3-15.0 
(304) 
-2.56 
(0.01) 
14.9,14.8-
15.0 (2798) 
14.8,14.1-
14.7 (59) 
-0.39 
(0.70) 
Fast thinking 14.9,14.8-15.0 
(2211) 
15.0,14.8-15.2 
(655) 
-1.09 
(0.28) 
14.9,14.8-
15.0 (2847) 
13.9,13.7-
15.5 (15) 
-0.67 
(0.50) 
Weight loss 14.8,14.7-14.9 
(2660) 
15.3,15.1-15.7 
(206) 
-3.78 
(<0.001) 
14.9,14.8-
15.0 (2489) 
15.0,13.6-
15.5 (179) 
-1.70 
(0.09) 
E
ith
e
r 
fo
rm
 
o
f 
T
D
  
Lethargy 14.8 14.7-14.9 
(2408) 
15.3,15.0-15.4 
(460) 
-3.91 
(<0.001) 
14.9,14.8-
15.0 (2330) 
15.0,14.7-
15.1 (512) 
-1.13 
(0.26) 
Weak muscles 14.9,14.8-15.0 
(2458) 
14.9,14.7-15.2 
(408) 
-0.54 
(0.59) 
14.9,14.8-
15.0 (2397) 
14.9,14.8-
15.4 (465) 
-0.35 
(0.73) 
Poor memory 14.9, 14.8-
15.0 (2596) 
15.0,14.8-15.2 
(273) 
-1.62 
(0.11) 
14.9,14.8-
15.0 (2394) 
14.9,14.7-
15.1 (473) 
-0.27 
(0.79) 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 14.9,14.8-15.0 
(2688) 
14.7,14.2-15.1 
(177) 
-0.64 
(0.64) 
14.9,14.8-
15.0 (2692) 
14.5,14.1-
14.8 (141) 
-2.54 
(0.01) 
Deep voice 14.9,14.8-15.0 
(2674) 
14.9,14.7-15.1 
(188) 
-0.85 
(0.39) 
14.9,14.8-
15.0 (2789) 
14.5,13.9-
15.1 (57) 
- 0.97 
(0.33) 
Dry skin 14.9, 14.8-
15.0 (1940) 
14.8,14.7-15.0 
(924) 
-0.58 
(0.56) 
14.9,14.8-
15.1 
(2495) 
14.9,14.6-
16.9 (368) 
-0.07 
(0.95) 
Puffy eyes 14.9,14.8-15.0 
(2475) 
14.9,14.7-15.1 
(390) 
-0.94 
(0.35) 
14.9,14.8-
15.0 (2685) 
14.9,14.4-
15.1 (173) 
-1.50 
(0.13) 
Muscle cramps 14.9,1.79-1.89 
(2434) 
14.7,14.6-15.0 
(433) 
-0.54 
(0.59) 
14.9,14.8-
15.0 (2488) 
14.8,14.6-
15.1 (377) 
-0.43 
(0.67) 
Constipation  14.9,14.6-15.0 
(2485) 
14.7,14.5-14.9 
(373) 
-2.17 
(0.03) 
14.9,14.8-
15.0 (2662) 
15.0,11.6-
14.6 (194) 
-0.64 
(0.52) 
Sensitivity to 
cold  
14.8,1.76-1.88 
(1837) 
15.0,14.8-15.1 
(985) 
-1.09 
(0.28) 
14.9,14.8-
15.0 (2492) 
15.1,14.7-
15.2 (365) 
-1.15 
(0.25) 
Slow thinking 14.9,14.0-15.0 
(2638) 
15.0,14.8-15.2 
(228) 
-0.91 
(0.36) 
14.9,14.8-
15.0 (2525) 
15.0,14.7-
15.1 (337) 
-0.10 
(0.92) 
Weight gain 15.0,14.9-15.1 
(1470) 
14.8,14.6-14.9 
(1396) 
-3.49 
(<0.001) 
14.9, 14.8-
15.0 (2405) 
14.7,14.5-
15.0 (463) 
-2.11 
(0.04) 
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The Kruskal Wallis test was use to examine the difference in median serum FT4 
concentration between groups reporting absence of symptoms, presence of mild 
intensity symptoms and presence of severe intensity symptoms. At the Bonferroni 
adjusted alpha level ( p<0.003) no significant differences were observed between these 
groups with respect to median serum FT4 concentration. (Table A9.2) 
  380 
 
Table A9.2 Presence versus absence of current mild and severe intensity symptoms; 
comparison of serum FT4 concentration  
   Median serum FT4 concentration 
 Symptom  Symptom 
absent  
%,95%CI (n) 
Mild symptom 
present  
%,95%CI (n) 
Severe 
intensity 
symptom 
 %,95%CI (n) 
p value 
S
u
g
g
e
s
tiv
e
 o
f 
h
y
p
e
rth
y
ro
id
is
m
 
Excessive perspiration 14.9,14.8-15.0 
(2778) 
14.7,13.7-15.5 
(73) 
15.1,14.0-17.4 
(17) 
0.873 
Trembling hands 14.9, 14.8-
1.86 (2749) 
15.1,14.4-15.6 
(90) 
15.2,13.7-16.3 
(30) 
0.578 
Frequent palpitations  14.9,14.8-15.0 
(2693) 
15.2, 14.8-15.6 
(145) 
15.1,1.5-16.5 
(26) 
0.102 
Sensitivity to heat  14.9,14.8-15.0 14.7, 14.3-15.0 
(277) 
14.4,13.8-15.8 
(27) 
0.111 
Fast thinking 14.9,14.8-15.0 
(2211) 
15.0,14.8-15.1 
(595) 
14.9,14.1-15.4 
(60) 
0.428 
Weight loss 14.8,14.7-14.9 
(2660) 
15.3, 15.1-15.7 
(190) 
15.6, 14.0-18.0 
(16) 
0.010 
E
ith
e
r 
fo
rm
 
o
f T
D
  
Lethargy 14.8 14.7-14.9 
(2408) 
15.3, 15.0-15.5 
(380) 
15.3, 14.8-15.5 
(80) 
0.020 
Weak muscles 14.9,14.8-15.0 
(2458) 
14.9,14.6-15.1 
(375) 
15.3,14.5-16.0 
(33) 
0.938 
Poor memory 14.9, 14.8-
15.0 (2596) 
15.0,14.7-15.2 
(253) 
15.1,14.8-17.1 
(20) 
0.584 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 14.9,14.8-15.0 
(2688) 
14.7,14.3-15.2 
(170) 
13.6,11.7-25.0  0.284 
Deep voice 14.9,14.8-15.0 
(2674) 
14.9,14.7-15.4 
(184) 
13.9, 11.7-16.8 
(4) 
0.827 
Dry skin 14.9, 14.8-
15.0 (1940) 
14.8,14.6-15.0 
(781) 
15.2, 14.8-15.5 
(143) 
0.237 
Puffy eyes 14.9,14.8-15.0 
(2475) 
14.9,14.7-15.1 
(373) 
14.8,14.8-15.0 
(2434) 
0.841 
Muscle cramps 14.9,1.79-1.89 
(2434) 
14.71.69-1.90 
(368) 
14.8,1.50-2.04 
(65) 
0.544 
Constipation  14.9,14.6-15.0 
(2485) 
14.7, 14.2-14.9 
(288) 
18.0,14.6-15.4 
(90) 
0.203 
Sensitivity to cold  14.8,1.76-1.88 
(1837) 
15.0,1.77-1.94 
(849) 
14.8,1.77-2.17 
(136) 
0.104 
Slow thinking 14.9,14.0-15.0 
(2638) 
15.0,14.8-15.2 
(215) 
15.6,13.7-17.4 
(13) 
0.427 
Weight gain 15.0,14.9-15.1 
(1470) 
14.8,14.6-14.9 
(1211) 
14.7,14.3-15.0 
(185) 
0.080 
    Bonferroni adjusted alpha level,p<0.003 (0.05/18) 
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In terms of severity of changed symptoms no significant differences in serum FT4 
concentration were observed between groups at the Bonferroni adjusted alpha value of 
p<0.003. 
Table A9.3 Presence versus absence of mild and severe intensity changed symptoms; 
comparison of serum FT4 concentration  
   Median serum FT4 concentration 
 Symptom  Symptom absent  
%,95%CI (n) 
Mild symptom 
present  
%,95%CI  
(n) 
Severe 
intensity 
symptom 
 %,95%CI (n) 
p value 
S
u
g
g
e
s
tiv
e
 o
f 
h
y
p
e
rth
y
ro
id
is
m
 
Excessive perspiration 14.9,14.8-15.0 
(2802) 
14.7,14.0-15.0 
(2802) 
15.1,14.4-18.4 
(4) 
0.50 
Trembling hands 14.9,14.8-15.0 
(2719) 
14.7,14.4-15.1 
(129) 
16.1,14.0-17.8 
(11) 
0.44 
Frequent palpitations  14.9,14.8-15.0 
(2728) 
15.2,14.6-15.8 
(122) 
14.5,9.1-17.9 
(6) 
0.48 
Sensitivity to heat  14.9,14.8-15.0 
(2798) 
15.1,14.1-15.7 
(48) 
14.4,11.2-16.4 
(11) 
0.77 
Fast thinking 14.9,14.8-15.0 
(2847) 
15.3,13.7-15.5 
(12) 
13.7,12.6-13.9 
(3) 
0.72 
Weight lose 14.9,14.8-15.0 
(2489) 
14.9,14.7-15.2 
(362) 
15.5, 13.3-
17.8 (17) 
0.66 
E
ith
e
r fo
rm
 
o
f T
D
 
Lethargy 14.9,14.8-15.0 
(2330) 
14.9,14.7-15.0 
(475) 
15.5, 14.7-
16.1 (57) 
0.71 
Weak muscles 14.9,14.8-15.0 
(2397) 
14.9, 14.7-15.1 
(443) 
14.7,13.4-16.5 
(22) 
0.77 
Poor memory 14.9,14.8-15.0 
(2394) 
14.9,14.7-15.1 
(457) 
15.3,14.5-17.3 
(16) 
0.90 
S
u
g
g
e
s
tiv
e
 o
f h
y
p
o
th
y
ro
id
is
m
 
Hoarse voice 14.9,14.8-15.0 
(2692) 
14.4,13.5-14.8 
(134) 
15.5,13.9-20.4 
(7) 
0.01 
Deep voice 14.9,14.8-15.0 
(2789) 
14.4,14.0-15.1 
(55) 
12.5,11.7-13.2 
(2) 
0.23 
Dry skin 14.9,14.8-15.1 
(2495) 
14.8,14.0-14.7 
(337) 
15.2,14.6-16.1 
(31) 
0.97 
Puffy eyes 14.9,14.8-15.0 
(2685) 
14.9,14.4-15.1 
(164) 
14.0,13.2-16.1 
(9) 
0.84 
Muscle cramps 14.9,14.8-15.0 
(2488) 
14.814.8-15.0 
(347) 
15.3,14.2-16.0 
(30) 
0.38 
Constipation  14.9,14.8-15.0 
(2662) 
14.9,14.3-15.2 
(168) 
15.2,14.5-16.5 
(26) 
0.82 
Sensitivity to cold  14.9,14.8-15.0 
(2492) 
15.0,14.6-15.2 
(339) 
16.7, 4.8-17.4 
(26) 
0.28 
Slow thinking 14.9,14.8-15.0 
(2525) 
15.0,14.7-15.1  
(327) 
14.9,13.3-19.9 
(10) 
0.58 
Weight gain 14.9, 14.8-15.0 
(2405) 
14.7,14.5-15.0 
(440) 
14.8,13.1-15.7 
(23) 
0.23 
        Bonferroni adjusted alpha level, p<0.003 (0.05/18)
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Serum FT4 and pairs of current hyperthyroid symptoms  
At the Bonferroni adjusted alpha level of p<0.0013 no significant differences in median 
serum FT4 were observed between groups with respect to prevalence of the 36 possible 
pairs of symptoms suggestive of overt hyperthyroidism. At a level of 5% however a 
significant difference in median serum FT4 existed with respect to prevalence of six 
combinations of hyperthyroid symptoms; excessive perspiration with sensitivity to heat, 
frequent palpitation with poor memory, frequent palpitation with weight loss, fast thinking 
with weight loss, lethargy with weak muscles, lethargy with poor memory. (Table A9.4) 
Median FT4 was significantly higher in the group reporting presence of frequent 
palpitation with poor memory than in the group reporting absence of this symptom pair 
(16.60 mIU/L versus 14.90 mIU/L, Z-2.070, p<0.0038). Similarly, the presence of 
symptoms pairs; fast thinking with weight loss and frequent palpitation with weight loss 
was associated with significantly higher median FT4 concentrations compared with 
absence of these symptoms pairs (15.60 mIU/L versus 14.90 mIU/L, Z-2.357, p 0.018 
and  16.75 m IU/L versus 14.90 mIU/L, 2.922, p<0.003 respectively). These results were 
consistent with the symptom classification (e.g hyperthyroid symptoms) and the 
biochemical profile of overt hyperthyroidism (e.g. elevated free FT4 concentrations). In 
contrast however the relationship between serum FT4 concentration and the symptom 
pair; excessive perspiration with sensitivity to heat was in conflict with both the symptom 
classification and the biochemical profile of overt hyperthyroidism (14.00 mIU/L versus 
14.90 mIU/L, Z -2.245, p<0.025). Presence of lethargy with weak muscles (15.30 mIU/L 
versus 14.90 mIU/L, Z- 2.770, p<0.006) and lethargy with poor memory (15.30 mIU/L 
versus 14.90 mIU/L, Z- 2.222, p<0.020) was also associated with significantly higher 
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median serum concentration than absence of these symptom pairs. Since these 
symptoms manifest in both overt hyperthyroidism and overt hypothyroidism it is difficult 
to comment further upon this relationship.  
 
FT4 and pairs of hypothyroid symptoms  
With respect to combinations of symptoms suggestive of hypothyroidism at the 
Bonferroni adjusted alpha level of p<0.0008, no significant difference in median serum 
FT4 was observed with respect the possible 63 pairs of symptoms. At the 5% level 
however, a significant difference in serum FT4 was observed with respect to eight pairs 
of hypothyroid symptoms (Table A9.5) The relationship between serum FT4 
concentration and the symptom pair; lethargy with muscle cramps, lethargy with dry 
skin, lethargy with sensitivity to cold and lethargy with slow thinking was discordant with 
the biochemical profile of overt hypothyroidism and the corresponding symptom 
classification. Presence of lethargy with muscle cramps was associated with a 
significantly greater serum FT4 concentration than absence of this symptoms pair (15.50 
mIU/L versus 14.90 mIU/L, Z- 3.714, p<0.001). Similarly, presence of lethargy with dry 
skin (15.20 mIU/L versus 14.80 mIU/L, Z-2.398, p<0.016), lethargy with sensitivity to 
cold (15.30 mIU/L versus 14.90 mIU/L, Z-3.054, p<0.020) and lethargy with slow 
thinking (15.30 mIU/L versus 14.90 IU/L, Z-2.248, p<0.025) was associated with 
significantly greater serum FT4 concentrations than absence of these symptom pairs 
(ATable 9.5). 
In contrast, the presence of dry skin with constipation ( 14.60 mIU/L versus 14.90 mIU/L, 
Z-3.037,p<0.002), dry skin with puffy eyes (14.50 mIU/L versus 14.90 mIU/L, Z-2.120, 
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p<0.034), constipation with weight gain (14.40 mIU/L versus 14.90 mIU/L, Z-3.307, 
p<0.001) and puffy eyes with weight gain (14.70 mIU/L versus 14.90 mIU/L, Z-2.025, p< 
0.043) were associated with significantly lower concentrations of serum FT4 (Table 
A9.5). 
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Table A9.4 Presence versus absence of pairs of hyperthyroid symptoms; comparison of serum FT4 concentration     
 
Excessive perspiration with sensitivity to heat Z=-2.245 p 0.025, frequent palpitation with weight loss Z=-2.922,p 0.003, frequent palpitation with 
Poor memory Z=-2.070, p 0.038,  fast thinking with weight loss  Z=-2.357,p 0.018, lethargy with poor memory  Z= -2.222, p 0.020, lethargy with 
weak muscles Z=-2.770, p 0.006. 
 Trembling hands Frequent 
palpitation 
Sensitivity to 
heat 
 
Fast thinking Weight loss Lethargy Weak muscles Poor memory 
 Absent Present Absent Present Absent Present Absent Present Absent Present Absent Present Absent Present Absent Present 
 Median 
n 
Median 
n 
Median 
n 
Median 
n 
Median 
n 
Median 
n 
Median 
n 
Median 
n 
Excessive 
perspiration  
1.82 
2865 
3.13 
5 
1.82 
2857 
1.79 
12 
1.82 
2829 
1.76 
41 
1.82 
2844 
1.85 
24 
1.82 
2869 
1.45 
1 
1.82 
2843 
1.72 
26 
1.82 
2841 
1.63 
29 
1.82 
2846 
1.85 
24 
Trembling 
hands   
1.82 
2855 
1.58 
15 
1.82 
2857 
1.56 
13 
1.82 
2856 
1.97 
14 
1.82 
2856 
1.98 
14 
1.82 
2822 
 
2.03 
48 
1.82 
2825 
1.92 
45 
1.82 
2856 
1.97 
14 
Frequent 
palpitations      
1.83 
2844 
1.38 
26 
1.82 
2834 
1.56 
36 
1.82 
2856 
1.37 
14 
1.82 
2811 
1.53 
59 
1.83 
2820 
1.45 
50 
1.82 
2842 
1.67 
28 
Sensitivity to 
heat        
1.83 
2793 
1.63 
77 
1.82 
2866 
1.07 
4 
1.82 
2810 
1.76 
60 
1.82 
2822 
1.76 
48 
1.82 
2845 
1.67 
25 
Fast thinking  
        
1.83 
2819 
1.66 
54 
1.82 
2791 
1.84 
79 
1.82 
2802 
2.00 
68 
1.82 
2852 
1.73 
18 
Weight lose 
          
1.82 
2831 
1.42 
39 
1.82 
2819 
1.89 
51 
1.82 
2846 
1.85 
24 
Lethargy  
            
1.82 
2670 
1.82 
200 
1.83 
2769 
1.61 
101 
Weak 
muscles               
1.82 
2779 
1.72 
91 
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Table A9.5 Presence versus absence of pairs of hypothyroid symptoms; comparison of serum FT4 concentration  
 Hoarse voice  
Median FT4 (n) 
Deep voice  
Median FT4 (n) 
Dry skin  
Median FT4 (n) 
Puffy eyes  
Median FT4 (n) 
 Abs Pres Abs Pres Abs Pres Abs Pres 
Lethargy 14.90 
2815 
15.10 
55 
14.90 
2836 
15.45 
34 
14.80 
2667 
15.20 
203 
14.90 
2787 
15.30 
83 
Weak muscles 14.90 
2816 
14.45 
54 
14.90 
2840 
15.10 
30 
14.90 
2659 
14.80 
211 
14.90 
2785 
15.10 
85 
Poor memory 14.90 
2833 
15.10 
37 
14.90 
2846 
15.90 
24 
14.90 
2746 
14.90 
124 
14.90 
2802 
15.30 
68 
Hoarse voice 
  
14.90 
2827 
15.60 
43 
14.90 
2790 
14.35 
80 
14.90 
2824 
14.80 
44 
Deep voice 
    
14.90 
2804 
14.75 
66 
14.90 
2823 
15.10 
47 
Dry skin 
      
14.90 
2705 
14.50 
165 
Puffy eyes 
        
Muscle cramps 
        
Constipation 
        
Sensitivity to cold 
        
Slow thinking  
        
Weight gain         
Lethargy with dry skin Z=-2.398, p 0.016, dry skin with puffy eyes  Z=-2.120, p 0.034,  
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Table 9.5A Presence versus absence of pairs of hypothyroid symptoms; comparison of serum FT4 concentration continued 
 Muscle cramps 
Median FT4 (n) 
Constipation  
Median FT4 (n) 
Sensitivity to cold 
Median FT4 (n) 
Slow thinking 
Median TF4 (n) 
Weight gain  
Median FT4 (n) 
 Abs Pres Abs Pres Abs Pres Abs Pres Abs Pres 
Lethargy  14.90 
2742 
15.50 
128 
14.90 
2765 
15.20 
105 
14.90 
2662 
15.30 
2068 
14.90 
2781 
15.30 
89 
14.90 
2601 
15.00 
269 
Weak muscles 14.90 
2736 
15.00 
134 
14.90 
2763 
14.70 
107 
14.90 
2668 
15.10 
202 
14.90 
2783 
15.10 
87 
14.90 
2666 
14.75 
204 
Poor memory 14.90 
2810 
15.25 
60 
14.90 
2794 
14.95 
76 
14.90 
2735 
15.10 
135 
14.90 
2745 
15.00 
125 
14.90 
2744 
15.05 
126 
Hoarse voice 14.90 
2813 
14.40 
57 
14.90 
2830 
14.30 
40 
14.90 
2794 
15.10 
76 
14.90 
2834 
15.20 
36 
14.90 
2780 
14.15 
90 
Deep voice 
 
14.90 
2831 
14.40 
39 
14.90 
2847 
14.90 
23 
14.90 
2802 
15.35 
68 
14.90 
2851 
15.30 
19 
14.90 
2756 
14.90 
114 
Dry skin  14.90 
2661 
14.80 
209 
14.90 
2703 
14.60 
167 
14.90 
2469 
15.00 
401 
14.90 
2759 
15.00 
111 
14.90 
2410 
14.80 
460 
Puffy eyes 14.90 
2774 
14.75 
96 
14.90 
2802 
14.75 
68 
14.90 
2707 
15.00 
163 
14.90 
2818 
15.25 
52 
14.90 
2662 
14.70 
208 
Muscle cramps 
  
14.90 
2766 
15.10 
104 
14.90 
2666 
14.70 
204 
14.90 
2824 
15.00 
46 
14.90 
2636 
14.60 
234 
Constipation 
    
14.90 
2692 
14.85 
178 
14.90 
2810 
14.95 
60 
14.90 
2692 
14.40 
178 
Sensitivity to cold  
      
14.80 
2749 
15.20 
121 
14.90 
2441 
14.90 
429 
Slow thinking 
         
14.90 
2762 
15.00 
108 
Weight gain           
Lethargy with muscle cramps Z=- 3.714, p <0.001, dry skin with constipation Z=-3.037,p 0.002, Constipation with weight gain  Z=- 3.307, p 0.001, 
puffy eyes with weight gain Z=-2.025, 0.043, lethargy with slow thinking Z=-2.248, p 0.025, Lethargy with sensitivity to cold Z= -3.054, p 0.020, 
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Symptom interactions and FT4 
A logistic model was constructed to determine whether the relationship between serum 
thyroxine concentration and the symptom fast thinking was modified by the presence of 
lethargy demonstrated a significant interaction between the two symptoms.  
 
Table A9.6 FT4 interaction model 1- Fast thinking and lethargy  
Model Co-efficient  Std. Error t p value 
Constant 14.879 .048 311.423 .000 
Fast thinking .219 .098 2.244 .025 
Lethargy .525 .115 4.564 .000 
Interaction term FTLA -.657 .271 -2.426 .015 
 
Table A9.7 FT4 interaction model 2 – Deep voice and muscle cramps 
Model Co-efficient Std. Error t p value 
Constant 14.980 .043 348.857 .000 
Deep voice .309 .174 1.774 .076 
Muscle cramp .011 .112 .097 .923 
Interaction term DVMC -.779 .386 -2.019 .044 
 
Table A9.8 FT4 interaction model 3 – Dry skin and constipation 
Model Co-efficient Std. Error t p value 
Constant 15.005 .049 304.256 .000 
Dry skin  .083 .089 .923 .356 
Constipation -.028 .149 -.190 .849 
Interaction term DVC -.548 .230 -2.381 .017 
  
 
Table A9.9 FT4 interaction model 4 – Lethargy with muscle cramps 
Model Co-efficient Std. Error t p value 
Constant 14.966 .045 335.762 .000 
Lethargy .246 .121 2.039 .042 
Muscle cramps  -.287 .125 -2.287 .022 
Interaction term LAMC .704 .247 2.853 .004 
 
Table A9.10 FT4 interaction model 5–Lethargy with weight gain 
Model Co-efficient Std. Error t p value 
Constant 15.041 .057 264.103 .000 
Lethargy  .689 .158 4.352 .000 
Weight gain -.232 .083 -2.787 .005 
Interaction term LAWG -.435 .210 -2.071 .038 
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Table A9.11 FT4 interaction model 6- Hoarse voice with constipation 
Model Co-efficient Std. Error t p value 
Constant 15.018 .042 354.876 .000 
Hoarse voice .203 .181 1.123 .261 
Constipation  -.184 .119 -1.540 .124 
Interaction term HVC -.767 .387 -1.981 .048 
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